dalteparin has been researched along with Deep Vein Thrombosis in 920 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Of 138 randomized patients, 100 patients with active malignancy presenting with acute deep venous thrombosis and still treated with chemotherapy were assigned to either oral apixaban therapy or subcutaneous low-molecular weight heparin (enoxaparin) through randomized clinical study in 1:1 ratio." | 9.41 | Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. ( Algaby, AZ; Hassan, A; Mokadem, ME, 2021) |
| "Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding." | 9.34 | Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G, 2020) |
| "The 80-mg betrixaban dose achieves higher plasma concentrations than the 40-mg dose and, in contrast to the 40-mg dose, is associated with improved efficacy across all cohorts relative to standard-dose enoxaparin without an excess risk of major bleeding in the management of medically ill subjects." | 9.24 | The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. ( Arbetter, DF; Bandman, O; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Korjian, S; Leeds, JM; Lu, SP; Yee, MK, 2017) |
| "Sixty-two PE patients with or without deep venous thrombosis (DVT) was randomized to rivaroxaban mono-therapy or standard-therapy with enoxaparin followed by vitamin K antagonist (VKA)." | 9.22 | Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism. ( Chen, R; Duan, L; Guo, Y; Hong, C; Liu, C; Su, X; Yan, H; Yang, X; Zhang, N; Zhong, N; Zhou, Y, 2016) |
| "In the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE) or venous thromboembolism-related death, with significantly less bleeding." | 9.20 | Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. ( Cohen, AT; Johnson, M; Liu, X; Mardekian, J; Phatak, H; Thompson, J, 2015) |
| "Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding." | 9.20 | Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015) |
| "The phase III EINSTEIN DVT and EINSTEIN PE trials demonstrated the potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)." | 9.19 | Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. ( Bamber, L; Correa de Carvalho, F; Lensing, AW; Prins, M; van Bellen, B; Wang, M, 2014) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 9.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Ambulatory treatment with enoxaparin plus warfarin seems to be effective in symptomatic healing and in clinical improvement by reducing thrombus formation and organization at all levels of lower extremity venous system with DVT, without a significant major bleeding risk." | 9.14 | Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial. ( Akcalı, Y; Filizcan, U; Hasan, E; Karabay, O; Koksoy, C; Kurtoglu, M, 2010) |
| "Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation." | 9.14 | Oral rivaroxaban for symptomatic venous thromboembolism. ( Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2010) |
| "Adults with newly diagnosed malignant glioma were randomized to receive dalteparin 5000 anti-Xa units or placebo, both subcutaneously once daily for 6 months starting within 4 weeks of surgery." | 9.14 | PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. ( Agnelli, G; Baker, R; Falanga, A; Finch, T; Geerts, W; Julian, JA; Laperriere, NJ; Levine, MN; Malkin, MG; Parpia, S; Perry, JR; Rogers, LR; Sawaya, R, 2010) |
| "We evaluated the effect of long-term anticoagulant treatment (enoxaparin vs coumarin) in patients with deep venous thrombosis (DVT) as to incidence of post-thrombotic syndrome (PTS) and recurrent venous thromboembolism." | 9.13 | Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. ( Castrodeza, J; González-Fajardo, JA; Martin-Pedrosa, M; Tamames, S; Vaquero-Puerta, C, 2008) |
| " To challenge this premise, we evaluated if deep vein thrombosis (DVT) prophylaxis with dalteparin sodium confers an excessive anticoagulant effect in critically ill patients with severe renal insufficiency." | 9.13 | Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ( Albert, M; Anderson, D; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Geerts, W; Granton, J; Guyatt, G; Hébert, P; Heels-Ansdell, D; Marshall, J; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients." | 9.12 | Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE, 2007) |
| "Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile." | 9.12 | Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. ( Büller, HR; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kurth, AA; Prins, MH; Rosencher, N; Schnee, J; van Dijk, CN, 2007) |
| "The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to hospital with an acute medical illness." | 9.12 | Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. ( Bondi, M; Casolari, B; Cenci, AM; Crowther, MA; Mannucci, C; Prisco, D; Tincani, E; Turrini, F, 2006) |
| " The objective of this study was to evaluate the efficacy of dalteparin during lower-limb immobilization after surgical treatment of Achilles tendon rupture." | 9.12 | Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study. ( de Bri, E; Elvin, A; Lapidus, LJ; Lärfars, G; Levander, C; Ponzer, S; Rosfors, S, 2007) |
| "Once-daily subcutaneous fondaparinux was at least as effective (not inferior) and safe as twice-daily, body weight-adjusted enoxaparin in the initial treatment of patients with symptomatic deep venous thrombosis." | 9.11 | Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. ( Büller, HR; Cariou, R; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Leeuwenkamp, O; Lensing, AW; Piovella, F; Prins, MH; Raskob, G; Segers, AE, 2004) |
| "Dalteparin 5000 IU once daily halved the rate of venous thromboembolism with a low risk of bleeding." | 9.11 | Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ( Cohen, AT; Goldhaber, SZ; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2004) |
| "The purpose of this study was to determine whether standard therapeutic doses of dalteparin maintain peak therapeutic levels of anticoagulation during pregnancy." | 9.11 | A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. ( Barbour, LA; Oja, JL; Schultz, LK, 2004) |
| "Similar compliance, health status, deep venous thrombosis, and bleeding rates were found between dalteparin and enoxaparin." | 9.10 | Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. ( Chan, KT; Chiou-Tan, FY; Donovan, WH; Garza, H; Graves, DE; Holmes, SA; Parsons, KC; Rintala, DH; Robertson, CS, 2003) |
| "This randomized, controlled, multicentre study evaluated the efficacy and tolerability of the oral direct thrombin inhibitor ximelagatran, compared with a low-molecular-weight heparin (dalteparin) followed by warfarin, in the treatment of deep vein thrombosis (DVT) of the lower extremity." | 9.10 | A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. ( Eriksson, H; Frison, L; Gustafsson, D; Schulman, S; Wåhlander, K; Welin, LT, 2003) |
| " The aim of this study was to evaluate the correlation between pre-operative plasma levels of soluble fibrin polymers (SFP), as determined by a recently developed enzyme-linked immunosorbent assay (ELISA) assay (TpP), and the incidence of deep vein thrombosis (DVT) after elective neurosurgery." | 9.09 | Pre-operative plasma levels of soluble fibrin polymers correlate with the development of deep vein thrombosis after elective neurosurgery. ( Agnelli, G; Baroni, M; D'Angelo, SV; Quintavalla, R; Severi, P; Sonaglia, F, 1999) |
| "In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe." | 9.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| " The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12." | 9.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| "This was a prospective cohort study of eligible patients with pulmonary embolism managed as outpatients using dalteparin (200 U/kg s/c daily) for a minimum of five days and warfarin for 3 months." | 9.09 | Outpatient treatment of pulmonary embolism with dalteparin. ( Anderson, D; Gray, L; Kovacs, MJ; Morrow, B; Touchie, D; Wells, PS, 2000) |
| "This randomised, double-blind, aspirin-controlled trial tested the safety and efficacy of treatment with high-dose tinzaparin (175 anti-Xa IU/kg daily; 487 patients), medium-dose tinzaparin (100 anti-Xa IU/kg daily; 508 patients), or aspirin (300 mg daily; 491 patients) started within 48 h of acute ischaemic stroke and given for up to 10 days." | 9.09 | Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. ( Bath, PM; Boysen, G; De Deyn, P; Friis, P; Leys, D; Lindenstrom, E; Marttila, R; O'Neill, D; Olsson, J; Orgogozo, J; Ringelstein, B; Turpie, AG; van der Sande, J, 2001) |
| "In conclusion, our results confirmed that direct Xa inhibitors (rivaroxaban and apixaban) were more effective for prevention of VTE after total knee replacement as compared with enoxaparin, without increasing major bleeding risk." | 8.91 | Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. ( Ma, G; Wang, D; Wu, X; Ying, K; Zhang, R, 2015) |
| " In a dose-ranging European study, preoperatively initiated subcutaneous melagatran 3 mg twice daily followed by oral ximelagatran 24 mg twice daily was significantly more effective than subcutaneous dalteparin sodium 5000IU once daily in preventing the occurrence of VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients undergoing hip or knee replacement." | 8.82 | Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. ( Evans, HC; Faulds, D; Perry, CM, 2004) |
| "The fondaparinux trials in venous thromboembolism (VTE) prevention after orthopaedic surgery have been subject to methodological criticisms recently summarised in this journal." | 8.82 | The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery. ( Turpie, AG, 2004) |
| "Apixaban has a higher rate of major bleeding in patients with luminal GI cancer compared with patients with non-GI cancer and compared with enoxaparin in patients with luminal GI cancer." | 8.02 | Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. ( Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2021) |
| " The objective of this analysis was to evaluate the cost-effectiveness of rivaroxaban compared with current SoC (enoxaparin overlapped with warfarin) for the treatment of acute deep vein thrombosis (DVT) in China." | 7.96 | Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China. ( Wu, J; Yang, L, 2020) |
| "to compare two anticoagulant therapy (ACT) regimens in the treatment of venous thrombosis (VT) in patients after catheter interventions - electrophysiological studies (EFIs) and ablations: enoxaparin followed by warfarin, and rivaroxaban monotherapy." | 7.91 | [Comparative efficacy and safety of enoxaparin followed by warfarin and rivaroxaban monotherapy in the treatment of venous thrombosis in patients after intracardiac catheter interventions]. ( Balakhonova, TV; Golitsyn, SP; Kropacheva, ES; Loginova, AI; Maykov, EB, 2019) |
| "Objective This study was performed to evaluate the efficacy of rivaroxaban versus nadroparin for preventing deep venous thrombosis (DVT) in elderly patients with osteoporosis undergoing initial total hip arthroplasty (THA) for femoral neck fractures." | 7.88 | Rivaroxaban versus nadroparin for preventing deep venous thrombosis after total hip arthroplasty following femoral neck fractures: A retrospective comparative study. ( Chen, D; Ge, Z; Liang, G; Wan, Z; Xu, B; Yang, C; Yu, W; Zeng, X; Zhang, C; Zhang, F; Zhang, X, 2018) |
| " In this study, the acute treatment effect of edoxaban on venous thrombosis is investigated in rats by single and multiple administrations, and compared to the conventional parenteral anticoagulants, enoxaparin and fondaparinux." | 7.80 | Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats. ( Honda, Y; Kamisato, C; Morishima, Y, 2014) |
| "The in-hospital incidence of pulmonary embolism (PE) in patients undergoing elective joint arthroplasty who receive a minimum of 10 days of dalteparin prophylaxis is reported to be less than 1%." | 7.76 | High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis. ( Kerr, J; Linkins, LA, 2010) |
| "To compare efficacy and safety of warfarin and enoxaparin used in the first month of treatment of patients with an episode of deep vein thrombosis (DVT) and/or pulmonary artery thromboembolism (PATE)." | 7.75 | [Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment]. ( Andriiashkin, VV; Balakhonova, TV; Dobrovol'skiĭ, AB; Ermolina, OV; Kirienko, AI; Leont'ev, SG; Panchenko, EP; Titaeva, EV; Vorob'eva, NM, 2009) |
| "Deep vein thrombosis (DVT) remains a major burden and fondaparinux represents a new option for DVT therapy." | 7.74 | Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. ( Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007) |
| "In ICU patients with renal insufficiency, the incidence of DVT and major bleeding are considerable but appear related to patient comorbidities rather than to an inadequate or excessive anticoagulant from thromboprophylaxis with dalteparin." | 7.74 | Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. ( Albert, M; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Friedrich, J; Geerts, W; Granton, J; Guyatt, G; Hebert, P; Heels-Ansdell, D; Karachi, T; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "This multicenter, prospective, open label, observational study evaluated practice patterns of physicians using tinzaparin, a low-molecular-weight heparin (LMWH), and warfarin for the treatment of deep venous thrombosis (DVT) with or without pulmonary embolism (PE)." | 7.74 | Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. ( Hyers, TM; Spyropoulos, AC, 2007) |
| "The antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold (LK-732, LK-639 and LK-731) and their amidoxime prodrugs (LK-658, LK-633 and LK-730) was studied in comparison to argatroban and nadroparin in two rat models of venous thrombosis, induced either by complete stasis combined with hypercoagulability (model 1) or by partial stasis combined with vessel injury (model 2)." | 7.73 | Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models. ( Bozic, M; Budihna, MV; Cerne, M; Drevensek, G; Peternel, L; Stalc, A; Stegnar, M; Urleb, U; Zega, A, 2005) |
| "We were concerned that a fixed rather than a weight-based dosing regimen of dalteparin sodium to prevent venous thromboembolism (VTE) might result in decreased efficacy in obese patients and decreased safety in elderly patients." | 7.73 | Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. ( Cohen, AT; Goldhaber, SZ; Kucher, N; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2005) |
| " The low-molecular-weight heparin dalteparin sodium is clinically effective in reducing the incidence of venous thromboembolism (VTE) in these patients." | 7.73 | Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery. ( Heerey, A; Suri, S, 2005) |
| "To evaluate and compare the efficacy and safety of low molecular weight heparin (LMWH) (nadroparine) and acenocoumarol in the treatment of deep venous thrombosis (DVT)." | 7.72 | Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients. ( Ganotakis, ES; Mazokopakis, EE; Vrentzos, GE, 2003) |
| "The selective antithrombotic fondaparinux is more effective than the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism (deep-vein thrombosis [DVT] or pulmonary embolism) in patients undergoing major orthopedic surgery, but its cost-effectiveness is undetermined." | 7.72 | The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. ( Borris, L; Bossuyt, P; de Pouvourville, G; Gordois, A; Jönsson, B; Levy, E; Posnett, J, 2003) |
| "Warfarin-induced skin necrosis is a rare complication associated with the use of oral anticoagulants." | 7.72 | A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency. ( Alexander, JB; Ierardi, R; Tai, CY, 2004) |
| "Homocysteine has been recognized as a risk factor for atherosclerosis and arterial and venous thrombosis." | 7.72 | Hyperhomocysteinemia and deep vein thrombosis in orthotopic heart transplantation: a case report. ( Bhat, G; Costea, A, 2004) |
| "Many orthopaedic surgeons use warfarin to prevent venous thromboembolism (VTE) following hip or knee arthroplasty." | 7.72 | Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty. ( Brotman, DJ; Hurbanek, JG; Jaffer, AK; Morra, N, 2004) |
| "Of 263 patients who underwent total knee arthroplasty, 122 received adjusted low-dose warfarin and 141 received enoxaparin as deep vein thrombosis (DVT) prophylaxis." | 7.70 | Evaluation of the safety and efficacy of enoxaparin and warfarin for prevention of deep vein thrombosis after total knee arthroplasty. ( O'Connor, D; Stern, SH; Wixson, RL, 2000) |
| "Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence." | 6.90 | Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019) |
| "Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)." | 6.84 | Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017) |
| "However, upper limb deep vein thrombosis is poorly studied with scant data on the use of direct oral anticoagulants in noncatheter-related deep vein thrombosis." | 6.82 | Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review. ( Fioretti, AM; Giotta, F; Leopizzi, T; Lorusso, V; Luzzi, G; Oliva, S; Puzzovivo, A, 2022) |
| "Melagatran 2 mg was started immediately before surgery; 3 mg was then administered postoperatively, followed by 24 mg of oral ximelagatran b." | 6.71 | The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ( Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N, 2003) |
| "The incidence of deep vein thrombosis (DVT) was significantly higher in the thalidomide arm hazard ratio: 4." | 6.71 | Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. ( Anaissie, E; Barlogie, B; Eddlemon, P; Fassas, A; Fink, L; Jacobson, J; Lee, CK; Saghafifar, F; Talamo, G; Thertulien, R; Thomas, T; Tricot, G; Van Rhee, F; Zangari, M, 2004) |
| "Warfarin dosing with a target international normalized ratio (INR) range of 1." | 6.71 | Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. ( Enyart, JJ; Jones, RJ, 2005) |
| "Hypercoagulability is observed in patients with inherited thrombophilia, e." | 6.70 | The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation. ( Eberl, E; Geisen, U; Grossmann, R; Keller, F; Schambeck, CM, 2001) |
| " The study did not evaluate a dose-response for efficacy, and no differences between the three dose levels of melagatran and ximelagatran were shown." | 6.70 | A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in ( Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P, 2002) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 6.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "Fondaparinux is a synthetic polysaccharide that selectively binds to antithrombin, the primary endogenous regulator of blood coagulation." | 6.41 | Fondaparinux versus enoxaparin for the prevention of venous thromboembolism. ( Doggrell, SA, 2002) |
| "Dalteparin was not stopped in any women." | 5.91 | Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data. ( Kozak, M; Novak, A; Novak, P; Šabović, M, 2023) |
| "Oral apixaban is an effective alternative to enoxaparin as a thromboprophylactic drug for patients undergoing elective total knee replacement surgery." | 5.62 | Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study. ( Ali Hasan, M; Azeez Alsaadi, M; Tahseen Mehsen, J, 2021) |
| "Rivaroxaban treatment was associated with a lower risk of PTS when compared to enoxaparin/warfarin; RVT however, was not a mediator in the association between PTS and type of treatment." | 5.56 | Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban. ( Annichino-Bizzacchi, JM; Bittar, LF; Colella, MP; de Moraes Martinelli, B; de Oliveira, LFG; de Paula, EV; Ferreira, T; Huber, SC; Junior, AL; Mello, TT; Menezes, FH; Montalvão, S; Orsi, FA; Rielli, G; Sodre, LR; Yamaguti-Hayakawa, GG, 2020) |
| "Nitrous oxide is a commonly abused inhalant by adolescents and young adults." | 5.56 | Venous thrombosis after nitrous oxide abuse, a case report. ( Patterson, KC; Pratt, DN; Quin, K, 2020) |
| "Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA." | 5.43 | Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016) |
| "ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries." | 5.43 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016) |
| "Of 138 randomized patients, 100 patients with active malignancy presenting with acute deep venous thrombosis and still treated with chemotherapy were assigned to either oral apixaban therapy or subcutaneous low-molecular weight heparin (enoxaparin) through randomized clinical study in 1:1 ratio." | 5.41 | Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis. ( Algaby, AZ; Hassan, A; Mokadem, ME, 2021) |
| "Priapism is a rare disorder defined as a persistent penile erection that continues hours beyond, or is unrelated to, sexual stimulation." | 5.35 | Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency. ( Abu Sham'a, RA; Kufri, FH; Yassin, IH, 2008) |
| "In this international, parallel-group, randomized, double-blind, noninferiority trial, we randomly assigned adult patients undergoing lower-limb nonmajor orthopedic surgery who were considered to be at risk for venous thromboembolism on the basis of the investigator's judgment to receive either rivaroxaban or enoxaparin." | 5.34 | Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery. ( Cucherat, M; Deygas, B; Duverger, D; Fisher, W; Girard, P; Laporte, S; Llau, J; Martínez-Martín, J; Mismetti, P; Mouret, P; Presles, E; Rosencher, N; Samama, CM, 2020) |
| "Oral apixaban was noninferior to subcutaneous dalteparin for the treatment of cancer-associated venous thromboembolism without an increased risk of major bleeding." | 5.34 | Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer. ( Agnelli, G; Bauersachs, R; Becattini, C; Brenner, B; Campanini, M; Cohen, A; Connors, JM; Fontanella, A; Gussoni, G; Huisman, MV; Lambert, C; Meyer, G; Muñoz, A; Sueiro, MR; Torbicki, A; Verso, M; Vescovo, G, 2020) |
| " This study supports the safety of dosing dalteparin based on actual body weight in obese patients." | 5.33 | The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. ( Al-Yaseen, E; Anderson, J; Kovacs, MJ; Martin, J; Wells, PS, 2005) |
| "Stasis ulcers are commonly the result of chronic venous insufficiency." | 5.31 | Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report. ( Bick, RL; Scott, RG, 2001) |
| "We examined the blood conserving effect of tranexamic acid in total hip arthroplasty using the direct anterior approach with enoxaparin as deep vein thrombosis (DVT) chemoprophylaxis, and whether this translates to an effect on functional outcomes in the perioperative period." | 5.30 | OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial. ( Duggan, J; Duncan, S; Fraval, A; Murray, T; Tirosh, O; Tran, P, 2019) |
| "Upper extremity deep vein thrombosis (DVT) is now recognized as a major cause of morbidity and mortality." | 5.30 | Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. ( Cruickshank, M; Goudie, D; Kovacs, MJ; Morrow, B; Savage, KJ; Schulz, V; Wells, PS, 1999) |
| " APEX investigated the efficacy of extended-duration betrixaban versus standard-duration enoxaparin to prevent a composite of symptomatic deep-vein thrombosis (proximal or distal), nonfatal pulmonary embolism, or venous thromboembolism (VTE)-related death in acute medically ill patients (n = 7513)." | 5.24 | Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy. ( Arbetter, DF; Cohen, AT; Gibson, CM; Gold, A; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Jain, P; Michalak, N; Yee, MK, 2017) |
| "Background The aim of this study was to evaluate the effect of betrixaban on the occurrence of deep vein thrombosis (DVT) and also the extent of thrombus and to assess the association of baseline D-dimer with subsequent thrombus burden." | 5.24 | Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial. ( Al Khalfan, F; Chi, G; Cohen, AT; Gibson, CM; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Kerneis, M, 2017) |
| "The 80-mg betrixaban dose achieves higher plasma concentrations than the 40-mg dose and, in contrast to the 40-mg dose, is associated with improved efficacy across all cohorts relative to standard-dose enoxaparin without an excess risk of major bleeding in the management of medically ill subjects." | 5.24 | The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial. ( Arbetter, DF; Bandman, O; Cohen, AT; Daaboul, Y; Gibson, CM; Gold, A; Goldhaber, SZ; Halaby, R; Harrington, RA; Hernandez, AF; Hull, R; Korjian, S; Leeds, JM; Lu, SP; Yee, MK, 2017) |
| "Sixty-two PE patients with or without deep venous thrombosis (DVT) was randomized to rivaroxaban mono-therapy or standard-therapy with enoxaparin followed by vitamin K antagonist (VKA)." | 5.22 | Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism. ( Chen, R; Duan, L; Guo, Y; Hong, C; Liu, C; Su, X; Yan, H; Yang, X; Zhang, N; Zhong, N; Zhou, Y, 2016) |
| "In the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) trial, apixaban was noninferior to enoxaparin/warfarin in preventing recurrent symptomatic venous thromboembolism (VTE) or venous thromboembolism-related death, with significantly less bleeding." | 5.20 | Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. ( Cohen, AT; Johnson, M; Liu, X; Mardekian, J; Phatak, H; Thompson, J, 2015) |
| "Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding." | 5.20 | Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial. ( Bauersachs, R; Janas, MS; Jarner, MF; Kamphuisen, PW; Khorana, AA; Lee, AYY; Meyer, G, 2015) |
| "The phase III EINSTEIN DVT and EINSTEIN PE trials demonstrated the potential of oral rivaroxaban for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)." | 5.19 | Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism. ( Bamber, L; Correa de Carvalho, F; Lensing, AW; Prins, M; van Bellen, B; Wang, M, 2014) |
| "Lenalidomide plus dexamethasone is effective in the treatment of multiple myeloma (MM) but is associated with an increased risk of venous thromboembolism (VTE)." | 5.16 | Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. ( Beggiato, E; Boccadoro, M; Bringhen, S; Cafro, AM; Carella, AM; Catalano, L; Cavalli, M; Cavallo, F; Cavo, M; Corradini, P; Crippa, C; Di Raimondo, F; Di Toritto, TC; Evangelista, A; Falanga, A; Larocca, A; Nagler, A; Palumbo, A; Patriarca, F; Peccatori, J; Petrucci, MT; Pezzatti, S; Siniscalchi, A; Stanevsky, A; Yehuda, DB, 2012) |
| "Edoxaban inhibited venous thrombosis comparably to warfarin and enoxaparin, and the attendant bleeding risk of edoxaban was lower than that of warfarin and enoxaparin in rats." | 5.16 | Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats. ( Edo, N; Honda, Y; Kamisato, C; Kita, A; Morishima, Y; Shibano, T; Tsuji, N, 2012) |
| "Ambulatory treatment with enoxaparin plus warfarin seems to be effective in symptomatic healing and in clinical improvement by reducing thrombus formation and organization at all levels of lower extremity venous system with DVT, without a significant major bleeding risk." | 5.14 | Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial. ( Akcalı, Y; Filizcan, U; Hasan, E; Karabay, O; Koksoy, C; Kurtoglu, M, 2010) |
| "Rivaroxaban offers a simple, single-drug approach to the short-term and continued treatment of venous thrombosis that may improve the benefit-to-risk profile of anticoagulation." | 5.14 | Oral rivaroxaban for symptomatic venous thromboembolism. ( Agnelli, G; Bauersachs, R; Berkowitz, SD; Bounameaux, H; Brenner, B; Buller, HR; Cohen, A; Davidson, BL; Decousus, H; Gallus, AS; Lensing, AW; Misselwitz, F; Piovella, F; Prins, MH; Raskob, GE; Schellong, S; Segers, A; Verhamme, P; Wells, P, 2010) |
| "Adults with newly diagnosed malignant glioma were randomized to receive dalteparin 5000 anti-Xa units or placebo, both subcutaneously once daily for 6 months starting within 4 weeks of surgery." | 5.14 | PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. ( Agnelli, G; Baker, R; Falanga, A; Finch, T; Geerts, W; Julian, JA; Laperriere, NJ; Levine, MN; Malkin, MG; Parpia, S; Perry, JR; Rogers, LR; Sawaya, R, 2010) |
| "We investigated the efficacy of rivaroxaban, an orally active direct factor Xa inhibitor, in preventing venous thrombosis after total knee arthroplasty." | 5.13 | Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. ( Ageno, W; Bandel, TJ; Borris, LC; Lassen, MR; Lieberman, JR; Misselwitz, F; Rosencher, N; Turpie, AG, 2008) |
| "We evaluated the effect of long-term anticoagulant treatment (enoxaparin vs coumarin) in patients with deep venous thrombosis (DVT) as to incidence of post-thrombotic syndrome (PTS) and recurrent venous thromboembolism." | 5.13 | Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin. ( Castrodeza, J; González-Fajardo, JA; Martin-Pedrosa, M; Tamames, S; Vaquero-Puerta, C, 2008) |
| " To challenge this premise, we evaluated if deep vein thrombosis (DVT) prophylaxis with dalteparin sodium confers an excessive anticoagulant effect in critically ill patients with severe renal insufficiency." | 5.13 | Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study. ( Albert, M; Anderson, D; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Geerts, W; Granton, J; Guyatt, G; Hébert, P; Heels-Ansdell, D; Marshall, J; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "In the THRIVE Treatment study, no patient suffered from a recurrent VTE, but 1 patient randomised to enoxaparin/warfarin experienced major bleeding." | 5.12 | Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran. ( Harenberg, J; Jörg, I; Weiss, C, 2006) |
| "Deep vein thrombosis prevention efficacy using a new, miniature, mobile, battery-operated pneumatic system (continuous enhanced circulation therapy [CECT] system) combined with low-dose aspirin was compared to enoxaparin." | 5.12 | Deep vein thrombosis prevention in joint arthroplasties: continuous enhanced circulation therapy vs low molecular weight heparin. ( Gelfer, Y; Halperin, N; Oron, A; Peer, A; Robinson, D; Tavor, H, 2006) |
| "This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism." | 5.12 | Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism. ( Castro, DJ; Díaz, G; Escobar, C; García-Rull, S; Martí, D; Ortega, J; Picher, J; Sueiro, A, 2007) |
| "The current recommended doses of fondaparinux and heparins for the treatment of venous thromboembolism appear to provide similar protection against recurrence and major bleeding to one another and to obese and non-obese patients." | 5.12 | Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; Segers, AE, 2007) |
| "Oral dabigatran etexilate was as effective as enoxaparin in reducing the risk of venous thromboembolism after total hip replacement surgery, with a similar safety profile." | 5.12 | Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. ( Büller, HR; Dahl, OE; Eriksson, BI; Frostick, SP; Hantel, S; Hettiarachchi, R; Kurth, AA; Prins, MH; Rosencher, N; Schnee, J; van Dijk, CN, 2007) |
| "The aim of this prospective cohort study was to determine the incidence of dalteparin bioaccumulation (measured using anti-Xa levels), and bleeding during thromboprophylaxis in elderly patients with renal failure who were admitted to hospital with an acute medical illness." | 5.12 | Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. ( Bondi, M; Casolari, B; Cenci, AM; Crowther, MA; Mannucci, C; Prisco, D; Tincani, E; Turrini, F, 2006) |
| " The objective of this study was to evaluate the efficacy of dalteparin during lower-limb immobilization after surgical treatment of Achilles tendon rupture." | 5.12 | Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study. ( de Bri, E; Elvin, A; Lapidus, LJ; Lärfars, G; Levander, C; Ponzer, S; Rosfors, S, 2007) |
| "Once-daily subcutaneous fondaparinux was at least as effective (not inferior) and safe as twice-daily, body weight-adjusted enoxaparin in the initial treatment of patients with symptomatic deep venous thrombosis." | 5.11 | Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. ( Büller, HR; Cariou, R; Davidson, BL; Decousus, H; Gallus, A; Gent, M; Leeuwenkamp, O; Lensing, AW; Piovella, F; Prins, MH; Raskob, G; Segers, AE, 2004) |
| "Dalteparin 5000 IU once daily halved the rate of venous thromboembolism with a low risk of bleeding." | 5.11 | Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. ( Cohen, AT; Goldhaber, SZ; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2004) |
| "The purpose of this study was to determine whether standard therapeutic doses of dalteparin maintain peak therapeutic levels of anticoagulation during pregnancy." | 5.11 | A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. ( Barbour, LA; Oja, JL; Schultz, LK, 2004) |
| "Tinzaparin at two dosages, 175 anti-Xa U/kg subcutaneously administered for 7 days, followed by warfarin, and 175 anti-Xa U/kg subcutaneously given for 90 days was compared with continuous intravenous unfractionated heparin (UFH) for 5 days, followed by warfarin for 3 months, were tested in the treatment of patients with proximal deep vein thrombosis." | 5.11 | Laboratory analysis of blood samples from patients treated with tinzaparin. ( Fareed, J; Hoppensteadt, DA; Leitz, H; Nicolaides, A; Willows, L, 2004) |
| "Evaluation of the effectiveness and safety of the low molecular weight heparin (LMWH) tinzaparin versus unfractionated heparin (UFH) followed by acenocoumarol in proximal deep venous thrombosis (DVT)." | 5.11 | Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial. ( Daskalopoulos, ME; Daskalopoulou, SS; Dimitroulis, D; Kakissis, I; Liapis, CD; Nikolaou, A; Sfiridis, P; Tzortzis, E, 2005) |
| "Similar compliance, health status, deep venous thrombosis, and bleeding rates were found between dalteparin and enoxaparin." | 5.10 | Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury. ( Chan, KT; Chiou-Tan, FY; Donovan, WH; Garza, H; Graves, DE; Holmes, SA; Parsons, KC; Rintala, DH; Robertson, CS, 2003) |
| "In patients with cancer and acute venous thromboembolism, dalteparin was more effective than an oral anticoagulant in reducing the risk of recurrent thromboembolism without increasing the risk of bleeding." | 5.10 | Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. ( Baker, RI; Bowden, C; Gent, M; Haley, S; Julian, JA; Kakkar, AK; Kovacs, MJ; Lee, AY; Levine, MN; Prins, M; Rickles, FR, 2003) |
| "This randomized, controlled, multicentre study evaluated the efficacy and tolerability of the oral direct thrombin inhibitor ximelagatran, compared with a low-molecular-weight heparin (dalteparin) followed by warfarin, in the treatment of deep vein thrombosis (DVT) of the lower extremity." | 5.10 | A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. ( Eriksson, H; Frison, L; Gustafsson, D; Schulman, S; Wåhlander, K; Welin, LT, 2003) |
| " The aim of this study was to evaluate the correlation between pre-operative plasma levels of soluble fibrin polymers (SFP), as determined by a recently developed enzyme-linked immunosorbent assay (ELISA) assay (TpP), and the incidence of deep vein thrombosis (DVT) after elective neurosurgery." | 5.09 | Pre-operative plasma levels of soluble fibrin polymers correlate with the development of deep vein thrombosis after elective neurosurgery. ( Agnelli, G; Baroni, M; D'Angelo, SV; Quintavalla, R; Severi, P; Sonaglia, F, 1999) |
| " Rates of overall venous thromboembolism (and proximal deep vein thrombosis or pulmonary embolism) for the 8-, 12-, 18-, and 24-mg doses of ximelagatran were 27% (6." | 5.09 | Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. ( Berkowitz, SD; Colwell, CW; Francis, CW; Ginsberg, JS; Heit, JA; Peters, G; Whipple, J, 2001) |
| "In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe." | 5.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| " The fondaparinux group had a significantly lower incidence of venous thromboembolism by day 11 (12." | 5.09 | Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2001) |
| "This was a prospective cohort study of eligible patients with pulmonary embolism managed as outpatients using dalteparin (200 U/kg s/c daily) for a minimum of five days and warfarin for 3 months." | 5.09 | Outpatient treatment of pulmonary embolism with dalteparin. ( Anderson, D; Gray, L; Kovacs, MJ; Morrow, B; Touchie, D; Wells, PS, 2000) |
| "The frequencies of deep vein thrombosis for patients with interpretable venograms receiving preoperative and postoperative dalteparin for all deep vein thrombosis were 36 (10." | 5.09 | Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators. ( Baylis, B; Bergqvist, D; Brant, R; Dear, R; Fellenius, C; Francis, C; Holmqvist, A; Hull, RD; Mah, A; Mant, M; Pineo, GF; Soderberg, K, 2000) |
| "Extended dalteparin prophylaxis resulted in significantly lower frequencies of deep vein thrombosis compared with in-hospital warfarin therapy." | 5.09 | Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators. ( Baylis, B; Bergqvist, D; Brant, R; Dear, R; Fellenius, C; Francis, C; Holmqvist, A; Hull, RD; Mah, A; Mant, M; Pineo, GF; Soderberg, K, 2000) |
| "5, or 10 mg once daily) relative to low-molecular-weight heparin (dalteparin, 100 IU/kg twice daily) in symptomatic proximal deep vein thrombosis." | 5.09 | Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators. ( , 2000) |
| "This randomised, double-blind, aspirin-controlled trial tested the safety and efficacy of treatment with high-dose tinzaparin (175 anti-Xa IU/kg daily; 487 patients), medium-dose tinzaparin (100 anti-Xa IU/kg daily; 508 patients), or aspirin (300 mg daily; 491 patients) started within 48 h of acute ischaemic stroke and given for up to 10 days." | 5.09 | Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial. ( Bath, PM; Boysen, G; De Deyn, P; Friis, P; Leys, D; Lindenstrom, E; Marttila, R; O'Neill, D; Olsson, J; Orgogozo, J; Ringelstein, B; Turpie, AG; van der Sande, J, 2001) |
| "In conclusion, our results confirmed that direct Xa inhibitors (rivaroxaban and apixaban) were more effective for prevention of VTE after total knee replacement as compared with enoxaparin, without increasing major bleeding risk." | 4.91 | Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials. ( Ma, G; Wang, D; Wu, X; Ying, K; Zhang, R, 2015) |
| "Studies reporting vein re-opening, inflammation expressed as Gadolinium enhancement and coagulation parameters were searched in the literature and pooled into a meta-analysis using an inverse variance with random effects." | 4.86 | P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis. ( Deatrick, KB; Henke, PK; Londy, FJ; Myers, DD; Ramacciotti, E; Rectenwald, JE; Schaub, RG; Wakefield, TW; Wrobleski, SK, 2010) |
| " A case report is detailed of a 28-year-old woman with antiphospholipid syndrome on warfarin for high risk of venous thrombosis who underwent tonsillectomy." | 4.84 | Tonsillectomy in the anticoagulated patient. ( Cole, SM; Cupp, CL; Patterson, MB, 2007) |
| " In a dose-ranging European study, preoperatively initiated subcutaneous melagatran 3 mg twice daily followed by oral ximelagatran 24 mg twice daily was significantly more effective than subcutaneous dalteparin sodium 5000IU once daily in preventing the occurrence of VTE, including deep vein thrombosis (DVT) and pulmonary embolism (PE), in patients undergoing hip or knee replacement." | 4.82 | Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery. ( Evans, HC; Faulds, D; Perry, CM, 2004) |
| "The fondaparinux trials in venous thromboembolism (VTE) prevention after orthopaedic surgery have been subject to methodological criticisms recently summarised in this journal." | 4.82 | The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery. ( Turpie, AG, 2004) |
| " The incidence of VTE and hematoma formation was evaluated and compared between patients who received aspirin versus enoxaparin or heparin." | 4.12 | Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures? ( Du, JY; Metcalf, KB; Ochenjele, G, 2022) |
| "Apixaban has a higher rate of major bleeding in patients with luminal GI cancer compared with patients with non-GI cancer and compared with enoxaparin in patients with luminal GI cancer." | 4.02 | Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism. ( Brunton, N; Casanegra, AI; Froehling, DA; Hodge, DO; Houghton, DE; McBane, RD; Meverden, RA; Peterson, LG; Vlazny, DT; Wysokinski, WE, 2021) |
| "We report a case of ophthalmic artery occlusion (OAO) in a young patient with COVID-19 infection that was on therapeutic anticoagulation with apixaban for deep venous thrombosis (DVT)." | 3.96 | Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban. ( Biousse, V; Bose, S; Dumitrascu, OM; Lyden, PD; Volod, O; Wang, Y, 2020) |
| " The objective of this analysis was to evaluate the cost-effectiveness of rivaroxaban compared with current SoC (enoxaparin overlapped with warfarin) for the treatment of acute deep vein thrombosis (DVT) in China." | 3.96 | Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China. ( Wu, J; Yang, L, 2020) |
| " The aim of our study was to evaluate the clinical impact of venous thromboembolism prophylaxis with fondaparinux versus enoxaparin among 100 hospitalized COVID-19 patients." | 3.96 | Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience. ( Agrusta, F; Amitrano, M; Bellizzi, A; Cardillo, G; Cavalli, A; Di Micco, P; Fontanella, A; Iannuzzo, M; Lodigiani, C; Mangiacapra, S; Russo, V; Sacco, C; Viggiano, GV, 2020) |
| "This study aims to validate the application of a multicriteria decision analysis in a real-world problem, the use of rivaroxaban and enoxaparin to prevent deep venous thrombosis." | 3.96 | Multi-Criteria Model for Evaluating Drugs to Prevent Deep Venous Thrombosis Associated With Orthopedic Surgery: A Hospital-Based Case Study. ( Morais, QCD; Santos, MS, 2020) |
| "to compare two anticoagulant therapy (ACT) regimens in the treatment of venous thrombosis (VT) in patients after catheter interventions - electrophysiological studies (EFIs) and ablations: enoxaparin followed by warfarin, and rivaroxaban monotherapy." | 3.91 | [Comparative efficacy and safety of enoxaparin followed by warfarin and rivaroxaban monotherapy in the treatment of venous thrombosis in patients after intracardiac catheter interventions]. ( Balakhonova, TV; Golitsyn, SP; Kropacheva, ES; Loginova, AI; Maykov, EB, 2019) |
| "Objective This study was performed to evaluate the efficacy of rivaroxaban versus nadroparin for preventing deep venous thrombosis (DVT) in elderly patients with osteoporosis undergoing initial total hip arthroplasty (THA) for femoral neck fractures." | 3.88 | Rivaroxaban versus nadroparin for preventing deep venous thrombosis after total hip arthroplasty following femoral neck fractures: A retrospective comparative study. ( Chen, D; Ge, Z; Liang, G; Wan, Z; Xu, B; Yang, C; Yu, W; Zeng, X; Zhang, C; Zhang, F; Zhang, X, 2018) |
| " She also developed right proximal femoral deep vein thrombosis, and was commenced on subcutaneous enoxaparin and warfarin." | 3.88 | Dengue shock syndrome complicated with acute liver failure and kidney injury, infective endocarditis, and deep vein thrombosis: a case report. ( Munasinghe, J; Samarasekara, K, 2018) |
| "5mg/kg subcutaneously daily for recent pulmonary embolism and deep vein thrombosis that developed while on warfarin therapy previously." | 3.85 | Pharmacological management of cerebral venous sinus thrombosis with full-dose IV heparin infusion and its clinical outcomes. ( Fernandez, A; Ho, J; Mckeone, A; Nair, V, 2017) |
| "There was no evidence that fondaparinux, enoxaparin, or warfarin were superior to aspirin in the prevention of pulmonary embolism, deep vein thrombosis, or venous thromboembolism or that aspirin was safer than these alternatives." | 3.85 | Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty. ( Bini, SA; Cafri, G; Cheetham, CT; Chen, Y; Gould, MK; Khatod, M; Paxton, EW; Sluggett, J, 2017) |
| "The Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism (RECORD) 1 to 4 trials compared rivaroxaban 10 mg daily with commonly used doses of enoxaparin and demonstrated similar rates of VTE and bleeding." | 3.83 | Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin. ( Cluck, D; Cornett, L; El-Bazouni, H; Freshour, J; Odle, B; Ricket, AL; Stewart, DW; Wood, RC, 2016) |
| "Treatment with rivaroxaban was preferable over standard ACT with enoxaparin/warfarin with regards to the lysis of thrombus when duration of thrombosis did not exceed 10 days." | 3.83 | [Ultrasound dynamics lysis apex thrombus as an objective criterion of effectiveness of anticoagulation therapy in venous thrombosis]. ( Agapov, AB; Kalinin, RE; Pshennikov, AS; Suchkov, IA, 2016) |
| "01) the rate of transfusion, units of packed red blood cells, hemoglobin drop, and hematocrit drop compared to aspirin in both unilateral and bilateral TKA patients, without significantly decreasing venous thromboembolism events (aspirin: 3 pulmonary embolisms and 4 deep venous thrombosis; Lovenox: 3 pulmonary embolisms and 2 deep venous thrombosis)." | 3.83 | Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin. ( Hall, KE; Nakasone, CK; Radzak, KN; Wages, JJ, 2016) |
| "A 90-year-old man with bladder cancer refractory to bacillius Calmette-Guérin was diagnosed with deep vein thrombosis (DVT) and started on warfarin one month before starting treatment with intravesical gemcitabine 2 g (one dose per week for six weeks)." | 3.83 | Evidence of a clinically significant interaction between warfarin and intravesical gemcitabine. ( Feuz, L; Gee, ME; Krajewski, KC; Kurtzhalts, K, 2016) |
| " In this study, the acute treatment effect of edoxaban on venous thrombosis is investigated in rats by single and multiple administrations, and compared to the conventional parenteral anticoagulants, enoxaparin and fondaparinux." | 3.80 | Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats. ( Honda, Y; Kamisato, C; Morishima, Y, 2014) |
| "Deep vein thrombosis was induced by exposure to ferric chloride or ligation of the infrarenal vena cava of C57BL/6 mice after pretreatment with enoxaparin, ticagrelor or vehicle and in P2Y(12-/-) mice." | 3.79 | Contrast ultrasound for the quantification of deep vein thrombosis in living mice: effects of enoxaparin and P2Y12 receptor inhibition. ( Bode, C; Boeynaems, JM; Duerschmied, D; Guenther, F; Hein, L; Herr, N; Idzko, M; Mauler, M; Robaye, B; Roming, F; Von Zur Muhlen, C; Witsch, T, 2013) |
| "Our institution has used a thromboprophylaxis regimen consisting of inpatient enoxaparin and outpatient aspirin for patients at standard risk for venous thrombosis after hip and knee arthroplasty." | 3.78 | Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study. ( Anderson, BJ; Bradbury, TL; Erens, GA; Hamilton, SC; Roberson, JR; Whang, WW, 2012) |
| "It is safe to continue low-dose (100 mg/day) aspirin in the perioperative period as a part of multimodal prophylaxis against deep vein thrombosis." | 3.78 | Safety of peri-operative low-dose aspirin as a part of multimodal venous thromboembolic prophylaxis for total knee and hip arthroplasty. ( Cossetto, DJ; Goudar, A; Parkinson, K, 2012) |
| "The in-hospital incidence of pulmonary embolism (PE) in patients undergoing elective joint arthroplasty who receive a minimum of 10 days of dalteparin prophylaxis is reported to be less than 1%." | 3.76 | High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis. ( Kerr, J; Linkins, LA, 2010) |
| "In the initial treatment of venous thromboembolism (VTE) fondaparinux, a pentasaccharide, is a good alternative to heparin." | 3.75 | Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. ( Büller, HR; Davidson, BL; Decousus, H; Gallus, A; Lensing, AW; Piovella, F; Prins, MH; Raskob, GE; van Doormaal, FF, 2009) |
| "To compare efficacy and safety of warfarin and enoxaparin used in the first month of treatment of patients with an episode of deep vein thrombosis (DVT) and/or pulmonary artery thromboembolism (PATE)." | 3.75 | [Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment]. ( Andriiashkin, VV; Balakhonova, TV; Dobrovol'skiĭ, AB; Ermolina, OV; Kirienko, AI; Leont'ev, SG; Panchenko, EP; Titaeva, EV; Vorob'eva, NM, 2009) |
| " These symptoms were first attributed to muscle pain and exertion but further examination revealed deep venous thrombosis (DVT) of the stump and a pulmonary embolism for which he was treated with nadroparine and acenocoumarol." | 3.74 | [Deep venous thrombosis in an amputation stump]. ( Baars, EC; Ettema, HB; Fritschy, WM, 2007) |
| "Deep vein thrombosis (DVT) remains a major burden and fondaparinux represents a new option for DVT therapy." | 3.74 | Minimizing costs for treating deep vein thrombosis: the role for fondaparinux. ( Jackson, WL; Moores, LK; Shorr, AF; Warkentin, TE, 2007) |
| "In ICU patients with renal insufficiency, the incidence of DVT and major bleeding are considerable but appear related to patient comorbidities rather than to an inadequate or excessive anticoagulant from thromboprophylaxis with dalteparin." | 3.74 | Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors. ( Albert, M; Cook, D; Crowther, M; Douketis, J; Fowler, R; Freitag, A; Friedrich, J; Geerts, W; Granton, J; Guyatt, G; Hebert, P; Heels-Ansdell, D; Karachi, T; Meade, M; Pagliarello, G; Rabbat, C; Skrobik, Y; Zytaruk, N, 2008) |
| "This multicenter, prospective, open label, observational study evaluated practice patterns of physicians using tinzaparin, a low-molecular-weight heparin (LMWH), and warfarin for the treatment of deep venous thrombosis (DVT) with or without pulmonary embolism (PE)." | 3.74 | Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. ( Hyers, TM; Spyropoulos, AC, 2007) |
| "The antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold (LK-732, LK-639 and LK-731) and their amidoxime prodrugs (LK-658, LK-633 and LK-730) was studied in comparison to argatroban and nadroparin in two rat models of venous thrombosis, induced either by complete stasis combined with hypercoagulability (model 1) or by partial stasis combined with vessel injury (model 2)." | 3.73 | Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models. ( Bozic, M; Budihna, MV; Cerne, M; Drevensek, G; Peternel, L; Stalc, A; Stegnar, M; Urleb, U; Zega, A, 2005) |
| " In a similar patient population, the Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) trial evaluated the use of long-term dalteparin for the prevention of recurrent venous thromboembolism (VTE) in patients with cancer." | 3.73 | Selecting an anticoagulant for recurrent venous thromboembolism in cancer. ( Goodin, S, 2005) |
| "We were concerned that a fixed rather than a weight-based dosing regimen of dalteparin sodium to prevent venous thromboembolism (VTE) might result in decreased efficacy in obese patients and decreased safety in elderly patients." | 3.73 | Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial. ( Cohen, AT; Goldhaber, SZ; Kucher, N; Leizorovicz, A; Olsson, CG; Turpie, AG; Vaitkus, PT, 2005) |
| "To compare the efficacy of dalteparin, a low-molecular-weight heparin, to unfractionated heparin (UFH) in the prevention of deep venous thrombosis (DVT) and pulmonary embolism in patients after surgery for gynecologic malignancy." | 3.73 | Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy. ( DeBernardo, RL; Duska, LR; Krasner, CN; Littell, RD; Perkins, RB, 2005) |
| "Dalteparin and other low-molecular-weight heparins are frequently used for the treatment of deep vein thrombosis and for other indications." | 3.73 | Life-threatening hemorrhage after dalteparin therapy in a patient with impaired renal function. ( Drewe, J; Egger, SS; Krähenbühl, S; Sawatzki, MG, 2005) |
| " The low-molecular-weight heparin dalteparin sodium is clinically effective in reducing the incidence of venous thromboembolism (VTE) in these patients." | 3.73 | Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery. ( Heerey, A; Suri, S, 2005) |
| "To evaluate and compare the efficacy and safety of low molecular weight heparin (LMWH) (nadroparine) and acenocoumarol in the treatment of deep venous thrombosis (DVT)." | 3.72 | Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients. ( Ganotakis, ES; Mazokopakis, EE; Vrentzos, GE, 2003) |
| "The selective antithrombotic fondaparinux is more effective than the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism (deep-vein thrombosis [DVT] or pulmonary embolism) in patients undergoing major orthopedic surgery, but its cost-effectiveness is undetermined." | 3.72 | The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery. ( Borris, L; Bossuyt, P; de Pouvourville, G; Gordois, A; Jönsson, B; Levy, E; Posnett, J, 2003) |
| "Warfarin-induced skin necrosis is a rare complication associated with the use of oral anticoagulants." | 3.72 | A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency. ( Alexander, JB; Ierardi, R; Tai, CY, 2004) |
| "Homocysteine has been recognized as a risk factor for atherosclerosis and arterial and venous thrombosis." | 3.72 | Hyperhomocysteinemia and deep vein thrombosis in orthotopic heart transplantation: a case report. ( Bhat, G; Costea, A, 2004) |
| "Many orthopaedic surgeons use warfarin to prevent venous thromboembolism (VTE) following hip or knee arthroplasty." | 3.72 | Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty. ( Brotman, DJ; Hurbanek, JG; Jaffer, AK; Morra, N, 2004) |
| "Fondaparinux and enoxaparin are both effective and safe in preventing post-operative venous thromboembolism." | 3.72 | In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. ( Chakroun, T; Elalamy, I; Gerotziafas, GT; Samama, MM, 2004) |
| " The initial treatment consisted of a 7-day course of subcutaneous dalteparin according to body weight." | 3.72 | Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study. ( Jiménez, JA; Monreal, M; Roncales, J; Vilaseca, B; Zacharski, L, 2004) |
| "Suspecting typhoid fever with ciprofloxacin was started." | 3.71 | [Fever and calf tenderness after travel in Thailand: murine typhus and deep vein thrombosis]. ( Döller, PC; Slesak, G, 2001) |
| "Of 263 patients who underwent total knee arthroplasty, 122 received adjusted low-dose warfarin and 141 received enoxaparin as deep vein thrombosis (DVT) prophylaxis." | 3.70 | Evaluation of the safety and efficacy of enoxaparin and warfarin for prevention of deep vein thrombosis after total knee arthroplasty. ( O'Connor, D; Stern, SH; Wixson, RL, 2000) |
| " Aspirin, 75 mg daily was given in addition to enoxaparin to women with antiphospholipid syndrome." | 3.70 | Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin. ( Blumenfeld, Z; Brenner, B; Hoffman, R; Weiner, Z; Younis, JS, 2000) |
| "(1) In the prevention of deep venous thrombosis after hip surgery, the recommended treatment period with dalteparin has been extended from seven days to 35 days." | 3.70 | Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed? ( , 2000) |
| "Nattokinase (NK) is a serine protease enzyme with fibrinolytic activity." | 3.01 | Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases. ( Cione, E; De Sarro, G; Di Mizio, G; Gallelli, G; Gallelli, L; Muraca, L; Palleria, C; Rubino, P; Salerno, M; Siniscalchi, A, 2021) |
| "NWS anticoagulation therapy was effective and safe in PVT patients with cirrhosis and could increase the level of albumin." | 2.94 | Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients: A Randomized Controlled Trial. ( Chen, X; Cheng, B; Gao, Y; Li, Y; Sun, X; Zhou, T, 2020) |
| "Pain was assessed using visual analogue scale at inclusion, one and six weeks." | 2.90 | Effect of anticoagulant treatment on pain in distal deep vein thrombosis: an ancillary analysis from the cactus trial. ( Blondon, M; Diamand, JM; Frappe, P; Galanaud, JP; Glauser, F; Kahn, SR; Le Gal, G; Ouvry, P; Quere, I; Righini, M; Robert-Ebadi, H; Tissot, A, 2019) |
| "This study aimed to assess whether low-molecular-weight heparin (LMWH) is effective and safe in preventing postoperative venous thromboembolism (VTE) in patients undergoing esophageal cancer surgery." | 2.90 | Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study. ( Hirata, S; Matsuhashi, N; Sakuratani, T; Shimokawa, T; Tanaka, H; Tanaka, Y; Yamada, A; Yamaguchi, K; Yoshida, K, 2019) |
| "Recommended treatment for cancer-associated thrombosis is 3-6 months of low-molecular-weight heparin." | 2.90 | Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial. ( Date, K; Hutchinson, A; Johnson, MJ; Maraveyas, A; Rees, S; Young, A, 2019) |
| "Patients with active cancer and venous thromboembolism (VTE) are at high risk of recurrence." | 2.90 | Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study. ( Buller, H; Carrier, M; Di Nisio, M; Garcia, D; Raskob, G; Segers, A; van Es, N; Wang, TF; Weitz, J, 2019) |
| "Individuals with deep vein thrombosis (DVT) have an increased risk of pulmonary embolism (PE), death, and long-term thrombotic complications." | 2.87 | Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial. ( Falciani, M; Garbade, T; Martinez-Gonzalez, J; Schellong, SM; Suchkov, IA, 2018) |
| " Asymptomatic deep vein thrombosis (DVT) diagnosed with compression ultrasound (CUS) is a common endpoint in trials assessing the efficacy of anticoagulants to prevent venous thromboembolism (VTE), but the relationship of asymptomatic thrombus to mortality remains uncertain." | 2.87 | Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial. ( Chi, G; Cohen, AT; Datta, S; Gibson, CM; Goldhaber, SZ; Gurin, M; Haroian, N; Harrington, RA; Hernandez, AF; Hull, RD; Kalayci, A; Korjian, S; Nafee, T; Qamar, I; Yee, MK, 2018) |
| "The primary outcome was deep vein thrombosis (DVT) identified by color Doppler ultrasonography and/or pulmonary embolism (PE)." | 2.84 | Enoxaparin versus No Anticoagulation Prophylaxis after Total Knee Arthroplasty in Thai Patients: A Randomized Controlled Trial. ( Intiyanaravut, T; Kunopart, M; Sinthuvanich, N; Teavirat, S; Thongpulsawasdi, N, 2017) |
| "Although venous thromboembolism is one of the leading causes of morbidity after knee arthroplasty, little data exist on the risk of deep venous thrombosis (DVT) after unicompartmental knee arthroplasty (UKA)." | 2.84 | Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin. ( Boettner, F; Mayman, DJ; Pearle, AD; Schmidt-Braekling, T; Waldstein, W; Westrich, GH, 2017) |
| "However, upper limb deep vein thrombosis is poorly studied with scant data on the use of direct oral anticoagulants in noncatheter-related deep vein thrombosis." | 2.82 | Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review. ( Fioretti, AM; Giotta, F; Leopizzi, T; Lorusso, V; Luzzi, G; Oliva, S; Puzzovivo, A, 2022) |
| "The incidence of symptomatic VTE (deep vein thrombosis and pulmonary embolism) events was lower (0/377) in participants who received bemiparin than in those who received no pharmacologic intervention (12/380, 3." | 2.80 | Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial. ( Al Tawil, NG; Alalaf, SK; Ali, MS; Jawad, AK; Jawad, RK, 2015) |
| "Prevention of deep venous thrombosis (DVT) and associated pulmonary embolism following major orthopedic surgeries is challenging, and there is an increased interest in developing new treatment strategies." | 2.80 | Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement. ( Altıntaş, F; Önal, A; Özler, T; Uluçay, Ç, 2015) |
| " It seems that the dosage of anticoagulant drug does not have a significant impact on thrombus resolution." | 2.80 | Time course and the recanalization rate of superficial vein thrombosis treated with low-molecular-weight heparin. ( Jezovnik, MK; Poredos, P; Spirkoska, A, 2015) |
| "The Hokusai VTE-cancer study is a randomised, open-label, clinical trial to evaluate whether edoxaban, an oral factor Xa inhibitor, is non-inferior to LMWH for treatment of VTE in patients with cancer." | 2.80 | Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study. ( Beyer-Westendorf, J; Bleker, SM; Boda, Z; Büller, HR; Carrier, M; Chlumsky, J; Décousus, H; Di Nisio, M; Garcia, D; Gibbs, H; Grosso, MA; Kakkar, A; Kamphuisen, PW; Mercuri, MF; Monreal, M; Ockelford, P; Pabinger, I; Raskob, GE; Schwocho, L; Segers, A; van Es, N; Verhamme, P; Weitz, JI, 2015) |
| " We hypothesized that using ΔR-guided dosing would result in decreased DVT rates." | 2.79 | Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial. ( Barton, JS; Differding, JA; Ginzburg, E; Kunio, NR; Louis, SG; Rick, E; Riha, GM; Schreiber, MA; Underwood, SJ; Van, PY, 2014) |
| "In the group of patients without pulmonary embolism at baseline, 2." | 2.79 | Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin. ( Becker, LK; Harenberg, J; Melzer, N; Riess, H, 2014) |
| " The authors hypothesize that early chemoprophylaxis in patients with TBI is safe and efficacious." | 2.78 | Safety and efficacy of early thromboembolism chemoprophylaxis after intracranial hemorrhage from traumatic brain injury. ( Barnes, SL; Farooqui, A; Hiser, B; Litofsky, NS, 2013) |
| "Patients with iliac deep vein thrombosis (DVT) have a poor prognosis and high incidence of postthrombotic syndrome (PTS)." | 2.78 | Effect of long-term LMWH on post-thrombotic syndrome in patients with iliac/noniliac venous thrombosis: a subanalysis from the home-LITE study. ( Hull, RD; Liang, J; Merali, T, 2013) |
| "Venous thrombosis was identified in 149 children with 21% (31/149) developing a rVTE." | 2.77 | The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children. ( Estepp, JH; Reiss, UM; Smeltzer, M, 2012) |
| "Traditionally, patients with pulmonary embolism (PE) are initially treated in the hospital with low molecular weight heparin (LMWH)." | 2.76 | Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. ( Creemers-Schild, D; de Vreede, MJ; Dekkers, OM; Dolsma, J; Eijsvogel, M; Faber, LM; Hofstee, HM; Hoogerbrugge, AD; Hovens, MM; Huisman, MV; Jonkers, GJ; Kruip, MJ; Mos, IC; van Kralingen, KW; Vlasveld, T; Zondag, W, 2011) |
| "Major bleeding was comparable and minor bleedings (0." | 2.76 | Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY. ( Abletshauser, C; Bauersachs, R; Bramlage, P; Gerlach, HE; Haas, S; Melzer, N; Riess, H; Schellong, SM; Sieder, C; Tebbe, U, 2011) |
| " IRIS aimed to assess whether LMWH is at least as safe as UFH in this population." | 2.76 | Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS). ( Clonier, F; Janas, M; Leizorovicz, A; Maddalena, M; Mottier, D; Siguret, V; Stinson, J; Townshend, G, 2011) |
| " The first received low-molecular-weight heparin for 10 days at therapeutic dosage (nadroparin 180 anti-activated factor X units once daily) and compression therapy for three months, and the second received compression therapy alone." | 2.75 | Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study. ( Beyer, J; Buschmann, L; Halbritter, K; Rastan, A; Schellong, S; Schwarz, T, 2010) |
| "In acutely ill medical patients of at least 40 years of age, thromboprophylaxis with certoparin 3000 IU daily is effective and safe in comparison with 7500 IU twice daily UFH." | 2.75 | An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN. ( Abletshauser, C; Bramlage, P; Greinacher, A; Haas, S; Riess, H; Schellong, SM; Schwanebeck, U; Sieder, C, 2010) |
| "Edoxaban is a new oral direct factor Xa inhibitor." | 2.75 | Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study. ( Bocanegra, T; Cohen, AT; Eriksson, BI; Puskas, D; Raskob, G; Shi, M; Weitz, JI, 2010) |
| " The betrixaban dosage was blinded, but enoxaparin was not." | 2.74 | A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). ( Bauer, KA; Davidson, BL; Fisher, WD; Gent, M; Gretler, DD; Huo, MH; Sinha, U; Turpie, AG, 2009) |
| " After initial LMWH, patients received 6 months of treatment with full therapeutic dosage of tinzaparin or acenocoumarol." | 2.74 | A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis. ( Bonell, A; Cairols, MA; Colomé, E; Lapiedra, O; Martí, X; Romera, A; Vila-Coll, R, 2009) |
| "The risk of venous thromboembolism is equally high in medical patients admitted to the hospital and those treated in the surgery wards." | 2.73 | [Two models of thromboprophylaxis in acutely ill medical inpatients]. ( Firek, A; Kochanowski, Z; Luba, M, 2007) |
| "Consecutive patients with hematologic malignancies requiring intensive chemotherapy including autologous stem cell transplantation were eligible." | 2.73 | Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. ( Baarslag, HJ; Biemond, BJ; Büller, HR; Di Nisio, M; Klerk, CP; Niers, TM, 2007) |
| "Major bleeding was observed in nine of 260 patients (3." | 2.73 | Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT). ( Dunn, AS; Spyropoulos, AC; Turpie, AG, 2007) |
| "A significant dose-response effect for VTE was observed for SR123781A (p < 0." | 2.73 | SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study. ( Dahl, O; Lassen, MR; Mismetti, P; Turpie, AG; Zielske, D, 2008) |
| " Using enoxaparin pharmacokinetic parameters to simulate anti-Xa time profiles, we observed that the maintenance of the same doses throughout pregnancy resulted in a progressive reduction in mean and peak anti-Xa activities." | 2.73 | Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. ( Amoura, Z; Ankri, A; Conard, J; Cornet, A; Costedoat-Chalumeau, N; Dommergues, M; Hulot, JS; Lebaudy, C; Lechat, P; Piette, JC; Serreau, R, 2008) |
| "Eight (1." | 2.73 | Safety of deep venous thrombosis prophylaxis with low-molecular-weight heparin in brain surgery. Prospective study on 746 patients. ( Chibbaro, S; Tacconi, L, 2008) |
| "The optimal thromboprophylactic dosage regimen of low-molecular-weight heparins in high-risk general surgery remains debatable." | 2.72 | A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer. ( Bergman, JF; Derlon, A; Laporte, S; Mismetti, P; Samama, CM; Samii, K; Simonneau, G, 2006) |
| " The primary efficacy analysis did not demonstrate any significant trend in dose-response relationship for BAY 59-7939." | 2.72 | Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. ( Borris, L; Dahl, OE; Eriksson, BI; Haas, S; Huisman, MV; Kakkar, AK; Kälebo, P; Misselwitz, F, 2006) |
| "Aspirin was started on the day of surgery, whereas enoxaparin was started 48 hours after surgery." | 2.72 | VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty. ( Bottner, F; Haas, SB; Laskin, RS; Sculco, TP; Westrich, GH; Windsor, RE, 2006) |
| "Patients with stroke are at substantial risk of thromboembolic complications and therefore require antithrombotic prophylaxis." | 2.72 | Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial. ( Brom, J; Csányi, A; Diener, HC; Harenberg, J; Klingelhöfer, J; Koppenhagen, K; Landgraf, H; Rektor, I; Ringelstein, EB; Schneider, D; von Kummer, R; Weidinger, G, 2006) |
| "Subjects were patients with cancer and acute symptomatic proximal-vein thrombosis." | 2.72 | Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. ( Brant, RF; Burke, N; Cook, R; Dear, R; Hull, RD; Mah, AF; Pineo, GF; Poon, MC; Raskob, G; Solymoss, S; Wong, T, 2006) |
| "Forty-three major postoperative hemorrhages (1." | 2.71 | Risk of postoperative hemorrhage after intracranial surgery after early nadroparin administration: results of a prospective study. ( Beck, J; Gerlach, R; Raabe, A; Scheuer, T; Seifert, V; Woszczyk, A, 2003) |
| "Pulmonary embolism was discovered at autopsy in 10 of 63 patients in the nadroparin group and in 17 of 60 in the placebo group [relative risk reduction 0." | 2.71 | Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study. ( Bergmann, JF; Caulin, C; d'Azémar, P; Mahé, I; Vaissie, JJ, 2005) |
| " This trial shows that bemiparin started postoperatively is as effective and safe as enoxaparin started preoperatively in the prevention of venous thromboembolism in patients undergoing total knee replacement." | 2.71 | Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. ( Castellet, E; Navarro-Quilis, A; Paz-Jiménez, J; Planès, A; Rocha, E, 2003) |
| "Ximelagatran was to be initiated within the first two postoperative days." | 2.71 | Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. ( Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N, 2003) |
| "We randomized 60 symptomatic pulmonary embolism patients in a 2:1 ratio to 90 days of enoxaparin as monotherapy without warfarin (N=40) or to intravenous unfractionated heparin as a "bridge" to warfarin, target INR 2." | 2.71 | Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism. ( Beckman, JA; Dunn, K; Goldhaber, SZ; Sasahara, AA, 2003) |
| "Melagatran 2 mg was started immediately before surgery; 3 mg was then administered postoperatively, followed by 24 mg of oral ximelagatran b." | 2.71 | The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. ( Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N, 2003) |
| "Fondaparinux was compared with enoxaparin in four multicenter, randomized, double-blind trials of major orthopedic surgery." | 2.71 | Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2004) |
| "The incidence of deep vein thrombosis (DVT) was significantly higher in the thalidomide arm hazard ratio: 4." | 2.71 | Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation. ( Anaissie, E; Barlogie, B; Eddlemon, P; Fassas, A; Fink, L; Jacobson, J; Lee, CK; Saghafifar, F; Talamo, G; Thertulien, R; Thomas, T; Tricot, G; Van Rhee, F; Zangari, M, 2004) |
| " The primary efficacy endpoint was recurrent DVT (confirmed by venography or ultrasonography), and safety endpoints included bleeding and serious adverse events." | 2.71 | An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis. ( Araújo, GR; Dietrich-Neto, F; Karaoglan de Moura, L; Lastoria, S; Maffei, FH; Michaelis, W; Ramacciotti, E; Sandri, JL, 2004) |
| "When there was a suspicion of pulmonary embolism (PE), patients were evaluated with spiral computed tomography." | 2.71 | Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin. ( Bilsel, Y; Buyukkurt, D; Granit, V; Guloglu, R; Kizilirmak, S; Kurtoglu, M; Yanar, H, 2004) |
| "The primary end points of the study were deep vein thrombosis (DVT), confirmed by venography of the CVC limb performed 6 weeks after randomization, or clinically overt pulmonary embolism, confirmed by objective testing during the study drug administration." | 2.71 | Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. ( Ageno, W; Agnelli, G; Bazzan, M; Bertoglio, S; Di Somma, FC; Imberti, D; Mosca, S; Naglieri, E; Paoletti, F; Parise, P; Quintavalla, R; Santoro, A; Sorarù, M; Verso, M, 2005) |
| "Warfarin dosing with a target international normalized ratio (INR) range of 1." | 2.71 | Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery. ( Enyart, JJ; Jones, RJ, 2005) |
| "The low molecular weight heparin (LMWH), reviparin-sodium was studied in dose-finding and pharmacokinetic studies in children with central venous lines (CVLs)." | 2.71 | Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients. ( Andrew, M; Bacher, P; Chan, AK; Gent, M; Julian, JA; Kohne, S; Marzinotto, V; Massicotte, P; Shepherd, S; Shields, K; Szechtman, B, 2003) |
| "Clivarin was administered subcutaneously at a fixed daily dosage of 1750 U without any adjustment or loading dosage." | 2.71 | Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients. ( Ahmad, S; Bacher, HP; Fareed, J; Hoppensteadt, DA; Lassen, MR; Leitz, H; Misselwitz, F; Walenga, JM, 2003) |
| "Patients were screened for deep vein thrombosis by sonography every week." | 2.71 | Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients. ( Becker, C; Bodamer, I; Brom, J; Eisele, RR; Galster, H; Grambach, K; Kolb, G; Koudela, K; Paal, V; Seidlmayer, C; Spannagel, U; Weidinger, G, 2003) |
| " Because of a severe pulmonary embolism in one study patient, an interim analysis was performed, and the dosage of certoparin was increased to 3,000 IU twice daily." | 2.71 | Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study. ( Dünser, MW; Fries, DR; Friesenecker, BE; Hasibeder, WR; Jochberger, S; Lorenz, I; Luckner, G; Mayr, AJ; Mayr, V; Schobersberger, W; Ulmer, H, 2005) |
| "Patients with advanced malignancy (N = 385) were randomly assigned to receive either a once-daily subcutaneous injection of dalteparin (5,000 IU), a low molecular weight heparin, or placebo for 1 year." | 2.71 | Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). ( Kadziola, Z; Kakkar, AK; Lemoine, NR; Levine, MN; Low, V; Patel, HK; Quigley, M; Rustin, G; Thomas, M; Williamson, RC, 2004) |
| "DUSG showed deep venous thrombosis (DVT) on the 7th postoperative day in 10 patients in Group 1, in 8 patients in Group 2 and in 3 patients in Group 3." | 2.70 | [Thromboembolic prophylaxis after major abdominal surgery]. ( Adigüzel, H; Balik, AA; Başoğlu, M; Celebi, F; Oren, D; Yildirgan, MI, 2001) |
| "Deep vein thrombosis was assessed by routine bilateral contrast venography performed between postoperative day 5 and 9, or earlier if clinically suspected." | 2.70 | Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial. ( Anderson, DR; Atkinson, KG; Barton, P; Burnstein, M; Burul, CJ; Geerts, WH; Greenwood, C; Gregoire, RC; Marshall, JC; McLeod, RS; Ross, T; Silverman, RE; Sniderman, KW; Taylor, BM; Wilson, SR, 2001) |
| "Venous thromboembolism is a frequent complication of total hip replacement." | 2.70 | A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement. ( Gallus, AS; Hoek, JA; Turpie, AG, 2001) |
| "To determine the specificity of pulmonary embolism (PE) symptoms and lung scan perfusion defects in patients with deep vein thrombosis (DVT), we analyzed data on 400 patients with phlebography-proven proximal DVT included in a prospective trial." | 2.70 | Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy. ( Buchmuller, A; Decousus, M; Girard, P; Hervé, P; Lamer, C; Laporte, S; Parent, F; Tardy, B, 2001) |
| "Hypercoagulability is observed in patients with inherited thrombophilia, e." | 2.70 | The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation. ( Eberl, E; Geisen, U; Grossmann, R; Keller, F; Schambeck, CM, 2001) |
| " They also have a more comfortable dosage for the patient, avoiding the i." | 2.70 | [Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis]. ( Ferreira-Pasos, EM; Fisac-Herrero, RM; Grasa, J; Herrero-Domingo, A; Moreno-Palomares, JJ; Reverte-Cejudo, D, 2001) |
| "Venous thrombosis was diagnosed in two patients receiving low molecular weight heparin and in one patient receiving external pneumatic compression." | 2.70 | Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial. ( Carroll, B; Clarke-Pearson, DL; Dodge, R; Maxwell, GL; Synan, I, 2001) |
| " The study did not evaluate a dose-response for efficacy, and no differences between the three dose levels of melagatran and ximelagatran were shown." | 2.70 | A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in ( Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P, 2002) |
| "The composite endpoint of screened deep vein thrombosis (DVT) and symptomatic pulmonary embolism (PE) during prophylaxis did not differ significantly between patients with or without these mutations." | 2.70 | Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. ( Andersson, C; Bylock, A; Eriksson, BI; Frison, L; Gustafsson, D; Larson, G; Lindahl, TL; Wåhlander, K, 2002) |
| "We conducted population anticoagulant pharmacodynamic analysis for patients administered the low-molecular weight heparin tinzaparin." | 2.70 | Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis. ( Barrett, JS; Gastonguay, M; Gibiansky, E; Hainer, JW; Hua, TA; Hull, RD; Pentikis, H; Planès, A, 2001) |
| " We conclude that one daily subcutaneous injection of calcium nadroparin in a fixed, weight-adjusted dosage scheme is superior to intermittent pneumatic compression of the foot for thromboprophylaxis after TKA." | 2.69 | Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system. ( Blanchard, J; Bounameaux, H; Didier, D; Hoffmeyer, P; Leyvraz, PF; Meuwly, JY; Miron, MJ; Schneider, PA, 1999) |
| "Bleedings were all minor, mostly during hospital stay." | 2.69 | Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis. ( Barsotti, A; Belcaro, G; Cesarone, MR; Christopoulos, D; Corsi, M; De Sanctis, MT; Incandela, L; Laurora, G; Lennox, A; Malouf, M; Nicolaides, AN; Vasdekis, S, 1999) |
| "The incidence of deep vein thrombosis in group 1 was 14% (14 patients, 5 proximal vein thromboses and 9 distal vein thromboses) while in group 2, no patients developed deep vein thrombosis." | 2.69 | Use of low molecular weight heparin for prevention of deep vein thrombosis in total knee arthroplasty--a study of its efficacy in an Asian population. ( Fong, YK; Lee, BP; Lo, NN; Ng, SC; Ruban, P; Seow, KH; Yeo, SJ, 2000) |
| "Both regimens were equally safe and the risk of clinically evident DVT and PE was similar." | 2.69 | Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients. ( Büchler, MW; Egger, B; Naef, M; Schmid, SW; Wildi, S, 2000) |
| "The overall incidence of deep venous thrombosis was 42% (33 of 78 patients)." | 2.69 | How "gold" is the standard? Interobservers' variation on venograms. ( Al-Kutoubi, A; Cunningham, DA; Kalodiki, E; Mandalia, S; Nicolaides, AN, 1998) |
| "To assess whether uncomplicated deep vein thrombosis could be treated in an out-patient setting without increasing the frequency of complications, and to determine the proportion of patients with deep vein thrombosis, traditionally treated as in-patients at the Departments of Medicine, who are eligible for such treatment." | 2.69 | Out-patient treatment of acute deep vein thrombosis. ( Berntorp, E; Bornhov, S; Lagerstedt, C; Lethagen, S; Mattiasson, I; Persson, J; Timberg, I; Torstensson, I, 1998) |
| " Following is an overview of major insights from the prophylaxis in Medical patients with Enoxaparin (MEDENOX) trial, which was undertaken to evaluate the efficacy of 2 dosage regimens of the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism in acutely ill medical patients." | 2.69 | Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. ( Turpie, AG, 2000) |
| "None of our patients with proximal deep vein thrombosis used a vena cava filter." | 2.69 | The home treatment of deep vein thrombosis with low molecular weight heparin, forced mobilisation and compression. ( Cambal, M; Labas, P; Ohrádka, B; Vladimír, J, 2000) |
| " However, body weight-adjusted dosage of low-molecular-weight heparin may be cumbersome and could lead possibly to incorrect dosing." | 2.69 | Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators. ( Büller, HR; Harenberg, J; Huisman, MV; Koppenhagen, K; Schmidt, JA; Tolle, A, 2000) |
| " Therefore, tinzaparin administered in a dosage of 75 U anti-Xa/kg BW 12 hours before surgery is significantly more protective against proximal DVT and safer than the standard regimen of 50 U anti-Xa/kg BW started 2 hours before surgery in patients undergoing primary elective hip arthroplasty." | 2.69 | Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty. ( Andersen, BS; Borris, LC; Ejstrud, P; Jensen, HP; Lassen, MR; Poulsen, KA, 2000) |
| "In THA patients, the rate of deep vein thrombosis (DVT) was lower with factor Xa inhibitors than LMWH." | 2.61 | Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis. ( Cheng, K; Jia, J; Liang, Q; Sun, G; Wang, Q; Wang, Z; Wu, J, 2019) |
| "No significant increase in major intracranial hemorrhage (p = 0." | 2.58 | Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis. ( Khan, NR; Lee, SL; Patel, PG; Sharpe, JP; Sorenson, J, 2018) |
| "Venous thromboembolism, specifically pulmonary embolism, is a rare complication following elective pediatric orthopedic surgery." | 2.58 | Symptomatic bilateral pulmonary embolism without deep venous thrombosis in an adolescent following arthroscopic anterior cruciate ligament reconstruction: a case report and review of the literature. ( Bourget-Murray, J; Clarke, MA; Gorzitza, S; Phillips, LA, 2018) |
| "Multiple studies have addressed deep vein thrombosis chemoprophylaxis timing in traumatic brain injuries." | 2.52 | Timing for deep vein thrombosis chemoprophylaxis in traumatic brain injury: an evidence-based review. ( Abdel-Aziz, H; Dunham, CM; Hileman, BM; Malik, RJ, 2015) |
| "The low incidence and prevalence of Lemierre's syndrome contribute to the many controversies pertaining to its therapeutic management, one of which is the use of anticoagulation for associated internal jugular vein thrombus." | 2.48 | Use of anticoagulation therapy for jugular vein thrombus in pediatric patients with Lemierre's syndrome. ( Phan, T; So, TY, 2012) |
| "Dabigatran was not superior to enoxaparin for prevention of VTE (RR 1." | 2.47 | Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison. ( Kwok, CS; Loke, YK, 2011) |
| "The incidence of deep vein thrombosis (DVT) varies from 5 to 63% depending on patients' risk factors, modality of prophylaxis, and methods of detection." | 2.44 | Postinjury thromboprophylaxis. ( Balogh, Z; Bendinelli, C, 2008) |
| "Rivaroxaban (BAY 59-7939) is an oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of venous thromboembolism (VTE)." | 2.44 | Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies. ( Bauer, KA; Borris, L; Dahl, OE; Eriksson, BI; Fisher, WD; Gent, M; Haas, S; Homering, M; Huisman, MV; Kakkar, AK; Kälebo, P; Kwong, LM; Misselwitz, F; Turpie, AG, 2007) |
| " Fondaparinux is also characterized by a simple dosing regimen, no need for coagulation monitoring, and potentially a lower risk of HIT compared with LMWH." | 2.44 | The pharmacoeconomics of deep vein thrombosis treatment. ( Shorr, AF, 2007) |
| "Venous thrombosis is a common disease." | 2.44 | Anticoagulant treatment of deep vein thrombosis and pulmonary embolism. ( Ginsberg, J; McRae, S; Tran, H, 2008) |
| "The antiphospholipid syndrome is described with a review of its historical development as a recognized syndrome, what constitutes an antiphospholipid antibody, how it is measured, and how the syndrome is treated." | 2.43 | The antiphospholipid syndrome: what are we really measuring? How do we measure it? And how do we treat it? ( Ortel, TL, 2006) |
| "Lemierre's syndrome is characterized by acute oropharyngeal infection complicated by internal jugular venous thrombosis secondary to septic thrombophlebitis, and metastatic abscesses." | 2.43 | Lemierre's syndrome presenting with peritonsillar abscess and VIth cranial nerve palsy. ( Jones, C; O'Reilly, BJ; Seymour, FK; Siva, TM, 2006) |
| "Cardiovascular disease, to which venous thrombosis and pulmonary embolism contribute a major part, are the leading cause of death in industrialized countries." | 2.42 | [Venous thrombosis and thrombophilic management of prevention and therapy]. ( Katus, HA; Ruef, J, 2003) |
| "Fondaparinux has been recently approved for use in thromboprophylaxis after major orthopedic surgery." | 2.42 | New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2003) |
| " Due to a longer plasma half life together with high bioavailability and a linear dose-response relationship, the drugs can be safely and effectively administered in the hospital or ambulatory settings without the need to monitor the anticoagulant effect." | 2.42 | Clinical application of enoxaparin. ( Hofmann, T, 2004) |
| "Venous thromboembolism is a multifactorial silent disease and tends not to be suspected by physicians, especially in medical patients." | 2.42 | Prophylaxis of venous thromboembolism in medical patients. ( Gerotziafas, GT; Samama, MM, 2004) |
| "Fondaparinux was superior to enoxaparin 40 mg once/day in the setting of hip fracture surgery, with no increased risk of major bleeding." | 2.42 | Emerging options for thromboprophylaxis after orthopedic surgery: a review of clinical data. ( Lobo, BL, 2004) |
| " Various clinical studies in unstable angina and acute coronary syndrome have proved that clivarine in a dosage of 3436anti-Xa units twice daily is an effective antithrombotic agent." | 2.42 | Reviparin sodium clivarine: a review of its therapeutic use. ( Gore, M; Kelkar, P; Rege, N; Ross, C, 2004) |
| " No dose "cap" is required for obese patients, and no initial dosing adjustments are necessary in elderly and/or renally impaired patients, although some monitoring is recommended." | 2.42 | Tinzaparin: considerations for use in clinical practice. ( Feinstein, H; Nutescu, EA; Rivers, CW; Shapiro, NL, 2003) |
| " Key advantages of LMWHs include improved bioavailability and longer half-life, more predictable anticoagulation that requires less laboratory monitoring, and fewer serious side effects." | 2.41 | Pharmacology department. ( Gylys, KH, 2001) |
| "Fondaparinux also appears to be a very promising candidate for the treatment of patients with existing VTE." | 2.41 | Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism. ( Bauer, KA; Eriksson, BI; Lassen, MR; Turpie, AG, 2002) |
| "Guidelines for deep venous thrombosis (DVT) and pulmonary embolism (PE) prophylaxis have been developed for patients undergoing total hip arthroplasty (THA)." | 2.41 | Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty. ( Hawkins, DW; Wade, WE, 2000) |
| "Therapy to prevent deep venous thrombosis (DVT) and pulmonary embolism remains essential for inpatients, despite short periods of bedrest and hospitalization." | 2.41 | Deep venous thrombosis prophylaxis in patients with heart disease. ( Shively, BK, 2001) |
| "Fondaparinux is a synthetic polysaccharide that selectively binds to antithrombin, the primary endogenous regulator of blood coagulation." | 2.41 | Fondaparinux versus enoxaparin for the prevention of venous thromboembolism. ( Doggrell, SA, 2002) |
| " As prophylaxis, reviparin 1,750 anti-XaIU once daily was as effective as unfractionated heparin 5,000IU twice daily in 1,311 patients undergoing abdominal surgery and, in a once daily dosage of 4,200 anti-XaIU, was as effective as subcutaneous enoxaparin sodium 40 mg/day or acenocoumarol in patients undergoing hip replacement surgery." | 2.41 | Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism. ( Jarvis, B; McClellan, K; Wellington, K, 2001) |
| "Patients with acute deep vein thrombosis (DVT) were treated with a body-weight independent dosage of 2 x 8000 aXa IU low-molecular-weight heparin (LMWH) Certoparin." | 2.41 | Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis. ( Harenberg, J, 2002) |
| "If patients with pulmonary embolism meet criteria demonstrated to result in a higher risk of death, it is, of course, reasonable to not treat such patients on an outpatient basis." | 2.41 | Outpatient treatment of patients with deep-vein thrombosis or pulmonary embolism. ( Wells, PS, 2001) |
| "Dalteparin sodium has been subjected to a large number of well-designed randomised clinical trials for the prevention and treatment of thrombotic disorders." | 2.41 | Dalteparin sodium. ( Hull, RD; Pineo, GF, 2001) |
| "The chemistry, pharmacokinetics, pharmacodynamics, clinical efficacy, dosage and administration, adverse effects, and therapeutic role of tinzaparin are reviewed." | 2.41 | Tinzaparin sodium: a low-molecular-weight heparin. ( Carlson, SS; Lenhart, SE; Neely, JL, 2002) |
| " Danaparoid, a low-molecular-weight heparinoid, and once-daily enoxaparin are recently released dosage forms that have been evaluated as pharmacoprophylaxis for DVT after hip replacement surgery." | 2.40 | Cost effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery. ( Wade, WE, 1999) |
| "For discriminating arterial and venous thrombosis, there was no significant difference between the ADA vs." | 1.91 | External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial. ( Chi, G; Cohen, AT; Gibson, CM; Goldhaber, SZ; Harrington, RA; Hernandez, AF; Hull, RD; Loffredo, L; Pignatelli, P; Spagnoli, A; Vestri, A; Violi, F, 2023) |
| " No serious adverse reactions occurred in the two groups during treatment." | 1.91 | Efficacy and safety of salvianolate and enoxaparin in the prevention of perioperative deep venous thrombosis in gastrointestinal surgery. ( Chai, YN; Lu, YY; Qin, CZ; Wang, XR; Wu, ML; Zhang, JM; Zhang, WD, 2023) |
| "The incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) after total joint arthroplasty (TJA) procedures are lower in Asian populations than in Caucasian populations." | 1.91 | Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population. ( Chang, WL; Chen, CF; Chen, WM; Chou, TA; Pai, FY; Tsai, SW; Wu, PK, 2023) |
| "Dalteparin was not stopped in any women." | 1.91 | Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data. ( Kozak, M; Novak, A; Novak, P; Šabović, M, 2023) |
| "History of deep vein thrombosis (DVT), location of SVT above the knee, and palpable induration were the only independent factors associated with prolonged treatment duration." | 1.91 | Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin. ( Chatzis, D; Georgiadis, G; Giannoukas, AD; Ioannou, C; Kakkos, SK; Karathanos, C; Latzios, P; Vasdekis, S, 2023) |
| "Despite standard thromboprophylaxis, venous thrombosis is common in critically ill patients with COVID-19." | 1.72 | [Deep venous thrombosis incidence in patients with COVID-19 acute respiratory distress syndrome, under intermediate dose of chemical thromboprophylaxis]. ( Bonelli, I; Hunter, M; López Saubidet, I; Lurbet, MF; Mandó, F; Parodi, J; Rodríguez, PO, 2022) |
| "The management of a patient with venous thrombosis with perinephric hematoma post renal biopsy can be difficult if occurred." | 1.72 | Double trouble - management of perinephric hematoma and renal vein thrombosis post percutaneous renal biopsy. ( Daud, MAM; Kamarudin, MI; Nadarajan, C, 2022) |
| "Central venous catheter (CVC) related venous thrombosis (VT) after pediatric cardiac surgery increases morbidity and mortality." | 1.72 | Enoxaparin Reduces Catheter-associated Venous Thrombosis After Infant Cardiac Surgery. ( Alfieris, GM; Cholette, JM; Hutchinson, DJ; Stauber, SD; Swartz, MF; Taillie, ER, 2022) |
| " Current literature suggests weight-based dosing is superior to standard dosing for adequate chemoprophylaxis." | 1.72 | Effective use of weight-based enoxaparin for deep vein thrombosis chemoprophylaxis in patients with traumatic brain injury. ( Huang, E; Martinez-Quinones, P; Robinson, T; Taylor, A; White, CQ, 2022) |
| "The hemorrhagic form of cerebral venous thrombosis can be a diagnostic challenge and is treated by anticoagulation therapy, despite the existence of an intracerebral hemorrhage." | 1.62 | Superficial Cerebral Venous Thrombosis and Intracerebral Hematoma in a 48-Year-Old Man with SARS-CoV-2 Infection: A Case Report. ( Bains, SS; Cardoso, ER; Farkas, J; Robison, B, 2021) |
| "Coronavirus is a source of deep venous thrombosis (DVT) due to complications such as over-coagulation, blood stasis, and endothelial damage." | 1.62 | Ovarian vein thrombosis after coronavirus disease (COVID-19) mimicking acute abdomen: two case reports. ( Abdeladim, S; Bensahi, I; Elouarradi, A; Fatimazahra, M; Harras, ME; Kassimi, M; Oualim, S; Sabry, M, 2021) |
| "Oral apixaban is an effective alternative to enoxaparin as a thromboprophylactic drug for patients undergoing elective total knee replacement surgery." | 1.62 | Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study. ( Ali Hasan, M; Azeez Alsaadi, M; Tahseen Mehsen, J, 2021) |
| "In human patients with liver cirrhosis, portal vein thrombosis (PVT) is a common complication." | 1.62 | Long-term follow-up of portal vein thrombosis in an American Cocker Spaniel with lobular dissecting hepatitis: a case report. ( Ishikawa, C; Kagawa, Y; Nakayama, T; Sakai, M; Sakamoto, Y; Sato, K, 2021) |
| "History of prior deep vein thrombosis (HR 2." | 1.62 | Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study - The SeVEN EXTension study. ( Chatzis, D; Giannoukas, AD; Goumas, K; Karathanos, C; Latzios, P; Papakostas, I, 2021) |
| "VTE was defined as symptomatic deep vein thrombosis or pulmonary embolism and was confirmed via radiological imaging or autopsy." | 1.56 | Nadroparin Plus Compression Stockings versus Nadroparin Alone for Prevention of Venous Thromboembolism in Cerebellopontine Angle Tumour Excisions: A Cohort Study. ( Cannegieter, SC; Koopmans, RJ; Koot, RW; Vleggeert-Lankamp, CLA, 2020) |
| "Rivaroxaban treatment was associated with a lower risk of PTS when compared to enoxaparin/warfarin; RVT however, was not a mediator in the association between PTS and type of treatment." | 1.56 | Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban. ( Annichino-Bizzacchi, JM; Bittar, LF; Colella, MP; de Moraes Martinelli, B; de Oliveira, LFG; de Paula, EV; Ferreira, T; Huber, SC; Junior, AL; Mello, TT; Menezes, FH; Montalvão, S; Orsi, FA; Rielli, G; Sodre, LR; Yamaguti-Hayakawa, GG, 2020) |
| "Nitrous oxide is a commonly abused inhalant by adolescents and young adults." | 1.56 | Venous thrombosis after nitrous oxide abuse, a case report. ( Patterson, KC; Pratt, DN; Quin, K, 2020) |
| "The evidence for outpatient pulmonary embolism (PE) management apart from hospitalization is expanding." | 1.56 | Primary care physicians comprehensively manage acute pulmonary embolism without higher-level-of-care transfer: A report of two cases. ( Hofmann, ER; Isaacs, DJ; Johnson, EJ; Rangarajan, S; Vinson, DR, 2020) |
| "Incidence of postoperative deep venous thrombosis (DVT), pulmonary embolism (PE), bleeding-related complications, postoperative anaemia, and transfusion were identified at 2 weeks, 30 days, 6 weeks, and 90 days." | 1.56 | Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors? ( Amanatullah, DF; Bala, A; Burk, DR; Goodman, SB; Huddleston, JI; Maloney, WJ; Murasko, MJ, 2020) |
| "Hyperhomocysteinemia is a metabolic disorder caused by various enzyme defects in methionine metabolism." | 1.51 | Multifactorial Painful Leg Ulcers Due to Hyperhomocysteinemia, Plasminogen Activator Inhibitor-1 4G/5G Heterozygote Gene Mutation, and Beta Thalassemia Minor: A Case Report. ( Büyükbabani, N; Çaytemel, C; Topaloğlu Demir, F; Türkoğlu, Z; Uzuner, EG, 2019) |
| "Early pharmacological deep vein thrombosis (DVT) prophylaxis is recommended by guidelines, but rarely started within 48 h." | 1.51 | Early thrombosis prophylaxis with enoxaparin is not associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage. ( Addis, A; Ammenwerth, E; Beer, R; Gaasch, M; Hackl, W; Helbok, R; Huber, L; Ianosi, B; Kofler, M; Pfausler, B; Rass, V; Rhomberg, P; Schiefecker, AJ; Thomé, C, 2019) |
| "Geographic region, patient age, gender, deep vein thrombosis prophylaxis strategy, and complications were obtained." | 1.51 | Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates. ( Gottschalk, MB; Pour, AE; Roberson, JR; Runner, RP; Staley, CA, 2019) |
| " While 30-mg twice-daily enoxaparin is accepted as the standard prophylactic dose, recent evidence in injured patients suggests this dosing strategy may result in sub-optimal pharmacologic DVT prophylaxis." | 1.51 | Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients. ( Berndtson, AE; Box, K; Costantini, TW; Cronin, BJ; Godat, LN; Kolan, S; Lee, JG; Pham, A, 2019) |
| " The risk of under dosing seems less predictable; therefore, anti-Xa assay may be useful in severe clinical situations that require higher anticoagulant activity." | 1.48 | Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure? ( Corrà, L; Di Francesco, V; Facchinetti, R; Fantin, F; Fontana, G; Pellizzari, L; Sepe, A; Zamboni, M, 2018) |
| "Adults with active cancer and an acute VTE were included." | 1.48 | Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients. ( Anselmo, L; Borrego, ME; Burnett, A; Fuller, K; Jakeman, B; Malecki, S, 2018) |
| "A personal history of malignancy and type 2 diabetes increase the risk of PMVT." | 1.48 | Assessing risk factors, presentation, and management of portomesenteric vein thrombosis after sleeve gastrectomy: a multicenter case-control study. ( Blanco, DG; Boyce, SG; De La Cruz-Munoz, N; Domkowski, P; Funes, DR; Ghanem, M; Jawad, MA; Menzo, EL; Moon, RC; Radecke, J; Rosenthal, R; Teixeira, AF; Young, MK, 2018) |
| "Dabigatran etexilate is an oral anticoagulant recognized as noninferior to LMWH." | 1.48 | Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada. ( Banica, A; Benoit, B; Delisle, J; Fernandes, JC; Laflamme, GY; Malo, M; Nguyen, H; Ranger, P; Senay, A; Trottier, M, 2018) |
| " We describe the first case report, to our knowledge, of a severely burned patient who, despite prophylactic dosing of enoxaparin 30 mg subcutaneously twice daily, developed an acute DVT that required high-dose enoxaparin (100 mg [1." | 1.48 | Increased Enoxaparin Dosing Requirements for Treatment of Deep Vein Thrombosis in a Severely Burned Patient: Case Report and Literature Review. ( Haan, BJ; Mangan, KC; Yost, RJ, 2018) |
| " Once-daily dosing was associated with a lower bleeding risk as compared with twice-daily." | 1.46 | Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis. ( Biedermann, JS; Cannegieter, SC; Kruip, MJHA; Lijfering, WM; Reitsma, PH; van der Meer, FJM; van Rein, N; Vermaas, HW; Wiersma, N, 2017) |
| " Although low-molecular-weight heparin (LMWH) is recommended in CVT, the specific type and dosage regimen of LMWH have never been specifically suggested." | 1.46 | Comparison of the efficacy of fixed-dose enoxaparin and adjusted-dose unfractionated heparin in patients with cerebral venous thrombosis. ( Korathanakhun, P; Petpichetchian, C; Petpichetchian, W; Sathirapanya, P, 2017) |
| "One patient had deep venous thrombosis in the 6 weeks postpartum, in the GROUP P." | 1.46 | Is a therapeutic anticoagulation window needed for delivery when using prophylactic low molecular weight heparin during pregnancy? A retrospective monocentric study. ( Agman, A; Amsellem, J; Cesario, E; Nizard, J; Roueli, A; Vauthier-Brouzes, D, 2017) |
| "BACKGROUND Femoral neuropathy as a result of retroperitoneal hemorrhage most commonly occurs following pelvic and lower extremity trauma, but has been described to develop as a less frequent complication of anticoagulation." | 1.46 | Bilateral Femoral Neuropathy Following Psoas Muscle Hematomas Caused by Enoxaparin Therapy. ( Akkad, I; Bhardwaj, S; Demir, S; Kakar, P; Macauley, P; Shankar, S; Soni, P, 2017) |
| "Twelve additional patients experienced deep vein thrombosis and 6 had pulmonary embolism." | 1.46 | Abdominal thrombotic complications following bariatric surgery. ( Elazary, R; Kalish, Y; Rottenstreich, A, 2017) |
| " Venous thrombosis is frequently treated with low-molecular-weight heparins (LMWHs) such as enoxaparin, but optimal dosing of LMWH must balance the morbidity of venous thrombosis with the potential adverse affects of anticoagulation." | 1.46 | Treatment and follow-up of venous thrombosis in the neonatal intensive care unit: a retrospective study. ( Aneja, RK; Bohnhoff, JC; Brozanski, BS; DiSilvio, SA; Domnina, YA; Good, M; Shenk, JR, 2017) |
| "Optimal enoxaparin dosing for deep venous thrombosis (DVT) prophylaxis remains elusive." | 1.46 | Goal directed enoxaparin dosing provides superior chemoprophylaxis against deep vein thrombosis. ( Basharat, U; Bogert, JN; Davis, KM; Kopelman, TR; Pieri, PG; Pressman, MA; Quan, AN; Vail, SJ; Walters, JW, 2017) |
| "The rate of VTE recurrences was similar in both subgroups." | 1.46 | Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism. ( Bascuñana, J; Bergmann, JF; Bortoluzzi, C; Ferrazzi, P; Giorgi-Pierfranceschi, M; López-Reyes, R; López-Sáez, JB; Monreal, M; Suriñach, JM; Trujillo-Santos, J, 2017) |
| " The primary outcome was the incidence of symptomatic pulmonary embolism after surgery, and the secondary outcome was the incidence of bleeding as an adverse effect of enoxaparin injection." | 1.46 | Safety and efficacy of postoperative pharmacologic thromboprophylaxis with enoxaparin after pancreatic surgery. ( Adachi, T; Eguchi, S; Fujita, F; Hidaka, M; Imamura, H; Kitasato, A; Kuroki, T; Soyama, A; Takatsuki, M; Tanaka, T, 2017) |
| "After a few days the patient developed deep vein thrombosis of the subclavian, axillary and brachial veins, which was successfully treated with nadroparin." | 1.43 | [Thrombosis of the subclavian vein after conservative treatment of a clavicular fracture: A rare complication]. ( Baecker, H; Haas, NP; Märdian, S; Ranke, H, 2016) |
| "Workup revealed bilateral submassive pulmonary embolism and proximal right lower extremity deep vein thrombosis." | 1.43 | Inherited antithrombin deficiency and anabolic steroids: a risky combination. ( Choe, H; DeSancho, MT; Elfil, M, 2016) |
| "Tranexamic acid (TXA) is an antifibrinolytic that reduces blood loss after THA and TKA." | 1.43 | Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid. ( Campbell, JC; Mirocha, JM; Sharfman, ZT; Spitzer, AI, 2016) |
| "Acute pancreatitis is an acute inflammatory process of the pancreas that can trigger a systemic inflammatory response." | 1.43 | Acute pancreatitis complicated with deep vein thrombosis and pulmonary embolism: a case report. ( Herath, HM; Kulatunga, A, 2016) |
| " Dosage was adjusted to a prophylactic peak anti-Xa level of 0." | 1.43 | Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients. ( Ginzburg, E; Karcutskie, CA; Lieberman, HM; Lineen, EB; Namias, N; Riggi, G; Singer, GA; Vaghaiwalla, TM, 2016) |
| "Calf deep vein thrombosis (CDVT) is frequently found in symptomatic outpatients, but CDVT ultrasound diagnostic criteria are still debated." | 1.43 | Ultrasound Characteristics of Calf Deep Vein Thrombosis and Residual Vein Obstruction After Low Molecular Weight Heparin Treatment. ( Cosmi, B; Favaretto, E; Ghirarduzzi, A; Giusto, L; Iotti, M; Lessiani, G; Migliaccio, L; Palareti, G; Sartori, M, 2016) |
| "The high prevalence of deep vein thrombosis (DVT) reported in prospective studies and the unreliability of clinical diagnosis mandates prospective screening for DVT in burn patients." | 1.43 | An analysis of deep vein thrombosis in burn patients (Part 1): Comparison of D-dimer and Doppler ultrasound as screening tools. ( Ahuja, RB; Bansal, P; Pradhan, GS; Subberwal, M, 2016) |
| "Venous thrombosis complicating SAPHO syndrome seems to be uncommon with an unclear pathogenesis (3-9)." | 1.43 | Antiphospholipid Syndrome with Antiβ2glicoprotein-1 Antibodies as the Cause of Recurrent Tibial Vein Thrombosis in SAPHO syndrome. ( Brzosko, M; Przepiera-Będzak, H, 2016) |
| "ESSENTIALS: Does thrombus stability alter the presentation of venous thromboembolism and do anticoagulants alter this? In a murine model, we imaged a femoral vein thrombus and quantified emboli in the pulmonary arteries." | 1.43 | Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism. ( Gross, PL; Ni, R; Saldanha, LJ; Shaya, SA; Vaezzadeh, N; Zhou, J, 2016) |
| "Pulmonary tuberculosis was confirmed with positive culture for Mycobacterium tuberculosis." | 1.42 | A rare complication of pulmonary tuberculosis: a case report. ( Jayalath, WA; Kumarihamy, KW; Ralapanawa, DM, 2015) |
| " Adverse events, based on the Common Terminology Criteria for Adverse Events, Version 4, were recorded." | 1.42 | Safety and efficacy of thromboprophylaxis using enoxaparin sodium after cesarean section: A multi-center study in Japan. ( Eguchi, F; Goto, M; Miyamoto, S; Nakahara, H; Ogawa, M; Sanui, A; Satoh, S; Takashima, T; Tatsumura, M; Yoshizato, T, 2015) |
| "There were virtually no formation of venous thrombosis in any of the rats that received enoxaparin encapsulated in nanoparticles (0." | 1.42 | Polymeric Nanoparticles of Enoxaparin as a Delivery System: In Vivo Evaluation in Normal Rats and in a Venous Thrombosis Rat Model. ( Alessio, AM; Annichino-Bizzacchi, JM; Durán, N; Höehr, NF; Marcato, PD; Montalvão, S; Paixão, D; Pazzini, C; Prado, LB, 2015) |
| "Incidences of symptomatic deep vein thrombosis (DVT) and PE, and major or minor bleeding complications were evaluated." | 1.42 | Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients. ( Cho, KJ; Fang, R; Kim, TK; Kim, YH; Na, YG, 2015) |
| "Intrahepatic bleeding is exceptional and only very few cases have been described." | 1.40 | Fatal intrahepatic hemorrhage after nadroparin use for total hip arthroplasty. ( Bonsignore, A; De Stefano, F; Palmiere, C; Pizzorno, E; Ventura, F, 2014) |
| "Treatment with rivaroxaban cost $2,448 per-patient less and was associated with 0." | 1.40 | Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism. ( Bookhart, BK; Coleman, CI; Huynh, L; Lefebvre, P; Mody, SH; Nutescu, EA; Tran, KN; Wang, ST; Zhuo, DY, 2014) |
| " The DVT rate did not differ between trauma and general surgery populations or in patients receiving once-daily vs twice-daily dosing regimens." | 1.40 | Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients. ( Anderson, R; Barton, JS; Cho, SD; Differding, J; Geraci, T; Louis, SG; Riha, GM; Sato, M; Schreiber, MA; Underwood, S; Van, PY; Watters, JM, 2014) |
| "Venous thromboembolism (VTE) (deep vein thrombosis [DVT] and pulmonary embolism [(PE]) represents a substantial economic burden to the healthcare system." | 1.40 | Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program. ( Bamber, L; Bookhart, BK; Haskell, L; Mody, SH; Schein, J; Wang, M, 2014) |
| "Iliofemoral deep vein thrombosis is a medical emergency associated with pulmonary embolism, severe postthrombotic morbidity and increased rates of recurrence." | 1.40 | Challenges in the management of iliofemoral deep vein thrombosis in a resource limited setting: a case series. ( Eluehike, S; Isabu, P; Kesieme, EB; Okokhere, P, 2014) |
| "Patients undergoing elective colorectal cancer surgery from 2007 to 2009 at the Royal Adelaide and Queen Elizabeth hospitals were identified from a prospective database." | 1.39 | Is extended thromboprophylaxis necessary in elective colorectal cancer surgery? ( Chandra, R; Hunter, RA; Lawrence, MJ; Melino, G; Moore, J; Thomas, M, 2013) |
| "Untreated hereditary antithrombin deficiency in pregnancy is associated with maternal venous thromboembolism (VTE) and possibly with fetal loss." | 1.39 | How I treat heterozygous hereditary antithrombin deficiency in pregnancy. ( Bramham, K; Hunt, BJ; Mitchell, M; Moore, GW; Retter, A; Robinson, SE, 2013) |
| "Laparoscopic procedures for morbid obesity are becoming standard of care which, in experienced hands, has a very low mortality and morbidity." | 1.39 | Superior mesenteric vein thrombosis after laparoscopic sleeve gastrectomy. ( Ahmed, L; Pineda, L; Sarhan, M, 2013) |
| "05) the oral bioavailability of enoxaparin in comparison to plain enoxaparin solution as revealed by threefold increase in AUC of plasma drug concentration time curve and around 60% reduction in thrombus formation in rat venous thrombosis model." | 1.39 | Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment. ( Bagre, AP; Jain, K; Jain, NK, 2013) |
| "With patients in whom it is indicated, the home therapy ankle pathway has proved to be a safe and resource sparing method of managing ankle fractures prior to surgery." | 1.39 | Home therapy pathway - safe and streamlined method of initial management of ankle fractures. ( Baraza, N; Dhukaram, V; Lever, S, 2013) |
| "One fatal pulmonary embolism was recorded (1/1093, 0." | 1.39 | Therapeutic effect of low-molecular weight heparin and incidence of lower limb deep venous thrombosis and pulmonary embolism after laparoscopic bariatric surgery. ( Al-Asfar, F; Al-Bader, I; Al-Mozaini, A; Fingerhut, A; Khoursheed, M; Marouf, R; Sayed, A, 2013) |
| " There is variable bioavailability of LMWH with standard therapy." | 1.39 | The effects of location and low-molecular-weight heparin administration on deep vein thrombosis outcomes in trauma patients. ( Alonzo, BJ; Differding, J; Hamilton, G; Kremenevskiy, I; Lee, TH; McNamara, S; Schreiber, MA; Underwood, SJ, 2013) |
| " This study was designed to analyse our experience in paediatric-specific dosage requirements for enoxaparin therapy." | 1.39 | Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital. ( Andrade-Campos, MM; Fernandez-Mosteirin, N; Lucia-Cuesta, JF; Montes-Limón, AE; Rubio-Felix, D; Salvador-Osuna, C; Torres, M, 2013) |
| "Previous reports have associated Klinefelter's syndrome with increased risk of thrombosis." | 1.39 | Klinefelter's syndrome and venous thrombosis. ( Penn, RL; Rajpal, S; Seth, A, 2013) |
| "The purpose of this study was to analyze whether 2 standard dosing regimens of enoxaparin (30 mg twice daily vs 40 mg once daily) would result in different deep vein thrombosis (DVT) rates and anti-factor Xa activity (anti-Xa) in surgical patients." | 1.38 | Incidence of deep vein thrombosis is increased with 30 mg twice daily dosing of enoxaparin compared with 40 mg daily. ( Differding, JA; Riha, GM; Schreiber, MA; Van, PY, 2012) |
| "SVT favors the relapse of esophageal varices, but rebleeding can be effectively prevented by standard scheduled band ligations." | 1.38 | Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis. ( Amitrano, L; Guardascione, MA; Lampasi, F; Lanza, AG; Manguso, F; Martino, R; Menchise, A; Scaglione, M, 2012) |
| "Animal models studying venous thrombosis are scarce and, in most cases, very crude and rely on sacrificing the animals to excise formed thrombi." | 1.38 | In vivo monitoring of venous thrombosis in mice. ( Aghourian, MN; Blostein, MD; Lemarié, CA, 2012) |
| " Compliance with prophylaxis was complete but compliance with the recommended dosage was suboptimal, which may result in venous thromboembolism after CS despite thromboprophylaxis." | 1.38 | Thromboprophylaxis for women undergoing caesarean section. ( Farah, N; Kennedy, C; Kennelly, M; O'Dwyer, V; O'Kelly, S; Turner, MJ, 2012) |
| "Dependent variables included symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) within the first 60 postoperative days and time to DVT or PE." | 1.37 | Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients. ( Bailey, SH; Dreszer, G; Fisher Wachtman, C; Hamill, JB; Hoxworth, RE; Hume, KM; Jaber, RM; Kalliainen, LK; Neligan, PC; Pannucci, CJ; Pusic, AL; Rubin, JP; Wilkins, EG; Zumsteg, JW, 2011) |
| " Areas under the curve (AUCs) for a 12-hour dosing interval were estimated." | 1.37 | Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients. ( Albert, M; Blais, L; Boulanger, I; Champagne, MC; Vincent, PD; Williamson, DR; Zikos, T, 2011) |
| "Eighty percent of deep venous thrombosis resolves spontaneously and less than 15% embolize to pulmonary arteries." | 1.37 | Saddle pulmonary thromboembolism with zero Wells' score. ( Brown, TA; Kangath, RV; Pai, RP, 2011) |
| "Darexaban (YM150) is an oral factor Xa inhibitor developed for the prophylaxis of venous and arterial thromboembolic disease." | 1.37 | Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor. ( Funatsu, T; Iwatsuki, Y; Kaku, S; Kawasaki, T; Moritani, Y; Sato, T; Shigenaga, T; Suzuki, M, 2011) |
| "Hospitalized cancer patients are at an increased risk for venous thromboembolism (VTE) and it is recommended they receive pharmacologic prophylaxis unless otherwise contraindicated." | 1.36 | Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population. ( Liu, CY; Reeves, D, 2010) |
| "Membranous nephropathy is uncommon in Chinese children and could be a possible early presentation of SLE." | 1.36 | An unusual case of loin pain and nephritis. ( Chiu, MC; Lai, WM; Ma, AL, 2010) |
| " Standard prophylaxis for high risk patients includes twice-daily dosing with 30 mg enoxaparin." | 1.36 | Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients. ( Ardary, C; Baje, M; Barrios, C; Cinat, ME; Conniff, H; Dolich, MO; Ewing, T; Hoyt, DB; Jafari, F; Kong, A; Lekawa, ME; Malinoski, D, 2010) |
| "Given that deep vein thrombosis coincided with obstetric delivery, it was crucial to decide on anesthetic and therapeutic approaches that would assure maternal and fetal safety and prevent such complications as massive pulmonary thromboembolism." | 1.36 | [Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery]. ( Amorós, B; Bermejo, L; Dueñas, N; Fernández, E; Perea, M; Villafranca, A, 2010) |
| " Multiple drugs and dosing regimens have been suggested for pharmacoprophylaxis." | 1.36 | Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients. ( Arnold, JD; Barker, DE; Burkholder, HC; Dart, BW; Longley, JM; Maxwell, RA; Mejia, VA; Smith, PW, 2010) |
| " Standard enoxaparin dosing was defined as 0." | 1.36 | Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients. ( Blanc, PD; Boettger, RF; Golden, J; Hoopes, C; Huang, MY; Hui, C; Leard, LE; Singer, JP; Watkins, K, 2010) |
| "The diagnosis of pulmonary embolism was made by computed tomography, which showed the typical changes." | 1.36 | [Pulmonary embolism as a cause of a reduced performance capacity of endurance trained men - report of 2 cases]. ( Dickhuth, HH; König, D; Korsten-Reck, U; Winterer, J, 2010) |
| "The pregnancy was carried to term and she delivered a healthy boy at 38 weeks of gestation." | 1.36 | Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia. ( Corbi, P; Hajj-Chahine, J; Jayle, C; Tomasi, J, 2010) |
| "To evaluate the rates of deep vein thrombosis (DVT) and pulmonary embolism (PE) in hip fracture patients receiving mechanical thromboprophylaxis." | 1.36 | Mechanical thromboprophylaxis for patients undergoing hip fracture surgery. ( Lee, HC; Loh, JS; Mehta, KV, 2010) |
| "Gastrointestinal stromal tumors are the commonest stromal tumors of the digestive tract." | 1.36 | [Gastrointestinal stromal tumor in pregnancy and control. Case report]. ( Cuerva-González, MJ; de la Calle-Fernández, M; Lacoponi, S; Pozo-Krielinger, J, 2010) |
| "Dalteparin was used as a reference compound." | 1.36 | Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats. ( Elg, M; Johansson, K; Kjaer, M; Pehrsson, S, 2010) |
| "Enoxaparin significantly decreased deep venous thrombosis risk in patients undergoing circumferential abdominoplasty." | 1.35 | Thromboembolic risk assessment and the efficacy of enoxaparin prophylaxis in excisional body contouring surgery. ( Abtahi, F; Brown, SA; Farkas, JP; Hatef, DA; Kenkel, JM; Nguyen, MQ; Rohrich, RJ, 2008) |
| "We discuss the cases of 2 patients with prostate cancer who were taking Dr." | 1.35 | Prostasol and venous thromboembolism. ( Bubley, G; Clement, J, 2008) |
| "Priapism is a rare disorder defined as a persistent penile erection that continues hours beyond, or is unrelated to, sexual stimulation." | 1.35 | Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency. ( Abu Sham'a, RA; Kufri, FH; Yassin, IH, 2008) |
| "Although the incidence of symptomatic pulmonary thromboembolism did not differ significantly between groups 1 and 2 (1." | 1.35 | The efficacy of prophylactic low-molecular-weight heparin to prevent pulmonary thromboembolism in immediate breast reconstruction using the TRAM flap. ( Ahn, SH; Eom, JS; Kim, EK; Lee, TJ; Son, BH, 2009) |
| " Evidence suggests inconsistent bioavailability in intensive care unit (ICU) patients." | 1.35 | Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients. ( Cho, SD; Morris, MS; Schreiber, MA; Underwood, SJ; Van, PY; Watters, JM, 2009) |
| "Underuse of deep vein thrombosis (DVT) prophylaxis persists, despite guidelines supporting its use in hospitalized cancer patients." | 1.35 | Use of deep vein thrombosis prophylaxis in hospitalized cancer patients. ( Awar, Z; Sheikh-Taha, M, 2009) |
| "We present three cases who developed deep vein thrombosis (DVT) and subsequent pulmonary thromboembolism (PTE) after transatlantic air travel." | 1.35 | Air travel and pulmonary embolism: "economy class syndrome". ( Arora, P; Bhatia, V; Kaul, U; Mittal, A; Pandey, AK; Parida, AK, 2009) |
| "But dabigatran was associated with surgical wound seepage in 7% of patients, versus 4." | 1.35 | Dabigatran: new drug. Continue to use heparin, a better-known option. ( , 2009) |
| "Major bleedings were reported as secondary endpoints in only two hospitalized patients." | 1.35 | [Prophylaxis of deep vein thrombosis with enoxaparin 40 mg in outpatients compared to hospitalized medically ill patients]. ( Kröger, K, 2009) |
| " Early surgical intervention and standard management combined with Iloprost infusion may help in healing the lesions by increasing extremity perfusion and may prevent extremity loss." | 1.35 | Successful surgical treatment of Nicolau's syndrome combined with intravenous iloprost. ( Duman, A; Durgut, K; Gormus, N; Senaran, H; Solak Görmüs, ZI; Tanyeli, O, 2009) |
| "The cumulative rate of unprovoked recurrence in patients with a positive D-dimer was 20% at 5 years [5." | 1.35 | Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. ( Baglin, C; Baglin, T; Luddington, R; Palmer, CR, 2008) |
| "The other two patients with history of pulmonary embolism, and one patient having mechanical aortic valve and atrial fibrillation, recovered uneventfully when reduced doses of low molecular weight heparin bridging therapy were administered." | 1.35 | The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases. ( Armstrong, E; Hernesniemi, J; Niemi, T; Silvasti-Lundell, M, 2009) |
| "The recommended dosage of tinzaparin in the treatment of thromboembolism during pregnancy is 175 IU/kg/day, as for non-pregnant subjects." | 1.35 | Treatment of deep venous thrombosis in pregnant women. ( Grønlykke, T; Langhoff-Roos, J; Lykke, JA, 2008) |
| "Oral rivaroxaban (BAY 597939) is a new, highly selective and potent direct factor-Xa (FXa) inhibitor with a predictable pharmacodynamic and pharmacokinetic profile and could therefore be an attractive antithrombotic drug." | 1.34 | Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. ( Biemond, BJ; Buetehorn, U; Büller, HR; Friederich, PW; Levi, M; Perzborn, E, 2007) |
| "No proximal deep venous thrombosis or other thromboembolic events occurred." | 1.34 | Prophylaxis of venous thromboembolism in minor orthopedic surgery with parnaparin. ( Bugamelli, S; Calò, P; Ferrari, P; Montebugnoli, M; Zangheri, E, 2007) |
| "Bemiparin has shown to be effective and safe in clinical trials in total knee or hip replacement." | 1.34 | A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery. ( Abad, JI; Gómez-Outes, A; Martínez-González, J; Rocha, E, 2007) |
| "Many cancer patients are still poorly assessed for risk of VTE." | 1.34 | Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice. ( Altimiras, J; Balibrea, JL; Gómez-Outes, A; Larruzea, I; Martínez-González, J; Rocha, E, 2007) |
| " Positively charged dendrimers increased the relative bioavailability of enoxaparin by 40%, while a negatively charged dendrimer had no effect." | 1.34 | Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin. ( Ahsan, F; Bai, S; Thomas, C, 2007) |
| "Authors describe a case of systemic sclerosis with deep venous thrombosis." | 1.34 | [Hereditary thrombophilia and systemic sclerosis. An unusual case report]. ( Albanese, L; D'Amore, M; D'Amore, S; Minenna, G; Scagliusi, P, 2007) |
| "Clinically symptomatic proximal deep vein thrombosis (DVT) or pulmonary embolism (PE) rates were 1." | 1.34 | Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial. ( Chan, E; Chittock, D; de Lemos, J; Gorman, SK; Ho, SG; Simons, RK; Slavik, RS; Wing, PC, 2007) |
| " We propose a new orally active heparin, Db-LHD, in a solid dosage form to effectively prevent DVT and PE." | 1.34 | A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study. ( Byun, Y; Kim, CY; Kim, SK; Lee, DY; Moon, HT; Nam, JH, 2007) |
| "The incidence of deep venous thrombosis in both cohorts was 0." | 1.34 | Best Poster Award. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin. ( Kothari, SN; Lambert, PJ; Mathiason, MA, 2007) |
| "Clinically symptomatic deep venous thrombosis was detected in association with four (0." | 1.34 | Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. ( Boutary, M; Dorr, LD; Gendelman, V; Long, WT; Maheshwari, AV; Wan, Z, 2007) |
| "Once-daily dosing of prophylactic LMWH dalteparin is feasible, safe, and effective in high-risk trauma patients." | 1.34 | Utility of once-daily dose of low-molecular-weight heparin to prevent venous thromboembolism in multisystem trauma patients. ( Cothren, CC; Moore, EE; Morgan, SJ; Smith, WR, 2007) |
| "Fondaparinux sodium is a new antithrombotic agent that is indicated for prophylaxis of VTE after major orthopedic surgery." | 1.33 | Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis. ( Bjorvatn, A; Kristiansen, F, 2005) |
| " The efficacy of daily dosing in critically ill patients is unknown." | 1.33 | Optimal dose of enoxaparin in critically ill trauma and surgical patients. ( Abrams, JE; Rutherford, EJ; Schooler, WG; Skeete, DA; Sredzienski, E, 2005) |
| "Fondaparinux is a synthetic penta-saccharide which may be regarded as an extreme low-molecular-weight heparin with a ratio of anti-factor Xa : anti-factor IIa activity as 1 : 0, and with a promising efficacy/safety profile." | 1.33 | [Is there a difference between low-molecular-weight heparins?]. ( Eritsland, J, 2005) |
| "Pulmonary thromboembolism is the leading direct cause of maternal deaths in the UK." | 1.33 | Thromboprophylaxis post vaginal delivery: are we forgetting it? Audit on thromboprophylaxis prescription post vaginal births. ( Tan, EK; Wisdom, SJ, 2006) |
| "To develop an appropriate dosing strategy for continuous intravenous infusions (CII) of enoxaparin by minimizing the percentage of steady-state anti-Xa concentration (C(ss)) outside the therapeutic range of 0." | 1.33 | Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation. ( Bies, RR; Bobek, MB; Duffull, SB; Feng, Y; Green, B; Kane-Gill, SL, 2006) |
| "After 48 h, the rate of venous thrombosis, as evaluated microscopically, was significantly decreased in hemodiluted animals (1/8) as compared with controls (10/10); in rats treated with dextran-40 (7/10) and enoxaparin (5/10) the rate of venous thrombosis was significantly higher as compared with rats of the group hemodiluted." | 1.33 | Comparative study of isovolemic hemodilution with 3% albumin, dextran-40, and prophylactic enoxaparin (LMWH) on thrombus formation at venous microanastomosis in rats. ( Campos, AD; Farina, JA; Piccinato, CE; Rossi, MA, 2006) |
| " This study supports the safety of dosing dalteparin based on actual body weight in obese patients." | 1.33 | The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients. ( Al-Yaseen, E; Anderson, J; Kovacs, MJ; Martin, J; Wells, PS, 2005) |
| "Other main symptoms of PNH are venous thrombosis and deficient hematopoiesis." | 1.33 | [Anesthetic management of a patient with paroxysmal nocturnal hemoglobinuria and suspected abdominal venous thrombosis]. ( Ishikawa, S; Kawauchi, Y; Makita, K; Nakazawa, K; Yamakawa, N, 2005) |
| "Pulmonary thromboembolism is rarely recognized in young children, even in hospital settings." | 1.33 | A six-year old with fatal pulmonary embolism. ( Chakraborty, S; Rao, NK; Sridhar, AV, 2005) |
| "Inflammatory bowel diseases (IBD)--ulcerative colitis and Crohn's disease--are associated with increased risk for thrombotic complications both in the arterial and venous system." | 1.32 | [Cerebral sinus thrombosis and ulcerative colitis: two cases]. ( Debreczeni, R; Ilniczky, S; Kovács, T; Szirmai, I, 2003) |
| "12 patients (2,6%) had pulmonary embolism and 8 of them (1,7%) had died." | 1.32 | [Venous thromboembolism prophylaxis with low molecular weight heparins in polytraumatized patients in intensive care unit (extended serie)]. ( Akar, U; Büyükkurt, CD; Dural, CA; Güloğlu, R; Kurtoğlu, M, 2003) |
| " Dosing was determined individually by the investigators with a goal of maintaining an AT activity of 80 to 150 percent." | 1.32 | Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures. ( Bauer, KA; Bonfiglio, J; Greist, A; Holmes, HE; Konkle, BA; Weinstein, R, 2003) |
| " The rates of minor bleeding complications in the aspirin group, the < 12-hour postoperative dosing of the enoxaparin group, and the 12 to 24-hour postoperative dosing of the enoxaparin group were 3." | 1.32 | Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting. ( Ennis, RS, 2003) |
| "Venous thromboembolism was previously regarded as a surgical problem, but occurs at least as frequently among medical patients." | 1.32 | Venous thromboembolic risk and prevention in acute medical illness. ( Hampton, KK, 2003) |
| "The efficacy of LMWH in resolving thrombus in children is, however, unknown and may differ from what has been observed in adults due to known differences in the hemostatic system." | 1.32 | Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound. ( Chan, A; Daneman, A; Dix, D; Marzinotto, V; Massicotte, P; Revel-Vilk, S; Sharathkumar, A, 2004) |
| "The early detection of deep venous thrombosis (DVT) and treatment with systemic anticoagulation to prevent pulmonary embolism (PE) are essential in the management of patients undergoing total joint arthroplasty (TJA)." | 1.32 | Surveillance venous duplex is not clinically useful after total joint arthroplasty when effective deep venous thrombosis prophylaxis is used. ( Endean, ED; Hartford, JM; Kwolek, CJ; Matthews, MR; Mentzer, RM; Minion, DJ; Quick, RC; Schwarcz, TH, 2004) |
| " However, emerging evidence suggests that different dosing strategies may be equivalent." | 1.32 | Daily vs twice daily enoxaparin in the prevention of venous thromboembolic disorders during rehabilitation following acute spinal cord injury. ( Chen, D; Crandall, S; Hebbeler, SL; Marciniak, CM; Mendelewski, S; Nussbaum, S, 2004) |
| " The low antifactor Xa levels that were observed suggest that a reduced dose-response relationship may exist between subcutaneously administered enoxaparin and antifactor Xa activity in patients with severe burn injuries." | 1.32 | Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism. ( Angood, PB; Gandhi, PJ; Smith, BS; Yogaratnam, D, 2004) |
| "To study the incidence of deep vein thrombosis in Indian patients undergoing total hip arthroplasty with or without prophylaxis, and the effect of enoxaparin on deep vein thrombosis." | 1.32 | Deep vein thrombosis after total hip arthroplasty in Indian patients with and without enoxaparin. ( Dhal, AK; Dhaon, BK; Jain, V; Pradhan, G, 2004) |
| " The drugs are marked by bioavailability approximating 100%, linear dose-dependent pharmacokinetic profile at subcutaneous injection; they do not undergo metabolism and are excreted largely with urine." | 1.32 | [Prevention and treatment of venous thromboses and thromboembolism: pentasaccharides as novel anticoagulants selectively blocking Xe factor, their position and potential (data of the XIX International Congress on Thromboses and Hemostasis)]. ( Averkov, OV, 2004) |
| "The twenty patients with deep vein thrombosis who were assisted in the "hospital at home" unit of the Clínica Nuestra Señora de la Concepción in Madrid from December 1999 to December 2000." | 1.32 | [Treatment of deep vein thrombosis with low molecular weight heparins at home]. ( Arboiro Pinel, R; Bellver Alvarez, TM; García Cañete, J; Herrero Mendoza, MD; Suárez Alvarez, CG, 2003) |
| "Deep vein thrombosis is a condition associated with common complications, both in the acute period and in the long-term." | 1.31 | [Short-term and long-term evolution of deep vein thrombosis treated by a health care unit]. ( Armengol, JG; Fernández-Cruz, A; Jiménez Rodríguez-Madridejos, R; Martín-Carbonero, L; Pedrajas, JM; Salgado, X, 2002) |
| "The overall deep vein thrombosis (DVT) rate in group 1 was 3." | 1.31 | Dose-adjusted thrombosis prophylaxis in trauma surgery according to levels of D-Dimer. ( Hafner, G; Hansen, M; Mayer, A; Peetz, D; Prellwitz, W; Rippin, G; Rommens, PM, 2000) |
| " Today we know that the real advantage of LMWHs is due to their high bioavailability which makes safe and reliable their subcutaneous administration without laboratory monitoring." | 1.31 | [State of the art: low-molecular-weight heparin and beyond]. ( Casali, G; Cimminiello, C; Vitali, L, 2000) |
| "Outpatient treatment of deep venous thrombosis (DVT) with low molecular weight heparin (LMWH) seems as safe and effective as inpatient treatment with unfractionated heparin (UFH)." | 1.31 | Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism. ( Ferrer, R; Grau, E; Medrano, J; Pastor, E; Real, E; Selfa, S; Tenias, JM, 2001) |
| "Patients with chronic renal failure and hyperphosphatemia may be predisposed to develop calcinosis cutis." | 1.31 | Nadroparin-induced Calcinosis cutis in renal transplant recipients. ( Hilbrands, LB; Ruiter, DJ; van Haren, FM, 2001) |
| "Home treatment of deep vein thrombosis (DVT) has been shown to be safe and effective." | 1.31 | Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients. ( Beyer, J; Schellong, SM; Schmidt, B; Schröder, HE; Schwarz, T, 2001) |
| "To compare the frequency of deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing gynecological operations without low molecular weight heparin (LMWH) prophylaxis and those receiving such prophylaxis." | 1.31 | Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin. Gynecological ward retrospective analysis. ( Cyrkowicz, A, 2002) |
| " In this report, we describe a woman with primary antiphospholipid antibody syndrome who developed extensive pulmonary embolism despite receiving a proven therapeutic dosage of low molecular weight heparin." | 1.31 | Low-molecular weight heparin: treatment failure in a patient with primary antiphospholipid antibody syndrome. ( Ahmed, S; Karim, A; Mattana, J; Patel, D; Siddiqui, R, 2002) |
| "In the venous thrombosis model at the maximally effective dose, C921-78 had minimal extension of ex vivo clotting parameters, while enoxaparin and unfractionated heparin demonstrated a two to sevenfold increase in activated partial thromboplastin times, and PPACK had a threefold extension of thrombin clotting times." | 1.31 | Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. ( Hollenbach, SJ; Ku, P; Lin, PH; Malinowski, J; Marlowe, CK; Scarborough, RM; Sinha, U; Wong, PW; Zhu, BY, 2000) |
| "We investigated the incidence of venous thrombosis in patients hospitalised from 1992 to 1996 and related our findings to literature reports." | 1.31 | Thrombosis prophylaxis in hospitalised medical patients: does prophylaxis in all patients make sense? ( den Heijer, M; Nijs, AM; Schuurman, B, 2000) |
| " Anti-Xa levels were elevated at 15 minutes after dosing in the OHEP/SNAC group and remained significantly elevated at 4 hours (P<0." | 1.31 | Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis. ( Baughman, RA; Gonze, MD; Leone-Bay, A; Money, SR; Salartash, K; Sternbergh, WC, 2000) |
| "Deep venous thrombosis is 1 of the most common postoperative complications resulting in significant mortality and morbidity in patients undergoing total hip and total knee arthroplasty." | 1.31 | Noncompliance in the inpatient administration of enoxaparin in conjunction with epidural or spinal anesthesia. ( Bailey, M; Del Schutte, H; McEvoy, MD; Taylor, D, 2000) |
| "Major bleeding was defined as a postoperative drop of > or = 5 g/dL) of hemoglobin." | 1.31 | Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery. ( Abdullah, H; Camblin, J; Fareed, J; Hakki, SI; Hamadeh, O; Hoppensteadt, DA; Nasseri, AF; Wright, T, 2000) |
| "By way of consensus of opinion of trauma surgeons and pharmacists, enoxaparin DVT prophylaxis guidelines were developed, implemented, and evaluated." | 1.31 | Implementation and evaluation of guidelines for use of enoxaparin as deep vein thrombosis prophylaxis after major trauma. ( Devlin, JW; Moed, B; Tyburski, JG, 2001) |
| "Patients with clinical suspicion of deep venous thrombosis or pulmonary embolism were investigated as appropriate." | 1.31 | Prophylaxis of thromboembolism in spinal injuries--results of enoxaparin used in 276 patients. ( Deep, K; Fraser, MH; Jigajinni, MV; McLean, AN, 2001) |
| "Thromboprophylaxis with 60 mg enoxaparin daily, in split doses, starting before surgery, is safe and appropriate in patients with hip fractures." | 1.31 | Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery. ( Greiner, N; Korninger, C; Roller, RE; Sim, E; Thaler, HW, 2001) |
| "Treatment and prevention of deep vein thrombosis (DVT) raise a number of important economic issues." | 1.31 | Economic issues in the treatment and prevention of deep vein thrombosis from a managed care perspective. ( de Lissovoy, G, 2001) |
| "The time to formation of an occlusive thrombus in the femoral arteries averaged 69+/-5 min in the control group compared to 127+/-19, 192+/-33 and 219+/-15 min in the low-, mid- and high-dose CI-1031 groups." | 1.31 | The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. ( Hicks, GW; Janiczek-Dolphin, N; Juneau, PL; Leadley, R; McClanahan, TB; Mertz, TE; Morrison, AL; Morser, J; Peng, YW; Sullivan, ME, 2001) |
| "Incidence, seriousness and causality of maternal, fetal and neonatal adverse events, pregnancy outcome, and incidence of venous thromboembolism." | 1.31 | Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies. ( Borel-Derlon, A; Borg, JY; Boudignat, O; Cohen, C; Conard, J; Darmon, JY; Francoual, C; Lepercq, J; Priollet, P; Schved, JF; Tournaire, M; Yvelin, N, 2001) |
| "Home treatment of DVT is possible and effective, safe and cost-effective." | 1.31 | Could deep vein thrombosis be safely treated at home? ( Cambal, M; Labas, P; Ohradka, B, 2001) |
| " All patients received a multi-modality DVT prophylaxis protocol that included: early ambulation, graduated compression stockings, intermittent pneumatic compression, and enoxaparin (LMWH) in two dosage groups." | 1.31 | A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. ( Hoedema, RM; Scholten, DJ; Scholten, SE, 2002) |
| "Outpatient treatment of acute proximal deep vein thrombosis with enoxaparin has also been shown to be cost effective compared with inpatient treatment using UFH." | 1.31 | Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes. ( Bergqvist, D, 2002) |
| "A deep vein thrombosis was identified in 2 (2%) of 106 patients." | 1.31 | Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries. ( Berne, JD; Grahm, TW; Kerns, DB; McAuley, CE; McLarty, JW; Norwood, SH; Short, K; Vallina, VL, 2002) |
| " The treatment protocols for low molecular weight heparin and warfarin, using dosing protocols determined by weight and INR results, are described." | 1.31 | Outpatient treatment of community acquired venous thromboembolism--the Christchurch experience. ( Han, DY; Heaton, D; Inder, A, 2002) |
| "The observed recurrence rate of 0." | 1.31 | Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study. ( Bonet, M; Büller, H; Fraile, M; Lensing, AW; Monreal, M; Muchart, J; Roncales, J, 2002) |
| "We report a pregnant woman with systemic lupus erythematosus and recurrent venous thromboembolism who suffered from heparin-induced thrombocytopenia type II while treated with dalteparin sodium." | 1.31 | Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. ( Geberth, M; Harenberg, J; Heene, DL; Hoffmann, U; Huhle, G, 2000) |
| "Dalteparin and warfarin treatment was started, and symptoms relieved rapidly." | 1.31 | Superior mesenteric and portal vein thrombosis following laparoscopic nissen fundoplication. ( Kemppainen, E; Kiviluoto, T; Kokkola, A; Sirén, J, 2000) |
| " Incremental cost-effectiveness ratio calculations demonstrate that warfarin dosed to an international normalized ratio of 2-2." | 1.31 | Cost effectiveness of deep venous thrombosis prophylaxis after hip fracture. ( Chisholm, MA; Wade, WE, 2000) |
| "Stasis ulcers are commonly the result of chronic venous insufficiency." | 1.31 | Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report. ( Bick, RL; Scott, RG, 2001) |
| " One daily dosage of 5,000 IU anti-Xa resulted in a measurable level of FXa for 24 h in pregnancy week 40, compared with 17h at pregnancy week 37." | 1.31 | Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy. ( Blombäck, M; Bremme, K; van Rooijen, M; Yu, A, 2001) |
| " This study evaluates the dose-response relationship using a selectin receptor antagonist." | 1.31 | P-selectin antagonism causes dose-dependent venous thrombosis inhibition. ( Chapman, AM; Fex, BA; Greenfield, LJ; Londy, FJ; Myers, DD; Schaub, R; Wakefield, TW; Wrobleski, SK, 2001) |
| "Venous thrombosis is a very rare occurrence in patients with haemophilia A." | 1.31 | Thrombosis in a duplicated superficial femoral vein in a patient with haemophilia A. ( Allan, PL; Dennis, R; Ludlam, CA; Manson, LM; Stewart, AJ, 2000) |
| " LMWH allows for consistent dosing in postoperative patients without the need for laboratory monitoring." | 1.30 | Intrahepatic hemorrhage after use of low-molecular-weight heparin for total hip arthroplasty. ( Houde, JP; Steinberg, G, 1999) |
| " Patient and operative characteristics, hematologic values, and timing of enoxaparin dosing were analyzed as related to major and minor bleeding complications." | 1.30 | Bleeding complications with enoxaparin for deep venous thrombosis prophylaxis. ( Atkinson, RE; Shaieb, MD; Watson, BN, 1999) |
| "Standard treatment of deep venous thrombosis (DVT) previously required hospitalization so patients could receive continuous intravenous infusion of unfractionated heparin." | 1.30 | Reimbursement of enoxaparin for outpatient therapy. Proceedings of regional meetings. ( , 1999) |
| "Upper extremity deep vein thrombosis (DVT) is now recognized as a major cause of morbidity and mortality." | 1.30 | Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity. ( Cruickshank, M; Goudie, D; Kovacs, MJ; Morrow, B; Savage, KJ; Schulz, V; Wells, PS, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 39 (4.24) | 18.2507 |
| 2000's | 529 (57.50) | 29.6817 |
| 2010's | 281 (30.54) | 24.3611 |
| 2020's | 71 (7.72) | 2.80 |
| Authors | Studies |
|---|---|
| Gao, Z | 1 |
| Li, S | 3 |
| Zhao, J | 1 |
| Li, J | 3 |
| Gao, Y | 2 |
| Koopmans, RJ | 1 |
| Cannegieter, SC | 2 |
| Koot, RW | 1 |
| Vleggeert-Lankamp, CLA | 1 |
| Zhou, T | 2 |
| Sun, X | 1 |
| Li, Y | 1 |
| Chen, X | 1 |
| Cheng, B | 1 |
| van Rein, N | 1 |
| Biedermann, JS | 1 |
| van der Meer, FJM | 1 |
| Wiersma, N | 1 |
| Vermaas, HW | 1 |
| Reitsma, PH | 1 |
| Kruip, MJHA | 1 |
| Lijfering, WM | 1 |
| Zhang, C | 1 |
| Xu, B | 1 |
| Liang, G | 1 |
| Zeng, X | 1 |
| Yang, C | 2 |
| Zhang, F | 1 |
| Wan, Z | 2 |
| Yu, W | 1 |
| Chen, D | 2 |
| Ge, Z | 1 |
| Zhang, X | 1 |
| Righini, M | 2 |
| Robert-Ebadi, H | 2 |
| Glauser, F | 1 |
| Blondon, M | 1 |
| Ouvry, P | 1 |
| Diamand, JM | 1 |
| Tissot, A | 1 |
| Frappe, P | 1 |
| Quere, I | 2 |
| Kahn, SR | 5 |
| Galanaud, JP | 2 |
| Le Gal, G | 2 |
| Guarnera, G | 1 |
| Abeni, D | 1 |
| Antignani, PL | 2 |
| Apollonio, A | 1 |
| Conti, F | 1 |
| Mollo, PL | 1 |
| Murgiano, A | 1 |
| Ofria, F | 1 |
| Ruggeri, M | 1 |
| Ventura, F | 1 |
| Bonsignore, A | 1 |
| De Stefano, F | 1 |
| Pizzorno, E | 1 |
| Palmiere, C | 1 |
| Ranke, H | 1 |
| Märdian, S | 1 |
| Haas, NP | 1 |
| Baecker, H | 1 |
| Guenneguez, H | 1 |
| Brisot, D | 1 |
| Diard, A | 1 |
| Faisse, P | 1 |
| Barrellier, MT | 1 |
| Hamel-Desnos, C | 1 |
| Jurus, C | 1 |
| Pichot, O | 1 |
| Martin, M | 1 |
| Mazzolai, L | 1 |
| Choquenet, C | 1 |
| Accassat, S | 1 |
| Carrier, M | 4 |
| Mermilllod, B | 1 |
| Laroche, JP | 1 |
| Bounameaux, H | 4 |
| Perrier, A | 1 |
| Bruntink, MM | 1 |
| Groutars, YME | 1 |
| Schipper, IB | 1 |
| Breederveld, RS | 1 |
| Tuinebreijer, WE | 1 |
| Derksen, RJ | 1 |
| Ofosu, FA | 1 |
| Kistler, U | 1 |
| Kramers-de Quervain, I | 1 |
| Munzinger, U | 1 |
| Kucher, N | 2 |
| Uncu, H | 1 |
| Adişen, E | 1 |
| Seker, U | 1 |
| Gürer, MA | 1 |
| Dogan, M | 1 |
| Acikgoz, M | 1 |
| Bora, A | 1 |
| Başaranoğlu, M | 1 |
| Oner, AF | 1 |
| Tsukanov, IuT | 1 |
| Noskov, VK | 1 |
| Dziuba, GG | 1 |
| Epanchintsev, PM | 1 |
| Tarkovskiĭ, AA | 1 |
| Zudin, AM | 1 |
| Aleksandrova, ES | 1 |
| Colagiovanni, A | 1 |
| Rizzi, A | 1 |
| Buonomo, A | 1 |
| De Pasquale, T | 1 |
| Pecora, V | 1 |
| Sabato, V | 1 |
| Aruanno, A | 1 |
| Pascolini, L | 1 |
| Nucera, E | 1 |
| Schiavino, D | 1 |
| Schwarz, T | 2 |
| Buschmann, L | 1 |
| Beyer, J | 3 |
| Halbritter, K | 2 |
| Rastan, A | 1 |
| Schellong, S | 3 |
| Zondag, W | 1 |
| Mos, IC | 1 |
| Creemers-Schild, D | 1 |
| Hoogerbrugge, AD | 1 |
| Dekkers, OM | 1 |
| Dolsma, J | 1 |
| Eijsvogel, M | 1 |
| Faber, LM | 1 |
| Hofstee, HM | 1 |
| Hovens, MM | 1 |
| Jonkers, GJ | 1 |
| van Kralingen, KW | 1 |
| Kruip, MJ | 1 |
| Vlasveld, T | 1 |
| de Vreede, MJ | 1 |
| Huisman, MV | 8 |
| Hull, RD | 17 |
| Liang, J | 3 |
| Townshend, G | 2 |
| Bellido, M | 1 |
| van der Velden, VH | 1 |
| Leebeek, FW | 1 |
| te Boekhorst, PA | 1 |
| Hufeland, M | 1 |
| Braun, M | 1 |
| Marnitz, T | 1 |
| Schroeder, J | 1 |
| Lindner, T | 1 |
| O'Flaherty, M | 1 |
| Lerum, K | 1 |
| Martin, P | 1 |
| Grassi, D | 1 |
| Martín-Carbonero, L | 1 |
| Salgado, X | 1 |
| Pedrajas, JM | 1 |
| Armengol, JG | 1 |
| Jiménez Rodríguez-Madridejos, R | 1 |
| Fernández-Cruz, A | 1 |
| Heizmann, M | 1 |
| Baerlocher, GM | 1 |
| Steinmann, F | 1 |
| Horber, FF | 1 |
| Wuillemin, W | 1 |
| Betrosian, AP | 1 |
| Theodossiades, G | 1 |
| Lambroulis, G | 1 |
| Kostantonis, D | 1 |
| Balla, M | 1 |
| Papanikolaou, M | 1 |
| Georgiades, G | 1 |
| Makatsaria, AD | 1 |
| Bitsadze, VO | 1 |
| Dolgushina, NV | 1 |
| Ilniczky, S | 1 |
| Debreczeni, R | 1 |
| Kovács, T | 1 |
| Szirmai, I | 1 |
| Gerlach, R | 2 |
| Scheuer, T | 1 |
| Beck, J | 2 |
| Woszczyk, A | 2 |
| Seifert, V | 2 |
| Raabe, A | 2 |
| Mazokopakis, EE | 1 |
| Vrentzos, GE | 1 |
| Ganotakis, ES | 1 |
| Wang, CJ | 2 |
| Wang, JW | 1 |
| Weng, LH | 1 |
| Hsu, CC | 1 |
| Huang, CC | 1 |
| Yu, PC | 1 |
| Laporte, S | 5 |
| Decousus, H | 7 |
| Mismetti, P | 5 |
| Biesek, D | 1 |
| Ksiazkiewicz, B | 1 |
| Wanat-Słupska, E | 1 |
| Peternel, L | 2 |
| Stegnar, M | 3 |
| Drevensek, G | 2 |
| Budihna, MV | 2 |
| Bozic, M | 2 |
| Zega, A | 1 |
| Stalc, A | 2 |
| Cerne, M | 2 |
| Urleb, U | 1 |
| Mahé, I | 1 |
| Bergmann, JF | 2 |
| d'Azémar, P | 1 |
| Vaissie, JJ | 1 |
| Caulin, C | 1 |
| Giorgini, S | 1 |
| Martinelli, C | 1 |
| Massi, D | 1 |
| Lumini, A | 1 |
| Mannucci, M | 1 |
| Giglioli, L | 1 |
| Simonneau, G | 2 |
| Derlon, A | 1 |
| Samii, K | 1 |
| Samama, CM | 4 |
| Bergman, JF | 1 |
| Giannoni, MF | 1 |
| Ciatti, R | 1 |
| Capoccia, L | 1 |
| Ruggiero, M | 1 |
| Dauri, M | 1 |
| Mariani, PP | 1 |
| Tosetto, A | 1 |
| Biemond, BJ | 2 |
| Perzborn, E | 1 |
| Friederich, PW | 1 |
| Levi, M | 1 |
| Buetehorn, U | 1 |
| Büller, HR | 13 |
| Luba, M | 1 |
| Firek, A | 1 |
| Kochanowski, Z | 1 |
| Niers, TM | 1 |
| Di Nisio, M | 3 |
| Klerk, CP | 2 |
| Baarslag, HJ | 1 |
| Pavlović, S | 1 |
| Zivković, S | 1 |
| Koraćević, G | 1 |
| Baars, EC | 1 |
| Ettema, HB | 1 |
| Fritschy, WM | 1 |
| Suri, C | 1 |
| Liptay, L | 1 |
| Gáspár, L | 1 |
| Blanchard, J | 1 |
| Meuwly, JY | 1 |
| Leyvraz, PF | 1 |
| Miron, MJ | 1 |
| Hoffmeyer, P | 1 |
| Didier, D | 1 |
| Schneider, PA | 1 |
| Giedrojć, J | 1 |
| Klimiuk, M | 1 |
| Radziwon, P | 1 |
| Kłoczko, J | 1 |
| Bielawiec, M | 1 |
| Breddin, HK | 6 |
| Belcaro, G | 1 |
| Nicolaides, AN | 2 |
| Cesarone, MR | 1 |
| Laurora, G | 1 |
| De Sanctis, MT | 1 |
| Incandela, L | 1 |
| Barsotti, A | 1 |
| Corsi, M | 1 |
| Vasdekis, S | 5 |
| Christopoulos, D | 1 |
| Lennox, A | 1 |
| Malouf, M | 1 |
| Fraisse, F | 1 |
| Holzapfel, L | 1 |
| Couland, JM | 1 |
| Bedock, B | 1 |
| Feissel, M | 1 |
| Herbecq, P | 1 |
| Pordes, R | 1 |
| Poussel, JF | 1 |
| Roux, L | 1 |
| Peetz, D | 1 |
| Hafner, G | 1 |
| Hansen, M | 1 |
| Mayer, A | 1 |
| Rippin, G | 1 |
| Rommens, PM | 1 |
| Prellwitz, W | 1 |
| Miljić, P | 1 |
| Colović, MD | 1 |
| Suvajdzić, N | 1 |
| Fong, YK | 1 |
| Ruban, P | 1 |
| Yeo, SJ | 1 |
| Lee, BP | 1 |
| Lo, NN | 1 |
| Seow, KH | 1 |
| Ng, SC | 1 |
| Pottier, P | 1 |
| Planchon, B | 1 |
| Truchaud, F | 1 |
| Pistorius, MA | 1 |
| Furic, I | 1 |
| Grolleau, JY | 1 |
| Egger, B | 1 |
| Schmid, SW | 1 |
| Naef, M | 1 |
| Wildi, S | 1 |
| Büchler, MW | 1 |
| Manganaro, A | 1 |
| Giannino, D | 1 |
| Lembo, D | 1 |
| Bruni, F | 1 |
| Consolo, F | 1 |
| Cimminiello, C | 2 |
| Casali, G | 1 |
| Vitali, L | 1 |
| Grau, E | 1 |
| Tenias, JM | 1 |
| Real, E | 1 |
| Medrano, J | 1 |
| Ferrer, R | 1 |
| Pastor, E | 1 |
| Selfa, S | 1 |
| van Haren, FM | 1 |
| Ruiter, DJ | 1 |
| Hilbrands, LB | 1 |
| Brun, P | 1 |
| Gylys, KH | 1 |
| Horne, MK | 1 |
| Couturaud, F | 1 |
| Julian, JA | 6 |
| Kearon, C | 1 |
| Celebi, F | 1 |
| Balik, AA | 1 |
| Yildirgan, MI | 1 |
| Başoğlu, M | 1 |
| Adigüzel, H | 1 |
| Oren, D | 1 |
| Schmidt, B | 1 |
| Schröder, HE | 1 |
| Schellong, SM | 8 |
| Cyrkowicz, A | 1 |
| Schaepkens Van Riempst, JT | 1 |
| Van Hee, RH | 1 |
| Weyler, JJ | 1 |
| Cosmi, B | 3 |
| Filippini, M | 2 |
| Campana, F | 1 |
| Avruscio, G | 2 |
| Ghirarduzzi, A | 3 |
| Bucherini, E | 2 |
| Camporese, G | 3 |
| Imberti, D | 3 |
| Legnani, C | 1 |
| Palareti, G | 4 |
| Bernardi, E | 1 |
| Noventa, F | 1 |
| Tonti, D | 1 |
| Montebugnoli, M | 1 |
| Bugamelli, S | 1 |
| Calò, P | 1 |
| Zangheri, E | 1 |
| Ferrari, P | 1 |
| Yu, R | 1 |
| Nansubuga, F | 1 |
| Yang, J | 2 |
| Ding, W | 2 |
| Li, K | 1 |
| Weng, D | 1 |
| Wu, P | 1 |
| Chen, G | 1 |
| Ma, D | 1 |
| Wei, J | 1 |
| García-Boyano, M | 1 |
| Caballero-Caballero, JM | 1 |
| Escosa García, L | 1 |
| Gutiérrez Alvariño, M | 1 |
| Blanco Bañares, MJ | 1 |
| Climent Alcalá, FJ | 1 |
| Sagüillo, K | 1 |
| Pérez-Flecha, F | 1 |
| Almeida, F | 1 |
| Picón, M | 1 |
| Acero, J | 1 |
| Revilla-Peñaloza, F | 1 |
| Olsoff-Pagovich, PJ | 1 |
| Ochoa-Gomez, JR | 1 |
| Castaneda-Gaxiola, R | 1 |
| Rubio-Gayosso, ÁI | 1 |
| Ceballos, G | 1 |
| Molina-Guarneros, JA | 1 |
| Suchkov, IA | 3 |
| Martinez-Gonzalez, J | 5 |
| Garbade, T | 1 |
| Falciani, M | 1 |
| Muñoa, L | 1 |
| González, AB | 1 |
| Díaz de Rada, P | 1 |
| Valentí, A | 1 |
| Valentí, JR | 1 |
| Ciccone, MM | 1 |
| Cortese, F | 1 |
| Corbo, F | 1 |
| Corrales, NE | 1 |
| Al-Momen, AK | 1 |
| Silva, A | 1 |
| Zito, A | 1 |
| Pinto, M | 1 |
| Gesualdo, M | 1 |
| Scicchitano, P | 1 |
| Alalaf, SK | 1 |
| Jawad, AK | 1 |
| Jawad, RK | 1 |
| Ali, MS | 1 |
| Al Tawil, NG | 1 |
| Briassoulis, G | 1 |
| Fitrolaki, MD | 1 |
| Spanaki, AM | 1 |
| Abad Rico, JI | 1 |
| Lozano Sánchez, FS | 1 |
| Rocha, E | 6 |
| Gallardo Jiménez, P | 1 |
| Guijarro Merino, R | 1 |
| Vallejo Herrera, V | 1 |
| Sánchez Morales, D | 1 |
| Villalobos Sánchez, A | 1 |
| Perelló González-Moreno, JI | 1 |
| Gómez-Huelgas, R | 1 |
| Kakkar, VV | 4 |
| Gebska, M | 1 |
| Kadziola, Z | 4 |
| Saba, N | 1 |
| Carrasco, P | 1 |
| Navarro-Quilis, A | 1 |
| Castellet, E | 2 |
| Paz-Jiménez, J | 1 |
| Planès, A | 7 |
| Chapman, TM | 1 |
| Goa, KL | 1 |
| Gómez-Outes, A | 5 |
| Modesto-Alapont, M | 1 |
| Nauffal-Manzur, D | 1 |
| Ansótegui-Barrera, E | 1 |
| Menéndez-Villanueva, R | 1 |
| Ballesta, A | 1 |
| Touza, R | 1 |
| Perpiñá-Tordera, M | 1 |
| Santamaría, A | 1 |
| Juárez, S | 1 |
| Reche, A | 1 |
| Fontcuberta, J | 1 |
| Abad, JI | 1 |
| Balibrea, JL | 1 |
| Altimiras, J | 1 |
| Larruzea, I | 1 |
| Ares-Rodriguez, O | 1 |
| Martinez, AH | 1 |
| Fernandez, AH | 1 |
| Quilis, AN | 1 |
| Howes, J | 1 |
| Sharma, V | 1 |
| Saini, A | 1 |
| Cavalcante, R | 1 |
| Crisanto, LA | 1 |
| Sasaki, J | 1 |
| Marini, CP | 1 |
| Lewis, E | 1 |
| Petrone, P | 1 |
| Zenilman, A | 1 |
| Lu, Z | 1 |
| Rivera, A | 1 |
| McNelis, J | 1 |
| Hunter, M | 1 |
| Lurbet, MF | 1 |
| Parodi, J | 1 |
| Mandó, F | 1 |
| Bonelli, I | 1 |
| Rodríguez, PO | 1 |
| López Saubidet, I | 1 |
| Metcalf, KB | 1 |
| Du, JY | 1 |
| Ochenjele, G | 1 |
| Fioretti, AM | 1 |
| Leopizzi, T | 1 |
| Puzzovivo, A | 1 |
| Giotta, F | 1 |
| Lorusso, V | 1 |
| Luzzi, G | 1 |
| Oliva, S | 1 |
| Westerman, ME | 1 |
| Bree, KK | 1 |
| Msaouel, P | 1 |
| Kukreja, JB | 1 |
| Mantaring, C | 1 |
| Rukundo, I | 1 |
| Gonzalez, MG | 1 |
| Gregg, JR | 1 |
| Casteel, KN | 1 |
| Matin, SF | 1 |
| Kamarudin, MI | 1 |
| Nadarajan, C | 1 |
| Daud, MAM | 1 |
| Chi, G | 4 |
| Violi, F | 1 |
| Pignatelli, P | 1 |
| Vestri, A | 1 |
| Spagnoli, A | 1 |
| Loffredo, L | 1 |
| Hernandez, AF | 6 |
| Cohen, AT | 21 |
| Harrington, RA | 6 |
| Goldhaber, SZ | 12 |
| Gibson, CM | 6 |
| Elmi, G | 1 |
| Allegri, D | 1 |
| Aluigi, L | 1 |
| Aspide, R | 1 |
| Camaggi, V | 1 |
| DI Giulio, R | 1 |
| Domanico, A | 1 |
| Rinaldi, ER | 1 |
| Martignani, A | 1 |
| Wu, ML | 1 |
| Wang, XR | 1 |
| Zhang, WD | 1 |
| Zhang, JM | 1 |
| Lu, YY | 1 |
| Chai, YN | 1 |
| Qin, CZ | 1 |
| Tsai, SW | 1 |
| Chang, WL | 1 |
| Pai, FY | 1 |
| Chou, TA | 1 |
| Chen, CF | 2 |
| Wu, PK | 1 |
| Chen, WM | 2 |
| Dziri, C | 1 |
| Ben Hmida, W | 1 |
| Dougaz, W | 1 |
| Khalfallah, M | 1 |
| Samaali, I | 1 |
| Jerraya, H | 1 |
| Bouasker, I | 1 |
| Nouira, R | 1 |
| Seo, WW | 1 |
| Park, MS | 1 |
| Kim, SE | 1 |
| Lee, JH | 2 |
| Park, DG | 1 |
| Han, KR | 1 |
| Oh, DJ | 1 |
| Hyon, MS | 1 |
| Çaytemel, C | 1 |
| Topaloğlu Demir, F | 1 |
| Büyükbabani, N | 1 |
| Türkoğlu, Z | 1 |
| Uzuner, EG | 1 |
| Jarab, AS | 1 |
| Al-Azzam, S | 1 |
| Badaineh, R | 1 |
| Mukattash, TL | 1 |
| Bsoul, R | 1 |
| Schneiderman, H | 1 |
| Lopetegui-Lia, N | 1 |
| Nichols, J | 1 |
| Ferreira, T | 1 |
| Huber, SC | 1 |
| de Moraes Martinelli, B | 1 |
| Junior, AL | 1 |
| Menezes, FH | 1 |
| Orsi, FA | 1 |
| Bittar, LF | 1 |
| de Oliveira, LFG | 1 |
| Sodre, LR | 1 |
| Mello, TT | 1 |
| Rielli, G | 1 |
| Colella, MP | 1 |
| de Paula, EV | 1 |
| Yamaguti-Hayakawa, GG | 1 |
| Montalvão, S | 2 |
| Annichino-Bizzacchi, JM | 2 |
| Yun, R | 1 |
| Sciubba, DM | 1 |
| Lewin, JJ | 1 |
| Streiff, MB | 1 |
| Haut, ER | 2 |
| Lau, BD | 1 |
| Shermock, KM | 1 |
| Kraus, PS | 1 |
| Popoola, VO | 1 |
| Dalpoas, SE | 1 |
| Pratt, DN | 1 |
| Patterson, KC | 1 |
| Quin, K | 1 |
| Auñón-Chancellor, SM | 1 |
| Pattarini, JM | 1 |
| Moll, S | 2 |
| Sargsyan, A | 1 |
| Weitz, JI | 5 |
| Bauersachs, R | 8 |
| Becker, B | 1 |
| Berkowitz, SD | 5 |
| Freitas, MCS | 1 |
| Lassen, MR | 18 |
| Metzig, C | 1 |
| Raskob, GE | 6 |
| Lee, JK | 1 |
| Koo, JW | 1 |
| Jeong, SY | 1 |
| Choi, S | 1 |
| Park, KC | 1 |
| Hwang, KT | 1 |
| Rosencher, N | 7 |
| Girard, P | 4 |
| Llau, J | 1 |
| Mouret, P | 3 |
| Fisher, W | 2 |
| Martínez-Martín, J | 1 |
| Duverger, D | 1 |
| Deygas, B | 1 |
| Presles, E | 1 |
| Cucherat, M | 1 |
| Pérez-Ardavín, J | 1 |
| Serrano Durbá, A | 1 |
| Miró, I | 1 |
| Conca Baena, MA | 1 |
| March-Villalba, JA | 1 |
| Polo Rodrigo, A | 1 |
| Sangüesa, CC | 1 |
| Domínguez Hinarejos, C | 1 |
| Loginova, AI | 1 |
| Kropacheva, ES | 1 |
| Maykov, EB | 1 |
| Balakhonova, TV | 4 |
| Golitsyn, SP | 1 |
| La Mura, V | 1 |
| Artoni, A | 1 |
| Martinelli, I | 1 |
| Rossio, R | 1 |
| Gualtierotti, R | 1 |
| Ghigliazza, G | 1 |
| Fusco, S | 1 |
| Ierardi, AM | 1 |
| Andrisani, MC | 1 |
| Carrafiello, G | 1 |
| Peyvandi, F | 1 |
| Santoliquido, A | 1 |
| Porfidia, A | 1 |
| Nesci, A | 1 |
| De Matteis, G | 1 |
| Marrone, G | 1 |
| Porceddu, E | 1 |
| Cammà, G | 1 |
| Giarretta, I | 1 |
| Fantoni, M | 1 |
| Landi, F | 1 |
| Gasbarrini, A | 1 |
| Pola, R | 1 |
| D'Alfonso, ME | 1 |
| Lo Monaco, MR | 1 |
| Ross, ME | 1 |
| Glickman, A | 1 |
| Brennecke, A | 1 |
| Tayebnejad, A | 1 |
| Guntupalli, SR | 1 |
| Dumitrascu, OM | 1 |
| Volod, O | 1 |
| Bose, S | 1 |
| Wang, Y | 1 |
| Biousse, V | 1 |
| Lyden, PD | 1 |
| Moll, M | 1 |
| Zon, RL | 1 |
| Sylvester, KW | 1 |
| Chen, EC | 1 |
| Cheng, V | 1 |
| Connell, NT | 1 |
| Fredenburgh, LE | 1 |
| Baron, RM | 1 |
| Cho, MH | 1 |
| Woolley, AE | 1 |
| Connors, JM | 2 |
| Lal, S | 1 |
| Hashmi, J | 1 |
| Yang, L | 1 |
| Wu, J | 3 |
| Russo, V | 1 |
| Cardillo, G | 1 |
| Viggiano, GV | 1 |
| Mangiacapra, S | 1 |
| Cavalli, A | 1 |
| Fontanella, A | 2 |
| Agrusta, F | 1 |
| Bellizzi, A | 1 |
| Amitrano, M | 1 |
| Iannuzzo, M | 1 |
| Sacco, C | 1 |
| Lodigiani, C | 1 |
| Di Micco, P | 1 |
| Mokadem, ME | 1 |
| Hassan, A | 1 |
| Algaby, AZ | 1 |
| Isaacs, DJ | 1 |
| Johnson, EJ | 1 |
| Hofmann, ER | 1 |
| Rangarajan, S | 1 |
| Vinson, DR | 1 |
| Morais, QCD | 1 |
| Santos, MS | 1 |
| Osborne, SA | 1 |
| Masci, PP | 1 |
| Du, QS | 1 |
| Daniel, RA | 1 |
| Desilva, K | 1 |
| Vitetta, L | 1 |
| Zhao, KN | 1 |
| Seymour, RB | 1 |
| Faustino, EVS | 2 |
| Shabanova, V | 2 |
| Raffini, LJ | 2 |
| Kandil, SB | 2 |
| Pinto, MG | 2 |
| Cholette, JM | 3 |
| Hanson, SJ | 2 |
| Nellis, ME | 2 |
| Silva, CT | 2 |
| Chima, R | 1 |
| Sharathkumar, A | 2 |
| Thomas, KA | 1 |
| McPartland, T | 2 |
| Tala, JA | 2 |
| Spinella, PC | 2 |
| Cardoso, ER | 1 |
| Bains, SS | 1 |
| Robison, B | 1 |
| Farkas, J | 1 |
| Yamashita, S | 1 |
| Nishi, M | 1 |
| Ikemoto, T | 1 |
| Yoshikawa, K | 1 |
| Higashijima, J | 1 |
| Tokunaga, T | 1 |
| Takasu, C | 1 |
| Kashihara, H | 1 |
| Eto, S | 1 |
| Yoshimoto, T | 1 |
| Shimada, M | 1 |
| Thurber, MI | 1 |
| Doss, G | 1 |
| Kory, P | 1 |
| Tarula, E | 1 |
| Sladky, K | 1 |
| Ni, Q | 1 |
| Long, J | 1 |
| Guo, X | 1 |
| Yang, S | 2 |
| Meng, X | 1 |
| Zhang, L | 1 |
| Fang, X | 1 |
| Ye, M | 1 |
| Qian, C | 1 |
| Huhtakangas, J | 1 |
| Juvela, S | 1 |
| Bode, MK | 1 |
| Tatlisumak, T | 2 |
| Savolainen, M | 1 |
| Numminen, H | 1 |
| Ollikainen, J | 1 |
| Luostarinen, L | 1 |
| Kupila, L | 1 |
| Tetri, S | 1 |
| Perera, D | 1 |
| Bolina, AK | 1 |
| Hoque, N | 1 |
| Razvi, K | 1 |
| Sadeghipour, P | 2 |
| Talasaz, AH | 2 |
| Rashidi, F | 1 |
| Sharif-Kashani, B | 1 |
| Beigmohammadi, MT | 1 |
| Farrokhpour, M | 1 |
| Sezavar, SH | 1 |
| Payandemehr, P | 1 |
| Dabbagh, A | 1 |
| Moghadam, KG | 1 |
| Jamalkhani, S | 1 |
| Khalili, H | 2 |
| Yadollahzadeh, M | 1 |
| Riahi, T | 1 |
| Rezaeifar, P | 1 |
| Tahamtan, O | 1 |
| Matin, S | 1 |
| Abedini, A | 1 |
| Lookzadeh, S | 1 |
| Rahmani, H | 1 |
| Zoghi, E | 1 |
| Mohammadi, K | 1 |
| Abri, H | 1 |
| Tabrizi, S | 1 |
| Mousavian, SM | 1 |
| Shahmirzaei, S | 1 |
| Bakhshandeh, H | 1 |
| Amin, A | 1 |
| Rafiee, F | 1 |
| Baghizadeh, E | 1 |
| Mohebbi, B | 1 |
| Parhizgar, SE | 1 |
| Aliannejad, R | 1 |
| Eslami, V | 1 |
| Kashefizadeh, A | 1 |
| Kakavand, H | 1 |
| Hosseini, SH | 1 |
| Shafaghi, S | 1 |
| Ghazi, SF | 1 |
| Najafi, A | 1 |
| Jimenez, D | 1 |
| Gupta, A | 1 |
| Madhavan, MV | 1 |
| Sethi, SS | 1 |
| Parikh, SA | 1 |
| Monreal, M | 7 |
| Hadavand, N | 1 |
| Hajighasemi, A | 1 |
| Maleki, M | 1 |
| Sadeghian, S | 1 |
| Piazza, G | 1 |
| Kirtane, AJ | 1 |
| Van Tassell, BW | 1 |
| Dobesh, PP | 1 |
| Stone, GW | 1 |
| Lip, GYH | 1 |
| Krumholz, HM | 1 |
| Bikdeli, B | 1 |
| Fatimazahra, M | 1 |
| Harras, ME | 1 |
| Bensahi, I | 1 |
| Kassimi, M | 1 |
| Oualim, S | 1 |
| Elouarradi, A | 1 |
| Abdeladim, S | 1 |
| Sabry, M | 1 |
| Özbek, DA | 1 |
| Bilgin, E | 1 |
| Onur, MR | 1 |
| Karadağ, Ö | 1 |
| Kiraz, S | 1 |
| Pieralli, F | 1 |
| Pomero, F | 1 |
| Giampieri, M | 1 |
| Marcucci, R | 1 |
| Prisco, D | 3 |
| Luise, F | 1 |
| Mancini, A | 1 |
| Milia, A | 1 |
| Sammicheli, L | 1 |
| Tassinari, I | 1 |
| Caldi, F | 1 |
| Innocenti, F | 1 |
| Faraone, A | 1 |
| Beltrame, C | 1 |
| Pini, R | 1 |
| Ungar, A | 1 |
| Fortini, A | 1 |
| Swartz, MF | 1 |
| Hutchinson, DJ | 1 |
| Stauber, SD | 1 |
| Taillie, ER | 1 |
| Alfieris, GM | 1 |
| Ali Hasan, M | 1 |
| Azeez Alsaadi, M | 1 |
| Tahseen Mehsen, J | 1 |
| Husain, SA | 1 |
| Mozafari, N | 1 |
| Farjami, M | 1 |
| Jamali, E | 1 |
| Rostami, H | 1 |
| Ketabi, Y | 1 |
| Gallelli, G | 1 |
| Di Mizio, G | 1 |
| Palleria, C | 1 |
| Siniscalchi, A | 2 |
| Rubino, P | 1 |
| Muraca, L | 1 |
| Cione, E | 1 |
| Salerno, M | 1 |
| De Sarro, G | 1 |
| Gallelli, L | 1 |
| Briggs, RG | 1 |
| Lin, YH | 1 |
| Dadario, NB | 1 |
| Young, IM | 1 |
| Conner, AK | 1 |
| Xu, W | 1 |
| Tanglay, O | 1 |
| Kim, SJ | 1 |
| Fonseka, RD | 1 |
| Bonney, PA | 1 |
| Chakraborty, AR | 1 |
| Nix, CE | 1 |
| Flecher, LR | 1 |
| Yeung, JT | 1 |
| Teo, C | 1 |
| Sughrue, ME | 1 |
| Taylor, A | 1 |
| Martinez-Quinones, P | 1 |
| Huang, E | 1 |
| Robinson, T | 1 |
| White, CQ | 1 |
| Farooqui, AB | 1 |
| Humbert, ML | 1 |
| Montague, MS | 1 |
| Doré, S | 1 |
| Simpkins, AN | 1 |
| Houghton, DE | 1 |
| Vlazny, DT | 1 |
| Casanegra, AI | 1 |
| Brunton, N | 1 |
| Froehling, DA | 1 |
| Meverden, RA | 1 |
| Hodge, DO | 1 |
| Peterson, LG | 1 |
| McBane, RD | 1 |
| Wysokinski, WE | 1 |
| Fernandez, A | 1 |
| Nair, V | 1 |
| Mckeone, A | 1 |
| Ho, J | 1 |
| Korathanakhun, P | 1 |
| Petpichetchian, C | 1 |
| Petpichetchian, W | 1 |
| Sathirapanya, P | 1 |
| Perry, LA | 1 |
| Berge, E | 1 |
| Bowditch, J | 1 |
| Forfang, E | 1 |
| Rønning, OM | 1 |
| Hankey, GJ | 1 |
| Villanueva, E | 1 |
| Al-Shahi Salman, R | 1 |
| Bala, A | 3 |
| Huddleston, JI | 2 |
| Goodman, SB | 2 |
| Maloney, WJ | 2 |
| Amanatullah, DF | 2 |
| Tamborini Permunian, E | 1 |
| Mumoli, N | 2 |
| Callegari, L | 1 |
| Tragni, CM | 1 |
| Ageno, W | 6 |
| Gourzoulidis, G | 1 |
| Kourlaba, G | 1 |
| Kakisis, J | 1 |
| Matsagkas, M | 1 |
| Giannakoulas, G | 1 |
| Gourgoulianis, KI | 1 |
| Vassilakopoulos, T | 1 |
| Maniadakis, N | 1 |
| Roueli, A | 1 |
| Cesario, E | 1 |
| Amsellem, J | 1 |
| Agman, A | 1 |
| Vauthier-Brouzes, D | 1 |
| Nizard, J | 1 |
| Cafri, G | 1 |
| Paxton, EW | 1 |
| Chen, Y | 2 |
| Cheetham, CT | 1 |
| Gould, MK | 1 |
| Sluggett, J | 1 |
| Bini, SA | 1 |
| Khatod, M | 1 |
| Kaenkumchorn, T | 1 |
| Kesavan, A | 1 |
| Rottenstreich, A | 2 |
| Kleinstern, G | 1 |
| Spectre, G | 1 |
| Da'as, N | 1 |
| Ziv, E | 1 |
| Kalish, Y | 2 |
| Pellizzari, L | 1 |
| Facchinetti, R | 1 |
| Corrà, L | 1 |
| Sepe, A | 1 |
| Fantin, F | 1 |
| Fontana, G | 1 |
| Zamboni, M | 1 |
| Di Francesco, V | 1 |
| Swanson, E | 2 |
| Arbetter, DF | 2 |
| Jain, P | 1 |
| Yee, MK | 3 |
| Michalak, N | 1 |
| Gold, A | 3 |
| Macauley, P | 1 |
| Soni, P | 1 |
| Akkad, I | 1 |
| Demir, S | 1 |
| Shankar, S | 1 |
| Kakar, P | 1 |
| Bhardwaj, S | 1 |
| Jones, CW | 1 |
| Spasojevic, S | 1 |
| Goh, G | 1 |
| Joseph, Z | 1 |
| Wood, DJ | 1 |
| Yates, PJ | 1 |
| Oliveira, GN | 1 |
| Basso, S | 1 |
| Sevivas, T | 1 |
| Neves, N | 1 |
| Januzzi, JL | 1 |
| Korjian, S | 3 |
| Daaboul, Y | 2 |
| Fuller, K | 1 |
| Malecki, S | 1 |
| Anselmo, L | 1 |
| Borrego, ME | 1 |
| Jakeman, B | 1 |
| Burnett, A | 1 |
| Hamilton, CE | 1 |
| King, BA | 1 |
| Cowper, SE | 1 |
| Hochster, H | 1 |
| Leventhal, JS | 1 |
| Campbell, ST | 1 |
| Jiang, SY | 1 |
| Gardner, MJ | 1 |
| Bishop, JA | 1 |
| Moon, RC | 1 |
| Ghanem, M | 1 |
| Teixeira, AF | 1 |
| De La Cruz-Munoz, N | 1 |
| Young, MK | 1 |
| Domkowski, P | 1 |
| Radecke, J | 1 |
| Boyce, SG | 1 |
| Rosenthal, R | 1 |
| Menzo, EL | 1 |
| Blanco, DG | 1 |
| Funes, DR | 1 |
| Jawad, MA | 1 |
| Khan, NR | 1 |
| Patel, PG | 1 |
| Sharpe, JP | 1 |
| Lee, SL | 1 |
| Sorenson, J | 1 |
| Kerneis, M | 1 |
| Al Khalfan, F | 1 |
| Grübler, B | 1 |
| Diamond, CE | 1 |
| Hennessey, C | 1 |
| Meldau, J | 1 |
| Guelcher, CJ | 1 |
| Guerrera, MF | 1 |
| Conklin, LS | 1 |
| Sharma, KV | 1 |
| Diab, YA | 1 |
| Altieri, MS | 1 |
| Hajagos, J | 1 |
| Spaniolas, K | 1 |
| Park, J | 2 |
| Gasparis, AP | 1 |
| Bates, AT | 1 |
| Docimo, S | 1 |
| Talamini, M | 1 |
| Shroyer, AL | 1 |
| Pryor, AD | 1 |
| Senay, A | 1 |
| Trottier, M | 1 |
| Delisle, J | 1 |
| Banica, A | 1 |
| Benoit, B | 1 |
| Laflamme, GY | 1 |
| Malo, M | 1 |
| Nguyen, H | 2 |
| Ranger, P | 1 |
| Fernandes, JC | 1 |
| Zhang, Z | 1 |
| Li, Z | 1 |
| Liu, L | 1 |
| Intiyanaravut, T | 1 |
| Thongpulsawasdi, N | 1 |
| Sinthuvanich, N | 1 |
| Teavirat, S | 1 |
| Kunopart, M | 1 |
| Luce, EA | 1 |
| Wang, J | 1 |
| Chai, JS | 1 |
| Zhang, YM | 1 |
| Bourget-Murray, J | 1 |
| Clarke, MA | 1 |
| Gorzitza, S | 1 |
| Phillips, LA | 1 |
| Kim, BY | 1 |
| Moon, AS | 1 |
| Vasquez, R | 1 |
| Warrier, R | 1 |
| Fraval, A | 1 |
| Duncan, S | 1 |
| Murray, T | 1 |
| Duggan, J | 1 |
| Tirosh, O | 1 |
| Tran, P | 1 |
| Yost, RJ | 1 |
| Haan, BJ | 1 |
| Mangan, KC | 1 |
| Hoang, L | 1 |
| Islam, S | 1 |
| Hindenburg, A | 1 |
| Bawa, H | 1 |
| Weick, JW | 1 |
| Dirschl, DR | 1 |
| Luu, HH | 1 |
| Rodriguez-Castro, KI | 1 |
| Vitale, A | 1 |
| Fadin, M | 1 |
| Shalaby, S | 1 |
| Zerbinati, P | 1 |
| Sartori, MT | 2 |
| Landi, S | 1 |
| Pettinari, I | 1 |
| Piscaglia, F | 1 |
| Han, G | 1 |
| Burra, P | 1 |
| Simioni, P | 1 |
| Senzolo, M | 1 |
| Ianosi, B | 1 |
| Gaasch, M | 1 |
| Rass, V | 1 |
| Huber, L | 1 |
| Hackl, W | 1 |
| Kofler, M | 1 |
| Schiefecker, AJ | 1 |
| Addis, A | 1 |
| Beer, R | 1 |
| Rhomberg, P | 1 |
| Pfausler, B | 1 |
| Thomé, C | 1 |
| Ammenwerth, E | 1 |
| Helbok, R | 1 |
| Samarasekara, K | 1 |
| Munasinghe, J | 1 |
| Kalayci, A | 1 |
| Datta, S | 1 |
| Nafee, T | 1 |
| Gurin, M | 1 |
| Haroian, N | 1 |
| Qamar, I | 1 |
| Woon, CYL | 1 |
| Shah, RR | 1 |
| Pardi, BM | 1 |
| Schwartz, BE | 1 |
| Goldstein, JM | 1 |
| Cipparrone, NE | 1 |
| Goldstein, WM | 1 |
| Runner, RP | 1 |
| Gottschalk, MB | 1 |
| Staley, CA | 1 |
| Pour, AE | 1 |
| Roberson, JR | 2 |
| Sun, G | 2 |
| Wang, Q | 1 |
| Liang, Q | 1 |
| Jia, J | 1 |
| Cheng, K | 1 |
| Wang, Z | 1 |
| Cronin, BJ | 1 |
| Godat, LN | 1 |
| Berndtson, AE | 1 |
| Pham, A | 1 |
| Kolan, S | 1 |
| Box, K | 1 |
| Lee, JG | 1 |
| Costantini, TW | 1 |
| Bethea, A | 1 |
| Samanta, D | 1 |
| Deshaies, D | 1 |
| Richmond, BK | 1 |
| Murasko, MJ | 1 |
| Burk, DR | 1 |
| Tanaka, Y | 1 |
| Yamada, A | 1 |
| Hirata, S | 1 |
| Tanaka, H | 1 |
| Sakuratani, T | 1 |
| Matsuhashi, N | 1 |
| Yamaguchi, K | 1 |
| Shimokawa, T | 1 |
| Yoshida, K | 1 |
| Dalen, JE | 1 |
| Stein, PD | 2 |
| Plitt, JL | 1 |
| Jaswal, N | 1 |
| Alpert, JS | 1 |
| Lazea, C | 1 |
| Asavoaie, C | 1 |
| Ruiz-Artacho, P | 1 |
| Pérez Peña, C | 1 |
| Iriarte, A | 1 |
| Martín-Sánchez, FJ | 1 |
| Guenther, F | 1 |
| Herr, N | 1 |
| Mauler, M | 1 |
| Witsch, T | 1 |
| Roming, F | 1 |
| Hein, L | 1 |
| Boeynaems, JM | 1 |
| Robaye, B | 1 |
| Idzko, M | 1 |
| Bode, C | 1 |
| Von Zur Muhlen, C | 1 |
| Duerschmied, D | 1 |
| Fukuda, T | 1 |
| Kamisato, C | 3 |
| Honda, Y | 3 |
| Matsushita, T | 1 |
| Kojima, T | 1 |
| Furugohri, T | 1 |
| Morishima, Y | 3 |
| Shibano, T | 2 |
| Ruiz Artacho, P | 1 |
| Merlo Loranca, M | 1 |
| Jiménez Hernández, S | 1 |
| Chandra, R | 1 |
| Melino, G | 1 |
| Thomas, M | 2 |
| Lawrence, MJ | 1 |
| Hunter, RA | 1 |
| Moore, J | 1 |
| Bamber, L | 3 |
| Wang, MY | 1 |
| Prins, MH | 8 |
| Ciniglio, C | 1 |
| Lensing, AW | 9 |
| Cano, SJ | 1 |
| Bramham, K | 2 |
| Retter, A | 1 |
| Robinson, SE | 1 |
| Mitchell, M | 1 |
| Moore, GW | 1 |
| Hunt, BJ | 1 |
| Pineda, L | 1 |
| Sarhan, M | 1 |
| Ahmed, L | 1 |
| Bagre, AP | 1 |
| Jain, K | 1 |
| Jain, NK | 1 |
| Farooqui, A | 1 |
| Hiser, B | 1 |
| Barnes, SL | 1 |
| Litofsky, NS | 1 |
| Baraza, N | 1 |
| Lever, S | 1 |
| Dhukaram, V | 1 |
| Sasaki, H | 1 |
| Ishida, K | 1 |
| Shibanuma, N | 1 |
| Tei, K | 1 |
| Tateishi, H | 1 |
| Toda, A | 1 |
| Yamashiro, Y | 1 |
| Matsumoto, T | 1 |
| Kuroda, R | 1 |
| Kurosaka, M | 1 |
| Hirsh, J | 3 |
| Ginsberg, JS | 4 |
| Chan, N | 1 |
| Guyatt, G | 5 |
| Eikelboom, JW | 3 |
| Lefebvre, P | 1 |
| Coleman, CI | 1 |
| Bookhart, BK | 2 |
| Wang, ST | 1 |
| Mody, SH | 2 |
| Tran, KN | 1 |
| Zhuo, DY | 1 |
| Huynh, L | 1 |
| Nutescu, EA | 2 |
| Tak, S | 2 |
| Basu, S | 1 |
| Pantvaidya, G | 1 |
| Malvadkar, S | 1 |
| Khoursheed, M | 1 |
| Al-Bader, I | 1 |
| Al-Asfar, F | 1 |
| Sayed, A | 1 |
| Al-Mozaini, A | 1 |
| Marouf, R | 1 |
| Fingerhut, A | 1 |
| van Bellen, B | 1 |
| Correa de Carvalho, F | 1 |
| Prins, M | 2 |
| Wang, M | 2 |
| Liu, F | 1 |
| Chu, X | 1 |
| Huang, J | 1 |
| Tian, K | 1 |
| Hua, J | 1 |
| Tong, P | 1 |
| Gritsiouk, Y | 1 |
| Hegsted, DA | 1 |
| Schlesinger, P | 1 |
| Gardiner, SK | 1 |
| Gubler, KD | 1 |
| Hauck-Dlimi, B | 1 |
| Zimmermann, R | 1 |
| Eckstein, R | 1 |
| Ringwald, J | 1 |
| Galante, JM | 1 |
| Louis, SG | 2 |
| Sato, M | 1 |
| Geraci, T | 1 |
| Anderson, R | 1 |
| Cho, SD | 2 |
| Van, PY | 4 |
| Barton, JS | 2 |
| Riha, GM | 3 |
| Underwood, S | 1 |
| Differding, J | 2 |
| Watters, JM | 2 |
| Schreiber, MA | 5 |
| Kunio, NR | 1 |
| Underwood, SJ | 3 |
| Differding, JA | 2 |
| Rick, E | 1 |
| Ginzburg, E | 2 |
| Ishi, SV | 1 |
| Lakshmi, M | 1 |
| Kakde, ST | 1 |
| Sabnis, KC | 1 |
| Jagannati, M | 1 |
| Girish, TS | 1 |
| Jeyaseelan, L | 1 |
| Cherian, AM | 1 |
| Fuji, T | 1 |
| Fujita, S | 1 |
| Kawai, Y | 1 |
| Kimura, T | 1 |
| Tachibana, S | 1 |
| Haskell, L | 1 |
| Schein, J | 1 |
| Yamashita, Y | 1 |
| Bekki, Y | 1 |
| Imai, D | 1 |
| Ikegami, T | 1 |
| Yoshizumi, T | 1 |
| Ikeda, T | 1 |
| Kawanaka, H | 1 |
| Nishie, A | 1 |
| Shirabe, K | 1 |
| Maehara, Y | 1 |
| Barbot, M | 1 |
| Daidone, V | 1 |
| Zilio, M | 1 |
| Albiger, N | 1 |
| Mazzai, L | 1 |
| Frigo, AC | 1 |
| Scanarini, M | 1 |
| Denaro, L | 1 |
| Boscaro, M | 1 |
| Casonato, S | 1 |
| Ceccato, F | 1 |
| Scaroni, C | 1 |
| Kirienko, AI | 7 |
| Andriiashkin, VV | 2 |
| Lebedev, IS | 1 |
| Bagirian, MS | 1 |
| Babakova, NA | 1 |
| Bethune, C | 1 |
| Bhanot, S | 1 |
| Gailani, D | 1 |
| Monia, BP | 1 |
| Segers, A | 4 |
| Verhamme, P | 4 |
| Kesieme, EB | 1 |
| Okokhere, P | 1 |
| Eluehike, S | 1 |
| Isabu, P | 1 |
| Sengupta, N | 1 |
| Feuerstein, JD | 1 |
| Patwardhan, VR | 1 |
| Tapper, EB | 1 |
| Ketwaroo, GA | 1 |
| Thaker, AM | 1 |
| Leffler, DA | 1 |
| Diaz, JA | 2 |
| Wrobleski, SK | 6 |
| Alvarado, CM | 2 |
| Hawley, AE | 4 |
| Doornbos, NK | 1 |
| Lester, PA | 1 |
| Lowe, SE | 1 |
| Gabriel, JE | 1 |
| Roelofs, KJ | 1 |
| Henke, PK | 5 |
| Schaub, RG | 5 |
| Wakefield, TW | 7 |
| Myers, DD | 8 |
| Ma, G | 1 |
| Zhang, R | 1 |
| Wu, X | 2 |
| Wang, D | 1 |
| Ying, K | 1 |
| Vazquez, FJ | 1 |
| Paulin, P | 1 |
| Rodriguez, P | 1 |
| Lubertino, M | 1 |
| Gándara, E | 1 |
| Cui, SB | 1 |
| Shu, RH | 1 |
| Yan, SP | 1 |
| Wu, H | 1 |
| Wang, L | 1 |
| Zhu, Q | 1 |
| Abdel-Aziz, H | 1 |
| Dunham, CM | 1 |
| Malik, RJ | 1 |
| Hileman, BM | 1 |
| Kumarihamy, KW | 1 |
| Ralapanawa, DM | 1 |
| Jayalath, WA | 1 |
| He, C | 1 |
| Fan, X | 1 |
| Goto, M | 1 |
| Yoshizato, T | 1 |
| Tatsumura, M | 1 |
| Takashima, T | 1 |
| Ogawa, M | 1 |
| Nakahara, H | 1 |
| Satoh, S | 1 |
| Sanui, A | 1 |
| Eguchi, F | 1 |
| Miyamoto, S | 1 |
| Özler, T | 1 |
| Uluçay, Ç | 1 |
| Önal, A | 1 |
| Altıntaş, F | 1 |
| Matta, F | 1 |
| Hughes, PG | 1 |
| Ghiardi, M | 1 |
| Marsh, JH | 1 |
| Khwarg, J | 1 |
| Brandon, MS | 1 |
| Fowkes, HA | 1 |
| Kazan, V | 1 |
| Wiepking, M | 1 |
| Keyes, DC | 1 |
| Kakish, EJ | 1 |
| Hughes, MJ | 1 |
| Singh, RR | 1 |
| Gupte-Singh, KR | 1 |
| Wilson, JP | 1 |
| Moffett, BS | 1 |
| Pazzini, C | 1 |
| Marcato, PD | 1 |
| Prado, LB | 1 |
| Alessio, AM | 1 |
| Höehr, NF | 1 |
| Paixão, D | 1 |
| Durán, N | 1 |
| Choe, H | 1 |
| Elfil, M | 1 |
| DeSancho, MT | 1 |
| Liu, X | 1 |
| Johnson, M | 1 |
| Mardekian, J | 1 |
| Phatak, H | 1 |
| Thompson, J | 1 |
| Adams, CB | 1 |
| Vollman, KE | 1 |
| Leventhal, EL | 1 |
| Acquisto, NM | 1 |
| Toman, E | 1 |
| Beaven, A | 1 |
| Balogun, M | 1 |
| Porter, K | 1 |
| Na, YG | 1 |
| Fang, R | 1 |
| Kim, YH | 1 |
| Cho, KJ | 1 |
| Kim, TK | 1 |
| Fundora, MP | 1 |
| Rudnick, C | 1 |
| Barbur, C | 1 |
| Sharfman, ZT | 1 |
| Campbell, JC | 1 |
| Mirocha, JM | 1 |
| Spitzer, AI | 1 |
| Ricket, AL | 1 |
| Stewart, DW | 1 |
| Wood, RC | 1 |
| Cornett, L | 1 |
| Odle, B | 1 |
| Cluck, D | 1 |
| Freshour, J | 1 |
| El-Bazouni, H | 1 |
| Campbell, PM | 1 |
| Ippoliti, C | 1 |
| Parmar, S | 1 |
| Pruitt, LG | 1 |
| Mosley, JC | 1 |
| Lasseigne, RF | 1 |
| Kalinin, RE | 2 |
| Pshennikov, AS | 2 |
| Agapov, AB | 2 |
| Helviz, Y | 1 |
| Dzigivker, I | 1 |
| Raveh-Brawer, D | 1 |
| Hersch, M | 1 |
| Zevin, S | 1 |
| Einav, S | 1 |
| Ning, GZ | 1 |
| Kan, SL | 1 |
| Chen, LX | 1 |
| Shangguan, L | 1 |
| Feng, SQ | 1 |
| Zhou, Y | 2 |
| Duan, L | 1 |
| Zhang, N | 1 |
| Yan, H | 1 |
| Guo, Y | 1 |
| Hong, C | 1 |
| Yang, X | 1 |
| Su, X | 1 |
| Chen, R | 1 |
| Zhong, N | 1 |
| Liu, C | 2 |
| Guella, E | 1 |
| Mitchell, LJ | 1 |
| Sobolewska, J | 1 |
| Khan, K | 1 |
| Herath, HM | 1 |
| Kulatunga, A | 1 |
| Harmos, S | 1 |
| Wang, TK | 1 |
| Hawkins, S | 1 |
| Reynolds, R | 1 |
| Xu, M | 1 |
| Xue, W | 1 |
| Ma, Z | 1 |
| Bai, J | 1 |
| Wu, S | 1 |
| Elazary, R | 1 |
| Singer, GA | 1 |
| Riggi, G | 1 |
| Karcutskie, CA | 1 |
| Vaghaiwalla, TM | 1 |
| Lieberman, HM | 1 |
| Namias, N | 1 |
| Lineen, EB | 1 |
| Rebelo, J | 1 |
| Nayan, S | 1 |
| Choong, K | 1 |
| Fulford, M | 1 |
| Chan, A | 2 |
| Sommer, DD | 1 |
| Radzak, KN | 1 |
| Wages, JJ | 1 |
| Hall, KE | 1 |
| Nakasone, CK | 1 |
| Cheung, YW | 1 |
| Middeldorp, S | 1 |
| Pap, AF | 1 |
| Ten Cate-Hoek, AJ | 1 |
| Villalta, S | 1 |
| Milan, M | 1 |
| Beyer-Westendorf, J | 2 |
| Bauersachs, RM | 1 |
| Prandoni, P | 2 |
| Sartori, M | 1 |
| Lessiani, G | 1 |
| Favaretto, E | 1 |
| Migliaccio, L | 1 |
| Iotti, M | 1 |
| Giusto, L | 1 |
| Ahuja, RB | 2 |
| Bansal, P | 2 |
| Pradhan, GS | 2 |
| Subberwal, M | 2 |
| Kurtzhalts, K | 1 |
| Gee, ME | 1 |
| Feuz, L | 1 |
| Krajewski, KC | 1 |
| Schmidt-Braekling, T | 1 |
| Pearle, AD | 1 |
| Mayman, DJ | 1 |
| Westrich, GH | 2 |
| Waldstein, W | 1 |
| Boettner, F | 1 |
| Bohnhoff, JC | 1 |
| DiSilvio, SA | 1 |
| Aneja, RK | 1 |
| Shenk, JR | 1 |
| Domnina, YA | 1 |
| Brozanski, BS | 1 |
| Good, M | 1 |
| Jeon, OC | 1 |
| Yun, J | 1 |
| Nam, H | 1 |
| Hwang, J | 1 |
| Al-Hilal, TA | 1 |
| Kim, K | 2 |
| Byun, Y | 2 |
| León, VJ | 1 |
| Lengua, MA | 1 |
| Calvo, V | 1 |
| Lisón, AJ | 1 |
| Kopelman, TR | 1 |
| Walters, JW | 1 |
| Bogert, JN | 1 |
| Basharat, U | 1 |
| Pieri, PG | 1 |
| Davis, KM | 1 |
| Quan, AN | 1 |
| Vail, SJ | 1 |
| Pressman, MA | 1 |
| Trujillo-Santos, J | 1 |
| Bortoluzzi, C | 1 |
| López-Reyes, R | 1 |
| Giorgi-Pierfranceschi, M | 2 |
| López-Sáez, JB | 1 |
| Ferrazzi, P | 1 |
| Bascuñana, J | 1 |
| Suriñach, JM | 1 |
| Przepiera-Będzak, H | 1 |
| Brzosko, M | 1 |
| Imamura, H | 1 |
| Adachi, T | 1 |
| Kitasato, A | 1 |
| Tanaka, T | 1 |
| Soyama, A | 1 |
| Hidaka, M | 1 |
| Fujita, F | 1 |
| Takatsuki, M | 1 |
| Kuroki, T | 1 |
| Eguchi, S | 1 |
| Halaby, R | 1 |
| Hull, R | 2 |
| Lu, SP | 1 |
| Bandman, O | 1 |
| Leeds, JM | 1 |
| Narin, C | 1 |
| Reyhanoglu, H | 1 |
| Tülek, B | 1 |
| Onoglu, R | 1 |
| Ege, E | 1 |
| Sarigül, A | 1 |
| Yeniterzi, M | 1 |
| Durmaz, I | 1 |
| Eriksson, BI | 25 |
| Borris, LC | 5 |
| Friedman, RJ | 3 |
| Haas, S | 8 |
| Kakkar, AK | 6 |
| Bandel, TJ | 3 |
| Beckmann, H | 1 |
| Muehlhofer, E | 1 |
| Misselwitz, F | 10 |
| Geerts, W | 7 |
| Lieberman, JR | 2 |
| Turpie, AG | 35 |
| Lohrmann, J | 1 |
| Becker, RC | 1 |
| Hatef, DA | 1 |
| Kenkel, JM | 1 |
| Nguyen, MQ | 1 |
| Farkas, JP | 1 |
| Abtahi, F | 1 |
| Rohrich, RJ | 1 |
| Brown, SA | 1 |
| Clement, J | 1 |
| Bubley, G | 1 |
| González-Fajardo, JA | 1 |
| Martin-Pedrosa, M | 1 |
| Castrodeza, J | 1 |
| Tamames, S | 1 |
| Vaquero-Puerta, C | 1 |
| Abu Sham'a, RA | 1 |
| Kufri, FH | 1 |
| Yassin, IH | 1 |
| Kalu, ON | 1 |
| Al-Khoury, G | 1 |
| Reck, CA | 1 |
| Velcek, F | 1 |
| Cunningham, MS | 1 |
| Gilmore, R | 1 |
| O'Donnell, D | 1 |
| O'Donnell, JS | 1 |
| Kittisupamongkol, W | 1 |
| Bendinelli, C | 1 |
| Balogh, Z | 2 |
| Villalba, JC | 1 |
| Ozpolat, B | 1 |
| Yazkan, R | 1 |
| Aksoy, M | 1 |
| Doğan, S | 1 |
| Kim, EK | 1 |
| Eom, JS | 1 |
| Ahn, SH | 1 |
| Son, BH | 1 |
| Lee, TJ | 1 |
| Bauer, KA | 14 |
| Davidson, BL | 11 |
| Fisher, WD | 4 |
| Gent, M | 11 |
| Huo, MH | 2 |
| Sinha, U | 2 |
| Gretler, DD | 1 |
| Heidenreich, C | 1 |
| Hohmann, V | 2 |
| Bramlage, P | 6 |
| Albaladejo, P | 1 |
| Stiefelhagen, P | 1 |
| Kligman, MD | 1 |
| Zyromski, NJ | 1 |
| McCullough, DG | 1 |
| Gunning, WT | 1 |
| de Maistre, E | 2 |
| Terriat, B | 1 |
| Lesne-Padieu, AS | 1 |
| Abello, N | 1 |
| Bouchot, O | 1 |
| Steinmetz, EF | 1 |
| O'Brien, SH | 1 |
| Smith, KJ | 1 |
| Venkateswaran, L | 1 |
| Scaglia, F | 1 |
| McLin, V | 1 |
| Hertel, P | 1 |
| Shchelochkov, OA | 1 |
| Karpen, S | 1 |
| Mahoney, D | 1 |
| Yee, DL | 1 |
| van Doormaal, FF | 1 |
| Gallus, A | 3 |
| Piovella, F | 4 |
| Sems, SA | 1 |
| Levy, BA | 1 |
| Dajani, K | 1 |
| Herrera, DA | 1 |
| Templeman, DC | 1 |
| Bertini, G | 1 |
| Perugi, S | 1 |
| Dani, C | 1 |
| Fonda, C | 1 |
| Reeves, D | 1 |
| Liu, CY | 1 |
| Peral, D | 1 |
| Higueras, R | 1 |
| Onrubia, X | 1 |
| Bellver, J | 1 |
| Kwong, LM | 3 |
| Cushner, FD | 1 |
| Lotke, PA | 2 |
| Benson, A | 1 |
| Reiff, DA | 1 |
| Haricharan, RN | 1 |
| Bullington, NM | 1 |
| Griffin, RL | 1 |
| McGwin, G | 1 |
| Rue, LW | 1 |
| Varpe, P | 1 |
| Huhtinen, H | 1 |
| Rantala, A | 1 |
| Grönroos, J | 1 |
| Morris, MS | 1 |
| Awar, Z | 1 |
| Sheikh-Taha, M | 1 |
| Salomon, O | 1 |
| Dulitzky, M | 1 |
| Apter, S | 1 |
| Bhatia, V | 1 |
| Arora, P | 1 |
| Parida, AK | 1 |
| Mittal, A | 1 |
| Pandey, AK | 1 |
| Kaul, U | 1 |
| Kröger, K | 2 |
| Stief, T | 1 |
| Raju, NC | 1 |
| Dimmitt, S | 1 |
| Suárez-Gea, ML | 1 |
| Blázquez-Pérez, A | 1 |
| Pozo-Hernández, C | 1 |
| Vargas-Castrillón, E | 1 |
| Ma, AL | 1 |
| Lai, WM | 1 |
| Chiu, MC | 1 |
| Wathen, AB | 1 |
| Zajkowski, P | 1 |
| Flory, G | 1 |
| Hankenson, FC | 1 |
| Iturbe, T | 1 |
| Español, I | 1 |
| Sánchez, A | 1 |
| Rivera, J | 1 |
| Izzedine, H | 1 |
| Gharbi, C | 1 |
| Alperin, S | 1 |
| Bourry, E | 1 |
| Cluzel, P | 1 |
| Vorob'eva, NM | 3 |
| Panchenko, EP | 4 |
| Dobrovol'skiĭ, AB | 3 |
| Titaeva, EV | 3 |
| Ermolina, OV | 3 |
| Leont'ev, SG | 1 |
| Bindelglass, DF | 1 |
| Rosenblum, DS | 1 |
| De, A | 1 |
| Roy, P | 1 |
| Garg, VK | 1 |
| Pandey, NK | 1 |
| Zenáhlíková, Z | 1 |
| Kvasnicka, J | 1 |
| Kudrnová, Z | 1 |
| Sudrová, M | 1 |
| Brzezková, R | 1 |
| Mazoch, J | 1 |
| Malíková, I | 1 |
| Vyborny, J | 1 |
| Erhart, D | 1 |
| Pecen, L | 1 |
| Amezyane, T | 1 |
| Abouzahir, A | 1 |
| El Kharrass, A | 1 |
| Bassou, D | 1 |
| Fatihi, J | 1 |
| Hammi, S | 1 |
| Mahassin, F | 1 |
| Ghafir, D | 1 |
| Ohayon, V | 1 |
| Ramacciotti, E | 2 |
| Deatrick, KB | 1 |
| Londy, FJ | 3 |
| Rectenwald, JE | 1 |
| Hegazi, MO | 1 |
| Ahmed, S | 2 |
| Sakr, MG | 1 |
| Hassanien, OA | 1 |
| Gormus, N | 1 |
| Tanyeli, O | 1 |
| Senaran, H | 2 |
| Duman, A | 1 |
| Solak Görmüs, ZI | 1 |
| Durgut, K | 1 |
| Sood, V | 1 |
| Luke, C | 1 |
| Miller, E | 1 |
| Mitsuya, M | 1 |
| Upchurch, GR | 1 |
| Hong, CH | 1 |
| Napeñas, JJ | 1 |
| Brennan, MT | 1 |
| Furney, SL | 1 |
| Lockhart, PB | 1 |
| Kiudelis, M | 1 |
| Gerbutavicius, R | 1 |
| Gerbutaviciene, R | 1 |
| Griniūte, R | 1 |
| Mickevicius, A | 1 |
| Endzinas, Z | 1 |
| Pundzius, J | 1 |
| Malinoski, D | 1 |
| Jafari, F | 1 |
| Ewing, T | 1 |
| Ardary, C | 1 |
| Conniff, H | 1 |
| Baje, M | 1 |
| Kong, A | 1 |
| Lekawa, ME | 1 |
| Dolich, MO | 1 |
| Cinat, ME | 1 |
| Barrios, C | 1 |
| Hoyt, DB | 1 |
| Axon, RN | 1 |
| Cawley, PJ | 1 |
| Fernández, E | 1 |
| Dueñas, N | 1 |
| Villafranca, A | 1 |
| Perea, M | 1 |
| Amorós, B | 1 |
| Bermejo, L | 1 |
| Arnold, JD | 1 |
| Dart, BW | 1 |
| Barker, DE | 1 |
| Maxwell, RA | 1 |
| Burkholder, HC | 1 |
| Mejia, VA | 1 |
| Smith, PW | 2 |
| Longley, JM | 1 |
| Berguer, AM | 1 |
| Baker, NK | 1 |
| Lucchesi, BR | 1 |
| Singer, JP | 1 |
| Huang, MY | 1 |
| Hui, C | 1 |
| Blanc, PD | 1 |
| Boettger, RF | 1 |
| Golden, J | 1 |
| Watkins, K | 1 |
| Hoopes, C | 1 |
| Leard, LE | 1 |
| Korsten-Reck, U | 1 |
| Winterer, J | 1 |
| König, D | 1 |
| Dickhuth, HH | 1 |
| Hajj-Chahine, J | 1 |
| Jayle, C | 1 |
| Tomasi, J | 1 |
| Corbi, P | 2 |
| Kurtoglu, M | 4 |
| Koksoy, C | 1 |
| Hasan, E | 1 |
| Akcalı, Y | 1 |
| Karabay, O | 1 |
| Filizcan, U | 1 |
| Voelker, R | 1 |
| Cao, C | 1 |
| Kupfer, S | 1 |
| Raskob, G | 8 |
| Spaeder, J | 1 |
| Zufferey, PJ | 1 |
| Sachithanandan, A | 1 |
| Farahmand, S | 1 |
| Saeedi, M | 1 |
| Seyed Javadi, HH | 1 |
| Khashayar, P | 1 |
| Tsiridis, E | 1 |
| Gamie, Z | 1 |
| George, MJ | 1 |
| Hamilton-Baille, D | 1 |
| West, RM | 1 |
| Giannoudis, PV | 1 |
| Pannucci, CJ | 1 |
| Bailey, SH | 1 |
| Dreszer, G | 1 |
| Fisher Wachtman, C | 1 |
| Zumsteg, JW | 1 |
| Jaber, RM | 1 |
| Hamill, JB | 1 |
| Hume, KM | 1 |
| Rubin, JP | 1 |
| Neligan, PC | 1 |
| Kalliainen, LK | 1 |
| Hoxworth, RE | 1 |
| Pusic, AL | 1 |
| Wilkins, EG | 1 |
| Amagada, JO | 1 |
| Pembridge, J | 1 |
| Brenner, B | 3 |
| Gallus, AS | 2 |
| Wells, P | 1 |
| Agnelli, G | 11 |
| Cohen, A | 2 |
| Mukand, JA | 1 |
| Mukand, NH | 1 |
| Mehta, KV | 1 |
| Lee, HC | 1 |
| Loh, JS | 1 |
| Loke, YK | 1 |
| Kwok, CS | 1 |
| Chung, LH | 1 |
| Chen, TH | 1 |
| Liu, CL | 1 |
| Dahl, OE | 9 |
| Kurth, AA | 3 |
| Hantel, S | 3 |
| Hermansson, K | 1 |
| Schnee, JM | 1 |
| Godier, A | 1 |
| Misra, D | 1 |
| Aledort, L | 1 |
| Mansurali, N | 1 |
| Maclaren, G | 1 |
| Sundar, G | 1 |
| Oliveira, SS | 1 |
| Oliveira, FS | 1 |
| Gaitani, CM | 1 |
| Marchetti, JM | 1 |
| Landman, GW | 1 |
| Gans, RO | 1 |
| Wang, H | 1 |
| Kopac, D | 1 |
| Brisebois, R | 1 |
| Sample, C | 1 |
| Shapiro, AM | 1 |
| Vincent, PD | 1 |
| Albert, M | 3 |
| Champagne, MC | 1 |
| Zikos, T | 1 |
| Boulanger, I | 1 |
| Blais, L | 1 |
| Williamson, DR | 1 |
| Pai, RP | 1 |
| Kangath, RV | 1 |
| Brown, TA | 1 |
| Dashti-Khavidaki, S | 1 |
| Najmedin, F | 1 |
| Hosseinpoor, R | 1 |
| Stark, JE | 1 |
| Smith, WJ | 1 |
| Rosenberger, LH | 1 |
| Sawyer, RG | 1 |
| Park, WJ | 1 |
| Jo, SH | 1 |
| Kim, SA | 1 |
| Kim, HS | 1 |
| Han, SJ | 1 |
| Choi, YJ | 1 |
| Rhim, CY | 1 |
| Rachinger, JC | 1 |
| Koman, G | 1 |
| Scheller, C | 1 |
| Prell, J | 1 |
| Rampp, S | 1 |
| Strauss, C | 1 |
| Minshall, CT | 1 |
| Eriksson, EA | 1 |
| Leon, SM | 1 |
| Doben, AR | 1 |
| McKinzie, BP | 1 |
| Fakhry, SM | 1 |
| Larocca, A | 1 |
| Cavallo, F | 1 |
| Bringhen, S | 1 |
| Di Raimondo, F | 1 |
| Falanga, A | 2 |
| Evangelista, A | 1 |
| Cavalli, M | 1 |
| Stanevsky, A | 1 |
| Corradini, P | 1 |
| Pezzatti, S | 1 |
| Patriarca, F | 1 |
| Cavo, M | 1 |
| Peccatori, J | 1 |
| Catalano, L | 1 |
| Carella, AM | 1 |
| Cafro, AM | 1 |
| Crippa, C | 1 |
| Petrucci, MT | 1 |
| Yehuda, DB | 1 |
| Beggiato, E | 1 |
| Di Toritto, TC | 1 |
| Boccadoro, M | 1 |
| Nagler, A | 1 |
| Palumbo, A | 1 |
| Olah, Z | 2 |
| Bereczky, Z | 1 |
| Szarvas, M | 1 |
| Boda, Z | 3 |
| Fecher, K | 1 |
| Ewald, W | 1 |
| Fürst, A | 1 |
| Khasanova, ZB | 1 |
| Postnov, AIu | 1 |
| Cuerva-González, MJ | 1 |
| Lacoponi, S | 1 |
| de la Calle-Fernández, M | 1 |
| Pozo-Krielinger, J | 1 |
| Iwatsuki, Y | 1 |
| Sato, T | 1 |
| Moritani, Y | 1 |
| Shigenaga, T | 1 |
| Suzuki, M | 1 |
| Kawasaki, T | 1 |
| Funatsu, T | 1 |
| Kaku, S | 1 |
| Xia, XY | 1 |
| Tan, YL | 1 |
| Sun, YW | 1 |
| Yan, GD | 1 |
| Rong, YX | 1 |
| Ren, QH | 1 |
| Liu, JY | 1 |
| Xu, XZ | 1 |
| Shan, GP | 1 |
| Jin, L | 1 |
| Estepp, JH | 1 |
| Smeltzer, M | 1 |
| Reiss, UM | 1 |
| Kerenyi, A | 1 |
| Kappelmayer, J | 1 |
| Schlammadinger, A | 1 |
| Razso, K | 1 |
| Martino, MA | 1 |
| George, JG | 1 |
| Chen, CC | 1 |
| Galic, V | 1 |
| Kapoor, R | 1 |
| Murray, KC | 1 |
| Shubella, J | 1 |
| Riker, E | 1 |
| Lancaster, JM | 1 |
| Hoffman, MS | 1 |
| Hamilton, SC | 1 |
| Whang, WW | 1 |
| Anderson, BJ | 1 |
| Bradbury, TL | 1 |
| Erens, GA | 1 |
| Tsuji, N | 1 |
| Kita, A | 1 |
| Edo, N | 1 |
| Aispuru, GR | 1 |
| Clavier, MM | 1 |
| Cardone, AJ | 1 |
| Gilberto, DO | 1 |
| Barousse, AP | 1 |
| Patel, M | 1 |
| Rumore, MM | 1 |
| Galante, M | 1 |
| Languasco, A | 1 |
| Gotta, D | 1 |
| Bell, S | 1 |
| Lancelotti, T | 1 |
| Knaze, V | 1 |
| Saubidet, CL | 1 |
| Grand, B | 1 |
| Milberg, M | 1 |
| Phan, T | 1 |
| So, TY | 1 |
| Uppal, S | 1 |
| Hernandez, E | 1 |
| Dutta, M | 1 |
| Dandolu, V | 1 |
| Rose, S | 1 |
| Hartenbach, E | 1 |
| Encke, A | 1 |
| Weber, AA | 1 |
| Paar, WD | 2 |
| Amitrano, L | 1 |
| Guardascione, MA | 1 |
| Scaglione, M | 1 |
| Menchise, A | 1 |
| Martino, R | 1 |
| Manguso, F | 1 |
| Lanza, AG | 1 |
| Lampasi, F | 1 |
| Khalafallah, AA | 1 |
| Renu, S | 1 |
| Sharp, C | 1 |
| Hannan, T | 1 |
| Cossetto, DJ | 1 |
| Goudar, A | 1 |
| Parkinson, K | 1 |
| Gasior, AC | 1 |
| Marty Knott, E | 1 |
| St Peter, SD | 1 |
| Lee, TH | 2 |
| Alonzo, BJ | 1 |
| Hamilton, G | 1 |
| Kremenevskiy, I | 1 |
| McNamara, S | 1 |
| Andrade-Campos, MM | 1 |
| Montes-Limón, AE | 1 |
| Fernandez-Mosteirin, N | 1 |
| Salvador-Osuna, C | 1 |
| Torres, M | 1 |
| Lucia-Cuesta, JF | 1 |
| Rubio-Felix, D | 1 |
| Seth, A | 1 |
| Rajpal, S | 1 |
| Penn, RL | 1 |
| Spyropoulos, AC | 3 |
| Hurley, JS | 1 |
| Ciesla, GN | 1 |
| de Lissovoy, G | 4 |
| Thumbikat, P | 1 |
| Poonnoose, PM | 1 |
| Balasubrahmaniam, P | 1 |
| Ravichandran, G | 1 |
| McClelland, MR | 1 |
| Garces, K | 1 |
| Bergqvist, D | 6 |
| Lai, TF | 1 |
| Henderson, T | 1 |
| Winlaw, W | 1 |
| Malcolm, SJ | 1 |
| MacLaughlin, EJ | 1 |
| Fitzpatrick, KT | 1 |
| Sbar, E | 1 |
| Jewell, C | 1 |
| Borja, J | 2 |
| Olivella, P | 2 |
| Curto, J | 1 |
| Morris, E | 1 |
| Thaler, H | 1 |
| Sim, E | 2 |
| Karim, A | 1 |
| Patel, D | 1 |
| Siddiqui, R | 1 |
| Mattana, J | 1 |
| Vormfelde, SV | 1 |
| Hughes, SJ | 1 |
| Subedi, P | 1 |
| Botteman, MF | 1 |
| Caprini, J | 1 |
| Stephens, JM | 1 |
| Nadipelli, V | 1 |
| Bell, CF | 1 |
| Pashos, CL | 1 |
| Reiter, M | 1 |
| Bucek, RA | 1 |
| Koca, N | 1 |
| Heger, J | 1 |
| Minar, E | 1 |
| Eskilson, C | 2 |
| Nylander, I | 1 |
| Frison, L | 4 |
| Ogren, M | 1 |
| Büyükkurt, CD | 1 |
| Dural, CA | 1 |
| Güloğlu, R | 2 |
| Akar, U | 1 |
| Alikhan, R | 4 |
| Keays, AC | 1 |
| Mason, M | 1 |
| Keays, SL | 1 |
| Newcombe, PA | 1 |
| White, RH | 1 |
| Konkle, BA | 1 |
| Weinstein, R | 1 |
| Greist, A | 1 |
| Holmes, HE | 1 |
| Bonfiglio, J | 1 |
| Kleber, FX | 1 |
| Witt, C | 1 |
| Vogel, G | 1 |
| Koppenhagen, K | 4 |
| Schomaker, U | 1 |
| Flosbach, CW | 1 |
| Gutknecht, DR | 1 |
| Wade, WE | 6 |
| Spruill, WJ | 3 |
| Leslie, RB | 2 |
| Frederiksen, SG | 1 |
| Hedenbro, JL | 1 |
| Norgren, L | 3 |
| Ennis, RS | 1 |
| Pless, T | 1 |
| Loertzer, H | 1 |
| Brandt, S | 1 |
| Radke, J | 1 |
| Fornara, P | 1 |
| Soukup, J | 1 |
| Priglinger, U | 1 |
| Delle Karth, G | 1 |
| Geppert, A | 1 |
| Joukhadar, C | 1 |
| Graf, S | 1 |
| Berger, R | 1 |
| Hülsmann, M | 1 |
| Spitzauer, S | 1 |
| Pabinger, I | 2 |
| Heinz, G | 1 |
| Beckman, JA | 1 |
| Dunn, K | 1 |
| Sasahara, AA | 1 |
| Hidalgo-Ovejero, AM | 1 |
| Garcia-Mata, S | 1 |
| Martinez-Grande, M | 1 |
| Otermin-Maya, I | 1 |
| Lalourcey, L | 1 |
| Mishnev, OD | 1 |
| Tsitsiashvili, MSh | 1 |
| Agafonov, VF | 1 |
| Hampton, KK | 1 |
| Vayá, A | 1 |
| Mira, Y | 1 |
| Aznar, J | 1 |
| Todolí, J | 1 |
| Arguedas, J | 1 |
| Solá, E | 1 |
| Kim, KH | 1 |
| Lynfield, Y | 1 |
| Piecuch, W | 1 |
| Sokołowska, B | 1 |
| Dmoszyńska, A | 1 |
| Furmanik, F | 1 |
| Carroll, DN | 1 |
| Hudson, EB | 1 |
| Combe, S | 3 |
| Samama, MM | 9 |
| Desjardins, L | 4 |
| Eldor, A | 5 |
| Janbon, C | 4 |
| Leizorovicz, A | 9 |
| Olsson, CG | 8 |
| Chiou-Tan, FY | 1 |
| Garza, H | 1 |
| Chan, KT | 1 |
| Parsons, KC | 1 |
| Donovan, WH | 1 |
| Robertson, CS | 1 |
| Holmes, SA | 1 |
| Graves, DE | 1 |
| Rintala, DH | 1 |
| Echtibi, SS | 1 |
| Bashir, MO | 1 |
| Ahmed, MU | 1 |
| Branicki, FJ | 1 |
| Abu-Zidan, FM | 1 |
| Colwell, CW | 3 |
| Neubauer, J | 1 |
| McElhattan, JL | 1 |
| Peters, GR | 1 |
| Francis, CW | 2 |
| Gordois, A | 1 |
| Posnett, J | 1 |
| Borris, L | 3 |
| Bossuyt, P | 1 |
| Jönsson, B | 2 |
| Levy, E | 1 |
| de Pouvourville, G | 1 |
| Nader, F | 1 |
| Ruef, J | 1 |
| Katus, HA | 1 |
| Kälebo, P | 8 |
| Panfilov, S | 1 |
| Andersson, M | 1 |
| Freij, A | 1 |
| Rowan, JA | 1 |
| McLintock, C | 1 |
| Taylor, RS | 1 |
| North, RA | 1 |
| Revel-Vilk, S | 1 |
| Massicotte, P | 4 |
| Marzinotto, V | 4 |
| Daneman, A | 1 |
| Dix, D | 1 |
| Beigi, RH | 1 |
| Wiensenfeld, HC | 1 |
| Evans, HC | 1 |
| Perry, CM | 1 |
| Faulds, D | 1 |
| Lev, EI | 1 |
| Hasdai, D | 1 |
| Scapa, E | 1 |
| Tobar, A | 1 |
| Assali, A | 1 |
| Lahav, J | 1 |
| Battler, A | 1 |
| Badimon, JJ | 1 |
| Kornowski, R | 1 |
| Covin, RB | 1 |
| Rich, NL | 1 |
| Aysola, A | 1 |
| Bara, L | 2 |
| Boutitie, F | 1 |
| McGarry, LJ | 1 |
| Thompson, D | 1 |
| Hofmann, T | 2 |
| Segers, AE | 2 |
| Cariou, R | 1 |
| Leeuwenkamp, O | 1 |
| Sullivan, SD | 1 |
| Muntz, JE | 1 |
| Oster, G | 1 |
| Schwarcz, TH | 2 |
| Matthews, MR | 1 |
| Hartford, JM | 1 |
| Quick, RC | 2 |
| Kwolek, CJ | 2 |
| Minion, DJ | 2 |
| Endean, ED | 2 |
| Mentzer, RM | 1 |
| Tai, CY | 1 |
| Ierardi, R | 1 |
| Alexander, JB | 1 |
| Gerotziafas, GT | 2 |
| Lobo, BL | 1 |
| Zangari, M | 1 |
| Barlogie, B | 1 |
| Anaissie, E | 1 |
| Saghafifar, F | 1 |
| Eddlemon, P | 1 |
| Jacobson, J | 1 |
| Lee, CK | 1 |
| Thertulien, R | 1 |
| Talamo, G | 1 |
| Thomas, T | 1 |
| Van Rhee, F | 1 |
| Fassas, A | 1 |
| Fink, L | 1 |
| Tricot, G | 1 |
| Araújo, GR | 1 |
| Lastoria, S | 1 |
| Maffei, FH | 1 |
| Karaoglan de Moura, L | 1 |
| Michaelis, W | 1 |
| Sandri, JL | 1 |
| Dietrich-Neto, F | 2 |
| Haentjens, P | 1 |
| De Groote, K | 1 |
| Annemans, L | 1 |
| Costea, A | 1 |
| Bhat, G | 1 |
| Offord, R | 1 |
| Lloyd, AC | 1 |
| Anderson, P | 1 |
| Bearne, A | 1 |
| Yanar, H | 1 |
| Bilsel, Y | 1 |
| Kizilirmak, S | 1 |
| Buyukkurt, D | 1 |
| Granit, V | 1 |
| Hebbeler, SL | 1 |
| Marciniak, CM | 1 |
| Crandall, S | 1 |
| Nussbaum, S | 1 |
| Mendelewski, S | 1 |
| Lynd, LD | 3 |
| O'brien, BJ | 3 |
| Gates, S | 1 |
| Brocklehurst, P | 1 |
| Ayers, S | 1 |
| Bowler, U | 1 |
| Boedeker, CC | 1 |
| Ridder, GJ | 1 |
| Weerda, N | 1 |
| Maier, W | 1 |
| Klenzner, T | 1 |
| Schipper, J | 1 |
| Brotman, DJ | 1 |
| Jaffer, AK | 1 |
| Hurbanek, JG | 2 |
| Morra, N | 1 |
| Lawrence, YR | 1 |
| Pulido, PA | 1 |
| Copp, SN | 1 |
| Walker, RH | 1 |
| Reden, LM | 1 |
| Hardwick, ME | 1 |
| Chakroun, T | 1 |
| Elalamy, I | 1 |
| Yogaratnam, D | 1 |
| Smith, BS | 1 |
| Angood, PB | 1 |
| Gandhi, PJ | 1 |
| Jain, V | 1 |
| Dhal, AK | 1 |
| Dhaon, BK | 1 |
| Pradhan, G | 1 |
| Shapiro, NI | 1 |
| Spear, J | 1 |
| Sheehy, S | 1 |
| Brown, J | 1 |
| Edlow, JA | 1 |
| Bjorvatn, A | 1 |
| Kristiansen, F | 1 |
| Röttger, C | 1 |
| Madlener, K | 1 |
| Heil, M | 1 |
| Gerriets, T | 1 |
| Walberer, M | 1 |
| Wessels, T | 1 |
| Bachmann, G | 1 |
| Kaps, M | 1 |
| Stolz, E | 1 |
| Hooker, EA | 1 |
| Carver, L | 1 |
| Verso, M | 3 |
| Bertoglio, S | 2 |
| Di Somma, FC | 1 |
| Paoletti, F | 2 |
| Bazzan, M | 2 |
| Parise, P | 1 |
| Quintavalla, R | 2 |
| Naglieri, E | 1 |
| Santoro, A | 1 |
| Sorarù, M | 1 |
| Mosca, S | 2 |
| Chan, AL | 1 |
| Enyart, JJ | 1 |
| Jones, RJ | 1 |
| Olsen, J | 1 |
| Gundgaard, J | 1 |
| Stannard, JP | 2 |
| Singhania, AK | 1 |
| Lopez-Ben, RR | 2 |
| Anderson, ER | 2 |
| Farris, RC | 1 |
| Volgas, DA | 2 |
| McGwin, GR | 2 |
| Alonso, JE | 2 |
| Akanmu, AS | 1 |
| Nnodu, OE | 1 |
| Giwa, SO | 1 |
| Salako, LA | 1 |
| Akinsete, I | 1 |
| Adebule, GT | 1 |
| Adekoya-Cole, TO | 1 |
| Odunubi, OO | 1 |
| Ernits, M | 1 |
| Mohan, PS | 1 |
| Fares, LG | 1 |
| Hardy, H | 1 |
| Rutherford, EJ | 1 |
| Schooler, WG | 1 |
| Sredzienski, E | 1 |
| Abrams, JE | 1 |
| Skeete, DA | 1 |
| Maciejczyk-Pencuła, M | 1 |
| Polak, G | 1 |
| Kotarski, J | 1 |
| Chong, BH | 1 |
| Brighton, TA | 1 |
| Baker, RI | 2 |
| Thurlow, P | 1 |
| Lee, CH | 1 |
| Munck, LK | 1 |
| Andersen, SE | 1 |
| Christensen, HR | 1 |
| Warkentin, TE | 4 |
| Cook, RJ | 2 |
| Marder, VJ | 1 |
| Sheppard, JA | 1 |
| Moore, JC | 1 |
| Greinacher, A | 3 |
| Kelton, JG | 1 |
| Kravitz, MS | 1 |
| Mishaal, RA | 1 |
| Shoenfeld, Y | 1 |
| Quenet, S | 1 |
| Levine, M | 1 |
| Merli, G | 2 |
| Derobert, E | 1 |
| Irwin, MW | 1 |
| Eritsland, J | 1 |
| Hesselschwerdt, HJ | 1 |
| von Hanstein, KL | 1 |
| Ferguson, RE | 1 |
| Critchfield, A | 1 |
| Leclaire, A | 1 |
| Ajkay, N | 1 |
| Vasconez, HC | 1 |
| Rajkumar, VS | 1 |
| Goodin, S | 1 |
| Schiff, RL | 1 |
| Shrier, I | 1 |
| Strulovitch, C | 1 |
| Hammouda, W | 1 |
| Cohen, E | 1 |
| Zukor, D | 1 |
| Acaroğlu, E | 1 |
| Ozdemir, HM | 1 |
| Atilla, B | 1 |
| Ol'binskaia, LI | 1 |
| Kolosova, KIu | 1 |
| Nesterova, SG | 1 |
| Egorova, TD | 1 |
| Fedorova, AIu | 1 |
| Bonneux, IM | 1 |
| Bellemans, J | 1 |
| Fabry, G | 1 |
| Potdar, N | 1 |
| Jabbar, B | 1 |
| Burrell, SJ | 1 |
| Tan, EK | 1 |
| Wisdom, SJ | 1 |
| Thamban, S | 1 |
| Opemuyi, IO | 1 |
| Swinhoe, JR | 1 |
| Cochrane, GW | 1 |
| Patel, RK | 1 |
| Ramasamy, K | 1 |
| Goss, D | 1 |
| Deane, C | 1 |
| Bonner, L | 1 |
| Arya, R | 1 |
| Harenberg, J | 10 |
| Jörg, I | 1 |
| Weiss, C | 1 |
| White, JM | 1 |
| Munn, SE | 1 |
| Seet, JE | 1 |
| Adams, N | 1 |
| Clement, M | 1 |
| Busbee, M | 1 |
| Karr, DK | 1 |
| Ortel, TL | 1 |
| Gelfer, Y | 1 |
| Tavor, H | 1 |
| Oron, A | 1 |
| Peer, A | 1 |
| Halperin, N | 1 |
| Robinson, D | 1 |
| Niazi, AU | 1 |
| Umer, M | 1 |
| Umar, M | 1 |
| Bischoff, A | 1 |
| Rodríguez, A | 1 |
| Vallano, A | 1 |
| Tapson, VF | 2 |
| Wildgoose, P | 1 |
| Yusen, RD | 3 |
| Feng, Y | 1 |
| Green, B | 1 |
| Duffull, SB | 1 |
| Kane-Gill, SL | 1 |
| Bobek, MB | 1 |
| Bies, RR | 1 |
| Farina, JA | 1 |
| Piccinato, CE | 1 |
| Campos, AD | 1 |
| Rossi, MA | 1 |
| Vadivelu, N | 1 |
| Freiberg, C | 1 |
| Kim, J | 1 |
| Wallace, M | 1 |
| Sinatra, R | 1 |
| Bottner, F | 1 |
| Windsor, RE | 1 |
| Laskin, RS | 1 |
| Haas, SB | 1 |
| Sculco, TP | 1 |
| Bedard, PW | 2 |
| Kaila, N | 2 |
| Shaw, G | 1 |
| Meier, TR | 3 |
| Buckenmaier, CC | 1 |
| Shields, CH | 1 |
| Auton, AA | 1 |
| Evans, SL | 1 |
| Croll, SM | 1 |
| Bleckner, LL | 1 |
| Brown, DS | 1 |
| Stojadinovic, A | 1 |
| Hummel, MC | 1 |
| Morse, BC | 1 |
| Hayes, LE | 1 |
| Somonova, OV | 1 |
| Madzhuga, AV | 1 |
| Elizarova, AL | 1 |
| Sel'chuk, VIu | 1 |
| Zubrikhina, GN | 1 |
| Bokhian, AIu | 1 |
| Shorr, AF | 3 |
| Jackson, WL | 1 |
| Moores, LK | 1 |
| Frezza, EE | 1 |
| Wachtel, MS | 1 |
| Schobess, R | 1 |
| Düring, C | 1 |
| Bidlingmaier, C | 1 |
| Heinecke, A | 1 |
| Merkel, N | 1 |
| Nowak-Göttl, U | 1 |
| Myers, J | 1 |
| Leykum, L | 1 |
| Pugh, J | 1 |
| Diuguid, D | 1 |
| Papadopoulos, K | 1 |
| Fraser, GL | 1 |
| Riker, RR | 1 |
| Bai, S | 1 |
| Thomas, C | 1 |
| Ahsan, F | 1 |
| Castro, DJ | 1 |
| Díaz, G | 1 |
| Martí, D | 1 |
| Escobar, C | 1 |
| Ortega, J | 1 |
| García-Rull, S | 1 |
| Picher, J | 1 |
| Sueiro, A | 1 |
| Schulz, SL | 1 |
| Kesselring, C | 1 |
| Seeberger, U | 1 |
| Andresen, D | 1 |
| Gladding, P | 1 |
| Larsen, F | 1 |
| Durrant, H | 1 |
| Black, P | 1 |
| Har-Noy, O | 1 |
| Meltzer, E | 1 |
| Quinlan, DJ | 1 |
| Sidhu, PS | 1 |
| Sherman, DG | 1 |
| Albers, GW | 1 |
| Bladin, C | 1 |
| Fieschi, C | 1 |
| Gabbai, AA | 1 |
| Kase, CS | 1 |
| O'Riordan, W | 1 |
| Pineo, GF | 8 |
| Stine, KC | 1 |
| Saylors, RL | 1 |
| Saccente, CS | 1 |
| Becton, DL | 1 |
| Jeong, GK | 1 |
| Gruson, KI | 1 |
| Egol, KA | 1 |
| Aharonoff, GB | 1 |
| Karp, AH | 1 |
| Zuckerman, JD | 1 |
| Koval, KJ | 1 |
| Minenna, G | 1 |
| Albanese, L | 1 |
| D'Amore, S | 1 |
| Scagliusi, P | 1 |
| D'Amore, M | 1 |
| Slavik, RS | 1 |
| Chan, E | 1 |
| Gorman, SK | 1 |
| de Lemos, J | 1 |
| Chittock, D | 1 |
| Simons, RK | 1 |
| Wing, PC | 1 |
| Ho, SG | 1 |
| Ma, Q | 1 |
| Anderson, K | 1 |
| Kaatz, S | 1 |
| Shepard, A | 1 |
| Workings, M | 1 |
| Rand, K | 1 |
| Homering, M | 1 |
| Kamal, MK | 1 |
| Reilly, PM | 1 |
| Stavropoulos, SW | 1 |
| Fazel, R | 1 |
| Froehlich, JB | 1 |
| Williams, DM | 1 |
| Saint, S | 1 |
| Nallamothu, BK | 1 |
| Goeree, R | 2 |
| Crowther, MA | 4 |
| Gaillard, ML | 1 |
| Meems, L | 1 |
| Dunn, AS | 1 |
| Eisenson, N | 1 |
| van Dijk, CN | 2 |
| Frostick, SP | 2 |
| Christiansen, AV | 1 |
| Hettiarachchi, R | 2 |
| Schnee, J | 2 |
| Melero, MJ | 1 |
| Bergroth, B | 1 |
| Contardo, DM | 1 |
| Mazzei, MM | 1 |
| Martins, HS | 1 |
| Scalabrini-Neto, A | 1 |
| Velasco, IT | 1 |
| Ball, ST | 1 |
| Pinsorsnak, P | 1 |
| Amstutz, HC | 1 |
| Schmalzried, TP | 1 |
| Cole, SM | 1 |
| Patterson, MB | 1 |
| Cupp, CL | 1 |
| Norrie, J | 1 |
| Kim, SK | 1 |
| Lee, DY | 1 |
| Kim, CY | 1 |
| Nam, JH | 1 |
| Moon, HT | 1 |
| Simmons, BB | 1 |
| Dubreuil, AL | 1 |
| Evanchuk, DM | 1 |
| Von Gehr, A | 1 |
| Zehnder, JL | 1 |
| Kothari, SN | 1 |
| Lambert, PJ | 1 |
| Mathiason, MA | 1 |
| Dorr, LD | 1 |
| Gendelman, V | 1 |
| Maheshwari, AV | 1 |
| Boutary, M | 1 |
| Long, WT | 1 |
| Di Gennaro, L | 1 |
| Maggi, F | 1 |
| Novarese, L | 1 |
| Cipriani, MC | 1 |
| Bonomo, L | 1 |
| Landolfi, R | 1 |
| Baglin, T | 1 |
| Palmer, CR | 1 |
| Luddington, R | 1 |
| Baglin, C | 1 |
| Zajkowski, PJ | 1 |
| Ballard, NE | 1 |
| Vlasuk, GP | 1 |
| Marc, K | 1 |
| Bourkadi, JE | 1 |
| Benamor, J | 1 |
| Iraqi, G | 1 |
| Kamphuisen, PW | 3 |
| Lazzaro, A | 1 |
| Paciaroni, M | 1 |
| Luthra, S | 1 |
| Theodore, S | 1 |
| Liava'a, M | 1 |
| Atkinson, V | 1 |
| Tatoulis, J | 1 |
| Baxi, S | 1 |
| Crandall, DL | 1 |
| Wrobleski, S | 1 |
| Hawley, A | 1 |
| Farris, D | 1 |
| Elokdah, H | 1 |
| Sigler, R | 1 |
| Wakefield, T | 1 |
| Myers, D | 1 |
| Dahl, O | 1 |
| Zielske, D | 1 |
| Tran, H | 1 |
| McRae, S | 1 |
| Ginsberg, J | 1 |
| Lebaudy, C | 1 |
| Hulot, JS | 1 |
| Amoura, Z | 1 |
| Costedoat-Chalumeau, N | 1 |
| Serreau, R | 1 |
| Ankri, A | 1 |
| Conard, J | 2 |
| Cornet, A | 1 |
| Dommergues, M | 1 |
| Piette, JC | 1 |
| Lechat, P | 1 |
| Daniels, AH | 1 |
| Wilson, CL | 1 |
| Harrison, RA | 1 |
| Mannari, D | 1 |
| Hughes, D | 1 |
| Mehta, A | 1 |
| Kalodiki, E | 1 |
| Al-Kutoubi, A | 1 |
| Cunningham, DA | 1 |
| Mandalia, S | 1 |
| Toksvig-Larsen, S | 1 |
| Magyar, G | 1 |
| Lindstrand, A | 1 |
| Albrechtsson, U | 1 |
| Vochelle, N | 1 |
| Fagola, M | 1 |
| Bellaud, M | 1 |
| Mattiasson, I | 1 |
| Berntorp, E | 1 |
| Bornhov, S | 1 |
| Lagerstedt, C | 1 |
| Lethagen, S | 1 |
| Persson, J | 1 |
| Timberg, I | 1 |
| Torstensson, I | 1 |
| Zolotukhin, IA | 2 |
| Chi, L | 1 |
| Saganek, LJ | 1 |
| Rogers, KL | 1 |
| Mertz, TE | 2 |
| Metz, AL | 1 |
| Uprichard, AC | 1 |
| Gallagher, KP | 1 |
| Connolly, ES | 1 |
| Mocco, J | 1 |
| McLaughlin, JA | 1 |
| Paulson, MM | 1 |
| Rosenthal, RE | 1 |
| Rodgers, GM | 2 |
| Houde, JP | 1 |
| Steinberg, G | 1 |
| Porterfield, LM | 1 |
| Etchells, E | 1 |
| McLeod, RS | 2 |
| Barton, P | 2 |
| Detsky, AS | 1 |
| Shaieb, MD | 1 |
| Watson, BN | 1 |
| Atkinson, RE | 1 |
| Darmon, JY | 2 |
| Weisslinger, N | 1 |
| Check, W | 1 |
| Montoya, JP | 1 |
| Pokala, N | 1 |
| Melde, SL | 1 |
| Stephan, D | 1 |
| Welsch, M | 1 |
| Chapatte, D | 1 |
| Weltin, D | 1 |
| Imbs, JL | 1 |
| Rossi, R | 1 |
| Taborelli, P | 1 |
| Fioroni, C | 1 |
| Zerbi, D | 1 |
| Pattacini, P | 1 |
| Giugni, E | 1 |
| Bagatella, P | 1 |
| Vaccarino, A | 1 |
| Barjot, P | 1 |
| Beucher, G | 1 |
| Le Querrec, A | 1 |
| Derlon-Borel, A | 1 |
| Herlicoviez, M | 1 |
| Miller, JL | 2 |
| Rybachuk, OI | 1 |
| Besiedyns'kyĭ, SM | 1 |
| Huliaiev, DV | 1 |
| Tseng, CW | 1 |
| Huntington, J | 1 |
| Ellis, MH | 1 |
| Manor, Y | 1 |
| Witz, M | 1 |
| Sonaglia, F | 1 |
| Baroni, M | 1 |
| Severi, P | 1 |
| D'Angelo, SV | 1 |
| Calderon, EJ | 1 |
| Varela, JM | 1 |
| Gonzalez de la Puente, MA | 1 |
| Mant, MJ | 1 |
| Russell, DB | 1 |
| Johnston, DW | 1 |
| Donahue, PA | 1 |
| Stern, SH | 1 |
| Wixson, RL | 1 |
| O'Connor, D | 1 |
| Bollinger, KA | 1 |
| Vermeulen, LC | 1 |
| Davis, SN | 1 |
| Geurkink, EA | 1 |
| Ku, P | 1 |
| Malinowski, J | 1 |
| Zhu, BY | 1 |
| Scarborough, RM | 1 |
| Marlowe, CK | 1 |
| Wong, PW | 1 |
| Lin, PH | 2 |
| Hollenbach, SJ | 1 |
| Schuurman, B | 1 |
| den Heijer, M | 1 |
| Nijs, AM | 1 |
| Hawkins, DW | 2 |
| Hoffman, R | 1 |
| Blumenfeld, Z | 1 |
| Weiner, Z | 1 |
| Younis, JS | 1 |
| Gonze, MD | 1 |
| Salartash, K | 1 |
| Sternbergh, WC | 1 |
| Baughman, RA | 1 |
| Leone-Bay, A | 1 |
| Money, SR | 1 |
| McEvoy, MD | 1 |
| Bailey, M | 1 |
| Taylor, D | 1 |
| Del Schutte, H | 1 |
| Panizo, C | 1 |
| Lecumberri, R | 1 |
| Burnakis, TG | 1 |
| Gonzalez, LS | 1 |
| Bussey, HI | 1 |
| Groce, JB | 1 |
| Hakki, SI | 2 |
| Fareed, J | 5 |
| Hoppensteadt, DA | 4 |
| Abdullah, H | 2 |
| Camblin, J | 2 |
| Nasseri, AF | 2 |
| Hamadeh, O | 2 |
| Wright, T | 2 |
| Tillman, DJ | 1 |
| Charland, SL | 1 |
| Witt, DM | 1 |
| Harvey, DM | 1 |
| Offord, RH | 1 |
| Spiro, TE | 4 |
| Krupski, WC | 1 |
| Champion, AH | 1 |
| Sorensen, SV | 1 |
| Morris, TA | 1 |
| Marsh, JJ | 1 |
| Konopka, R | 1 |
| Pedersen, CA | 1 |
| Chiles, PG | 1 |
| Shively, BK | 1 |
| Abildgaard, U | 1 |
| Elias, D | 1 |
| Grigg, A | 1 |
| Musset, D | 1 |
| Trowbridge, AA | 3 |
| Zawilska, K | 1 |
| Norwood, SH | 2 |
| McAuley, CE | 2 |
| Berne, JD | 2 |
| Vallina, VL | 2 |
| Kerns, DB | 2 |
| Grahm, TW | 2 |
| McLarty, JW | 2 |
| Geerts, WH | 2 |
| Sniderman, KW | 1 |
| Greenwood, C | 1 |
| Gregoire, RC | 1 |
| Taylor, BM | 1 |
| Silverman, RE | 1 |
| Atkinson, KG | 1 |
| Burnstein, M | 1 |
| Marshall, JC | 1 |
| Burul, CJ | 1 |
| Anderson, DR | 3 |
| Ross, T | 1 |
| Wilson, SR | 1 |
| Hoek, JA | 1 |
| Rosenberg, RD | 1 |
| Comp, PC | 1 |
| Whitsett, TL | 2 |
| Johnson, GJ | 1 |
| Gardiner, GA | 2 |
| Landon, GC | 1 |
| Jové, M | 1 |
| Harrison, SJ | 1 |
| Rafferty, I | 1 |
| McColl, MD | 1 |
| Labas, P | 2 |
| Ohrádka, B | 2 |
| Vladimír, J | 1 |
| Cambal, M | 2 |
| Kumar, PD | 1 |
| Solti, M | 1 |
| Marsland, T | 1 |
| Newton, W | 1 |
| Devlin, JW | 1 |
| Tyburski, JG | 1 |
| Moed, B | 1 |
| Lopez, LM | 1 |
| Deep, K | 1 |
| Jigajinni, MV | 1 |
| McLean, AN | 1 |
| Fraser, MH | 1 |
| Fitzgerald, RH | 1 |
| O'Connell, MB | 1 |
| Ohar, JA | 1 |
| Young, TR | 1 |
| Baykal, C | 1 |
| Al, A | 1 |
| Demirtaş, E | 1 |
| Ayhan, A | 1 |
| Zaw, HM | 1 |
| Landow, L | 1 |
| Pineo, G | 1 |
| Deitcher, SR | 1 |
| Bendz, B | 2 |
| Sevre, K | 1 |
| Andersen, TO | 1 |
| Sandset, PM | 2 |
| Kearney, PA | 1 |
| Thaler, HW | 1 |
| Roller, RE | 1 |
| Greiner, N | 1 |
| Korninger, C | 1 |
| Ramage, AS | 1 |
| Selby, R | 1 |
| Lopshire, JC | 1 |
| Darroca, AG | 1 |
| Gradus-Pizlo, I | 1 |
| O'Donnell, JA | 1 |
| Heit, JA | 2 |
| Whipple, J | 1 |
| Peters, G | 1 |
| Decousus, M | 1 |
| Buchmuller, A | 1 |
| Hervé, P | 1 |
| Lamer, C | 1 |
| Parent, F | 1 |
| Tardy, B | 1 |
| Abu-Samrah, S | 1 |
| McClanahan, TB | 1 |
| Hicks, GW | 1 |
| Morrison, AL | 1 |
| Peng, YW | 1 |
| Janiczek-Dolphin, N | 1 |
| Sullivan, ME | 1 |
| Morser, J | 1 |
| Juneau, PL | 1 |
| Leadley, R | 1 |
| Lepercq, J | 1 |
| Borel-Derlon, A | 1 |
| Boudignat, O | 1 |
| Francoual, C | 1 |
| Priollet, P | 1 |
| Cohen, C | 1 |
| Yvelin, N | 1 |
| Schved, JF | 1 |
| Tournaire, M | 1 |
| Borg, JY | 1 |
| Diuguid, DL | 1 |
| Perry, DJ | 1 |
| Krotenberg, R | 1 |
| Adler, U | 1 |
| Pomeranz, B | 1 |
| Miller, JD | 1 |
| Russell, MW | 1 |
| Scholten, DJ | 1 |
| Hoedema, RM | 1 |
| Scholten, SE | 1 |
| Murashige, N | 2 |
| Kami, M | 2 |
| Marlovits, S | 1 |
| Priestley, M | 1 |
| Scacewater, R | 1 |
| Nilsson, PE | 1 |
| Le Moigne-Amrani, A | 1 |
| Doggrell, SA | 1 |
| Mason, JA | 1 |
| Stellbrink, C | 1 |
| Hanrath, P | 1 |
| Nixdorff, U | 1 |
| Lehmacher, W | 1 |
| Kühle, K | 1 |
| Fetsch, T | 1 |
| Grewe, R | 1 |
| Schmidt-Lucke, JA | 1 |
| Warwick, D | 1 |
| Harrison, J | 1 |
| Whitehouse, S | 1 |
| Mitchelmore, A | 1 |
| Thornton, M | 1 |
| Short, K | 1 |
| Perneger, T | 1 |
| Hillbom, M | 1 |
| Erilä, T | 1 |
| Sotaniemi, K | 1 |
| Sarna, S | 1 |
| Kaste, M | 1 |
| Counsell, C | 1 |
| Sandercock, P | 1 |
| Hiebert, LM | 1 |
| Del Bono, R | 1 |
| Martini, G | 1 |
| Volpi, R | 1 |
| Lindhoff-Last, E | 1 |
| Nakov, R | 2 |
| Nakov, RL | 1 |
| Jersmann, HP | 1 |
| Takaue, Y | 1 |
| Shields, K | 3 |
| Chan, AK | 2 |
| Szechtman, B | 3 |
| Kohne, S | 1 |
| Shepherd, S | 1 |
| Bacher, P | 1 |
| Andrew, M | 3 |
| Ahmad, S | 1 |
| Bacher, HP | 1 |
| Leitz, H | 2 |
| Walenga, JM | 1 |
| Gore, M | 1 |
| Kelkar, P | 1 |
| Rege, N | 1 |
| Ross, C | 1 |
| Wellington, K | 1 |
| McClellan, K | 1 |
| Jarvis, B | 1 |
| Hoppenstead, DA | 1 |
| Scully, M | 2 |
| Riess, H | 6 |
| Becker, LK | 1 |
| Melzer, N | 3 |
| Schwanebeck, U | 1 |
| Sieder, C | 3 |
| Abletshauser, C | 3 |
| Gerlach, HE | 2 |
| Tebbe, U | 2 |
| Tolle, A | 2 |
| Kemkes-Matthes, B | 1 |
| Gräve, M | 1 |
| Patek, F | 1 |
| Drexler, M | 1 |
| Siemens, HJ | 1 |
| Weidinger, G | 4 |
| Brom, J | 4 |
| Kolb, G | 1 |
| Bodamer, I | 1 |
| Galster, H | 1 |
| Seidlmayer, C | 1 |
| Grambach, K | 1 |
| Koudela, K | 1 |
| Eisele, RR | 1 |
| Becker, C | 1 |
| Paal, V | 1 |
| Spannagel, U | 1 |
| Diener, HC | 2 |
| Jochberger, S | 1 |
| Mayr, V | 1 |
| Luckner, G | 1 |
| Fries, DR | 1 |
| Mayr, AJ | 1 |
| Friesenecker, BE | 1 |
| Lorenz, I | 1 |
| Hasibeder, WR | 1 |
| Ulmer, H | 1 |
| Schobersberger, W | 1 |
| Dünser, MW | 1 |
| Ringelstein, EB | 1 |
| von Kummer, R | 1 |
| Landgraf, H | 1 |
| Rektor, I | 1 |
| Csányi, A | 1 |
| Schneider, D | 1 |
| Klingelhöfer, J | 1 |
| Schmidt, JA | 1 |
| Tolle, AR | 1 |
| Kirchmaier, CM | 1 |
| Sakamoto, Y | 1 |
| Sato, K | 1 |
| Ishikawa, C | 1 |
| Kagawa, Y | 1 |
| Nakayama, T | 1 |
| Sakai, M | 1 |
| Novak, P | 1 |
| Novak, A | 1 |
| Šabović, M | 1 |
| Kozak, M | 1 |
| Han, JM | 1 |
| Koh, Y | 1 |
| Kim, SH | 1 |
| Suh, SY | 1 |
| Cho, YS | 1 |
| Yu, SJ | 1 |
| Yoon, JH | 1 |
| Gwak, HS | 1 |
| Becattini, C | 1 |
| Meyer, G | 4 |
| Muñoz, A | 1 |
| Torbicki, A | 1 |
| Sueiro, MR | 1 |
| Lambert, C | 1 |
| Gussoni, G | 1 |
| Campanini, M | 1 |
| Vescovo, G | 1 |
| Xia, ZN | 1 |
| Zhou, Q | 1 |
| Zhu, W | 1 |
| Weng, XS | 1 |
| Khorana, AA | 2 |
| Noble, S | 1 |
| Lee, AYY | 2 |
| Soff, G | 1 |
| O'Connell, C | 1 |
| Hutchinson, A | 1 |
| Rees, S | 1 |
| Young, A | 1 |
| Maraveyas, A | 1 |
| Date, K | 1 |
| Johnson, MJ | 1 |
| van Es, N | 2 |
| Wang, TF | 1 |
| Garcia, D | 2 |
| Weitz, J | 1 |
| Buller, H | 2 |
| Calder, JD | 1 |
| Liang, JJ | 2 |
| Goldberg, AD | 1 |
| Afessa, B | 1 |
| Ragsdell, B | 1 |
| Thachil, J | 1 |
| Spirkoska, A | 1 |
| Jezovnik, MK | 1 |
| Poredos, P | 1 |
| Larsen, AC | 1 |
| Brøndum Frøkjaer, J | 1 |
| Wishwanath Iyer, V | 1 |
| Vincents Fisker, R | 1 |
| Sall, M | 1 |
| Yilmaz, MK | 1 |
| Kuno Møller, B | 1 |
| Kristensen, SR | 1 |
| Thorlacius-Ussing, O | 1 |
| Tvito, A | 1 |
| Bakchoul, T | 1 |
| Rowe, JM | 1 |
| Ganzel, C | 1 |
| Bleker, SM | 1 |
| Mercuri, MF | 1 |
| Schwocho, L | 1 |
| Kakkar, A | 1 |
| Chlumsky, J | 1 |
| Gibbs, H | 1 |
| Ockelford, P | 1 |
| Grosso, MA | 1 |
| Shaya, SA | 1 |
| Saldanha, LJ | 1 |
| Vaezzadeh, N | 1 |
| Zhou, J | 1 |
| Ni, R | 1 |
| Gross, PL | 1 |
| Scarpioni, R | 1 |
| Croci, E | 1 |
| Dentali, F | 1 |
| Plante, S | 1 |
| Belzile, EL | 1 |
| Fréchette, D | 1 |
| Lefebvre, J | 1 |
| Douketis, J | 2 |
| Cook, D | 4 |
| Meade, M | 4 |
| Skrobik, Y | 2 |
| Granton, J | 2 |
| Hébert, P | 2 |
| Pagliarello, G | 2 |
| Marshall, J | 1 |
| Fowler, R | 2 |
| Freitag, A | 2 |
| Rabbat, C | 2 |
| Anderson, D | 2 |
| Zytaruk, N | 4 |
| Heels-Ansdell, D | 4 |
| Crowther, M | 4 |
| Henrich, W | 1 |
| Onügören, O | 1 |
| Kivelitz, D | 1 |
| Dudenhausen, JW | 1 |
| Goel, DP | 1 |
| Buckley, R | 1 |
| deVries, G | 1 |
| Abelseth, G | 1 |
| Ni, A | 1 |
| Gray, R | 1 |
| Dindo, D | 1 |
| Breitenstein, S | 1 |
| Hahnloser, D | 1 |
| Seifert, B | 1 |
| Yakarisik, S | 1 |
| Asmis, LM | 1 |
| Muller, MK | 1 |
| Clavien, PA | 1 |
| Niemi, T | 1 |
| Silvasti-Lundell, M | 1 |
| Armstrong, E | 1 |
| Hernesniemi, J | 1 |
| Scott, KC | 1 |
| Hansen, BD | 1 |
| DeFrancesco, TC | 1 |
| Kerr, J | 1 |
| Linkins, LA | 1 |
| Puskas, D | 1 |
| Shi, M | 1 |
| Bocanegra, T | 1 |
| Perry, JR | 1 |
| Laperriere, NJ | 1 |
| Rogers, LR | 1 |
| Malkin, MG | 1 |
| Sawaya, R | 1 |
| Baker, R | 1 |
| Parpia, S | 1 |
| Finch, T | 1 |
| Levine, MN | 3 |
| Pehrsson, S | 1 |
| Johansson, K | 1 |
| Kjaer, M | 1 |
| Elg, M | 1 |
| Walter, S | 1 |
| Cooper, DJ | 2 |
| Vallance, S | 2 |
| Qushmaq, I | 2 |
| Rocha, M | 2 |
| Berwanger, O | 2 |
| Vlahakis, NE | 1 |
| Walter, SD | 1 |
| Colwell, AS | 1 |
| Reish, RG | 1 |
| Kuter, DJ | 2 |
| Damjanovic, B | 1 |
| Austen, WG | 1 |
| Fogerty, AE | 1 |
| Smythe, MA | 1 |
| Koerber, JM | 1 |
| Esterbrook, G | 1 |
| Hart, S | 1 |
| Blackburn, TK | 1 |
| Java, KR | 1 |
| Lowe, D | 1 |
| Brown, JS | 1 |
| Rogers, SN | 1 |
| Aghourian, MN | 1 |
| Lemarié, CA | 1 |
| Blostein, MD | 1 |
| Bishu, KG | 1 |
| Anavekar, NS | 1 |
| Dey, M | 1 |
| Charles Bates, A | 1 |
| McMillan, P | 1 |
| Ulander, VM | 1 |
| Stenqvist, P | 1 |
| Kaaja, R | 2 |
| Heaton, D | 1 |
| Han, DY | 1 |
| Inder, A | 1 |
| Bonet, M | 1 |
| Roncales, J | 2 |
| Muchart, J | 1 |
| Fraile, M | 1 |
| Bick, RL | 4 |
| Lee, AY | 1 |
| Bowden, C | 1 |
| Rickles, FR | 1 |
| Haley, S | 1 |
| Kovacs, MJ | 7 |
| Arnesen, H | 1 |
| Aspelin, T | 1 |
| Seljeflot, I | 1 |
| Kierulf, P | 1 |
| Lyberg, T | 1 |
| Eriksson, H | 1 |
| Wåhlander, K | 2 |
| Gustafsson, D | 3 |
| Welin, LT | 1 |
| Schulman, S | 1 |
| Smorenburg, SM | 1 |
| Payne, S | 1 |
| MacKinnon, K | 1 |
| Keeney, M | 1 |
| Morrow, B | 5 |
| Blot, E | 1 |
| Gutman, F | 1 |
| Thannberger, A | 1 |
| Hull, JH | 1 |
| Hull, PJ | 1 |
| Kaufman, JL | 1 |
| Avritscher, EB | 1 |
| Cantor, SB | 1 |
| Shih, YC | 1 |
| Escalante, CP | 1 |
| Rivera, E | 1 |
| Elting, LS | 1 |
| Bäckman, K | 1 |
| Carlsson, P | 1 |
| Kentson, M | 1 |
| Hansen, S | 1 |
| Engquist, L | 1 |
| Hallert, C | 1 |
| Lemoine, NR | 1 |
| Low, V | 1 |
| Patel, HK | 1 |
| Rustin, G | 1 |
| Quigley, M | 1 |
| Williamson, RC | 1 |
| Bush, RL | 1 |
| Lumsden, AB | 1 |
| Vaitkus, PT | 3 |
| Zacharski, L | 1 |
| Jiménez, JA | 1 |
| Vilaseca, B | 1 |
| Barbour, LA | 1 |
| Oja, JL | 1 |
| Schultz, LK | 1 |
| Averkov, OV | 1 |
| Al-Yaseen, E | 1 |
| Wells, PS | 6 |
| Anderson, J | 1 |
| Martin, J | 1 |
| Rodger, MA | 1 |
| Forgie, MA | 1 |
| Florack, P | 1 |
| Touchie, D | 2 |
| Gray, L | 2 |
| O'Rourke, K | 1 |
| Wells, G | 1 |
| Kovacs, J | 1 |
| DeBernardo, RL | 1 |
| Perkins, RB | 1 |
| Littell, RD | 1 |
| Krasner, CN | 1 |
| Duska, LR | 1 |
| Egger, SS | 1 |
| Sawatzki, MG | 1 |
| Drewe, J | 1 |
| Krähenbühl, S | 1 |
| Yamakawa, N | 1 |
| Kawauchi, Y | 1 |
| Ishikawa, S | 1 |
| Nakazawa, K | 1 |
| Makita, K | 1 |
| Heerey, A | 1 |
| Suri, S | 1 |
| Rabbat, CG | 1 |
| Cook, DJ | 1 |
| McDonald, E | 1 |
| Clarke, F | 1 |
| Meade, MO | 1 |
| Lee, KA | 1 |
| Malý, J | 1 |
| Dulícek, P | 1 |
| Penka, M | 1 |
| Malý, R | 1 |
| Gumulec, J | 1 |
| Tincani, E | 1 |
| Mannucci, C | 1 |
| Casolari, B | 1 |
| Turrini, F | 1 |
| Cenci, AM | 1 |
| Bondi, M | 1 |
| Cothren, CC | 1 |
| Smith, WR | 1 |
| Moore, EE | 1 |
| Morgan, SJ | 1 |
| Lapidus, LJ | 2 |
| Rosfors, S | 2 |
| Ponzer, S | 2 |
| Levander, C | 2 |
| Elvin, A | 2 |
| Lärfars, G | 2 |
| de Bri, E | 2 |
| Rodger, M | 1 |
| Andreou, R | 1 |
| Mangel, JE | 1 |
| Clement, AM | 1 |
| Moore, A | 1 |
| Lau, E | 1 |
| Mackool, B | 1 |
| Heilmann, L | 1 |
| Rath, W | 1 |
| Pollow, K | 1 |
| Friedrich, J | 1 |
| Karachi, T | 1 |
| Seidel, C | 1 |
| Hjorth-Hansen, H | 1 |
| Borset, M | 1 |
| Hansen, JB | 1 |
| Sundan, A | 1 |
| Waage, A | 1 |
| Obernosterer, A | 1 |
| Schippinger, G | 1 |
| Lipp, RW | 1 |
| Wirnsberger, G | 1 |
| Roller, R | 1 |
| Pilger, E | 1 |
| Savage, KJ | 1 |
| Schulz, V | 1 |
| Goudie, D | 1 |
| Cruickshank, M | 1 |
| Huhle, G | 1 |
| Geberth, M | 1 |
| Hoffmann, U | 1 |
| Heene, DL | 1 |
| Kemppainen, E | 1 |
| Kokkola, A | 1 |
| Sirén, J | 1 |
| Kiviluoto, T | 1 |
| Chisholm, MA | 1 |
| Francis, C | 2 |
| Fellenius, C | 2 |
| Soderberg, K | 2 |
| Holmqvist, A | 2 |
| Mant, M | 2 |
| Dear, R | 4 |
| Baylis, B | 2 |
| Mah, A | 2 |
| Brant, R | 3 |
| Chung, TS | 1 |
| Kim, SC | 1 |
| Barnes, C | 1 |
| Deidun, D | 1 |
| Hynes, K | 1 |
| Monagle, P | 1 |
| Baldeweg, SE | 1 |
| Scott, RG | 1 |
| Bajjoka, AE | 1 |
| Bremme, K | 2 |
| van Rooijen, M | 1 |
| Yu, A | 1 |
| Blombäck, M | 2 |
| Schaub, R | 1 |
| Fex, BA | 1 |
| Chapman, AM | 1 |
| Greenfield, LJ | 1 |
| Schambeck, CM | 1 |
| Eberl, E | 1 |
| Geisen, U | 1 |
| Grossmann, R | 1 |
| Keller, F | 1 |
| Khinev, S | 1 |
| Tsoneva, D | 1 |
| Darfinova, K | 1 |
| Kamenova, B | 1 |
| Yar'mov, N | 1 |
| Moreno-Palomares, JJ | 1 |
| Fisac-Herrero, RM | 1 |
| Herrero-Domingo, A | 1 |
| Ferreira-Pasos, EM | 1 |
| Grasa, J | 1 |
| Reverte-Cejudo, D | 1 |
| Pettilä, V | 1 |
| Leinonen, P | 1 |
| Ylikorkala, O | 1 |
| Taylor, AA | 1 |
| Maxwell, GL | 1 |
| Synan, I | 1 |
| Dodge, R | 1 |
| Carroll, B | 1 |
| Clarke-Pearson, DL | 1 |
| Cho, JH | 1 |
| Yun, CH | 1 |
| Seo, HS | 1 |
| Koga, T | 1 |
| Dan, T | 1 |
| Koo, BA | 1 |
| Kim, HY | 1 |
| Arfwidsson, AC | 1 |
| Eriksson, UG | 1 |
| Bylock, A | 2 |
| Fager, G | 1 |
| Peternel, P | 1 |
| Terbizan, M | 1 |
| Tratar, G | 1 |
| Horvat, D | 1 |
| Salobir, B | 1 |
| Antovic, A | 1 |
| He, S | 1 |
| Larson, G | 1 |
| Lindahl, TL | 1 |
| Andersson, C | 1 |
| Karathanos, C | 5 |
| Kakkos, SK | 3 |
| Georgiadis, G | 3 |
| Ioannou, C | 4 |
| Chatzis, D | 4 |
| Latzios, P | 4 |
| Giannoukas, AD | 4 |
| Papakostas, I | 1 |
| Goumas, K | 1 |
| Giannoukas, A | 1 |
| Nikolakopoulos, K | 1 |
| Georgiadis, GS | 1 |
| Maltezos, C | 1 |
| Trelopoulos, G | 1 |
| Østergaard, S | 1 |
| Hvas, AM | 1 |
| Medrud, L | 1 |
| Fuglsang, J | 1 |
| Merali, T | 1 |
| Matikas, A | 1 |
| Vardakis, N | 1 |
| Souglakos, J | 1 |
| Georgoulias, V | 1 |
| Trog, LM | 1 |
| Kahle, B | 1 |
| Schindewolf, M | 1 |
| Jappe, U | 1 |
| Ludwig, RJ | 1 |
| Janas, MS | 1 |
| Jarner, MF | 1 |
| Varrier, M | 1 |
| Asgari, E | 1 |
| Makanjuola, D | 1 |
| Lykke, JA | 1 |
| Grønlykke, T | 1 |
| Langhoff-Roos, J | 1 |
| Romera, A | 1 |
| Cairols, MA | 1 |
| Vila-Coll, R | 1 |
| Martí, X | 1 |
| Colomé, E | 1 |
| Bonell, A | 1 |
| Lapiedra, O | 1 |
| Cook, R | 3 |
| Solymoss, S | 3 |
| Poon, MC | 3 |
| Viguier, JB | 1 |
| Amraoui, S | 1 |
| Solanilla, A | 1 |
| Boulon, C | 1 |
| Constans, J | 1 |
| Conri, C | 1 |
| Hoy, SM | 1 |
| Scott, LJ | 1 |
| Plosker, GL | 1 |
| Siguret, V | 3 |
| Mottier, D | 2 |
| Clonier, F | 1 |
| Janas, M | 1 |
| Stinson, J | 1 |
| Maddalena, M | 1 |
| Besse, B | 1 |
| Friard, S | 1 |
| Azarian, R | 1 |
| Monnet, I | 1 |
| Alifano, M | 1 |
| Chouaid, C | 1 |
| Descourt, R | 1 |
| Dennewald, G | 1 |
| Taillade, L | 1 |
| De Luca, K | 1 |
| Giraud, F | 1 |
| Pichon, E | 1 |
| Chatellier, G | 1 |
| Otero, R | 1 |
| Elias, T | 1 |
| Montes-Worboys, A | 1 |
| Dawson, G | 1 |
| Lampa, R | 1 |
| Jara, L | 1 |
| Kennedy, C | 1 |
| O'Dwyer, V | 1 |
| O'Kelly, S | 1 |
| Farah, N | 1 |
| Kennelly, M | 1 |
| Turner, MJ | 1 |
| Akram, J | 1 |
| Josefsson, P | 1 |
| Rømeling, F | 1 |
| Caro, JJ | 1 |
| Getsios, D | 1 |
| Caro, I | 1 |
| O'Brien, JA | 1 |
| Neely, JL | 1 |
| Carlson, SS | 1 |
| Lenhart, SE | 1 |
| Pautas, E | 1 |
| Gouin, I | 1 |
| Bellot, O | 1 |
| Andreux, JP | 1 |
| Backe, SK | 1 |
| Lyons, GR | 1 |
| Mousa, SA | 2 |
| Allart, C | 1 |
| Lecompte, T | 1 |
| Bollaert, PE | 1 |
| Saad, RA | 1 |
| Horn, L | 1 |
| Mankad, PS | 1 |
| Bath, PM | 2 |
| Taccone, FS | 1 |
| Starc, JM | 1 |
| Sculier, JP | 1 |
| Suárez Alvarez, CG | 1 |
| García Cañete, J | 1 |
| Herrero Mendoza, MD | 1 |
| Bellver Alvarez, TM | 1 |
| Arboiro Pinel, R | 1 |
| Shapiro, NL | 1 |
| Feinstein, H | 1 |
| Rivers, CW | 1 |
| Smith, MP | 1 |
| Norris, LA | 1 |
| Steer, PJ | 1 |
| Savidge, GF | 1 |
| Bonnar, J | 1 |
| Willows, L | 1 |
| Nicolaides, A | 1 |
| Zed, PJ | 1 |
| Filiatrault, L | 1 |
| Busser, JR | 1 |
| Daskalopoulos, ME | 2 |
| Daskalopoulou, SS | 2 |
| Tzortzis, E | 1 |
| Sfiridis, P | 1 |
| Nikolaou, A | 1 |
| Dimitroulis, D | 1 |
| Kakissis, I | 1 |
| Liapis, CD | 2 |
| Sridhar, AV | 1 |
| Rao, NK | 1 |
| Chakraborty, S | 1 |
| How, P | 1 |
| Cheng, KS | 1 |
| Sridhar, P | 1 |
| Hamilton, HE | 1 |
| Jones, C | 1 |
| Siva, TM | 1 |
| Seymour, FK | 1 |
| O'Reilly, BJ | 1 |
| Brant, RF | 2 |
| Mah, AF | 2 |
| Burke, N | 2 |
| Wong, T | 2 |
| Hyers, TM | 1 |
| Puskás, A | 1 |
| Hadadi, L | 1 |
| Imre, M | 1 |
| Orbán, E | 1 |
| Kósa, K | 1 |
| Brassai, Z | 1 |
| Opara, E | 1 |
| Gile, J | 1 |
| Zaidi, J | 1 |
| Davies, CW | 1 |
| Wimperis, J | 1 |
| Green, ES | 2 |
| Pendry, K | 1 |
| Killen, J | 1 |
| Mehdi, I | 1 |
| Tiplady, C | 1 |
| Kesteven, P | 1 |
| Rose, P | 2 |
| Oldfield, W | 1 |
| Chibbaro, S | 1 |
| Tacconi, L | 1 |
| Stewart, AJ | 1 |
| Manson, LM | 1 |
| Dennis, R | 1 |
| Allan, PL | 1 |
| Ludlam, CA | 1 |
| Jensen, HP | 1 |
| Poulsen, KA | 1 |
| Ejstrud, P | 1 |
| Andersen, BS | 1 |
| Booth, L | 1 |
| Clegg, A | 1 |
| Sands, G | 1 |
| Slesak, G | 1 |
| Döller, PC | 1 |
| Lindenstrom, E | 1 |
| Boysen, G | 1 |
| De Deyn, P | 1 |
| Friis, P | 1 |
| Leys, D | 1 |
| Marttila, R | 1 |
| Olsson, J | 1 |
| O'Neill, D | 1 |
| Orgogozo, J | 1 |
| Ringelstein, B | 1 |
| van der Sande, J | 1 |
| Barrett, JS | 1 |
| Gibiansky, E | 1 |
| Pentikis, H | 1 |
| Hainer, JW | 1 |
| Hua, TA | 1 |
| Gastonguay, M | 1 |
| Bell, D | 1 |
| Davenport, A | 1 |
| Fegan, C | 1 |
| Grech, H | 1 |
| O'Shaughnessy, D | 1 |
| Voke, J | 1 |
| Jørgensen, PS | 1 |
| Warming, T | 1 |
| Hansen, K | 1 |
| Paltved, C | 1 |
| Vibeke Berg, H | 1 |
| Jensen, R | 1 |
| Kirchhoff-Jensen, R | 1 |
| Kjaer, L | 1 |
| Kerbouche, N | 1 |
| Leth-Espensen, P | 1 |
| Narvestad, E | 1 |
| Rasmussen, SW | 1 |
| Sloth, C | 1 |
| Tørholm, C | 1 |
| Wille-Jørgensen, P | 1 |
| Alam, M | 1 |
| Goldberg, LH | 1 |
| Morrison, RB | 1 |
| Diran, LL | 1 |
| Creager, MA | 1 |
| Elliott, CG | 1 |
| Morrey, BF | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Contention Alone Versus Anticoagulation for Symptomatic Calf Vein Thrombosis Diagnosed by Ultrasonography[NCT00421538] | Phase 3 | 260 participants (Actual) | Interventional | 2008-01-31 | Completed | ||
| The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis[NCT04981327] | Phase 3 | 1,300 participants (Anticipated) | Interventional | 2022-09-01 | Not yet recruiting | ||
| Prophylaxis of Venous Thromboembolism in Patients With a Nonsurgical Fracture of the Lower Extremity Immobilised in a Below-Knee Plaster Cast[NCT00881088] | Phase 2/Phase 3 | 669 participants (Anticipated) | Interventional | 2009-04-30 | Recruiting | ||
| Criteria for Hospitalization or Outpatient Management of Patients With Pulmonary Embolism, Hestia Rule Versus Simplified PESI Score : an Open-label Controlled Randomized International Trial (HOME-PE)[NCT02811237] | 1,975 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| The Impact of Laparoscopic Versus Open Surgeries on the Incidence of Postoperative Deep Vein Thrombosis in Patients With Gastrointestinal Malignancy ---A Cohort Study[NCT02297269] | 230 participants (Anticipated) | Observational | 2014-12-31 | Not yet recruiting | |||
| A Multinational, Multicentre, Randomized, Open, Parallel Group Study on the Efficacy and Safety of Bemiparin Sodium (LMWH) Compared to Enoxaparin Sodium (LMWH) in the Treatment of Acute Deep Vein Thrombosis (DVT)[NCT01880216] | Phase 3 | 312 participants (Actual) | Interventional | 2013-06-30 | Completed | ||
| Bemiparin Versus Enoxaparin in the Prevention of Venous Thromboembolism Among ICU Patients[NCT02795065] | 100 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| A Randomized, Active-comparator-controlled, Multicenter Study to Assess the Safety and Efficacy of Different Doses of BAY1213790 for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Total Knee Arthroplasty, Open-label to Tr[NCT03276143] | Phase 2 | 813 participants (Actual) | Interventional | 2017-09-21 | Completed | ||
| A Multicentre, Randomised, Double-blind, Controlled, Phase IIIb Study to Assess the Efficacy and Safety of Rivaroxaban 10mg od Versus Enoxaparin 4000 UI for VTE PROphylaxis in NOn Major Orthopaedic Surgery[NCT02401594] | Phase 3 | 3,608 participants (Actual) | Interventional | 2015-12-08 | Terminated (stopped due to Remaining outdated treatments and additional costs too high for new manufacturing) | ||
| The Safety of Oral Apixaban (Eliquis) Versus Subcutaneous Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy; a Prospective Randomized Open Blinded End-point (PROBE) Design[NCT02366871] | Phase 2 | 400 participants (Actual) | Interventional | 2015-04-28 | Completed | ||
| Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[NCT00440193] | Phase 3 | 3,449 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Efficacy and Safety of Apixaban in Patients With Active Malignancy and Acute Deep Venous Thrombosis.[NCT04462003] | Phase 3 | 100 participants (Anticipated) | Interventional | 2019-07-03 | Recruiting | ||
| Prevention of Central Venous Catheter-associated Thrombosis in Critically Ill Children: A Multicenter Phase 2b Trial[NCT03003390] | Phase 2 | 51 participants (Actual) | Interventional | 2017-04-05 | Terminated (stopped due to Met protocol defined stopping rule for futility) | ||
| Intermediate-dose Versus Standard Prophylactic Anticoagulation In cRitically-ill pATIents With COVID-19: An opeN Label Randomized Controlled Trial---A Randomized Trial of Atorvastatin vs. Placebo In Critically-ill Patients With COVID-19[NCT04486508] | Phase 3 | 600 participants (Actual) | Interventional | 2020-07-30 | Completed | ||
| Evaluation of the Effect of Exogenous Surfactant Through Nebulizer Mask on Clinical Outcomes in Covid-19 Patients[NCT04847375] | 60 participants (Anticipated) | Interventional | 2021-04-20 | Not yet recruiting | |||
| Standardized, Guidelines Directed But Patients Oriented Clinical Practice Prospectively Registered[NCT03504007] | 10,000 participants (Anticipated) | Observational | 2013-03-01 | Recruiting | |||
| (Apex) Multicenter, Randomized, Active-Controlled Efficacy And Safety Study Comparing Extended Duration Betrixaban With Standard Of Care Enoxaparin For The Prevention Of Venous Thromboembolism In Acute Medically Ill Patients[NCT01583218] | Phase 3 | 7,513 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Apixaban for the Secondary Prevention of Thromboembolism: a Prospective Randomized Outcome Pilot Study Among Patients With the AntiphosPholipid Syndrome[NCT02295475] | Phase 4 | 48 participants (Actual) | Interventional | 2014-12-10 | Completed | ||
| Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism[NCT00439777] | Phase 3 | 4,833 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Different Approach to Preventing Thrombosis (ADAPT): A Randomized Controlled Trial Comparing Low Molecular Weight Heparin to Acetylsalicylic Acid in Orthopedic Trauma Patients[NCT02774265] | Phase 3 | 329 participants (Actual) | Interventional | 2016-01-31 | Completed | ||
| A Phase 2b, Randomized, Multi-Dose Efficacy,Safety Study of the Oral Factor Xa Inhibitor DU-176b Versus Enoxaparin Sodium for Prevention of Venous Thromboembolism in Patients After Total Hip Arthroplasty (STARS J-2)[NCT01203098] | Phase 2 | 264 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| An Open-label, Randomized, Active Comparator-Controlled, Adaptive Parallel-group Phase 2 Study to Assess the Safety and Efficacy of Multiple Doses of ISIS 416858 Administered Subcutaneously to Patients Undergoing Total Knee Arthroplasty[NCT01713361] | Phase 2 | 315 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Safety and Efficacy Trial Evaluating the Use of Apixaban in the Treatment of Symptomatic Deep Vein Thrombosis and Pulmonary Embolism[NCT00643201] | Phase 3 | 5,614 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Prospective Randomised Study of the Effect of Vasopressors on the Anti Xa Response to Enoxaparin in Critically Ill Patients[NCT00351663] | Phase 4 | 39 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?[NCT02900170] | 8 participants (Actual) | Observational | 2016-07-31 | Completed | |||
| RECORD 1 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE, Controlled, Double-blind, Randomized Study of BAY 59-7939 in the Extended Prevention of VTE in Patients Undergoing Elective Total Hip Replacement[NCT00329628] | Phase 3 | 4,541 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| The Blood Saving Effect and Wound-related Complications of Tranexamic Acid in Mininally Invasive Total Knee Arthroplasty With Rivaroxaban as Thromboprophylaxis[NCT02458729] | Phase 4 | 294 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
| An Efficacy and Safety Study of New Oral Anticoagulants and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters: A Prospective Randomized Controlled Trial[NCT04066764] | Phase 3 | 200 participants (Anticipated) | Interventional | 2020-05-08 | Recruiting | ||
| Comparison of Topical and Infusion Tranexamic Acid on Blood Loss and Risk of Deep Vein Thrombosis After Total Knee Arthroplasty[NCT02453802] | Phase 4 | 90 participants (Anticipated) | Interventional | 2015-06-30 | Not yet recruiting | ||
| RECORD 3 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled., Double-blind, Randomized Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.[NCT00361894] | Phase 3 | 2,531 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| An Efficacy and Safety Study of Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression Treated With Stent Implantation (PLICTS)：A Prospective Randomized Controlled Trial[NCT04067505] | Phase 3 | 224 participants (Anticipated) | Interventional | 2020-05-18 | Recruiting | ||
| RECORD 4 Study: REgulation of Coagulation in ORthopedic Surgery to Prevent DVT and PE; a Controlled, Double-blind, Randomized Study of BAY59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement[NCT00362232] | Phase 3 | 3,148 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| Norwegian Intensive Care Unit Dalteparin Effect Study[NCT01721928] | 70 participants (Actual) | Observational | 2012-12-03 | Completed | |||
| XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis[NCT02506985] | Phase 4 | 10 participants (Actual) | Interventional | 2015-07-31 | Terminated | ||
| A Phase 2, Randomized, Active Comparator-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement[NCT00641732] | Phase 2 | 1,045 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Randomized Trial to Test the Effect of Rivaroxaban or Apixaban on Menstrual Blood Loss in Women[NCT02829957] | Phase 2/Phase 3 | 19 participants (Actual) | Interventional | 2016-09-30 | Completed | ||
| Once-daily Oral Direct Factor Xa Inhibitor Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis or Pulmonary Embolism. The Einstein-Extension Study[NCT00439725] | Phase 3 | 1,197 participants (Actual) | Interventional | 2007-02-28 | Completed | ||
| Comparison of the Efficacy of Rivroxaban to Coumadin( Warfarin ) in Cerebral Venous Thrombosis[NCT03191305] | 50 participants (Anticipated) | Interventional | 2017-08-31 | Not yet recruiting | |||
| A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Orally Administered 220 mg Dabigatran Etexilate Capsules (110 mg Administered on the Day of Surgery Followed by 220 mg Once Daily) Comp[NCT00657150] | Phase 3 | 2,055 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| Rosuvastatin for Prevention of Deep Vein Thrombosis in Patients Undergoing Total Knee Replacement Arthroplasty: STOP DVT - A Prospective Randomized Controlled Trial[NCT01021488] | Phase 4 | 180 participants (Anticipated) | Interventional | 2009-10-31 | Recruiting | ||
| Thrombosis in Newly Diagnosed Multiple Myeloma Patients: a Clinical Audit of Intermediate Dose Low Molecular Weight Heparin[NCT05541978] | 140 participants (Actual) | Observational | 2022-09-01 | Completed | |||
| A PHASE 3, MULTICENTRE, RANDOMIZED, CONTROLLED STUDY TO DETERMINE THE EFFICACY AND SAFETY OF LENALIDOMIDE, MELPHALAN AND PREDNISONE (MPR) Versus MELPHALAN (200 mg/m2) FOLLOWED BY STEM CELL TRANSPLANT IN NEWLY DIAGNOSED MULTIPLE MYELOMA SUBJECTS[NCT00551928] | Phase 3 | 402 participants (Actual) | Interventional | 2007-06-30 | Active, not recruiting | ||
| Evaluation of the Use of an Oral Direct Anti-Xa Anticoagulant, Apixaban, in Prevention of Venous Thromboembolic Disease in Patients Treated With IMiDs During Myeloma : a Pilot Study[NCT02066454] | Phase 3 | 105 participants (Anticipated) | Interventional | 2014-04-30 | Recruiting | ||
| Pharmacokinetics of Recombinant Antithrombin III in Neonates Undergoing Extracorporeal Membrane Oxygenation[NCT01913444] | Phase 4 | 0 participants (Actual) | Interventional | 2013-07-31 | Withdrawn (stopped due to Unable to enroll patients into study.) | ||
| Once Daily Enoxaparin for Outpatient Treatment of Acute Deep Venous Thrombosis and/or Pulmonary Embolism[NCT00413374] | 40 participants (Actual) | Interventional | 2006-05-31 | Completed | |||
| Fondaparinux as Monotherapy for Deep Vein Thrombosis and/or Pulmonary Embolism (Pilot Study)[NCT00413504] | 30 participants (Actual) | Interventional | 2006-04-30 | Completed | |||
| Trousseau Studie, Mortaliteit Door Maligniteit Bij patiënten Met Idiopatische Veneuze Tromboembolie[NCT01088334] | 630 participants (Actual) | Observational | 2002-12-31 | Terminated (stopped due to Terminated because of futility to continue, after planned interim analysis.) | |||
| Genetics of Antiphospholipid Antibody Syndrome[NCT00482794] | 2,800 participants (Anticipated) | Observational | 2006-06-30 | Recruiting | |||
| The Use of Tranexamic Acid to Reduce Blood Loss in Acetabular Surgery[NCT02684851] | Phase 3 | 87 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| Comparative Feasibility and Efficacy of a Five Compartment Technique Using 0.25% Bupivacaine vs a Mixture of 0.25% Bupivacaine and 1.3 % Liposomal Bupivacaine in Patients Undergoing Tka; a Single Blinded Randomized Controlled Study[NCT03303794] | Phase 3 | 25 participants (Actual) | Interventional | 2017-10-25 | Terminated (stopped due to Interim Analysis showed no significance) | ||
| An Open-Label, Randomized, Parallel-Group, Multi-Center Study to Evaluate the Efficacy and Safety of Enoxaparin Versus Unfractionated Heparin in the Prevention of Venous Thromboembolism in Patients Following Acute Ischemic Stroke[NCT00077805] | Phase 4 | 0 participants | Interventional | 2003-08-31 | Completed | ||
| A Phase III Randomised, Parallel Group, Double-blind, Active Controlled Study to Investigate the Efficacy and Safety of Two Different Dose Regimens of Orally Administered Dabigatran Etexilate Capsules [150 or 220 mg Once Daily Starting With Half Dose (75 [NCT00168818] | Phase 3 | 3,494 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Double Dummy, Parallel Group, Dose Ranging Study of Subcutaneous SR123781A With an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery[NCT00338897] | Phase 2/Phase 3 | 1,090 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Weight Based Enoxaparin for Venous Thromboembolism Prophylaxis in Trauma Patients[NCT01916707] | Phase 4 | 1,200 participants (Anticipated) | Interventional | 2013-07-31 | Active, not recruiting | ||
| The Use of Low Molecular Weight Heparin in Traumatic Brain Injury[NCT00170378] | Phase 4 | 300 participants | Interventional | 2002-12-31 | Completed | ||
| Extended Out-of-hospital Low-molecular-weight Heparin Prophylaxis Against Deep Venous Thrombosis and Pulmonary Embolus in Patients Undergoing Major Lung Resection: A Pilot Study to Evaluate the Incidence of DVT and PE After Major Lung Resection[NCT02258958] | 150 participants (Actual) | Observational | 2014-01-31 | Completed | |||
| Low-molecular-weight Heparin to Prevent Recurrent VTE in Pregnancy: a Randomized Controlled Trial of Two Doses[NCT01828697] | Phase 4 | 1,110 participants (Actual) | Interventional | 2013-04-24 | Completed | ||
| The Use of Fondaparinux in Preventing Thromboembolism in High Risk Trauma Patients[NCT00531843] | Phase 2/Phase 3 | 105 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Incidence of Venous Thromboembolic Disease and Portal Vein Thrombosis After Hepatectomy in a High-volume Center. A Cohort Study.[NCT02597218] | 350 participants (Anticipated) | Observational | 2015-10-31 | Recruiting | |||
| Effect of Anticoagulation in Reducing the Incidence of Splenic/Portal Vein Thrombosis Post-Laparoscopic Splenectomy Protocol Number: 5698[NCT00769873] | Phase 2 | 35 participants (Actual) | Interventional | 2006-10-31 | Terminated (stopped due to Recruitment was slower than anticipated. Insufficient funding to expand to multi-centered trial.) | ||
| Randomized, Phase III-b, Multi-centre, Open-label, Parallel Study of Enoxaparin (Low Molecular Weight Heparin) Given Concomitantly With Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Gastric and Gastro-oesophageal Cancer[NCT00718354] | Phase 3 | 740 participants (Actual) | Interventional | 2008-07-31 | Completed | ||
| Effects of Sequential Compression Devices on Coagulation Parameters Assessed by TEG® in Patients Undergoing Major Abdominal Surgery[NCT00726570] | 40 participants (Actual) | Interventional | 2008-08-31 | Terminated (stopped due to Failed to reach the expected enrollment rates by the end of 2010) | |||
| Evaluation of the Prevention of Thromboembolic Disease in Patients With a Lower Limb Trauma, Non Surgical, in Winter Sports Resort.[NCT01303523] | 1,627 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| An Open-label Comparison of the Efficacy and Safety of the Low-molecular-weight Heparin (3000 U Anti-Xa Once Daily) With Unfractionated Heparin for the Prevention of Thromboembolic Complications in Acutely Ill Non-surgical Patients[NCT00311753] | Phase 3 | 342 participants (Actual) | Interventional | 2006-02-28 | Completed | ||
| A Randomized, Double-blind, Multi-center Comparison of the Efficacy and Safety of Certoparin (3000 U Anti-Xa o.d.) With Unfractionated Heparin (5000 IU t.i.d.) in the Prophylaxis of Thromboembolic Events in Acutely Ill Medical Patients[NCT00451412] | Phase 3 | 3,254 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Apixaban for the Treatment of Venous Thromboembolism in Patients With Cancer: A Prospective Randomized Open Blinded End-Point (Probe) Study[NCT03045406] | Phase 3 | 1,168 participants (Actual) | Interventional | 2017-04-13 | Active, not recruiting | ||
| Prospective, Randomized, Double-blinded Trial of the Efficacy and Safety of Different Doses and Duration of Low Molecular Weight Heparin (Dalteparin) in Superficial Vein Thrombosis[NCT01245998] | Phase 4 | 68 participants (Actual) | Interventional | 2010-12-01 | Completed | ||
| A Phase 3b, Prospective, Randomized, Open-label, Blind Evaluator (PROBE) Study Evaluating the Efficacy and Safety of (LMW) Heparin/Edoxaban Versus Dalteparin in Venous Thromboembolism Associated With Cancer[NCT02073682] | Phase 3 | 1,046 participants (Actual) | Interventional | 2015-07-16 | Completed | ||
| Dalteparin's Influence on Renally Compromised: Anti-Ten-A Study (DIRECT)[NCT00138099] | 140 participants (Actual) | Observational | 2004-07-31 | Completed | |||
| Study of the Bioaccumulation of Tinzaparin in Renally Impaired Patients When Given at Prophylactic Doses[NCT02719418] | 28 participants (Actual) | Observational | 2016-02-01 | Completed | |||
| PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)[NCT00182143] | Phase 3 | 3,659 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Incidence and Characteristics of Pulmonary Embolism in COVID-19 Patients Hospitalized for Acute Respiratory Syndrome[NCT04420312] | 1,024 participants (Actual) | Observational | 2020-03-01 | Completed | |||
| Analysis of Pro-coagulant and Thrombin-generation Markers for the Prediction of Therapeutic Failure in Cancer Patients at Risk for Recurrence of Venous Thromboembolism: A Pilot Study[NCT01602445] | 700 participants (Anticipated) | Observational | 2012-07-31 | Completed | |||
| Anti Xa Activity in Cancer Patients Receiving Low-molecular-weight Heparin for Venous Thromboembolism[NCT02898051] | 370 participants (Actual) | Observational | 2011-08-31 | Active, not recruiting | |||
| Safety and Efficacy of Switching From Direct Oral Anticoagulants to Low Molecular Weight Heparin in Cancer Patients With Atrial Fibrillation During Antineoplastic Therapy[NCT04508855] | 240 participants (Anticipated) | Observational | 2020-08-01 | Recruiting | |||
| Long-term Treatment for Cancer Patients With Deep Venous Thrombosis or Pulmonary Embolism[NCT01164046] | Phase 3 | 56 participants (Actual) | Interventional | 2010-08-31 | Terminated (stopped due to Due to slow inclusion of patients) | ||
| Implementing a Tool to Identify Risk for Venous Thromboembolism in Cancer Patients[NCT01602432] | 0 participants (Actual) | Observational | 2012-11-30 | Withdrawn (stopped due to Project did not meet criteria of a research study and was confirmed as a Quality Initiative Project) | |||
| Comparison of Effectiveness and Safety of Two Methods for Installing Femoral Central Venous Catheters in Pediatric Intensive Care Units : Anatomical Method vs Ultrasound in Real Time.[NCT02318940] | 99 participants (Actual) | Interventional | 2014-12-31 | Completed | |||
| A Pilot Study in Cancer Patients With Central Venous Catheter Associated Deep Vein Thrombosis in the Upper Extremity Treated With Rivaroxaban (Catheter 2)[NCT01708850] | Phase 4 | 70 participants (Actual) | Interventional | 2012-11-30 | Completed | ||
| A Pilot Study of Central Venous Catheter Survival in Cancer Patients Using Low Molecular Weight Heparin (Dalteparin) for the Treatment of Deep Vein Thrombosis of the Upper Extremity[NCT00216866] | Phase 2 | 70 participants | Interventional | 2002-09-30 | Completed | ||
| Efficacy and Safety of Long-Term (6 Months) Innohep® Treatment Versus Anticoagulation With a Vitamin K Antagonist (Warfarin) for the Treatment of Acute Venous Thromboembolism in Cancer Patients / IN 0901 INT[NCT01130025] | Phase 3 | 900 participants (Actual) | Interventional | 2010-08-31 | Completed | ||
| Safety Profile of Innohep Versus Subcutaneous Unfractionated Heparin in Elderly Patients With Impaired Renal Function Treated for Acute Deep Vein Thrombosis[NCT00277394] | Phase 4 | 541 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants were monitored for up to 28 days. This was measured through self-report, patient diaries, and the return of all medication bottles/syringes. This was the number of participants that did not miss more than 2 days of study medication over 28 days (less than 4 pills or 2 injections missed). (NCT02366871)
Timeframe: Day 1 post-op/standard of care first dose of medication to Day 28 (+/- 4 days) post-op/standard of care
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Apixaban | 173 |
| Subcutaneous Enoxaparin | 164 |
Participants were monitored for up to 90 days. This is the number of participants with bleeding events that did not meet the ISTH criteria but still required intervention. This is the number of participants who had at least one non-major bleeding event during the time of observation. (NCT02366871)
Timeframe: Day 1 post-op/standard of care first dose of medication to day 90 (+/- 14 days) post-op/standard of care
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Apixaban | 12 |
| Subcutaneous Enoxaparin | 19 |
The International Society on Thrombosis and Hemostasis criteria (ISTH) will be used to assess incidence of major bleeding. Participants were monitored for up to 90 days. This is the number of participants who have had at least one major bleeding incidence during the time of observation. (NCT02366871)
Timeframe: Day 1 post-op/standard of care first medication dose to day 90 (+/-14 days) post-op/standard of care
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Apixaban | 1 |
| Subcutaneous Enoxaparin | 1 |
Participants were monitored for up to 90 days. Both DVTs and PEs will be measured using the Wells criteria, ultrasound, and/or CT. This is the number of participants who had at least one DVT or PE during the time of observation. (NCT02366871)
Timeframe: Day 1 post-op/standard of care to day first dose of medication 90 (+/- 14 days) post-op/standard of care
| Intervention | Participants (Count of Participants) |
|---|---|
| Oral Apixaban | 2 |
| Subcutaneous Enoxaparin | 3 |
This was measured through a validated health survey (SF-8™) provided by a healthcare company (Optum®), which measured overall physical and mental well-being, with responses ranging from none to very, not at all to extremely, etc. Change was calculated as the difference at baseline versus 28 days post op. The score was 0-100 and a higher score was considered a better outcome. (NCT02366871)
Timeframe: At baseline, and visit 4, which is 28 days (+/- 4 days) post-op/standard of care
| Intervention | score on a scale (Median) | |||||
|---|---|---|---|---|---|---|
| physical score-baseline | physical score-visit 4 | Physical change | mental score-baseline | mental score-visit 4 | Mental change | |
| Oral Apixaban | 50.7 | 39.2 | -5.9 | 50.7 | 50.7 | 0.8 |
| Subcutaneous Enoxaparin | 49.7 | 38.5 | -6.2 | 49.7 | 49.3 | 0.0 |
Participants were monitored at the 28 (+/- 4) day post-op visit. This was measured through administering a participant satisfaction questionnaire ranging from strongly agree to strongly disagree.This is the number of participants that completed the questionnaire in response to agreeing it was difficult to remember to take the medication, agreeing that there was pain associated with the medication, and agreeing that the medication was easy to use. (NCT02366871)
Timeframe: On visit 4, which is 28 days (+/- 4 days) post-op/standard of care
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Difficult remembering to take medication72102815 | Difficult remembering to take medication72102814 | Pain associated with taking the medication72102814 | Pain associated with taking the medication72102815 | Was medication easy to take72102814 | Was medication easy to take72102815 | |||||||||||||
| Agree | Neutral | Disagree | ||||||||||||||||
| Oral Apixaban | 23 | |||||||||||||||||
| Subcutaneous Enoxaparin | 23 | |||||||||||||||||
| Oral Apixaban | 16 | |||||||||||||||||
| Subcutaneous Enoxaparin | 15 | |||||||||||||||||
| Oral Apixaban | 149 | |||||||||||||||||
| Subcutaneous Enoxaparin | 149 | |||||||||||||||||
| Oral Apixaban | 4 | |||||||||||||||||
| Subcutaneous Enoxaparin | 92 | |||||||||||||||||
| Oral Apixaban | 10 | |||||||||||||||||
| Subcutaneous Enoxaparin | 25 | |||||||||||||||||
| Oral Apixaban | 173 | |||||||||||||||||
| Subcutaneous Enoxaparin | 70 | |||||||||||||||||
| Oral Apixaban | 186 | |||||||||||||||||
| Subcutaneous Enoxaparin | 110 | |||||||||||||||||
| Oral Apixaban | 2 | |||||||||||||||||
| Subcutaneous Enoxaparin | 21 | |||||||||||||||||
| Oral Apixaban | 0 | |||||||||||||||||
| Subcutaneous Enoxaparin | 56 | |||||||||||||||||
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE or major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.1 |
| Enoxaparin/VKA | 1.1 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.9 |
| Enoxaparin/VKA | 4.2 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding, cardiovascular death, myocardial infarctions, stroke, or non CNS systemic embolism. Major bleeding was associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography ( PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Enoxaparin/VKA | 1.3 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death, cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events confirmed by independent committee blinded to treatment, based on compression ultrasound, venography, spiral CT scan, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy, results/films/images of confirmatory testing and/or case summaries (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.6 |
| Enoxaparin/VKA | 4.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 8.1 |
| Enoxaparin/VKA | 8.1 |
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 |
| Enoxaparin/VKA | 0.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.6 |
| Enoxaparin/VKA | 0.3 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Enoxaparin/VKA | 1.6 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.8 |
| Enoxaparin/VKA | 0.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 3.0 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.2 |
| Enoxaparin/VKA | 1.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.0 |
| Enoxaparin/VKA | 5.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| All post-randomization | Treatment-emergent (time window: 2 days) | Treatment-emergent (time window: 7 days) | |
| Enoxaparin/VKA | 3.0 | 1.1 | 1.5 |
| Rivaroxaban (Xarelto, BAY59-7939) | 2.4 | 1.0 | 1.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00440193)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.07 | 0 | 0.1 | 0.3 | 0.1 | 0.3 | 0.8 | 0.6 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0 | 0.07 | 0 | 0.3 | 0.6 | 0.07 | 0.07 | 1.3 | 0.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00440193)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.3 | 0 | 1.0 | 1.6 | 0.3 | 0.2 | 2.0 | 1.3 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.06 | 0.2 | 0.06 | 1.2 | 0.8 | 0.06 | 0.1 | 1.8 | 0.9 |
Duration of stay in the hospital from the day of enrollment (NCT03003390)
Timeframe: Up to day of discharge from the hospital, an average of 18 days
| Intervention | days (Median) |
|---|---|
| Prophylaxis With Enoxaparin | 16 |
| Control Arm | 16 |
Duration of stay in the pediatric intensive care unit from the day of enrollment (NCT03003390)
Timeframe: Up to day of discharge from the pediatric intensive care unit, an average of 10 days
| Intervention | days (Median) |
|---|---|
| Prophylaxis With Enoxaparin | 12 |
| Control Arm | 8 |
Number of children in whom ultrasound was not performed. (NCT03003390)
Timeframe: Up to 24 hours after removal of CVC
| Intervention | Participants (Count of Participants) |
|---|---|
| All Enrolled Children | 47 |
Number of eligible children enrolled in the study. (NCT03003390)
Timeframe: Up to 24 hours after insertion of CVC
| Intervention | Participants (Count of Participants) |
|---|---|
| Eligible Children | 51 |
Number of doses of enoxaparin that were not administered. This outcome measure was only applicable to the enoxaparin arm. (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | Doses of enoxaparin (Number) |
|---|---|
| Prophylaxis With Enoxaparin | 8 |
In-hospital mortality during the subject's admission (NCT03003390)
Timeframe: Up to day of discharge from the hospital, average of 18 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 5 |
| Control Arm | 2 |
Thrombus in the central vein where the CVC was inserted that is clinically suspected then confirmed radiologically, an incidental radiologic finding, or diagnosed with the study-related active surveillance ultrasound (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 7 |
| Control Arm | 13 |
Bleeding that is fatal, associated with a decrease in hemoglobin by ≥2 g/dl in 24 hours, requires medical or surgical intervention to restore hemostasis, or is in the retroperitoneum, pulmonary, intracranial or central nervous system as defined by International Society of Thrombosis and Haemostasis (NCT03003390)
Timeframe: Up to 30 hours after the last enoxaparin dose
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 1 |
| Control Arm | 0 |
Heparin-induced thrombocytopenia that is diagnosed with a positive serotonin release assay (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 0 |
| Control Arm | 0 |
Thrombus in the deep vein of any extremity or PE that is clinically suspected then confirmed radiologically, an incidental radiologic finding, excluding DVT diagnosed with the study-related active surveillance ultrasound (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Prophylaxis With Enoxaparin | 1 |
| Control Arm | 1 |
Time to first dose of enoxaparin (NCT03003390)
Timeframe: Up to 48 hours after insertion of CVC
| Intervention | hours from insertion of CVC (Median) |
|---|---|
| Prophylaxis With Enoxaparin | 21.1 |
Time from insertion of the CVC to time that anti-Xa activity was within 0.2-0.5 IU/mL. (NCT03003390)
Timeframe: Up to removal of CVC, an average of 6 days
| Intervention | hours from insertion of CVC (Median) |
|---|---|
| Prophylaxis With Enoxaparin | 70.4 |
An established measure of coagulation status and is the best method to measure thrombin generation. It directly measures the amount of thrombin generation over time capturing the effects of natural (i.e., subject's coagulation status) and pharmacological (e.g., enoxaparin) pro- and anticoagulants. Endogenous thrombin potential is measured using thrombin generation assay. (NCT03003390)
Timeframe: Day of, day after and day 4 after insertion of the CVC
| Intervention | Nanomolar-minute (nM.min) (Median) | ||
|---|---|---|---|
| Day of CVC Insertion | Day After CVC Insertion | Day 4 After CVC Insertion | |
| Control Arm | 1035.6 | 896.58 | 969.89 |
| Prophylaxis With Enoxaparin | 919.7 | 851.19 | 826.97 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.30 |
| Enoxaparin | 1.90 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 1.03 |
| Enoxaparin | 1.45 |
mITT Cohort 2: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 2: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.70 |
| Enoxaparin | 6.02 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, or VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 42 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.94 |
| Enoxaparin | 1.45 |
mITT: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, VTE related death adjudicated by a blinded independent CEC between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 4.43 |
| Enoxaparin | 5.99 |
mITT Cohort 1: Percentage of participants experiencing either symptomatic DVT, non-fatal PE, venous thromboembolism (VTE) related death adjudicated by a blinded independent Clinical Events Committee (CEC) between randomization and on or before Visit 3 or Day 42 if patient did not have a Visit 3, or a blinded ultrasound core laboratory measuring of asymptomatic proximal DVT between randomization and Day 47. Visit 3 is between day 35-42 after randomization (day 1). (NCT01583218)
Timeframe: mITT Cohort 1: Between randomization and Day 47 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 5.70 |
| Enoxaparin | 7.18 |
Percentage of participants experiencing at least one major bleeding adjudicated by a blinded independent CEC between randomization (day 1) and up to seven days after discontinuation of all study medication. (NCT01583218)
Timeframe: Between randomization and Day 49 (max)
| Intervention | Percentage of Participants (Number) |
|---|---|
| Betrixaban | 0.67 |
| Enoxaparin | 0.57 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Enoxaparin/VKA | 1.2 |
Net clinical benefit 1: composite of recurrent DVT or non-fatal or fatal PE, and major bleeding. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 3.4 |
| Enoxaparin/VKA | 4.0 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Enoxaparin/VKA | 1.4 |
Net clinical benefit 2: composite of recurrent DVT or non-fatal or fatal PE, major bleeding (associated with 2 g/dL or greater fall in hemoglobin, leading to transfusion of ≥2 units, occurring in a critical site or contributing to death), cardiovascular death, myocardial infarction, stroke, and non CNS (central nervous system) systemic embolism. Net clinical benefit was considered greater in those participants with fewer composite events. All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound (DVT), venography (DVT), spiral CT scanning (PE), pulmonary angiography (PE), ventilation/perfusion lung scan (PE), lung scintigraphy (PE), autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.5 |
| Enoxaparin/VKA | 4.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Clinically relevant bleeding included major bleeding (overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of activities of daily life. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 10.3 |
| Enoxaparin/VKA | 11.4 |
All pre-defined vascular events (ST segment elevation myocardial infarction, non ST segment elevation myocardial infarction, unstable angina, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism or vascular death) were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Enoxaparin/VKA | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Enoxaparin/VKA | 0.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 |
| Enoxaparin/VKA | 0.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.4 |
| Enoxaparin/VKA | 1.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 1.8 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Enoxaparin/VKA | 0.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.1 |
| Enoxaparin/VKA | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6-, or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 4.0 |
| Enoxaparin/VKA | 3.4 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||
|---|---|---|---|
| All post-randomization | Treatment-emergent (time window: 2 days) | Treatment-emergent (time window: 7 days) | |
| Enoxaparin/VKA | 2.1 | 0.8 | 1.1 |
| Rivaroxaban (Xarelto, BAY59-7939) | 2.6 | 1.2 | 1.5 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439777)
Timeframe: Up to 30 days after the last intake of study medication
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0 | 0.05 | 0 | 0.5 | 0.1 | 0.09 | 0.05 | 0.7 | 0.5 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.09 | 0 | 0.09 | 0.5 | 0.2 | 0.09 | 0.3 | 0.8 | 0.3 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439777)
Timeframe: 3-, 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Death (PE) | Death (PE cannot be excluded) | Symptomatic PE and DVT | Symptomatic recurrent PE only | Symptomatic recurrent DVT only | Death (bleeding) | Death (cardiovascular) | Death (other) | Major bleeding | |
| Enoxaparin/VKA | 0.04 | 0.2 | 0.1 | 0.8 | 0.7 | 0.2 | 0.1 | 1.5 | 2.4 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.1 | 0.3 | 0.0 | 1.0 | 0.7 | 0.2 | 0.4 | 1.3 | 1.4 |
DVT and how the diagnosis was made will be recorded. The number of events in participants in each arm will be compared to evaluate efficacy. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 5 |
| VTE Prophylaxis With Aspirin 81mg BID | 9 |
Bases on imaging obtained for symptoms. (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 6 |
| VTE Prophylaxis With Aspirin 81mg BID | 2 |
Includes a greater than 2g/dL drop in hemoglobin, blood transfusion, hematoma evacuation, re-operation for a deep surgical site infection or minor procedure for bleeding and GI bleed (NCT02774265)
Timeframe: 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| VTE Prophylaxis With Enoxaparin 30mg BID | 52 |
| VTE Prophylaxis With Aspirin 81mg BID | 53 |
(NCT01203098)
Timeframe: 2 weeks
| Intervention | percentage of subjects with bleeds (Number) |
|---|---|
| DU-176b 15 mg | 2.2 |
| DU-176b 30 mg | 1.2 |
| Enoxaparin Sodium 20mg (2000IU) | 2.3 |
"The primary efficacy endpoint was the proportion of subjects who experienced at least one of the thromboembolic events listed below during the period from the start of study treatment to the venography at the end of study treatment.~Lower extremity DVT confirmed by bilateral venography at the end of study treatment~Definite diagnosis of symptomatic PE~Symptomatic DVT confirmed before the venography at the end of study treatment The objectives were to verify the non-inferiority of edoxaban to enoxaparin with regard to prevention of VTE" (NCT01203098)
Timeframe: 2 weeks
| Intervention | percent of participants with VTE event (Number) |
|---|---|
| DU-176b 15 mg | 3.8 |
| DU-176b 30 mg | 2.8 |
| Enoxaparin Sodium 20mg (2000IU) | 4.1 |
Bleeding defined by International Society on Thrombosis and Haemostasis: CRNM defined as acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0385 |
| Enoxaparin + Warfarin | 0.0800 |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie intent to treat (ITT) principle. Each participant scored as having an event only if they experienced one or more of the elements of the composite. Participants with missing endpoint information excluded. (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0322 |
| Enoxaparin + Warfarin | 0.0395 |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of efficacy evaluable participants, participants with missing endpoint information excluded). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received, ie, ITT principle. Each participant scored as having an event only if the participant experienced one or more of the elements of the composite. (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0234 |
| Enoxaparin + Warfarin | 0.0292 |
VTE included: nonfatal DVT or nonfatal PE. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major bleeding defined by International Society on Thrombosis and Haemostasis: acute, clinically overt bleeding associated with decrease in hemoglobin (Hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or bleeding that is fatal . Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period. Events included regardless of whether or not participant received treatment, ie, ITT principle (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0280 |
| Enoxaparin + Warfarin | 0.0448 |
VTE=Nonfatal DVT or nonfatal PE adjudicated by ICAC blinded to treatment. DVT: compression ultrasound and/or venography; PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Major Bleeding = acute, clinically overt bleeding: decrease in Hgb of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint and including those not in the efficacy evaluable population with a bleeding event that occurred during treatment period). Events included regardless of whether or not treatment was received (ITT). (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0699 |
| Enoxaparin + Warfarin | 0.1261 |
VTE: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants): n/N (n=number of participants with observation; N=total number of efficacy evaluable participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint: events at any time from randomization until end of intended treatment, regardless whether drug treatment was received. All randomized participants with a non-missing primary endpoint were summarized. Missing endpoint = outcomes which could not be documented on or after study Day 154. Participants were categorized to the assigned group regardless of the treatment actually received (intent-to-treat). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0226 |
| Enoxaparin + Warfarin | 0.0269 |
All events were adjudicated by an ICAC blinded to treatment. Bleeding defined by International Society on Thrombosis and Haemostasis: Major Bleeding: acute, clinically overt bleeding: decrease in hemoglobin (hgb) of 2 g/dL or more or bleeding leading to transfusion or bleeding in a critical site or fatal bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0056 |
| Enoxaparin + Warfarin | 0.0182 |
Major Bleeding = acute, clinically overt bleeding: decrease in hemoglobin of 2 g/dL or more, or bleeding leading to transfusion, or bleeding in a critical site, or fatal bleeding. CRNM = acute clinically overt bleeding: compromising hemodynamics, leading to hospitalization, hematoma, epistasis >5 minutes or repetitive, gingival bleeding, hematuria, macroscopic gastrointestinal hemorrhage, rectal blood loss, hemoptysis. Minor =: All acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events were adjudicated by an ICAC blinded to treatment. Total bleeding = any of major, or CRNM, or minor bleeding. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of treated (received at least 1 dose of study drug). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0430 |
| Enoxaparin + Warfarin | 0.0971 |
Bleeding defined by International Society on Thrombosis and Haemostasis: Minor bleeding: all acute clinically overt bleeding events not meeting the criteria for either major bleeding or CRNM. All events wre adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants) calculated as n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.1170 |
| Enoxaparin + Warfarin | 0.1878 |
DVT adjudicated by an ICAC blinded to treatment. DVT evaluated by: compression ultrasound and/or venography. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication, intent to treat principle (ITT). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). (NCT00643201)
Timeframe: Day 1 up to 24 Weeks + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0084 |
| Enoxaparin + Warfarin | 0.0133 |
PE adjudicated by an ICAC blinded to treatment. PE: spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). (NCT00643201)
Timeframe: Day 1 to Week 24 + + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0104 |
| Enoxaparin + Warfarin | 0.0095 |
Bleeding defined by International Society on Thrombosis and Haemostasis: Total Bleeding defined as any of major, CRNM, or minor bleeding. All events were adjudicated by an ICAC blinded to treatment. Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants in respective treatment group (all participants who received at least one dose of study drug). Participants were categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to the treatment received. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.1502 |
| Enoxaparin + Warfarin | 0.2514 |
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT was assessed by compression ultrasound and/or venography; PE was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0046 |
| Enoxaparin + Warfarin | 0.0061 |
Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occurred during the intended treatment period, regardless of whether the participant received study medication (ITT principle). Event rate (proportion of participants with event): n/N (n=number of participants with observation; N=Total number of participants, excluding those with missing endpoint information). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0157 |
| Enoxaparin + Warfarin | 0.0198 |
VTE-related death included: DVT-related death or PE-related death. All events were adjudicated by an ICAC blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of participants with observation; N=total number of participants in respective treatment groups excluding participants with missing endpoint information). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Includes events that occur during the intended treatment period regardless of whether or not the participant received study medication (ITT principle). (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | proportion of participants (Number) |
|---|---|
| Apixaban | 0.0058 |
| Enoxaparin + Warfarin | 0.0087 |
Treated Participants: all who received at least 1 dose of study drug. Participants categorized to the treatment group to which they were assigned unless incorrect study treatment was received throughout the study, in which case the participant was categorized according to treatment received. Included all SAEs and AEs with onset from first dose to last dose + 2 days (for AEs) or + 30 days (for SAEs); note; bleeding AEs and SAEs from first dose to last dose + 2 days included. Discontinuations due to AE included all AEs/SAEs from first dose until drug was discontinued. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00643201)
Timeframe: First dose to last dose of 24 Weeks + 2 days (AEs) or + 30 days (SAEs) or until drug discontinued
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| AE | SAE | Bleeding AE or SAE | Discontinued Due to AE or SAE | Death | |
| Apixaban | 1795 | 417 | 415 | 162 | 37 |
| Enoxaparin + Warfarin | 1923 | 410 | 695 | 199 | 44 |
Creatine kinase High: >5*ULN Units/Liter (U/L); Total Protein High/Low: < 0.9 *LLN or > 1.1*ULN, or if pre-dose < LLN then use 0.9* pre-dose or > ULN if pre-dose > ULN then use 1.1 *pre-dose or
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Creatine Kinase High (N=2601, 2596) | Uric Acid High (N=2601, 2596) | Total Protein Low (N=2601, 2596) | Total Protein High (N=2601, 2596) | |
| Apixaban | 20 | 6 | 15 | 0 |
| Enoxaparin + Warfarin | 24 | 3 | 16 | 0 |
Bicarbonate milliequivalents/Liter (mEq/L) Low/High: < 0.75*LLN or > 1.25*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Calcium mg/dL Low/High: < 0.8*LLN or > 1.2*ULN, or if pre-dose < LLN then use < 0.75*pre-dose or > ULN if pre-dose > ULN then use > 1.25*pre-dose or < LLN; Serum Chloride mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Potassium mEq/L: < 0.9*LLN or > 1.1*ULN, or if pre-dose < LLN then use < 0.9*pre-dose or > ULN if pre-dose > ULN then use > 1.1*pre-dose or < LLN; Serum Sodium mEq/L: < 0.95*LLN or > 1.05*ULN, or if pre-dose < LLN then use < 0.95*pre-dose or > ULN if pre-dose > ULN then use > 1.05*pre-dose or < LLN. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Bicarbonate Low (N=2600,2593) | Bicarbonate High (N=2600,2593) | Total Calcium Low (N=2601,2596) | Total Calcium High (N=2601,2596) | Chloride Low Total Calcium Low (N=2601,2596) | Chloride Low Total Calcium High (N=2601,2596) | Potassium Low (N=2601,2596) | Potassium High (N=2601,2596) | Sodium Low (N=2601,2596) | ||
| Apixaban | 44 | 17 | 3 | 12 | 5 | 0 | 26 | 19 | 10 | 4 |
| Enoxaparin + Warfarin | 31 | 11 | 10 | 11 | 3 | 1 | 22 | 22 | 6 | 4 |
Lower limit of normal (LLN). Upper limit of normal (ULN). Pre-therapy (PreRx). Absolute (Abs) neutrophil count, bands + neutrophils (ANC). Cells per microliter (c/µL). Grams per deciliter (g/dL). Cells per Liter (c/L). Millimeter (MM). White blood cells: < 0.75*LLN, > 1.25*ULN; Hemoglobin: <= 11.5 g/dL (males), <= 9.5 g/dL (females); Hematocrit: <= 37% (males), <= 32% (females); Erythrocytes: <0.75*10^6 c/µL*PreRx; Platelet count: < 75*10^9 c/L, > 700*10^9 c/L; ANC: < 1.00*10^3 c/µL; Abs eosinophils: > 0.750*10^3 c/µL; Abs Basophils: > 400/MM^3; Abs Monocytes> 2000/MM^3; Abs Lymphocytes: < 0.750*10*3 c/ µL, > 7.5*10^3 c/ µL. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Erthrocytes Low (N=2599, 2593) | Hematocrit Low (N=2588, 2587) | Hemoglobin Low (N=2599, 2593) | Platelet Count Low (N=2594, 2589) | Leukocytes Low (N=2528, 2519) | Leukocytes High (N=2528, 2519) | Absolute Basophils High (N=2594,2589) | Absolute Eosinophils High (N=2594,2589) | Absolute Lyphocytes Low (N=2594,2589) | Absolute Lyphocytes High (N=2594,2589) | Absolute Monocytes High (N=2594,2589) | Absolute Neutrophils Low (N=2594,2589) | |
| Apixaban | 23 | 26 | 96 | 23 | 41 | 26 | 1 | 84 | 94 | 4 | 1 | 9 |
| Enoxaparin + Warfarin | 17 | 20 | 101 | 13 | 41 | 15 | 2 | 79 | 76 | 3 | 2 | 20 |
Blood urea nitrogen (BUN), milligrams/deciliter (mg/dL), units per liter (U/L). BUN mg/dL High: > 1.5*ULN; Creatinine mg/dL: > 1.5*ULN; Alanine aminotransferase (ALT) U/L: > 3*ULN; Aspartate aminotransferase (AST) U/L: > 3*ULN; Alkaline phosphatase U/L: > 2*ULN; Bilirubin Direct mg/dL: > 1.5*ULN; Bilirubin Total mg/dL: > 2*ULN. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| BUN High (N=517, 523) | Creatinine High (N=2601, 2596) | ALT High (N=2601, 2598) | ALP High (N=2601, 2598) | AST High (N=2601, 2598) | Direct Bilirubin High (N=2601, 2593) | Total Bilirubin High (N=2601, 2597) | |
| Apixaban | 2 | 47 | 52 | 35 | 40 | 28 | 8 |
| Enoxaparin + Warfarin | 7 | 37 | 145 | 27 | 40 | 21 | 7 |
All tests in urine: Glucose: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Protein: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Blood: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; Leukocyte esterase: If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4;Red blood cells (RBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4; White blood cells (WBC): If missing pre-dose use ≥ 2, or if value ≥ 4, or if pre-dose = 0 or 0.5 use ≥ 2, or if pre-dose = 1 use ≥ 3, or if pre-dose = 2 or 3 use ≥ 4. (NCT00643201)
Timeframe: Day 1 to Week 24 + 2 Days or 355 Days (Discontinued Early)
| Intervention | participants (Number) | ||||||
|---|---|---|---|---|---|---|---|
| Blood in Urine High (N=2289, 2273) | Glucose in Urine High (N=2289, 2273) | Leukocyte Esterase in Urine High (N=2289, 2273) | Protein in Urine High (N=2289, 2273) | RBC + WBC in Urine High (N=1685, 1719) | RBC in Urine High (N=1293, 1389) | WBC in Urine High (N=1354, 1361) | |
| Apixaban | 85 | 46 | 105 | 41 | 359 | 111 | 274 |
| Enoxaparin + Warfarin | 127 | 31 | 102 | 50 | 361 | 140 | 263 |
Primary endpoint - Incidence of ARN is the primary outcome of this study and this is based on a documentation of AKI (defined as an increase in baseline serum creatinine ≥ 0.3 mg/dL), in the absence of any other obvious etiology for the AKI identified after a standard clinical evaluation and work up by the patient's primary care physician, cardiologist or nephrologist. This incidence will be expressed as a percentage. (NCT02900170)
Timeframe: 6 months
| Intervention | Percentage of participants (Number) |
|---|---|
| Participants | 0 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.71 |
| Enoxaparin 30 mg Twice a Day (Bid) | 9.34 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.94 |
| Enoxaparin 30 mg Twice a Day (Bid) | 10.11 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.32 |
| Enoxaparin 30 mg Twice a Day (Bid) | 8.97 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.37 |
| Enoxaparin 30 mg Twice a Day (Bid) | 8.66 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.14 |
| Enoxaparin 30 mg Twice a Day (Bid) | 1.88 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.04 |
| Enoxaparin 30 mg Twice a Day (Bid) | 1.48 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 47 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 0.31 |
| Enoxaparin 30 mg Twice a Day (Bid) | 0.21 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 47 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 0.35 |
| Enoxaparin 30 mg Twice a Day (Bid) | 0.11 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.16 |
| Enoxaparin 30 mg Twice a Day (Bid) | 1.98 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of deep vein thrombosis (DVT) and pulmonary embolism (PE), ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.09 |
| Enoxaparin 30 mg Twice a Day (Bid) | 1.47 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.25 |
| Enoxaparin 30 mg Twice a Day (Bid) | 2.25 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 1.09 |
| Enoxaparin 30 mg Twice a Day (Bid) | 1.67 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.84 |
| Enoxaparin 30 mg Twice a Day (Bid) | 9.80 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography (NCT00362232)
Timeframe: Up to 16 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 6.71 |
| Enoxaparin 30 mg Twice a Day (Bid) | 9.11 |
Blinded, adjudicated assessment of bilateral venography, clinical signs of DVT and PE, ultrasound, clinical chemistry and coagulation factors, autopsy report, electrocardiogram (ECG), pulmonary angiography, perfusion/ventilation lung scintigraphy, chest radiography, computed tomography, anesthesia and surgery reports, number of transfusions (NCT00362232)
Timeframe: Up to 47 days after surgery
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 2.04 |
| Enoxaparin 30 mg Twice a Day (Bid) | 2.33 |
Blinded, adjudicated assessments of all available information (eg, anesthesia and surgery reports, laboratory results, number of transfusions, autopsy report) (NCT00362232)
Timeframe: from start of double-blind study medication to last dose of double-blind study medication plus two days. The average duration of double-blind treatment was 12 days in each treatment group (safety population).
| Intervention | percentage of participants (Number) |
|---|---|
| Rivaroxaban 10 mg Once Daily (OD) (Xarelto, BAY59-7939) | 0.66 |
| Enoxaparin 30 mg Twice a Day (Bid) | 0.27 |
Measure Description: Normal hemoglobin range for adult women - 12 - 16 g/dL. Lower levels indicate worse outcomes. (NCT02829957)
Timeframe: 3 months
| Intervention | g/dl (Median) |
|---|---|
| Rivaroxaban | 12.8 |
| Apixaban | 13.25 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 3 |
| Apixaban | 1 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 4 |
| Apixaban | 2 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 3 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
(NCT02829957)
Timeframe: 1, 2, and 3 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban | 0 |
| Apixaban | 0 |
"Measure Description: A PBAC Score of < 100 indicates a normal menstrual cycle. The lowest possible score would be zero. Higher values indicate worse outcomes. The higher theoretical range value cannot be calculated. The scoring mechanism is as follows;~Towels~1 point for each lightly stained towel~5 points or each moderately soiled towel~20 points if the towel is completely saturated with blood~Tampons~1 point for each lightly stained tampon~5 points for each moderately soiled tampon~10 points if the tampon is completely saturated with blood~Clots~1 point for small clots~5 points for large clots" (NCT02829957)
Timeframe: 3 months
| Intervention | score on a scale (Median) |
|---|---|
| Rivaroxaban | 292 |
| Apixaban | 146 |
The RAND 36-Item Health Survey (Version 1.0) taps eight health concepts: physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. All items are scored so that a high score defines a more favorable health state. In addition, each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. (NCT02829957)
Timeframe: 3 months
| Intervention | Score (Median) |
|---|---|
| Rivaroxaban | 55.5 |
| Apixaban | 45.6 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.2 |
| Placebo | 0.0 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.0 |
| Placebo | 0.2 |
Events were adjudicated/confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral CT scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units, occurring in a critical site or contributing to death. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment, based on either compression ultrasound, venography, spiral computed tomography scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, autopsy or unexplained death for which DVT/PE could not be ruled out, results/films/images of confirmatory testing, and/or case summaries. Major bleeding was overt bleeding associated with 2 g/dL or greater fall in hemoglobin, leading to a transfusion of ≥2 units, occurring in a critical site or contributing to death. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 2.0 |
| Placebo | 7.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound or venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.9 |
| Placebo | 0.7 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound, venography, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.8 |
| Placebo | 5.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 7.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either spiral computed tomography (CT) scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Placebo | 0.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either spiral computed tomography (CT) scanning, pulmonary angiography, ventilation/perfusion lung scan, lung scintigraphy, results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 0.3 |
| Placebo | 2.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 0.9 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), and/or case summaries. For definition of DVT/PE, kindly refer to the link in the Protocol section. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.3 |
| Placebo | 7.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for deaths), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.2 |
| Placebo | 1.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), or lung scintigraphy (for PE), and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.3 |
| Placebo | 7.2 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), autopsy (for fatal PE) or unexplained death for which DVT/PE could not be ruled out (for fatal PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 30 days observational period after last intake of study medication
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.4 |
| Placebo | 1.1 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either compression ultrasound (for DVT), venography (for DVT), spiral computed tomography (CT) scanning (for PE), pulmonary angiography (for PE), ventilation/perfusion lung scan (for PE), lung scintigraphy (for PE), results/films/images of confirmatory testing, and/or case summaries. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) |
|---|---|
| Rivaroxaban (Xarelto, BAY59-7939) | 1.5 |
| Placebo | 7.4 |
All events were adjudicated and confirmed by a central independent adjudication committee blinded to treatment. Events were assessed based on either autopsy, results/films/images of confirmatory testing, and/or case summaries. Treatment-emergent events and all events post randomization were reported. Treatment-emergent: after intake of first tablet of study medication as randomized but not more than 2 days after stop of study medication (referred to as time window: 2 days) (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Treatment-emergent (time window: 2 days) | All post-randomization | |
| Placebo | 0.2 | 0.3 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.2 | 0.2 |
All events adjudicated/confirmed by CIAC blinded to treatment. Clinically relevant bleeding included major bleeding (definition: see outcome 7) and non-major bleeding associated with medical intervention, unscheduled physician contact, (temporary) cessation of study treatment, discomfort for the participants such as pain, or impairment of daily life activities. Treatment-emergent events (after intake of 1st study medication tablet as randomized up to 2 days after stop of study medication ['time window: 2 days']) and all events post randomization were reported (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Treatment-emergent (time window: 2 days) | All post-randomization | |
| Placebo | 1.2 | 1.9 |
| Rivaroxaban (Xarelto, BAY59-7939) | 6.0 | 6.0 |
All events were adjudicated and confirmed by a central independent adjudication committee (CIAC) blinded to treatment. Major bleeding event was overt bleeding associated with a 2 g/dL or greater fall in hemoglobin, leading to a transfusion of 2 or more units of packed red blood cells or whole blood, occurring in a critical site or contributing to death. Treatment-emergent [after intake of first tablet of study medication as randomized but not more than 2 days after stop of study medication (referred to as time window: 2 days)] events and all events post randomization were reported. (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| Treatment-emergent (time window: 2 days) | All post-randomization | |
| Placebo | 0.0 | 0.2 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.7 | 0.7 |
All pre-defined vascular events (acute coronary syndromes, ischemic stroke, transient ischemic attack, non-central nervous system systemic embolism and vascular death) were adjudicated/confirmed by a central independent adjudication committee blinded to treatment, based on results/films/images of confirmatory testing, and/or case summaries. On treatment events and all events post randomization were reported. On treatment: after intake of first tablet of study medication as randomized but not more than 1 day after stop of study medication (referred to as time window: 1 day) (NCT00439725)
Timeframe: 6- or 12-month study treatment period
| Intervention | Percentage of participants (Number) | |
|---|---|---|
| On treatment (time window: 1 day) | All post-randomization | |
| Placebo | 0.7 | 0.7 |
| Rivaroxaban (Xarelto, BAY59-7939) | 0.5 | 0.8 |
All cause death, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Enoxaparin | 1 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 18 |
| Enoxaparin | 33 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 17 |
| Enoxaparin | 31 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 1 |
| Enoxaparin | 2 |
Symptomatic Deep Vein Thrombosis, confirmed by venous duplex, ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 0 |
| Enoxaparin | 4 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 60 |
| Enoxaparin | 67 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 61 |
| Enoxaparin | 69 |
Volume of blood loss for treated and operated patients during surgery. (NCT00657150)
Timeframe: Day 1
| Intervention | mL (Mean) |
|---|---|
| Dabigatran 220mg | 404.9 |
| Enoxaparin | 411.0 |
Number of treated and operated patients with required blood transfusion on day of surgery. (NCT00657150)
Timeframe: Day 1
| Intervention | participants (Number) | |
|---|---|---|
| Transfusions required | Missing | |
| Dabigatran 220mg | 246 | 4 |
| Enoxaparin | 237 | 7 |
Frequency of patients with possible clinically significant abnormalities. (NCT00657150)
Timeframe: First administration to end of study
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase N=(964;962) | AST decrease N=(964;962) | ALT increase N=(966;962) | ALT decrease N=(966;962) | Bilirubin increase N=(966;962) | Bilirubin decrease N=(966;962) | |
| Dabigatran 220mg | 28 | 0 | 34 | 0 | 3 | 0 |
| Enoxaparin | 44 | 0 | 67 | 0 | 1 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma >=25 cm²~wound hematoma >=100 cm²~spontaneous nose bleed >5 min~macroscopic hematuria spontaneous or >24 hours if associated with an intervention~spontaneous rectal bleeding~gingival bleeding >5 min~any other bleeding event considered clinically relevant by the investigator~Any bleeding events were defined as major, clinically-relevant and minor bleeding events. Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00657150)
Timeframe: 28-35 days
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Major bleeding events | Major and clinically relevant bleeding events | Any bleeding events | |
| Dabigatran 220mg | 14 | 37 | 98 |
| Enoxaparin | 9 | 29 | 83 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine venography), symptomatic DVT (confirmed by venous duplex, ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00657150)
Timeframe: 3 months
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Total VTE and all-cause mortality | asymptomatic Deep Vein Thrombosis | symptomatic Deep Vein Thrombosis | Pulmonary Embolism | death | |
| Dabigatran 220mg | 2 | 0 | 1 | 1 | 0 |
| Enoxaparin | 4 | 1 | 0 | 2 | 1 |
All-cause mortality (NCT00413374)
Timeframe: 30 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Enoxaparin 1.5 mg/kg Once Daily | 0 |
| Enoxaparin 1 mg/kg Twice Daily | 0 |
Major bleeding complication as defined as spinal, retroperitoneal, or intracranial bleeding; drop in hemoglobin ≥2g/dl or transfusion ≥2U or surgical or medical intervention, death related to bleeding. (NCT00413374)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Enoxaparin 1.5 mg/kg Daily | 0 |
| Enoxaparin 1 mg/kg Twice Daily | 3 |
Major clotting complication (recurrent VTE) as defined as recurrent acute pulmonary embolism confirmed on chest CT or recurrent deep vein thrombosis in the contralateral extremity confirmed with venous ultrasound or CT scan while on once daily enoxaparin therapy. (NCT00413374)
Timeframe: 30 Days
| Intervention | participants (Number) |
|---|---|
| Enoxaparin 1.5 mg/kg Daily | 1 |
| Enoxaparin 1 mg/kg Twice Daily | 3 |
Number of participant received allogenic blood transfusions. (NCT02684851)
Timeframe: post-operative
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 21 |
| Placebo | 13 |
To measure average estimate perioperative blood loss (NCT02684851)
Timeframe: perioperative
| Intervention | mL (Mean) |
|---|---|
| Tranexamic | 727.6 |
| Placebo | 560.1 |
Do patients undergoing acetabular ORIF who receive tranexamic acid have a higher risk for thromboembolic events than patients who receive placebo? (NCT02684851)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic | 1 |
| Placebo | 0 |
Average units packed red blood cells transfused among participants (NCT02684851)
Timeframe: perioperative
| Intervention | Units of packed red blood cells (Mean) |
|---|---|
| Tranexamic | 2.65 |
| Placebo | 2.36 |
AM-PAC (activity measure for post-acute care) will be used to determine if a patient is fit to discharge based on mobility with 6 being unable to mobilize up to 24 being independent. Patients who scored above 20 were considered fit to discharge. (NCT03303794)
Timeframe: Post-Operation Day 1
| Intervention | score on scale (Mean) |
|---|---|
| Bupivicaine | 23 |
| Bupivicaine + Exparel | 23 |
Monitor how much opioid patient consumes (NCT03303794)
Timeframe: During the first 48 hours after surgery
| Intervention | milligram (Mean) |
|---|---|
| Bupivicaine | 90 |
| Bupivicaine + Exparel | 76 |
Will use Numeric Pain Rating Scale (NPRS) to measure pain with 0 being no pain and 10 being the worst pain. (NCT03303794)
Timeframe: 48 hours postoperatively
| Intervention | score on scale (Mean) |
|---|---|
| Bupivicaine | 4 |
| Bupivicaine + Exparel | 4 |
All cause death, as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 3 |
| Dabigatran 150mg | 3 |
| Enoxaparin | 0 |
Major Venous Thromboembolic Event (VTE) is defined as proximal DVT and PE, as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 28 |
| Dabigatran 150mg | 38 |
| Enoxaparin | 36 |
Proximal Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 23 |
| Dabigatran 150mg | 35 |
| Enoxaparin | 33 |
Pulmonary embolism confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy, and as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 5 |
| Dabigatran 150mg | 1 |
| Enoxaparin | 3 |
Symptomatic Deep Vein Thrombosis, confirmed by venous compression ultrasound, venography or autopsy, and as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 6 |
| Dabigatran 150mg | 9 |
| Enoxaparin | 1 |
Total Deep Vein Thrombosis as adjudicated by the VTE events committee (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 46 |
| Dabigatran 150mg | 72 |
| Enoxaparin | 57 |
"Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy).~All of these components and all deaths were centrally adjudicated by the VTE events committee, which was not aware of the treatment allocation of the patients." (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) |
|---|---|
| Dabigatran 220mg | 53 |
| Dabigatran 150mg | 75 |
| Enoxaparin | 60 |
Volume of blood loss for treated and operated patients during surgery. (NCT00168818)
Timeframe: Day 1
| Intervention | mL (Mean) |
|---|---|
| Dabigatran 220mg | 457 |
| Dabigatran 150mg | 435 |
| Enoxaparin | 463 |
Blood transfusion for treated and operated patients on Day of surgery. (NCT00168818)
Timeframe: Day 1
| Intervention | participants (Number) | |
|---|---|---|
| Patients with >=1 transfusions | Patients with >=1 non-autologous transfusions | |
| Dabigatran 150mg | 531 | 266 |
| Dabigatran 220mg | 517 | 259 |
| Enoxaparin | 542 | 286 |
Frequency of patients with possible clinically significant abnormalities. (NCT00168818)
Timeframe: First administration to end of study
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| AST increase N=(1103;1097;1103) | AST decrease N=(1103;1097;1103) | ALT increase N=(1103;1098;1103) | ALT decrease N=(1103;1098;1103) | Bilirubin increase N=(1102;1094;1102) | Bilirubin decrease N=(1102;1094;1102) | |
| Dabigatran 150mg | 16 | 0 | 29 | 0 | 24 | 0 |
| Dabigatran 220mg | 11 | 0 | 28 | 0 | 25 | 0 |
| Enoxaparin | 29 | 0 | 59 | 0 | 34 | 0 |
"Major bleeding events were defined as~fatal~clinically overt associated with loss of haemoglobin >=20g/L in excess of what was expected~clinically overt leading to the transfusion of >=2 units packed cells or whole blood in excess of what was expected~symptomatic retroperitoneal, intracranial, intraocular or intraspinal~requiring treatment cessation~leading to re-operation~Clinically-relevant was defined as~spontaneous skin hematoma greater than or equal to 25 cm²~wound hematoma greater than or equal to 100 cm²~spontaneous nose bleed lasting longer than 5 min~macroscopic hematuria spontaneous or lasting longer than 24 hours if associated with an intervention~spontaneous rectal bleeding (more than a spot on toilet paper)~gingival bleeding lasting longer than 5 min~any other bleeding event considered clinically relevant by the investigator~Minor bleeding events were defined as all other bleeding events that did not fulfil the criteria from above." (NCT00168818)
Timeframe: First administration until 31-38 days
| Intervention | Participants (Number) | |||
|---|---|---|---|---|
| Major | Clinical relevant | Minor | None | |
| Dabigatran 150mg | 15 | 55 | 72 | 1021 |
| Dabigatran 220mg | 23 | 48 | 70 | 1005 |
| Enoxaparin | 18 | 40 | 74 | 1022 |
Total Venous Thromboembolic Event (VTE) includes both proximal and distal deep vein thrombosis (DVT) (detected by routine bilateral venography), symptomatic DVT (confirmed by venous compression ultrasound, venography or autopsy) and pulmonary embolism (PE) (confirmed by pulmonary V-Q scintigraphy, chest x-ray, pulmonary angiography, spiral CT or autopsy). (NCT00168818)
Timeframe: end of treatment to day 91±7
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| Total VTE and all-cause mortality | asymptotic Deep Vein Thrombosis | symptotic Deep Vein Thrombosis | Pulmonary Embolism | death | |
| Dabigatran 150mg | 4 | 1 | 1 | 0 | 2 |
| Dabigatran 220mg | 1 | 0 | 1 | 0 | 0 |
| Enoxaparin | 5 | 3 | 0 | 1 | 1 |
Coagulopathic bleeding due to fondaparinux was suspected in patients requiring packed red cell transfusions after initiation of fondaparinux therapy only if the change in hematocrit prompting transfusion was not clinically commensurate with the degree of injuries that the patient had sustained (primarily orthopaedic) and/or the hematocrit did not respond appropriately post-transfusion. (NCT00531843)
Timeframe: 3 weeks post injury
| Intervention | participants (Number) |
|---|---|
| Fondaparinux Sodium | 0 |
Serum samples were collected 30 minutes before (trough) and 2 hours after (peak) the third dose of fondaparinux. Normative data plots comparing study participants with healthy volunteers were supplied by the company outsourced to analyze samples. (NCT00531843)
Timeframe: Day 3
| Intervention | Participants (Number) | |
|---|---|---|
| Trough values outside normative range | Peak values outside normative range | |
| Fondaparinux Sodium | 0 | 0 |
Color-flow duplex venous ultrasonography examinations of upper and lower extremities were performed within 48 hours of injury, and then weekly until discharge or 3 weeks. DVT was defined as any clot occurring in the subclavian, iliac, femoral, or popliteal location. Patients were examined daily for clinical signs and symptoms of venous thromboembolism (VTE) and PE. Small, nonocclusive clots discovered in other locations were observed for progression on sequential ultrasonography examinations. (NCT00531843)
Timeframe: within 3 weeks post injury
| Intervention | participants (Number) | ||
|---|---|---|---|
| DVT | DVT after fondaparinux | PE | |
| Fondaparinux Sodium | 2 | 1 | 0 |
| No Fondaparinux | 2 | NA | 0 |
The primary safety endpoint was major bleeding events during the On-Treatment Study Period (defined as on-study drug or up to 3 days after the last dose of study drug). (NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 32 |
| Dalteparin Group | 16 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 67 |
| Dalteparin Group | 71 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 19 |
| Dalteparin Group | 35 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 21 |
| Dalteparin Group | 24 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 41 |
| Dalteparin Group | 59 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 235 |
| Dalteparin Group | 228 |
(NCT02073682)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Edoxaban Group | 6 |
| Dalteparin Group | 4 |
Percentage of participants with Arterial puncture aspiration (NCT02318940)
Timeframe: intraoperative, an average of 1 hour
| Intervention | percentage of participants (Number) |
|---|---|
| Landmark Method | 25 |
| Ultrasound Method | 10 |
Percentage of Participants with successful installation on the first transcutaneous passage of the glass needle (NCT02318940)
Timeframe: intraoperative, an average of 1 hour
| Intervention | percentage of participants (Number) |
|---|---|
| Landmark Method | 18 |
| Ultrasound Method | 42 |
Percentage of participants with successful installation of guide without difficulty in the femoral vein (NCT02318940)
Timeframe: intraoperative, an average of 1 hour
| Intervention | percentage of participants (Number) |
|---|---|
| Landmark Method | 51 |
| Ultrasound Method | 84 |
Number of participants who succeeded in the installation of cvc in one, two, three, four or five attempts. (NCT02318940)
Timeframe: intraoperative, an average of 1 hour
| Intervention | participants (Number) | |||||
|---|---|---|---|---|---|---|
| first attempt | second attempt | third attempt | fourth attempt | fifth attempt | Unsuccessful cannulation | |
| Landmark Method | 9 | 4 | 6 | 2 | 4 | 24 |
| Ultrasound Method | 21 | 18 | 4 | 0 | 0 | 7 |
(NCT00277394)
Timeframe: prior to day 90 +/- 5
| Intervention | Patients (Number) |
|---|---|
| Innohep® | 32 |
| Heparin | 32 |
(NCT00277394)
Timeframe: prior to day 90 +/- 5
| Intervention | Patients (Number) |
|---|---|
| Innohep® | 12 |
| Heparin | 10 |
(NCT00277394)
Timeframe: prior to day 90 +/- 5
| Intervention | Patients (Number) |
|---|---|
| Innohep® | 16 |
| Heparin | 9 |
91 reviews available for dalteparin and Deep Vein Thrombosis
| Article | Year |
|---|---|
Long-term low-molecular-weight heparin and the post-thrombotic syndrome: a systematic review.
Topics: Anticoagulants; Dalteparin; Drug Administration Schedule; Enoxaparin; Heparin, Low-Molecular-Weight; | 2011 |
Use of the low-molecular-weight heparin nadroparin during pregnancy. A review.
Topics: Antiphospholipid Syndrome; Female; Fibrinolytic Agents; Heart Valve Prosthesis; Herpes Simplex; Huma | 2003 |
Low molecular weight heparins in the prevention of deep-vein thrombosis in general surgery.
Topics: Dalteparin; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Nadroparin; Surgical Procedures, Oper | 1999 |
[Evolution in the pharmacological treatment of venous thrombosis according to evidence-based medicine].
Topics: Acute Disease; Administration, Oral; Anticoagulants; Clinical Trials as Topic; Dalteparin; Enoxapari | 2000 |
[Treatment of deep vein thrombosis: from fraxiparine to fraxodi].
Topics: Ambulatory Care; Anticoagulants; Delayed-Action Preparations; Drug Monitoring; Hospitalization; Huma | 2001 |
Pharmacology department.
Topics: Anticoagulants; Dalteparin; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Nadroparin; Venous Th | 2001 |
Low molecular weight heparin administered once versus twice daily in patients with venous thromboembolism: a meta-analysis.
Topics: Acute Disease; Anticoagulants; Dalteparin; Drug Administration Schedule; Enoxaparin; Hemorrhage; Hep | 2001 |
Update on the clinical use of the low-molecular-weight heparin, parnaparin.
Topics: Acute Coronary Syndrome; Anticoagulants; Arterial Occlusive Diseases; Cardiovascular Diseases; Drug | 2009 |
Rivaroxaban is as efficient and safe as bemiparin as thromboprophylaxis in knee arthroscopy.
Topics: Adult; Aged; Arthroscopy; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Follow-Up Studies; Hepa | 2014 |
Bemiparin, an effective and safe low molecular weight heparin: a review.
Topics: Anticoagulants; Clinical Trials as Topic; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; | 2014 |
Clinical experience with bemiparin.
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Pulmonary Embolism; Surgical Procedures, Oper | 2010 |
Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism.
Topics: Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Postoperative | 2003 |
Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis.
Topics: Area Under Curve; Economics, Pharmaceutical; Heparin, Low-Molecular-Weight; Humans; Randomized Contr | 2003 |
Edoxaban: front-line treatment for brachiocephalic vein thrombosis in primitive mediastinal seminoma: A case report and literature review.
Topics: Adult; Anticoagulants; Brachiocephalic Veins; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Mal | 2022 |
Spontaneous spermatic vein thrombosis in pediatric patients: A condition to be considered.
Topics: Child; Enoxaparin; Fibrinolytic Agents; Humans; Male; Renal Nutcracker Syndrome; Spermatic Cord; Ult | 2020 |
Antithrombotic treatment after stroke due to intracerebral haemorrhage.
Topics: Cerebral Hemorrhage; Enoxaparin; Fibrinolytic Agents; Heparin; Humans; Intracranial Thrombosis; Rand | 2017 |
Chemical venous thromboembolism prophylaxis in neurosurgical patients: an updated systematic review and meta-analysis.
Topics: Anticoagulants; Enoxaparin; Evidence-Based Medicine; Hemorrhage; Heparin, Low-Molecular-Weight; Intr | 2018 |
Symptomatic bilateral pulmonary embolism without deep venous thrombosis in an adolescent following arthroscopic anterior cruciate ligament reconstruction: a case report and review of the literature.
Topics: Adolescent; Anterior Cruciate Ligament Reconstruction; Anticoagulants; Arthroscopy; Elective Surgica | 2018 |
Factor Xa Inhibitors and Direct Thrombin Inhibitors Versus Low-Molecular-Weight Heparin for Thromboprophylaxis After Total Hip or Total Knee Arthroplasty: A Systematic Review and Meta-Analysis.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enox | 2019 |
Mandatory contrast-enhanced venography to detect deep-vein thrombosis (DVT) in studies of DVT prophylaxis: upsides and downsides.
Topics: Anticoagulants; Cardiology; Clinical Trials as Topic; Contrast Media; Enoxaparin; Fibrinolytic Agent | 2014 |
Direct factor Xa inhibitors (rivaroxaban and apixaban) versus enoxaparin for the prevention of venous thromboembolism after total knee replacement: A meta-analysis of 6 randomized clinical trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Factor Xa Inhibitors; Hemorrhage; Human | 2015 |
The outcome of pulmonary vein thrombosis in non-surgical patients. A systematic review and case report.
Topics: Adult; Aged; Aged, 80 and over; Enoxaparin; Fatal Outcome; Female; Hemorrhage; Humans; Male; Middle | 2015 |
Timing for deep vein thrombosis chemoprophylaxis in traumatic brain injury: an evidence-based review.
Topics: Anticoagulants; Brain Injuries; Enoxaparin; Humans; Intracranial Hemorrhages; Risk Factors; Venous T | 2015 |
Rivaroxaban for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis with trial sequential analysis of randomized controlled trials.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Factor | 2016 |
Postinjury thromboprophylaxis.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Factor Xa Inhibitors; Fondaparinux; Humans; Incidence; | 2008 |
[Venous thromboembolism and immobilization for medical reason].
Topics: Age Factors; Aged; Anticoagulants; Dalteparin; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux | 2008 |
P-selectin/ PSGL-1 inhibitors versus enoxaparin in the resolution of venous thrombosis: a meta-analysis.
Topics: Animals; Blood Coagulation; Blood Coagulation Tests; Blood Platelets; Enoxaparin; Fibrin Fibrinogen | 2010 |
Early postoperative bleeding in polytrauma patients treated with fondaparinux: literature review and institutional experience.
Topics: Acetabulum; Adult; Anticoagulants; Enoxaparin; Female; Fondaparinux; Fractures, Bone; Humans; Male; | 2011 |
Dabigatran and rivaroxaban for prevention of venous thromboembolism--systematic review and adjusted indirect comparison.
Topics: Anticoagulants; Antithrombins; Benzimidazoles; beta-Alanine; Dabigatran; Enoxaparin; Factor Xa Inhib | 2011 |
Perioperative deep vein thrombosis prevention: what works, what does not work and does it improve outcome?
Topics: Anticoagulants; Bariatric Surgery; Enoxaparin; Guidelines as Topic; Humans; Neoplasms; Perioperative | 2011 |
Standard or extended-duration prophylaxis in medical patients? A review of the evidence.
Topics: Anticoagulants; Enoxaparin; Female; Hemorrhage; Humans; Male; Pulmonary Embolism; Randomized Control | 2011 |
Anaphylaxis with tissue plasminogen activator: case report and literature review.
Topics: Aged; Anaphylaxis; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Glucocorticoids; Humans; | 2012 |
Use of anticoagulation therapy for jugular vein thrombus in pediatric patients with Lemierre's syndrome.
Topics: Adolescent; Anti-Bacterial Agents; Anticoagulants; Child; Child, Preschool; Enoxaparin; Female; Huma | 2012 |
Factor Xa inhibition in the prevention of venous thromboembolism and treatment of patients with venous thromboembolism.
Topics: Animals; Anticoagulants; Clinical Trials, Phase III as Topic; Enoxaparin; Factor Xa Inhibitors; Fond | 2002 |
Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Confidence In | 2002 |
Venous thromboembolism in cancer patients: expanding horizons.
Topics: Antineoplastic Agents; Double-Blind Method; Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular- | 2002 |
A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Fondaparinux; Humans; Middle Aged; Orthopedic P | 2002 |
Low-molecular-weight heparins: are they all the same?
Topics: Angina, Unstable; Blood Coagulation Tests; Dalteparin; Enoxaparin; Factor Xa Inhibitors; Heparin, Lo | 2003 |
The design of venous thromboembolism prophylaxis trials: is enoxaparin more effective than fondaparinux?
Topics: Anticoagulants; Clinical Trials as Topic; Double-Blind Method; Enoxaparin; Fondaparinux; Humans; Pol | 2003 |
Enoxaparin-related fatal spontaneous retroperitoneal hematoma in the elderly.
Topics: Age Factors; Aged; Anticoagulants; Disease Susceptibility; Enoxaparin; Fatal Outcome; Female; Hemato | 2003 |
[Venous thrombosis and thrombophilic management of prevention and therapy].
Topics: Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Risk Factors; Thrombophilia; | 2003 |
New pentasaccharides for the prophylaxis of venous thromboembolism: clinical studies.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Factor | 2003 |
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Topics: Anticoagulants; Azetidines; Benzylamines; Drug Interactions; Drug Therapy, Combination; Enoxaparin; | 2004 |
Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely III medical inpatients in community practice.
Topics: Acute Disease; Aged; Anticoagulants; Databases, Factual; Enoxaparin; Humans; Inpatients; Pulmonary E | 2004 |
Clinical application of enoxaparin.
Topics: Anticoagulants; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Enoxaparin; Fibrinolytic Ag | 2004 |
The design of venous thromboembolism prophylaxis trials: fondaparinux is definitely more effective than enoxaparin in orthopaedic surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Fondaparinux; Humans; Orthopedic Procedu | 2004 |
Prophylaxis of venous thromboembolism in medical patients.
Topics: Anticoagulants; Dalteparin; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Hum | 2004 |
Emerging options for thromboprophylaxis after orthopedic surgery: a review of clinical data.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Humans; Meta-Analysis as Topic; Orthopedic Procedures; Pol | 2004 |
Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as Topic | 2004 |
[Primary prevention of deep vein thrombosis in non-surgical patients].
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Heparin; Humans; Meta-Analysis as Topic; Polysaccharides; | 2005 |
Enoxaparin in the treatment of deep vein thrombosis with or without pulmonary embolism: an individual patient data meta-analysis.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Pulmona | 2005 |
[Novel possibilities of antithrombotic therapy in patients with chronic heart failure].
Topics: Anticoagulants; Azetidines; Benzylamines; Dalteparin; Double-Blind Method; Enoxaparin; Fibrinolytic | 2005 |
Gestational thrombocythaemia associated with intrauterine death: case report and a review of the literature.
Topics: Anticoagulants; Enoxaparin; Female; Fetal Death; Humans; Placenta; Placenta Diseases; Pregnancy; Pre | 2006 |
The antiphospholipid syndrome: what are we really measuring? How do we measure it? And how do we treat it?
Topics: Aged; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; beta 2-Glycoprotein I | 2006 |
Clinical trials of deep vein thrombosis prophylaxis in medical patients.
Topics: Aged; Anticoagulants; Dalteparin; Enoxaparin; Fondaparinux; Humans; Middle Aged; Polysaccharides; Pu | 2005 |
Rivaroxaban for thromboprophylaxis after orthopaedic surgery: pooled analysis of two studies.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dos | 2007 |
Tonsillectomy in the anticoagulated patient.
Topics: Adult; Algorithms; Anticoagulants; Antiphospholipid Syndrome; Blood Loss, Surgical; Dose-Response Re | 2007 |
The pharmacoeconomics of deep vein thrombosis treatment.
Topics: Anticoagulants; Enoxaparin; Fondaparinux; Humans; Polysaccharides; Venous Thrombosis | 2007 |
Anticoagulant treatment of deep vein thrombosis and pulmonary embolism.
Topics: Anticoagulants; Antithrombin III; Enoxaparin; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; P | 2008 |
[Clexane++ treatment of acute venous thrombosis].
Topics: Acute Disease; Enoxaparin; Fibrinolytic Agents; Humans; Infusions, Intravenous; Safety; Treatment Ou | 1998 |
[Clexane in prevention of acute venous thrombosis and pulmonary thromboembolism].
Topics: Adult; Aged; Anticoagulants; Blood Coagulation; Cost-Benefit Analysis; Drug Administration Schedule; | 1998 |
Cost effectiveness of danaparoid compared with enoxaparin as deep vein thrombosis prophylaxis after hip replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Chondroitin Sulfates; Cost-Benefit Analysis; Dermata | 1999 |
Cost effectiveness of outpatient anticoagulant prophylaxis after total hip arthroplasty.
Topics: Adult; Ambulatory Care; Anticoagulants; Arthroplasty, Replacement, Hip; Clinical Trials as Topic; Co | 2000 |
[Treatment of venous thromboembolism].
Topics: Administration, Oral; Adult; Anticoagulants; Enoxaparin; Female; Fibrinolytic Agents; Heparin; Hepar | 2000 |
Management of venous and cardiovascular thrombosis: enoxaparin.
Topics: Angina, Unstable; Anticoagulants; Coronary Thrombosis; Enoxaparin; Fibrinolytic Agents; Humans; Myoc | 2000 |
Deep venous thrombosis prophylaxis in patients with heart disease.
Topics: Angina, Unstable; Anticoagulants; Critical Care; Enoxaparin; Heart Failure; Heparin; Humans; Myocard | 2001 |
Low-molecular-weight heparins are essentially the same for treatment and prevention of venous thromboembolism.
Topics: Clinical Trials as Topic; Dalteparin; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Pulmonary E | 2001 |
Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patient: The MEDENOX trial.
Topics: Anticoagulants; Enoxaparin; Humans; Randomized Controlled Trials as Topic; Thromboembolism; Treatmen | 2001 |
Overview of enoxaparin in the treatment of deep vein thrombosis.
Topics: Enoxaparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Managed Care Programs; Meta- | 2000 |
Treating venous thromboembolism: enoxaparin.
Topics: Ambulatory Care; Anticoagulants; Contraindications; Cost-Benefit Analysis; Drug Costs; Enoxaparin; H | 2001 |
Overview of the clinical results of pentasaccharide in major orthopedic surgery.
Topics: Clinical Trials, Phase III as Topic; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Huma | 2001 |
Fondaparinux versus enoxaparin for the prevention of venous thromboembolism.
Topics: Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Enoxaparin; Fondaparinux; Humans; P | 2002 |
Review of enoxaparin and its clinical applications in venous and arterial thromboembolism.
Topics: Anticoagulants; Biological Availability; Drug Evaluation; Economics, Pharmaceutical; Enoxaparin; Hal | 2002 |
Low-molecular-weight heparins or heparinoids versus standard unfractionated heparin for acute ischemic stroke (Cochrane review).
Topics: Acute Disease; Anticoagulants; Brain Ischemia; Chondroitin Sulfates; Databases, Factual; Dermatan Su | 2002 |
Update on low molecular weight heparins at the beginning of third millennium. Focus on reviparin.
Topics: Fibrinolytic Agents; Heparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Ri | 2011 |
Reviparin sodium clivarine: a review of its therapeutic use.
Topics: Anticoagulants; Coronary Disease; Coronary Restenosis; Heparin, Low-Molecular-Weight; Humans; Myocar | 2004 |
Reviparin: a review of its efficacy in the prevention and treatment of venous thromboembolism.
Topics: Adult; Anticoagulants; Catheterization, Central Venous; Child; Female; Hemorrhage; Heparin, Low-Mole | 2001 |
Reviparin sodium - a new low molecular weight heparin.
Topics: Absorption; Anticoagulants; Child; Drug Evaluation; Factor Xa Inhibitors; Female; Heparin, Low-Molec | 2002 |
Fixed-dose versus adjusted-dose low molecular weight heparin for the initial treatment of patients with deep venous thrombosis.
Topics: Anticoagulants; Fibrin Fibrinogen Degradation Products; Heparin, Low-Molecular-Weight; Humans; Injec | 2002 |
Low molecular weight heparin for the prevention of deep venous thrombosis after total knee arthroplasty: A systematic review and meta-analysis.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Transfusion; Dalteparin; Female; Hepari | 2018 |
Thrombosis prophylaxis in patient populations with a central venous catheter: a systematic review.
Topics: Anticoagulants; Antineoplastic Agents; Catheterization, Central Venous; Critical Illness; Dalteparin | 2003 |
Cancer-associated thrombosis: focus on extended therapy with dalteparin.
Topics: Anticoagulants; Dalteparin; Evidence-Based Medicine; Humans; Neoplasms; Thromboembolism; Venous Thro | 2006 |
[Prevention of venous thromboembolism in internal medicine and neurology].
Topics: Anticoagulants; Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Interna | 2006 |
New insights into extended prophylaxis after orthopaedic surgery - the North American Fragmin Trial experience.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Cost-Benefit Analysis; Dalteparin; Decision Making; | 2000 |
Outpatient treatment of patients with deep-vein thrombosis or pulmonary embolism.
Topics: Administration, Oral; Ambulatory Care; Anticoagulants; Dalteparin; Feasibility Studies; Heparin, Low | 2001 |
Dalteparin sodium.
Topics: Animals; Anticoagulants; Clinical Trials as Topic; Dalteparin; Humans; Myocardial Infarction; Venous | 2001 |
Tinzaparin sodium: a review of its use in the prevention and treatment of deep vein thrombosis and pulmonary embolism, and in the prevention of clotting in the extracorporeal circuit during haemodialysis.
Topics: Blood Coagulation; Clinical Trials as Topic; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Hum | 2010 |
Tinzaparin sodium: a low-molecular-weight heparin.
Topics: Biological Availability; Economics, Pharmaceutical; Fibrinolytic Agents; Half-Life; Heparin, Low-Mol | 2002 |
The low molecular weight heparin, tinzaparin, in thrombosis and beyond.
Topics: Anticoagulants; Clinical Trials as Topic; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans | 2002 |
Tinzaparin: considerations for use in clinical practice.
Topics: Animals; Clinical Trials as Topic; Heparin, Low-Molecular-Weight; Humans; Tinzaparin; Venous Thrombo | 2003 |
Lemierre's syndrome presenting with peritonsillar abscess and VIth cranial nerve palsy.
Topics: Abducens Nerve Diseases; Adolescent; Anti-Bacterial Agents; Cefotaxime; Female; Follow-Up Studies; H | 2006 |
257 trials available for dalteparin and Deep Vein Thrombosis
| Article | Year |
|---|---|
Anticoagulation therapy early is safe in portal vein thrombosis patients with acute variceal bleeding: a multi-centric randomized controlled trial.
Topics: Albumins; Anticoagulants; Esophageal and Gastric Varices; Fibrosis; Gastrointestinal Hemorrhage; Hum | 2023 |
Efficacy and Safety of Nadroparin Calcium-Warfarin Sequential Anticoagulation in Portal Vein Thrombosis in Cirrhotic Patients: A Randomized Controlled Trial.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Female; Fibrin Fibrinogen Degradation Products; | 2020 |
Effect of anticoagulant treatment on pain in distal deep vein thrombosis: an ancillary analysis from the cactus trial.
Topics: Anticoagulants; Canada; France; Humans; Nadroparin; Pain; Pain Measurement; Stockings, Compression; | 2019 |
Update on distal deep venous thrombosis. Reports of a multicenter study.
Topics: Aged; Anticoagulants; Combined Modality Therapy; Compression Bandages; Female; Humans; Leg; Male; Mi | 2014 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Anticoagulant therapy for symptomatic calf deep vein thrombosis (CACTUS): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Anticoagulants; Canada; Double-Blind Method; Early Termination of Clinical Trials; Exan | 2016 |
Nadroparin or fondaparinux versus no thromboprophylaxis in patients immobilised in a below-knee plaster cast (PROTECT): A randomised controlled trial.
Topics: Adult; Anticoagulants; Casts, Surgical; Female; Fondaparinux; Humans; Immobilization; Leg Injuries; | 2017 |
A comparison of low-molecular-weight heparin and combined therapy of low-molecular-weight heparin with an anti-inflammatory agent in the treatment of superficial vein thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; | 2009 |
Therapy of isolated calf muscle vein thrombosis: a randomized, controlled study.
Topics: Adult; Aged; Anticoagulants; Combined Modality Therapy; Compression Bandages; Disease Progression; D | 2010 |
Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study.
Topics: Acute Disease; Adult; Aged; Ambulatory Care; Anticoagulants; Female; Hemorrhage; Humans; Male; Middl | 2011 |
Anti-Xa activity in obese patients after double standard dose of nadroparin for prophylaxis.
Topics: Anticoagulants; Area Under Curve; Body Weight; Chromogenic Compounds; Dose-Response Relationship, Dr | 2002 |
Risk of postoperative hemorrhage after intracranial surgery after early nadroparin administration: results of a prospective study.
Topics: Adult; Aged; Anticoagulants; Bandages; Brain Diseases; Drug Administration Schedule; Female; Humans; | 2003 |
Prevention of deep-vein thrombosis after total knee arthroplasty in Asian patients. Comparison of low-molecular-weight heparin and indomethacin.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arthroplast | 2004 |
Thrombosis prophylaxis in cancer patients with a central venous catheter.
Topics: Anticoagulants; Catheterization, Central Venous; Humans; Nadroparin; Neoplasms; Pilot Projects; Pros | 2004 |
Lack of effect of a low-molecular-weight heparin (nadroparin) on mortality in bedridden medical in-patients: a prospective randomised double-blind study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Autopsy; Double-Blind Method; Female; | 2005 |
A randomized study comparing the efficacy and safety of nadroparin 2850 IU (0.3 mL) vs. enoxaparin 4000 IU (40 mg) in the prevention of venous thromboembolism after colorectal surgery for cancer.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Colorectal Neoplasms; Enoxaparin; Female; Fibrinolyt | 2006 |
[Two models of thromboprophylaxis in acutely ill medical inpatients].
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Feasibility Stud | 2007 |
Prevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Catheters, Indwelling; Female; Hematologic Neoplasms; H | 2007 |
Prevention of deep-vein thrombosis after total knee replacement. Randomised comparison between a low-molecular-weight heparin (nadroparin) and mechanical prophylaxis with a foot-pump system.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Female; Humans; Mid | 1999 |
Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis.
Topics: Ambulatory Care; Anticoagulants; Female; Fibrinolytic Agents; Follow-Up Studies; Health Care Costs; | 1999 |
Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France.
Topics: Aged; Anticoagulants; Double-Blind Method; Female; Humans; Incidence; Injections, Subcutaneous; Lung | 2000 |
Use of low molecular weight heparin for prevention of deep vein thrombosis in total knee arthroplasty--a study of its efficacy in an Asian population.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee | 2000 |
[Rationalization of risk factors for venous thromboembolism in medical inpatients. A prospective study].
Topics: Adult; Aged; Anticoagulants; France; Heparin, Low-Molecular-Weight; Humans; Incidence; Inpatients; M | 2000 |
Efficacy and safety of weight-adapted nadroparin calcium vs. heparin sodium in prevention of clinically evident thromboembolic complications in 1,190 general surgical patients.
Topics: Anticoagulants; Digestive System Surgical Procedures; Female; Heparin; Humans; Male; Middle Aged; Na | 2000 |
[Thromboembolic prophylaxis after major abdominal surgery].
Topics: Abdomen; Bandages; Female; Fibrinolytic Agents; Hematoma; Humans; Injections, Subcutaneous; Male; Mi | 2001 |
Risk factors for recurrent events in subjects with superficial vein thrombosis in the randomized clinical trial SteFlux (Superficial Thromboembolism Fluxum).
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Heparin, Low-Molecular- | 2014 |
A randomized double-blind study of low-molecular-weight heparin (parnaparin) for superficial vein thrombosis: STEFLUX (Superficial ThromboEmbolism and Fluxum).
Topics: Aged; Analysis of Variance; Anticoagulants; Chi-Square Distribution; Dose-Response Relationship, Dru | 2012 |
Efficiency and safety evaluation of prophylaxes for venous thrombosis after gynecological surgery.
Topics: Anticoagulants; Arginine; Endometrial Neoplasms; Female; Gynecologic Surgical Procedures; Heparin, L | 2020 |
Randomized Trial of Deep Vein Thrombosis Chemoprophylaxis with Bemiparin and Enoxaparin in Patients with Moderate to High Thrombogenic Risk Undergoing Plastic and Reconstructive Surgery Procedures.
Topics: Adult; Anticoagulants; Chemoprevention; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; P | 2020 |
Comparison of Once-Daily Bemiparin with Twice-Daily Enoxaparin for Acute Deep Vein Thrombosis: A Multicenter, Open-Label, Randomized Controlled Trial.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Drug Administration Schedule; Drug Therapy, Combination; | 2018 |
Bemiparin for thromboprophylaxis after benign gynecologic surgery: a randomized clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Female; Gynecologic Surgical Procedures; | 2015 |
Low-molecular-weight heparin in the acute and long-term treatment of deep vein thrombosis.
Topics: Adult; Aged; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Molecular Weight; Phl | 2003 |
Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial.
Topics: Aged; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Fibrinolytic Agents; Hemoglobins; Hemorrh | 2003 |
[Can home prophylaxis for venous thromboembolism reduce mortality rates in patients with chronic obstructive pulmonary disease?].
Topics: Aged; Female; Heparin, Low-Molecular-Weight; Home Nursing; Humans; Male; Prospective Studies; Pulmon | 2006 |
Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study.
Topics: Aged; Anticoagulants; Female; Health Care Costs; Heparin, Low-Molecular-Weight; Humans; Male; Middle | 2006 |
A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Female | 2000 |
Biosimilar versus branded enoxaparin to prevent postoperative venous thromboembolism after surgery for digestive tract cancer: Randomized trial.
Topics: Anticoagulants; Biosimilar Pharmaceuticals; Enoxaparin; Gastrointestinal Neoplasms; Humans; Postoper | 2023 |
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
Topics: Aged; Antibodies, Monoclonal, Humanized; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Respo | 2020 |
Rivaroxaban or Enoxaparin in Nonmajor Orthopedic Surgery.
Topics: Administration, Oral; Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hemorrhage; Hu | 2020 |
Efficacy and safety of apixaban in patients with active malignancy and acute deep venous thrombosis.
Topics: Administration, Oral; Aged; Anticoagulants; Egypt; Enoxaparin; Factor Xa Inhibitors; Female; Hemorrh | 2021 |
Efficacy of Early Prophylaxis Against Catheter-Associated Thrombosis in Critically Ill Children: A Bayesian Phase 2b Randomized Clinical Trial.
Topics: Adolescent; Anticoagulants; Bayes Theorem; Catheterization, Central Venous; Central Venous Catheters | 2021 |
Age-Dependent Heterogeneity in the Efficacy of Prophylaxis With Enoxaparin Against Catheter-Associated Thrombosis in Critically Ill Children: A Post Hoc Analysis of a Bayesian Phase 2b Randomized Clinical Trial.
Topics: Anticoagulants; Catheterization, Central Venous; Child; Child, Preschool; Critical Illness; Enoxapar | 2021 |
Early vs. late enoxaparin for the prevention of venous thromboembolism in patients with ICH: A double blind placebo controlled multicenter study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Cerebral Hemorrhage; Disease Progression; Double-Blind Meth | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinic
Topics: Aged; Anticoagulants; COVID-19; Drug Administration Schedule; Enoxaparin; Extracorporeal Membrane Ox | 2021 |
Data Recorded in Real Life Support the Safety of Nattokinase in Patients with Vascular Diseases.
Topics: Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Humans; Male; | 2021 |
Competing risk analysis in a large cardiovascular clinical trial: An APEX substudy.
Topics: Aged; Anticoagulants; Benzamides; Delayed-Action Preparations; Double-Blind Method; Enoxaparin; Fact | 2017 |
N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy.
Topics: Acute Disease; Aged; Aged, 80 and over; Benzamides; Enoxaparin; Female; Heart Failure; Hospitalizati | 2017 |
Thrombus Burden of Deep Vein Thrombosis and Its Association with Thromboprophylaxis and D-Dimer Measurement: Insights from the APEX Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzamides; Enoxaparin; Factor Xa Inhibitors; Female; Fibri | 2017 |
Enoxaparin versus No Anticoagulation Prophylaxis after Total Knee Arthroplasty in Thai Patients: A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method; Enoxa | 2017 |
OBTAIN E: outcome benefits of tranexamic acid in hip arthroplasty with enoxaparin: a randomised double-blinded controlled trial.
Topics: Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Blood Loss, Surgical; Doubl | 2019 |
Asymptomatic Deep Vein Thrombosis is Associated with an Increased Risk of Death: Insights from the APEX Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Asymptomatic Diseases; Benzamides; Enoxaparin; Female; Huma | 2018 |
Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study.
Topics: Aged; Enoxaparin; Esophageal Neoplasms; Esophagectomy; Female; Hemorrhage; Heparin, Low-Molecular-We | 2019 |
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; | 2013 |
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; | 2013 |
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; | 2013 |
Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of acute symptomatic deep-vein thrombosis.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; | 2013 |
Safety and efficacy of early thromboembolism chemoprophylaxis after intracranial hemorrhage from traumatic brain injury.
Topics: Adult; Aged; Anticoagulants; Brain Injuries; Chemoprevention; Clinical Protocols; Cohort Studies; En | 2013 |
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Pulmonar | 2014 |
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Pulmonar | 2014 |
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Pulmonar | 2014 |
Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Aged; Morpholines; Pulmonar | 2014 |
Administration of enoxaparin 24 h after total knee arthroplasty: safer for bleeding and equally effective for deep venous thrombosis prevention.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Enoxaparin; Female; Hum | 2014 |
Thromboelastogram-guided enoxaparin dosing does not confer protection from deep venous thrombosis: a randomized controlled pilot trial.
Topics: Blood Coagulation; Dose-Response Relationship, Drug; Enoxaparin; Factor Xa; Female; Fibrinolytic Age | 2014 |
Randomised controlled trial for efficacy of unfractionated heparin (UFH) versus low molecular weight heparin (LMWH) in thrombo-prophylaxis.
Topics: Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Heparin; Humans; Intention to Treat | 2013 |
Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
Topics: Aged; Antithrombins; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor Xa Inhi | 2014 |
Factor XI antisense oligonucleotide for prevention of venous thrombosis.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Coagulation; Clinical Protocols; | 2015 |
Efficacy and safety of anticoagulation therapy with different doses of enoxaparin for portal vein thrombosis in cirrhotic patients with hepatitis B.
Topics: Adult; China; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Hemorrhage; Hep | 2015 |
Comparison of switch-therapy modalities (enoxaparin to rivaroxaban/dabigatran) and enoxaparin monotherapy after hip and knee replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2015 |
Home treatment of deep venous thrombosis in the era of new oral anticoagulants.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Humans; Ma | 2015 |
Adherence to Anticoagulant Therapy in Pediatric Patients Hospitalized With Pulmonary Embolism or Deep Vein Thrombosis: A Retrospective Cohort Study.
Topics: Adolescent; Anticoagulants; Child; Enoxaparin; Female; Hospitalization; Humans; Male; Medicaid; Medi | 2016 |
Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial.
Topics: Aged; Anticoagulants; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Factor Xa Inhibito | 2015 |
Anti-Factor Xa Activity of Prophylactic Enoxaparin Regimens in Critically Ill Patients.
Topics: Administration, Intravenous; Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dose-Respons | 2016 |
Comparison of rivaroxaban mono-therapy and standard-therapy adjusted by CYP2C9 and VKORC1 genotypes in symptomatic pulmonary embolism.
Topics: Administration, Oral; Anticoagulants; Cytochrome P-450 CYP2C9; Enoxaparin; Genotype; Humans; Pulmona | 2016 |
Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Postt | 2016 |
An analysis of deep vein thrombosis in burn patients (part II): A randomized and controlled study of thrombo-prophylaxis with low molecular weight heparin.
Topics: Adolescent; Adult; Body Surface Area; Burns; Disease Management; Enoxaparin; Epistaxis; Female; Fibr | 2016 |
Deep Venous Thrombosis Prophylaxis After Unicompartmental Knee Arthroplasty: A Prospective Study on the Safety of Aspirin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin | 2017 |
The safety and efficacy of full- versus reduced-dose betrixaban in the Acute Medically Ill VTE (Venous Thromboembolism) Prevention With Extended-Duration Betrixaban (APEX) trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzamides; Double-Blind Method; Enoxaparin; Factor Xa Inhi | 2017 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Double-B | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Double-Blind Method | 2008 |
Effect of the anticoagulant therapy in the incidence of post-thrombotic syndrome and recurrent thromboembolism: Comparative study of enoxaparin versus coumarin.
Topics: Anticoagulants; Coumarins; Enoxaparin; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Ag | 2008 |
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT).
Topics: Administration, Oral; Adult; Aged; Arthroplasty, Replacement, Knee; Canada; Dose-Response Relationsh | 2009 |
[Outpatient treatment of deep vein thrombosis with low-molecular-weight heparins. Experience from an open, prospective study in daily practice].
Topics: Adult; Aged; Ambulatory Care; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxap | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.
Topics: Administration, Oral; Aged; Analysis of Variance; Anticoagulants; Arthroplasty, Replacement, Knee; D | 2009 |
Low-molecular-weight heparin and unfractionated heparin in prophylaxis against deep vein thrombosis in critically ill patients undergoing major surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Drug Administration Schedule; Elec | 2010 |
A combinative effect of low-molecular-weight heparin and intermittent pneumatic compression device for thrombosis prevention during laparoscopic fundoplication.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Factors; Coagulants; Enoxaparin; Female; Fibrin | 2010 |
Long-term efficacy and safety of once-daily enoxaparin plus warfarin for the outpatient ambulatory treatment of lower-limb deep vein thrombosis in the TROMBOTEK trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; B | 2010 |
A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Kne | 2010 |
High doses of warfarin are more beneficial than its low doses in patients with deep vein thrombosis.
Topics: Anticoagulants; Double-Blind Method; Drug Therapy, Combination; Enoxaparin; Female; Humans; Male; Mi | 2011 |
Early postoperative bleeding in polytrauma patients treated with fondaparinux: literature review and institutional experience.
Topics: Acetabulum; Adult; Anticoagulants; Enoxaparin; Female; Fondaparinux; Fractures, Bone; Humans; Male; | 2011 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acenocoumarol; Acute Disease; Administration, Oral; Aged; Anticoagulants; Double-Blind Method; Enoxa | 2010 |
Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II*). A randomised, double-blind, non-inferiority trial.
Topics: Administration, Oral; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimida | 2011 |
Randomized controlled trial to investigate the impact of anticoagulation on the incidence of splenic or portal vein thrombosis after laparoscopic splenectomy.
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Incidence; Laparoscopy; Male; M | 2011 |
Rationale and design of STOP DVT study: rosuvastatin for the prevention of deep vein thrombosis in patients undergoing total knee replacement arthroplasty--a prospective randomized open-label controlled trial.
Topics: Arthroplasty, Replacement, Knee; Drug Therapy, Combination; Enoxaparin; Fluorobenzenes; Heparin, Low | 2011 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.
Topics: Adult; Anticoagulants; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspiri | 2012 |
[Prophylaxis of thromboembolic events in surgery. DVT prophylaxis: a comparison of out-patient and hospitalized patients].
Topics: Ambulatory Care; Comorbidity; Enoxaparin; Female; Fibrinolytic Agents; Germany; Hospitalization; Hum | 2013 |
[Prolongation of enoxaparin therapy to one month promotes recanalization of the occlusively thrombosed deep veins].
Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combin | 2011 |
[Enoxaparin for the prevention of post surgical pulmonary embolism].
Topics: Adult; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; Postoperative C | 2011 |
The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children.
Topics: Adolescent; Adult; Child; Child, Preschool; Enoxaparin; Female; Fibrinolytic Agents; Humans; Infant; | 2012 |
Comparison of antithrombotic and haemorrhagic effects of edoxaban, an oral direct factor Xa inhibitor, with warfarin and enoxaparin in rats.
Topics: Administration, Oral; Animals; Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents | 2012 |
Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
Topics: Anticoagulants; Clinical Trials as Topic; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; En | 2002 |
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip | 2003 |
A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Fondaparinux; Humans; Middle Aged; Orthopedic P | 2002 |
Randomized comparison of enoxaparin with unfractionated heparin for the prevention of venous thromboembolism in medical patients with heart failure or severe respiratory disease.
Topics: Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Heart Failure; Hemorrhage; H | 2003 |
Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
Topics: Aged; Analysis of Variance; Anticoagulants; Antithrombin III; Body Mass Index; Creatinine; Critical | 2003 |
Enoxaparin monotherapy without oral anticoagulation to treat acute symptomatic pulmonary embolism.
Topics: Acute Disease; Adult; Aged; Enoxaparin; Feasibility Studies; Female; Hemorrhage; Heparin; Humans; Le | 2003 |
A pilot randomized double-blind comparison of a low-molecular-weight heparin, a nonsteroidal anti-inflammatory agent, and placebo in the treatment of superficial vein thrombosis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Dose-Response Relationship, Drug; Double-Blind | 2003 |
Venous thromboembolism prophylaxis conversion in nonsurgical inpatients.
Topics: Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Hemorrhage; Heparin; Hospitalization; Humans; Ris | 2003 |
Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Chronic Disease; Dose-Response Relationship, Drug; Double-B | 2003 |
Comparison of dalteparin and enoxaparin for deep venous thrombosis prophylaxis in patients with spinal cord injury.
Topics: Adolescent; Adult; Aged; Dalteparin; Enoxaparin; Female; Fibrinolytic Agents; Health Status Indicato | 2003 |
Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Azetidines; Benzylamines | 2003 |
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2003 |
Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study.
Topics: Aged; Blood Coagulation Factors; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Human | 2004 |
Can low molecular weight heparin replace unfractionated heparin during peripheral arterial reconstruction? An open label prospective randomized controlled trial.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Logistic Models; Male; Peripheral Vascula | 2004 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial.
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
Superiority of fondaparinux over enoxaparin in preventing venous thromboembolism in major orthopedic surgery using different efficacy end points.
Topics: Adolescent; Double-Blind Method; Endpoint Determination; Enoxaparin; Fibrinolytic Agents; Fondaparin | 2004 |
Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Humans; | 2004 |
An open-label, comparative study of the efficacy and safety of once-daily dose of enoxaparin versus unfractionated heparin in the treatment of proximal lower limb deep-vein thrombosis.
Topics: Adult; Ambulatory Care; Anticoagulants; Brazil; Causality; Comorbidity; Enoxaparin; Female; Hemorrha | 2004 |
Economic evaluation of enoxaparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Aged; Cost-Benefit Analysis; Double-Blind Method; Drug Administration Schedule; Enoxa | 2004 |
Venous thromboembolism prophylaxis after head and spinal trauma: intermittent pneumatic compression devices versus low molecular weight heparin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Brain Concussion; Cerebral Hemorrhage, Traumatic; Cervic | 2004 |
Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin.
Topics: Adult; Cesarean Section; Enoxaparin; Female; Fibrinolytic Agents; Humans; Osteoporosis; Patient Sele | 2004 |
Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients.
Topics: Adult; Anticoagulants; Catheterization, Central Venous; Catheters, Indwelling; Chi-Square Distributi | 2005 |
Low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery.
Topics: Angiography; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort | 2005 |
Efficacy and safety of enoxaparin, a low molecular weight heparin in the prevention of deep vein thrombosis in Nigerian patients after orthopaedic surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation Tests; Enoxaparin; Factor Xa Inhib | 2004 |
Serum acute phase protein concentrations after hysterectomy with and without low-molecular-weight heparin thrombosis prophylaxis.
Topics: Acute-Phase Proteins; Biomarkers; C-Reactive Protein; Dose-Response Relationship, Drug; Drug Adminis | 2005 |
Once-daily enoxaparin in the outpatient setting versus unfractionated heparin in hospital for the treatment of symptomatic deep-vein thrombosis.
Topics: Adult; Aged; Ambulatory Care; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; Heparin; | 2005 |
Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin.
Topics: Anticoagulants; Cross Reactions; Double-Blind Method; Enoxaparin; Fondaparinux; Hip; Humans; Immunoe | 2005 |
BAY 59-7939: an oral, direct factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Antithrombin III; Arthroplasty | 2005 |
Rates of proximal deep vein thrombosis as assessed by compression ultrasonography in patients receiving prolonged thromboprophylaxis with low molecular weight heparin after major orthopedic surgery.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Hospitalization; Humans; In | 2005 |
Enoxaparin and heparin comparison of deep vein thrombosis prophylaxis in total hip replacement patients.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Female; Heparin; Humans; Injections, Sub | 2006 |
Evaluation of wound healing after total knee arthroplasty in a randomized prospective trial comparing fondaparinux with enoxaparin.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Follow-Up Studies; Fondap | 2006 |
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relati | 2006 |
Ambulatory therapy of patients with free-floating proximal deep vein thrombosis is safe.
Topics: Adult; Aged; Ambulatory Care; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Pulmona | 2005 |
Incidence of recurrent venous thromboembolism of patients after termination of treatment with ximelagatran.
Topics: Administration, Oral; Anticoagulants; Arteries; Azetidines; Benzylamines; Drug Therapy, Combination; | 2006 |
Prophylaxis against deep-vein thrombosis following trauma: a prospective, randomized comparison of mechanical and pharmacologic prophylaxis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Humans; Middle Aged | 2006 |
Deep vein thrombosis prevention in joint arthroplasties: continuous enhanced circulation therapy vs low molecular weight heparin.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Female; | 2006 |
Prophylaxis of DVT with enoxaparin in patients undergoing total knee replacement.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Humans; Male; Midd | 2006 |
Extended-duration thromboprophylaxis in acutely ill medical patients with recent reduced mobility: methodology for the EXCLAIM study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Humans; Mal | 2006 |
VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anesthesia, Spinal; Arthroplasty, Replacement, Knee; Aspirin; Combin | 2006 |
[Low molecular-weight heparin (clexane) in the prevention of thrombotic events in patients with malignancies].
Topics: Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Neoplasms; Postoperative Care; Postoperative Comp | 2006 |
Monotherapy with enoxaparin for the prevention of recurrent venous thromboembolism.
Topics: Acenocoumarol; Aged; Aged, 80 and over; Enoxaparin; Female; Hemorrhage; Humans; In Vitro Techniques; | 2007 |
Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Fondaparinux; Hemorrhage; Heparin; Humans; Male; Mi | 2007 |
Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study.
Topics: Anticoagulants; Enoxaparin; Hip Prosthesis; Humans; Knee Prosthesis; Morpholines; Orthopedic Procedu | 2007 |
The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL Study): an open-label randomised comparison.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; Ischemic Attack, Tr | 2007 |
A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antithrombin III; Arthroplasty, Replacement, H | 2007 |
Bridging therapy in patients on long-term oral anticoagulants who require surgery: the Prospective Peri-operative Enoxaparin Cohort Trial (PROSPECT).
Topics: Administration, Oral; Aged; Ambulatory Care; Anticoagulants; Atrial Fibrillation; Blood Loss, Surgic | 2007 |
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial.
Topics: Acute Coronary Syndrome; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Benzimidazoles; Clin | 2007 |
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Double-Blind Metho | 2007 |
SR123781A: a new once-daily synthetic oligosaccharide anticoagulant for thromboprophylaxis after total hip replacement surgery: the DRIVE (Dose Ranging Study in Elective Total Hip Replacement Surgery) study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Response Relati | 2008 |
Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Gestational Age; Humans; Metabolic Clearance Rate; Postpa | 2008 |
How "gold" is the standard? Interobservers' variation on venograms.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Bandages; Enoxaparin; Female; Humans; Incidenc | 1998 |
Prevention of deep vein thrombosis in knee arthroplasty. Preliminary results from a randomized controlled study of low molecular weight heparin vs foot pump compression.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Bandages; Enoxaparin; Female; Humans; Intraop | 1998 |
Comparison of two low-molecular-weight heparins for the prevention of postoperative venous thromboembolism after elective hip surgery. Reviparin Study Group.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor | 1998 |
Out-patient treatment of acute deep vein thrombosis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Drug Adm | 1998 |
Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Factor Xa Inhibitor | 1999 |
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 1999 |
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 1999 |
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 1999 |
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 1999 |
Local versus central assessment of venographies in a multicenter trial on the prevention of deep vein thrombosis in neurosurgery.
Topics: Anticoagulants; Double-Blind Method; Enoxaparin; Humans; Neurosurgical Procedures; Observer Variatio | 1999 |
Study documents cost reduction with outpatient enoxaparin therapy.
Topics: Anticoagulants; Cost Savings; Enoxaparin; Health Care Costs; Humans; Outpatients; Quality of Life; V | 1999 |
[The prevention of postoperative deep venous thrombosis in orthopedic surgery].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Ortho | 1999 |
Pre-operative plasma levels of soluble fibrin polymers correlate with the development of deep vein thrombosis after elective neurosurgery.
Topics: Adult; Aged; Biomarkers; Brain Neoplasms; Elective Surgical Procedures; Enoxaparin; Female; Fibrin; | 1999 |
Intraoperative heparin in addition to postoperative low-molecular-weight heparin for thromboprophylaxis in total knee replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Heparin; Humans; Intraoperative Care; P | 2000 |
Comparative effectiveness of low-molecular-weight heparins after therapeutic interchange.
Topics: Aged; Anticoagulants; Dalteparin; Economics, Pharmaceutical; Enoxaparin; Female; Formularies as Topi | 2000 |
An equivalence study of two low-molecular-weight heparins in the prevention and treatment of deep-vein thrombosis after total hip replacement.
Topics: Adult; Aged; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Hemorrhage; Heparin, L | 2000 |
Cost for inpatient care of venous thrombosis: a trial of enoxaparin vs standard heparin.
Topics: Enoxaparin; Female; Fibrinolytic Agents; Health Care Costs; Heparin; Hospitalization; Humans; Male; | 2000 |
Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Administ | 2001 |
Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery.
Topics: Anticoagulants; Arthroplasty; Biomarkers; Blood Coagulation Tests; Colectomy; Double-Blind Method; E | 2001 |
Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial.
Topics: Aged; Anticoagulants; Critical Illness; Enoxaparin; Female; Humans; Male; Multicenter Studies as Top | 2000 |
Subcutaneous heparin versus low-molecular-weight heparin as thromboprophylaxis in patients undergoing colorectal surgery: results of the canadian colorectal DVT prophylaxis trial: a randomized, double-blind trial.
Topics: Anticoagulants; Blood Loss, Surgical; Canada; Colectomy; Double-Blind Method; Enoxaparin; Female; He | 2001 |
A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Dose-Res | 2001 |
Cost-effectiveness of prolonged out-of-hospital prophylaxis with low-molecular-weight heparin following total hip replacement.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Cost-Benefit Analysis; Drug Costs; Enoxaparin; Home | 2000 |
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. Enoxaparin Clinical Trial Group.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Dou | 2001 |
The home treatment of deep vein thrombosis with low molecular weight heparin, forced mobilisation and compression.
Topics: Anticoagulants; Bandages; Enoxaparin; Heparin, Low-Molecular-Weight; Home Nursing; Humans; Length of | 2000 |
Is once- or twice-a-day enoxaparin as effective as unfractionated heparin for the treatment of venous thromboembolism (VTE)?
Topics: Anticoagulants; Enoxaparin; Female; Guidelines as Topic; Humans; Male; Middle Aged; Reproducibility | 2001 |
Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Female; | 2001 |
Comparison of enoxaparin and standard heparin in gynaecologic oncologic surgery: a randomised prospective double-blind clinical study.
Topics: Adult; Aged; Anticoagulants; Aorta; Blood Loss, Surgical; Double-Blind Method; Drug Administration S | 2001 |
[The role of heparin in prevention of deep veins thrombosis and pulmonary artery thromboembolism in therapeutic regime patients].
Topics: Aged; Anticoagulants; Enoxaparin; Female; Heparin; Humans; Male; Pulmonary Artery; Severity of Illne | 2001 |
Low molecular weight heparin prevents activation of coagulation in a hypobaric environment.
Topics: Adult; Air Pressure; Aircraft; Anticoagulants; Antithrombin III; Blood Coagulation; Enoxaparin; Hepa | 2001 |
Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Azetidines; Benz | 2001 |
Diagnosis of pulmonary embolism in patients with proximal deep vein thrombosis: specificity of symptoms and perfusion defects at baseline and during anticoagulant therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiography; Anticoagulants; Enoxaparin; Hepar | 2001 |
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Topics: Aged; Double-Blind Method; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Hip Fr | 2001 |
Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
Topics: Aged; Double-Blind Method; Drug Administration Schedule; Elective Surgical Procedures; Enoxaparin; F | 2001 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin | 2002 |
Low molecular weight heparin for prevention of thromboembolic complications in cardioversion--rationale and design of the ACE study (Anticoagulation in Cardioversion using Enoxaparin).
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Atrial Fibrillation; Dose-Response Relationship, | 2002 |
A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Female; Foot; Gravity Suits; Huma | 2002 |
Postoperative fondaparinux versus preoperative enoxaparin for prevention of venous thromboembolism in elective hip-replacement surgery: a randomised double-blind comparison.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Fem | 2002 |
Postoperative fondaparinux versus postoperative enoxaparin for prevention of venous thromboembolism after elective hip-replacement surgery: a randomised double-blind trial.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Double-Blind Method; Enoxaparin; Fem | 2002 |
Enoxaparin vs heparin for prevention of deep-vein thrombosis in acute ischaemic stroke: a randomized, double-blind study.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Anticoagulants; Asp | 2002 |
Incidence and clinical relevance of heparin-induced antibodies in patients with deep vein thrombosis treated with unfractionated or low-molecular-weight heparin.
Topics: Anticoagulants; Autoantibodies; Drug Administration Schedule; Female; Heparin; Heparin, Low-Molecula | 2002 |
Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization.
Topics: Achilles Tendon; Adult; Anticoagulants; Braces; Casts, Surgical; Double-Blind Method; Female; Fractu | 2002 |
Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization.
Topics: Achilles Tendon; Adult; Anticoagulants; Braces; Casts, Surgical; Double-Blind Method; Female; Fractu | 2002 |
Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization.
Topics: Achilles Tendon; Adult; Anticoagulants; Braces; Casts, Surgical; Double-Blind Method; Female; Fractu | 2002 |
Use of the low-molecular-weight heparin reviparin to prevent deep-vein thrombosis after leg injury requiring immobilization.
Topics: Achilles Tendon; Adult; Anticoagulants; Braces; Casts, Surgical; Double-Blind Method; Female; Fractu | 2002 |
Dose-finding and pharmacokinetic profiles of prophylactic doses of a low molecular weight heparin (reviparin-sodium) in pediatric patients.
Topics: Adolescent; Catheterization, Central Venous; Child; Child, Preschool; Dose-Response Relationship, Dr | 2003 |
An open-label randomized controlled trial of low molecular weight heparin compared to heparin and coumadin for the treatment of venous thromboembolic events in children: the REVIVE trial.
Topics: Administration, Oral; Adolescent; Child; Child, Preschool; Drug Therapy, Combination; Heparin; Hepar | 2003 |
An open-label randomized controlled trial of low molecular weight heparin for the prevention of central venous line-related thrombotic complications in children: the PROTEKT trial.
Topics: Adolescent; Catheterization, Central Venous; Child; Child, Preschool; Female; Heparin, Low-Molecular | 2003 |
Investigations of the immunoglobulin subtype transformation of anti-heparin-platelet factor 4 antibodies during treatment with a low-molecular-weight heparin (clivarin) in orthopedic patients.
Topics: Adolescent; Antibodies, Anti-Idiotypic; Antibody Specificity; Enzyme-Linked Immunosorbent Assay; Fib | 2003 |
Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis.
Topics: Acute Disease; Anticoagulants; Biomarkers; Blood Coagulation Factors; Heparin; Heparin, Low-Molecula | 2002 |
Treatment of deep vein thrombosis in patients with pulmonary embolism: subgroup analysis on the efficacy and safety of certoparin vs. unfractionated heparin.
Topics: Aged; Anticoagulants; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Injections, Intravenou | 2014 |
An open-label comparison of the efficacy and safety of certoparin versus unfractionated heparin for the prevention of thromboembolic complications in acutely ill medical patients: CERTAIN.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Female; Follow-Up Studies; Hemorrhage; Hepar | 2010 |
Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study.
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Chemoprevention; Female; Hemorrhage; Heparin; | 2011 |
Heparin based prophylaxis to prevent venous thromboembolic events and death in patients with cancer - a subgroup analysis of CERTIFY.
Topics: Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Female; Hemorrhage; Heparin; Heparin, | 2011 |
Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.
Topics: Aged; Body Weight; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin; Heparin, Low-Molec | 2003 |
Comparison of six-month outcome of patients initially treated for acute deep vein thrombosis with a low molecular weight heparin Certoparin at a fixed, body-weight-independent dosage or unfractionated heparin.
Topics: Anticoagulants; Body Weight; Drug Administration Schedule; Female; Hemorrhage; Heparin; Heparin, Low | 2003 |
Reduction of venous thromboembolism following prolonged prophylaxis with the low molecular weight heparin Certoparin after endoprothetic joint replacement or osteosynthesis of the lower limb in elderly patients.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement; Biomarkers; Blood Coagulation; Female; Fracture | 2003 |
Antifactor Xa activity in critically ill patients receiving antithrombotic prophylaxis with standard dosages of certoparin: a prospective, clinical study.
Topics: Aged; Anticoagulants; Dose-Response Relationship, Drug; Epidemiologic Methods; Factor Xa; Female; Fi | 2005 |
Prophylaxis of thrombotic and embolic events in acute ischemic stroke with the low-molecular-weight heparin certoparin: results of the PROTECT Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Heparin; Heparin, Low-Molecular-Wei | 2006 |
Fixed-dose, body weight-independent subcutaneous LMW heparin versus adjusted dose unfractionated intravenous heparin in the initial treatment of proximal venous thrombosis. EASTERN Investigators.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Body Weight; Cohort Studies; Female; Hemorrhage; Heparin | 2000 |
Reduction in thrombus extension and clinical end points in patients after initial treatment for deep vein thrombosis with the fixed-dose body weight-independent low molecular weight heparin certoparin.
Topics: Aged; Dose-Response Relationship, Drug; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; M | 2001 |
Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer.
Topics: Administration, Oral; Aged; Anticoagulants; Dalteparin; Female; Hemorrhage; Humans; Incidence; Injec | 2020 |
Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Factor Xa Inhibito | 2019 |
Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Topics: Aged; Blood Coagulation; Dalteparin; Drug Administration Schedule; Factor Xa Inhibitors; Female; Hem | 2019 |
Time course and the recanalization rate of superficial vein thrombosis treated with low-molecular-weight heparin.
Topics: Aged; Anticoagulants; Dalteparin; Double-Blind Method; Female; Humans; Lower Extremity; Male; Middle | 2015 |
Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
Topics: Adult; Anticoagulants; Dalteparin; Double-Blind Method; Factor Xa Inhibitors; Hemorrhage; Humans; Ne | 2015 |
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dalteparin; Female; Humans; Male; Middle | 2008 |
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dalteparin; Female; Humans; Male; Middle | 2008 |
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dalteparin; Female; Humans; Male; Middle | 2008 |
Prophylaxis against deep vein thrombosis in critically ill patients with severe renal insufficiency with the low-molecular-weight heparin dalteparin: an assessment of safety and pharmacodynamics: the DIRECT study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Critical Illness; Dalteparin; Female; Humans; Male; Middle | 2008 |
Prophylaxis of deep-vein thrombosis in fractures below the knee: a prospective randomised controlled trial.
Topics: Adult; Aged; Ankle Injuries; Anticoagulants; Dalteparin; Double-Blind Method; Female; Fractures, Bon | 2009 |
Coagulation effects of low molecular weight heparin compared with heparin in dogs considered to be at risk for clinically significant venous thrombosis.
Topics: Animals; Anticoagulants; Dalteparin; Dog Diseases; Dogs; Risk Factors; Venous Thrombosis | 2009 |
Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Topics: Administration, Oral; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Canada; Dalteparin; Doub | 2010 |
PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Brain Neoplasms; Dalteparin; Factor Xa; Female; Glio | 2010 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Dalteparin versus unfractionated heparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Hemorrhage; Heparin; Humans; Incidence; Inject | 2011 |
Abdominal contouring procedures increase activity of the coagulation cascade.
Topics: Abdominoplasty; Adult; Anticoagulants; Biomarkers; Dalteparin; Humans; Intermittent Pneumatic Compre | 2012 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Dalteparin; Drug Therapy, Combination; Female; | 2003 |
Sustained prothrombotic profile after hip replacement surgery: the influence of prolonged prophylaxis with dalteparin.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Blood Coagulation Factors; Dalteparin; Female; | 2003 |
A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Aze | 2003 |
Deep venous thrombosis: a new task for primary health care. A randomised economic study of outpatient and inpatient treatment.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Direct Servic | 2004 |
Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
Topics: Aged; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Dalteparin; Double-Blind Metho | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Death, Sudden; Double-Bli | 2004 |
A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation.
Topics: Abortion, Spontaneous; Adult; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Female; | 2004 |
A randomized trial comparing 2 low-molecular-weight heparins for the outpatient treatment of deep vein thrombosis and pulmonary embolism.
Topics: Acute Disease; Adult; Aged; Ambulatory Care; Dalteparin; Female; Fibrinolytic Agents; Follow-Up Stud | 2005 |
Dalteparin thromboprophylaxis for critically ill medical-surgical patients with renal insufficiency.
Topics: Anticoagulants; Creatinine; Dalteparin; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intensive | 2005 |
Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study.
Topics: Aged; Aged, 80 and over; Cohort Studies; Dalteparin; Female; Hemorrhage; Heparin, Low-Molecular-Weig | 2006 |
Prolonged thromboprophylaxis with dalteparin after surgical treatment of achilles tendon rupture: a randomized, placebo-controlled study.
Topics: Achilles Tendon; Adolescent; Adult; Aged; Ankle Injuries; Anticoagulants; Dalteparin; Double-Blind M | 2007 |
Thromboprophylaxis with dalteparin in medical patients: which patients benefit?
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Double-Blind Method; Fema | 2007 |
The rheological changes after cesarean section: The influence of low molecular weight or unfractionated heparin on the rheological properties of blood.
Topics: Adult; Biomarkers; Blood Coagulation; Blood Viscosity; Cesarean Section; Dalteparin; Female; Hemorhe | 2007 |
Prolonged thromboprophylaxis with Dalteparin during immobilization after ankle fracture surgery: a randomized placebo-controlled, double-blind study.
Topics: Adolescent; Adult; Aged; Ankle Injuries; Anticoagulants; Casts, Surgical; Dalteparin; Double-Blind M | 2007 |
Hepatocyte growth factor in serum after injection of unfractionated and low molecular weight heparin in healthy individuals.
Topics: Adolescent; Adult; Anticoagulants; Dalteparin; Dose-Response Relationship, Drug; Enzyme-Linked Immun | 1999 |
Outpatient treatment of pulmonary embolism with dalteparin.
Topics: Adult; Aged; Ambulatory Care; Anticoagulants; Cohort Studies; Dalteparin; Disease-Free Survival; Fib | 2000 |
Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: a double-blind, randomized comparison. The North American Fragmin Trial Investigators.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Double-Blind Method; Humans; Injections, | 2000 |
Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. North American Fragmin Trial Investigators.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Canada; Dalteparin; Double-Blind Method; Humans; Inc | 2000 |
Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: A phase II evaluation. The Rembrandt Investigators.
Topics: Adult; Aged; Anticoagulants; Antithrombin III; Cohort Studies; Dalteparin; Dose-Response Relationshi | 2000 |
New insights into extended prophylaxis after orthopaedic surgery - the North American Fragmin Trial experience.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Cost-Benefit Analysis; Dalteparin; Decision Making; | 2000 |
The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation.
Topics: Adult; Anticoagulants; Case-Control Studies; Dalteparin; Factor V; Female; Hemostasis; Hemostatics; | 2001 |
[Low molecular weight heparin versus unfractionated heparin in the treatment of deep vein thrombosis].
Topics: Anticoagulants; Dalteparin; Female; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Middle Age | 2001 |
Increased thromboxane production in women with a history of venous thromboembolic event: effect of heparins.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Analysis of Variance; Anticoagulants; Body Mass Index; Case-Con | 2001 |
Pneumatic compression versus low molecular weight heparin in gynecologic oncology surgery: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Bandages; Dalteparin; Female; Genital Neoplasms, Fem | 2001 |
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in
Topics: Administration, Oral; Adolescent; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement | 2002 |
Markers of hemostatic system activation during treatment of deep vein thrombosis with subcutaneous unfractionated or low-molecular weight heparin.
Topics: Adult; Aged; Anticoagulants; Dalteparin; Female; Fibrin Fibrinogen Degradation Products; Hemostasis; | 2002 |
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthropl | 2002 |
Effect of long-term LMWH on post-thrombotic syndrome in patients with iliac/noniliac venous thrombosis: a subanalysis from the home-LITE study.
Topics: Cohort Studies; Drug Administration Schedule; Female; Fibrinolytic Agents; Heparin, Low-Molecular-We | 2013 |
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
Topics: Aged; Anticoagulants; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; International Norma | 2015 |
Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity.
Topics: Anticoagulants; Female; Health Care Costs; Heparin; Heparin, Low-Molecular-Weight; Humans; Male; Mid | 2008 |
A randomised open-label trial comparing long-term sub-cutaneous low-molecular-weight heparin compared with oral-anticoagulant therapy in the treatment of deep venous thrombosis.
Topics: Acenocoumarol; Administration, Oral; Age Factors; Anticoagulants; Female; Fibrin Fibrinogen Degradat | 2009 |
Home therapy of venous thrombosis with long-term LMWH versus usual care: patient satisfaction and post-thrombotic syndrome.
Topics: Administration, Oral; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Home Care Services | 2009 |
Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS).
Topics: Aged; Aged, 80 and over; Anticoagulants; Drug Administration Schedule; Female; Heparin; Heparin, Low | 2011 |
[Effect of tinzaparin on survival in non-small-cell lung cancer after surgery. TILT: tinzaparin in lung tumours].
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Protocols; Combined Modality Therapy; Follow-Up Studies; He | 2011 |
Safety profile of tinzaparin administered once daily at a standard curative dose in two hundred very elderly patients.
Topics: Age Factors; Aged; Aged, 80 and over; Antithrombin III; Atrial Fibrillation; Body Weight; Creatine; | 2002 |
Tinzaparin sodium for thrombosis treatment and prevention during pregnancy.
Topics: Female; Fibrinolytic Agents; Gestational Age; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Preg | 2004 |
Laboratory analysis of blood samples from patients treated with tinzaparin.
Topics: Biomarkers; Drug Administration Schedule; Drug Monitoring; Factor Xa Inhibitors; Heparin; Heparin, L | 2004 |
Long-term treatment of deep venous thrombosis with a low molecular weight heparin (tinzaparin): a prospective randomized trial.
Topics: Acenocoumarol; Administration, Oral; Adult; Aged; Aged, 80 and over; Drug Therapy, Combination; Fema | 2005 |
Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.
Topics: Adult; Aged; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Male; Middle Aged; | 2006 |
Self-managed long-term low-molecular-weight heparin therapy: the balance of benefits and harms.
Topics: Anticoagulants; Cause of Death; Female; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weig | 2007 |
Spontaneous recanalization in deep venous thrombosis: a prospective duplex ultrasound study.
Topics: Adult; Aged; Anticoagulants; Female; Fibrinolysis; Fibrinolytic Agents; Follow-Up Studies; Heparin, | 2007 |
Safety of deep venous thrombosis prophylaxis with low-molecular-weight heparin in brain surgery. Prospective study on 746 patients.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; F | 2008 |
Dose relation in the prevention of proximal vein thrombosis with a low molecular weight heparin (tinzaparin) in elective hip arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Blood Transfusion; Double-Blind Meth | 2000 |
Tinzaparin in acute ischaemic stroke (TAIST): a randomised aspirin-controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Fib | 2001 |
Population pharmacodynamics in patients receiving tinzaparin for the prevention and treatment of deep vein thrombosis.
Topics: Adult; Aged; Double-Blind Method; Female; Fibrinolytic Agents; Half-Life; Heparin, Low-Molecular-Wei | 2001 |
Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Casts, Surgical; Female; Fibrinolytic Agents; Heparin, L | 2002 |
Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Casts, Surgical; Female; Fibrinolytic Agents; Heparin, L | 2002 |
Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Casts, Surgical; Female; Fibrinolytic Agents; Heparin, L | 2002 |
Low molecular weight heparin (Innohep) as thromboprophylaxis in outpatients with a plaster cast: a venografic controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Casts, Surgical; Female; Fibrinolytic Agents; Heparin, L | 2002 |
Abbreviated hospitalization for deep venous thrombosis with the use of ardeparin.
Topics: Anticoagulants; Confidence Intervals; Drug Approval; Female; Follow-Up Studies; Hemorrhage; Heparin; | 1998 |
Ardeparin sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Ambulatory Care; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cause | 2000 |
575 other studies available for dalteparin and Deep Vein Thrombosis
| Article | Year |
|---|---|
Nadroparin Plus Compression Stockings versus Nadroparin Alone for Prevention of Venous Thromboembolism in Cerebellopontine Angle Tumour Excisions: A Cohort Study.
Topics: Adult; Aged; Anticoagulants; Body Mass Index; Cerebellar Neoplasms; Cerebellopontine Angle; Female; | 2020 |
Major bleeding risks of different low-molecular-weight heparin agents: a cohort study in 12 934 patients treated for acute venous thrombosis.
Topics: Acute Disease; Adult; Aged; Anticoagulants; Cohort Studies; Drug Administration Schedule; Female; He | 2017 |
Rivaroxaban versus nadroparin for preventing deep venous thrombosis after total hip arthroplasty following femoral neck fractures: A retrospective comparative study.
Topics: Aged; Arthroplasty, Replacement, Hip; Blood Coagulation; Demography; Female; Femoral Neck Fractures; | 2018 |
Fatal intrahepatic hemorrhage after nadroparin use for total hip arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Autopsy; Cause of Death; Chemical and Drug Ind | 2014 |
[Thrombosis of the subclavian vein after conservative treatment of a clavicular fracture: A rare complication].
Topics: Adolescent; Bandages; Clavicle; Conservative Treatment; Fibrinolytic Agents; Fractures, Bone; Humans | 2016 |
Differences in the safety profiles of two low-molecular-weight heparins.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Nadroparin; Orthopedic | 2008 |
Bleeding complications after systematic switch of routine thromboprophylaxis for major orthopaedic surgery.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Hemorrhage; Humans; Middle Aged; Nadropari | 2008 |
Rare cause of abdominal swelling and edema: iliac vein thrombosis.
Topics: Abdomen; Adult; Anticoagulants; Edema; Female; Humans; Iliac Vein; Magnetic Resonance Imaging; Nadro | 2009 |
Varicella-associated purpura fulminans and multiple deep vein thromboses: a case report.
Topics: Anticoagulants; Blood Coagulation Tests; Blood Component Transfusion; Chickenpox; Child; Glucocortic | 2009 |
[Outcomes of prolonged anticoagulant prevention of thrombosis of deep veins of the crus in closed comminuted fractures of tibial bones].
Topics: Anticoagulants; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Fractures, Closed; Frac | 2009 |
[Sequence of venous blood flow alterations in patients after recently endured acute thrombosis of lower-limb deep veins based on the findings of ultrasonographic duplex scanning].
Topics: Acute Disease; Adult; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Follow-Up Studies; Humans; Le | 2009 |
Delayed hypersensitivity to heparin in a patient with cancer: fondaparinux may be safe but needs to be tested.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Anticoagulants; Breast Neoplasms; Drug | 2010 |
Thrombotic complications without evidence of hemolysis in paroxysmal nocturnal hemoglobinuria: Is eculizumab indicated?
Topics: Adult; Anemia, Aplastic; Anticoagulants; Brain Ischemia; Cerebral Hemorrhage; Fatal Outcome; Hemoglo | 2012 |
Peroneal nerve palsy due to thrombosis of a crural vein in a healthy young woman.
Topics: Action Potentials; Female; Fibrinolytic Agents; Humans; Lower Extremity; Magnetic Resonance Imaging; | 2013 |
Low agreement for assessing the risk of postoperative deep venous thrombosis when deciding prophylaxis strategies: a study using clinical vignettes.
Topics: Adult; Aged; Aged, 80 and over; Argentina; Bandages; Decision Making; Early Ambulation; Female; Hepa | 2002 |
[Short-term and long-term evolution of deep vein thrombosis treated by a health care unit].
Topics: Aged; Ambulatory Care; Anticoagulants; Female; Heparin, Low-Molecular-Weight; Humans; Male; Middle A | 2002 |
Heparin-induced thrombocytopenia with pulmonary embolism and disseminated intravascular coagulation associated with low-molecular-weight heparin.
Topics: Arthroplasty, Replacement, Hip; Disseminated Intravascular Coagulation; Female; Humans; Immunoglobul | 2003 |
[Cerebral sinus thrombosis and ulcerative colitis: two cases].
Topics: Adult; Anticoagulants; Cerebrovascular Disorders; Colitis, Ulcerative; Female; Humans; Magnetic Reso | 2003 |
Low molecular weight heparin (nadroparine) versus oral anticoagulant (acenocoumarol) in the long-term treatment of deep venous thrombosis: comparison of efficacy, safety and hospitalisation period in 105 patients.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Female; Humans; Injections, Intravenous; Length | 2003 |
Postoperative nadroparin administration for prophylaxis of thromboembolic events is not associated with an increased risk of hemorrhage after spinal surgery.
Topics: Adult; Aged; Anticoagulants; Bandages; Cohort Studies; Female; Hematoma; Hemorrhage; Humans; Laminec | 2004 |
[Conus medullaris and cauda equina infarct in the course of thrombosis of deep veins of lower extremities].
Topics: Diabetes Mellitus, Type 2; Fibrinolytic Agents; Humans; Ischemia; Male; Middle Aged; Nadroparin; Pol | 2004 |
Antithrombotic potential of new direct thrombin inhibitors built on the azaphenylalanine scaffold in two rat venous thrombosis models.
Topics: Administration, Oral; Animals; Anticoagulants; Arginine; Blood Coagulation Tests; Disease Models, An | 2005 |
Evaluation of two experimental venous thrombosis models in the rat.
Topics: Animals; Blood Coagulation Tests; Chlorides; Disease Models, Animal; Female; Ferric Compounds; Hemos | 2005 |
Iatrogenic calcinosis cutis following nadroparin injection.
Topics: Aged; Aged, 80 and over; Anticoagulants; Calcinosis; Humans; Iatrogenic Disease; Injections, Subcuta | 2005 |
Total knee replacement: prevention of deep-vein thrombosis using pharmacological (low-molecular-weight heparin) and mechanical (intermittent foot sole pump system) combined prophylaxis. Preliminary results.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Combined Modality Therapy; Echocardiography, | 2006 |
Enoxaparin vs. nadroparin for venous thromboembolism prevention: too close to tell?
Topics: Anticoagulants; Clinical Trials as Topic; Data Interpretation, Statistical; Enoxaparin; Fibrinolytic | 2006 |
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation Tests; Disease Models, Animal; Dose | 2007 |
[Determination of factor Xa inhibition doses of low-molecular heparin, nadroparin and reviparin in urological patients].
Topics: Anticoagulants; Body Mass Index; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; Humans; Nadrop | 2007 |
[Deep venous thrombosis in an amputation stump].
Topics: Acenocoumarol; Adult; Amputation Stumps; Amputation, Surgical; Anticoagulants; Humans; Male; Nadropa | 2007 |
[Risk patients in dentistry].
Topics: Acenocoumarol; Adult; Anti-Bacterial Agents; Anticoagulants; Blood Coagulation Disorders; Blood Loss | 1999 |
Comparative study on the in vitro and in vivo activities of heparinoids derivative investigated on the animal model.
Topics: Animals; Blood Coagulation Factors; Disease Models, Animal; Fibrinolytic Agents; Heparin; Heparinoid | 1999 |
Dose-adjusted thrombosis prophylaxis in trauma surgery according to levels of D-Dimer.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Antithrombin III; Biomarkers; Female; Fibri | 2000 |
Thrombosis of lienal vein and acute consumptive coagulopathy following warfarin administration in a patient with severe protein C deficiency.
Topics: Acute Disease; Anticoagulants; Child; Disseminated Intravascular Coagulation; Humans; Male; Nadropar | 2000 |
[State of the art: low-molecular-weight heparin and beyond].
Topics: Anticoagulants; Biological Availability; Blood Coagulation Factors; Clinical Trials as Topic; Fibrin | 2000 |
Home treatment of deep venous thrombosis with low molecular weight heparin: Long-term incidence of recurrent venous thromboembolism.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Cohort Studies; Disease-Free Survival; Female; Foll | 2001 |
Nadroparin-induced Calcinosis cutis in renal transplant recipients.
Topics: Adult; Biopsy; Calcinosis; Calcium; Female; Humans; Kidney Failure, Chronic; Kidney Transplantation; | 2001 |
Secondary prophylaxis with low molecular weight heparin: the dose?
Topics: Acenocoumarol; Anticoagulants; Dose-Response Relationship, Drug; Drug Costs; Enoxaparin; Heparin; He | 2001 |
Eligibility for home treatment of deep vein thrombosis: a prospective study in 202 consecutive patients.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Bandages; Combined Modality Therapy | 2001 |
Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of low molecular weight heparin. Gynecological ward retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Electrocardiography; Female; Gynecologic Surgical Procedures; Hepari | 2002 |
Deep venous thrombosis after laparoscopic cholecystectomy and prevention with nadroparin.
Topics: Cholecystectomy, Laparoscopic; Female; Fibrinolytic Agents; Humans; Incidence; Male; Middle Aged; Na | 2002 |
Prophylaxis of venous thromboembolism in minor orthopedic surgery with parnaparin.
Topics: Adult; Anticoagulants; Arthroscopy; Female; Heparin, Low-Molecular-Weight; Humans; Knee Joint; Male; | 2007 |
Optimal dosing of bemiparin for deep vein thrombosis treatment in children: a retrospective study.
Topics: Child; Heparin, Low-Molecular-Weight; Humans; Retrospective Studies; Venous Thrombosis | 2021 |
Bemiparin vs enoxaparin in the prevention of thrombosis in microvascular head and neck reconstruction.
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Postoperative Complications; Post | 2022 |
Cerebral venous thrombosis associated with seat belt syndrome.
Topics: Accidents, Traffic; Child; Diagnosis, Differential; Heparin, Low-Molecular-Weight; Humans; Intracran | 2009 |
[Assessment of venous thromboembolism risk in hospitalized medical patients. Concordance between PRETEMED guide and the recommendations of the viii conference of the American College of Chest Physicians].
Topics: Adult; Aged; Aged, 80 and over; Cross-Sectional Studies; Decision Support Techniques; Enoxaparin; Fe | 2012 |
Cost effectiveness of bemiparin sodium versus unfractionated heparin and oral anticoagulants in the acute and long-term treatment of deep vein thrombosis.
Topics: Administration, Oral; Anticoagulants; Cost-Benefit Analysis; Decision Trees; Economics, Pharmaceutic | 2006 |
A prospective observational study on the effectiveness and safety of bemiparin, first dose administered 6 h after knee or hip replacement surgery.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Administ | 2007 |
Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Drug A | 2007 |
Survival curve and factors related to drainage during the first 24 h after total knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Volume; Drainage; Enoxaparin; Female; H | 2008 |
Outcomes of Catheter-Related Arterial and Venous Thrombosis After Enoxaparin Therapy in Neonates and Infants With Congenital Heart Disease.
Topics: Anticoagulants; Catheters; Child; Enoxaparin; Heart Defects, Congenital; Humans; Infant; Infant, New | 2021 |
Incidence and effects of deep vein thrombosis on the outcome of patients with coronavirus disease 2019 infection.
Topics: Adult; Aged; Anticoagulants; COVID-19; Enoxaparin; Female; Humans; Incidence; Male; Middle Aged; Pul | 2022 |
[Deep venous thrombosis incidence in patients with COVID-19 acute respiratory distress syndrome, under intermediate dose of chemical thromboprophylaxis].
Topics: Anticoagulants; COVID-19; Cross-Sectional Studies; Enoxaparin; Humans; Incidence; Respiratory Distre | 2022 |
Does Aspirin Provide Adequate Chemoprophylaxis for Venous Thromboembolic Events in Operative Pelvic and Acetabular Fractures?
Topics: Anticoagulants; Aspirin; Chemoprevention; Enoxaparin; Hematoma; Heparin; Hip Fractures; Humans; Pelv | 2022 |
Apixaban vs Enoxaparin for Post-Surgical Extended-Duration Venous Thromboembolic Event Prophylaxis: A Prospective Quality Improvement Study.
Topics: Aftercare; Anticoagulants; Enoxaparin; Humans; Patient Discharge; Prospective Studies; Pyrazoles; Py | 2022 |
Double trouble - management of perinephric hematoma and renal vein thrombosis post percutaneous renal biopsy.
Topics: Adult; Biopsy; Enoxaparin; Gastrointestinal Hemorrhage; Hematoma; Hematuria; Humans; Kidney Diseases | 2022 |
External validation of the ADA score for predicting thrombosis among acutely ill hospitalized medical patients from the APEX Trial.
Topics: Anticoagulants; COVID-19; Enoxaparin; Humans; Risk Assessment; Risk Factors; Venous Thromboembolism; | 2023 |
Management and outcomes of calf deep vein thrombosis in patients with contraindication to full anticoagulation due to bleeding.
Topics: Anticoagulants; Contraindications; Enoxaparin; Hemorrhage; Humans; Mesenteric Ischemia; Pulmonary Em | 2023 |
Efficacy and safety of salvianolate and enoxaparin in the prevention of perioperative deep venous thrombosis in gastrointestinal surgery.
Topics: Anticoagulants; Digestive System Surgical Procedures; Enoxaparin; Humans; Plant Extracts; Venous Thr | 2023 |
Combination of enoxaparin and low-dose aspirin for thromboprophylaxis in selective patients after primary total joint arthroplasty in a Taiwanese population.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; Humans; Postoperative Complicat | 2023 |
Neutrophil-Lymphocyte Ratio as a Predictor of Venous Thromboembolism after Total Knee Replacement.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Biomarkers; Chemoprevention; Enoxaparin; Fema | 2021 |
Multifactorial Painful Leg Ulcers Due to Hyperhomocysteinemia, Plasminogen Activator Inhibitor-1 4G/5G Heterozygote Gene Mutation, and Beta Thalassemia Minor: A Case Report.
Topics: Bandages; beta-Thalassemia; Biopsy; Diagnosis, Differential; Enoxaparin; Fibrinolytic Agents; Humans | 2019 |
Awareness and Perception of Thromboembolism and Thromboprophylaxis among Hospitalized Patients in Jordan.
Topics: Adult; Aged; Cross-Sectional Studies; Educational Status; Enoxaparin; Female; Fibrinolytic Agents; H | 2020 |
The Enduring and Practical Power of Physical Examination: Carnett Sign.
Topics: Abdominal Wall; Adult; Anticoagulants; Enoxaparin; Hematoma; Humans; Injections, Subcutaneous; Male; | 2020 |
Low prevalence of Post-thrombotic syndrome in patients treated with rivaroxaban.
Topics: Adult; Anticoagulants; Brazil; Cross-Sectional Studies; Enoxaparin; Factor Xa Inhibitors; Female; Hu | 2020 |
Defects in Processes of Care for Pharmacologic Prophylaxis Are Common Among Neurosurgery Patients Who Develop In-Hospital Postoperative Venous Thromboembolism.
Topics: Aged; Algorithms; Anticoagulants; Chemoprevention; Enoxaparin; Female; Guideline Adherence; Heparin; | 2020 |
Venous thrombosis after nitrous oxide abuse, a case report.
Topics: Adult; Enoxaparin; Female; Folic Acid; Humans; Nitrous Oxide; Sinus Thrombosis, Intracranial; Venous | 2020 |
Venous Thrombosis during Spaceflight.
Topics: Aerospace Medicine; Anticoagulants; Drug Administration Schedule; Enoxaparin; Humans; Jugular Veins; | 2020 |
Perioperative symptomatic venous thromboembolism after immediate chemoprophylaxis in patients with pelvic and lower-extremity fractures.
Topics: Adult; Aged; Anticoagulants; Bones of Lower Extremity; Chemoprevention; Dabigatran; Enoxaparin; Fema | 2020 |
[Comparative efficacy and safety of enoxaparin followed by warfarin and rivaroxaban monotherapy in the treatment of venous thrombosis in patients after intracardiac catheter interventions].
Topics: Anticoagulants; Cardiac Catheters; Enoxaparin; Humans; Rivaroxaban; Treatment Outcome; Venous Thromb | 2019 |
Acute Portal Vein Thrombosis in SARS-CoV-2 Infection: A Case Report.
Topics: Acute Disease; Aged; Anticoagulants; Betacoronavirus; Coronavirus Infections; COVID-19; Enoxaparin; | 2020 |
Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis.
Topics: Aged; Aged, 80 and over; COVID-19; Enoxaparin; Female; Fondaparinux; Guidelines as Topic; Hospitaliz | 2020 |
Adherence to postoperative thromboprophylactic medication among gynecologic oncology patients: A subanalysis.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Genital Neoplasms, Female; Humans; Medication Adherence; M | 2020 |
Acute ophthalmic artery occlusion in a COVID-19 patient on apixaban.
Topics: Arterial Occlusive Diseases; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatm | 2020 |
VTE in ICU Patients With COVID-19.
Topics: Adult; Aged; Anticoagulants; Betacoronavirus; C-Reactive Protein; Computed Tomography Angiography; C | 2020 |
A Rare Finding of Upper Limb Deep Venous Thrombosis in a Patient with COVID-19.
Topics: Anticoagulants; Arm; Aspirin; Betacoronavirus; Coronavirus Infections; COVID-19; Edema; Enoxaparin; | 2020 |
Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China.
Topics: Anticoagulants; China; Cost-Benefit Analysis; Enoxaparin; Humans; Rivaroxaban; Venous Thromboembolis | 2020 |
Fondaparinux Use in Patients With COVID-19: A Preliminary Multicenter Real-World Experience.
Topics: Aged; Anticoagulants; Antithrombins; Coronavirus Infections; COVID-19; Enoxaparin; Factor Xa Inhibit | 2020 |
Primary care physicians comprehensively manage acute pulmonary embolism without higher-level-of-care transfer: A report of two cases.
Topics: Acute Disease; Adult; Ambulatory Care; Anticoagulants; Antithrombins; Chest Pain; Computed Tomograph | 2020 |
Multi-Criteria Model for Evaluating Drugs to Prevent Deep Venous Thrombosis Associated With Orthopedic Surgery: A Hospital-Based Case Study.
Topics: Anticoagulants; Brazil; Enoxaparin; Hemorrhage; Humans; Orthopedic Procedures; Pharmaceutical Prepar | 2020 |
Oral administration of dermatan sulphate reduces venous thrombus formation in vivo: potential use as a formulation for venous thromboembolism.
Topics: Administration, Oral; Animals; Anticoagulants; Cattle; Collagen; Dermatan Sulfate; Disease Models, A | 2021 |
Superficial Cerebral Venous Thrombosis and Intracerebral Hematoma in a 48-Year-Old Man with SARS-CoV-2 Infection: A Case Report.
Topics: Anticoagulants; Cerebral Hemorrhage; COVID-19; Enoxaparin; Hematoma; Humans; Intracranial Thrombosis | 2021 |
Clinical analysis of postoperative venous thromboembolism in Japanese patients after colorectal cancer surgery.
Topics: Aged; Anticoagulants; Asian People; Colorectal Neoplasms; Enoxaparin; Female; Fibrin Fibrinogen Degr | 2021 |
MANAGEMENT OF MEDICAL COMPLICATIONS ASSOCIATED WITH A PRESUMED TETANUS INFECTION IN A NORTHWEST BORNEAN ORANGUTAN (
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Ape Disease | 2021 |
Clinical efficacy of one-stage thrombus removal via contralateral femoral and ipsilateral tibial venous access for pharmacomechanical thrombectomy in entire-limb acute deep vein thrombosis.
Topics: Anticoagulants; Cohort Studies; Enoxaparin; Female; Femoral Vein; Humans; Male; Middle Aged; Retrosp | 2021 |
Diagnosis and resection of a giant ovarian cyst presenting in a young patient with contralateral back pain and lower limb deep vein thrombosis.
Topics: Adult; Back Pain; Diagnosis, Differential; Diagnostic Imaging; Enoxaparin; Female; Fibrinolytic Agen | 2021 |
Ovarian vein thrombosis after coronavirus disease (COVID-19) mimicking acute abdomen: two case reports.
Topics: Abdomen, Acute; Adult; Anticoagulants; COVID-19; Diagnosis, Differential; Enoxaparin; Female; Fibrin | 2021 |
Successful treatment of penile Mondor's disease with infliximab in a patient with Behçet's disease.
Topics: Adult; Antirheumatic Agents; Behcet Syndrome; Enoxaparin; Humans; Infliximab; Male; Penile Diseases; | 2021 |
Incidence of deep vein thrombosis through an ultrasound surveillance protocol in patients with COVID-19 pneumonia in non-ICU setting: A multicenter prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; COVID-19; Enoxaparin; Female; Fondaparinux; Humans; Inciden | 2021 |
Enoxaparin Reduces Catheter-associated Venous Thrombosis After Infant Cardiac Surgery.
Topics: Anticoagulants; Cardiac Surgical Procedures; Catheters; Child; Enoxaparin; Hemorrhage; Humans; Infan | 2022 |
Effectiveness of apixaban versus enoxaparin in preventing wound complications and deep venous thrombosis following total knee replacement surgery: A retrospective study.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Postoperative Complications; Py | 2021 |
Is Blood Thicker Than Water? Perhaps Not Always….
Topics: Cardiac Surgical Procedures; Enoxaparin; Humans; Infant; Venous Thrombosis | 2022 |
Acute localized exanthematous pustulosis caused by enoxaparin.
Topics: Acute Generalized Exanthematous Pustulosis; Adult; Anticoagulants; Enoxaparin; Female; Humans; Injec | 2021 |
Optimal timing of post-operative enoxaparin after neurosurgery: A single institution experience.
Topics: Adult; Anticoagulants; Brain Neoplasms; Craniotomy; Enoxaparin; Female; Humans; Male; Middle Aged; R | 2021 |
Effective use of weight-based enoxaparin for deep vein thrombosis chemoprophylaxis in patients with traumatic brain injury.
Topics: Adult; Aged; Anticoagulants; Body Weight; Brain Injuries, Traumatic; Drug Dosage Calculations; Enoxa | 2022 |
Cerebral Venous Thrombosis and Hypercoagulability Associated With In Vitro Fertilization.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Fertilization in Vitro; Humans; Intracranial Thrombosis; | 2021 |
Bleeding in Patients With Gastrointestinal Cancer Compared With Nongastrointestinal Cancer Treated With Apixaban, Rivaroxaban, or Enoxaparin for Acute Venous Thromboembolism.
Topics: Enoxaparin; Factor Xa Inhibitors; Female; Gastrointestinal Neoplasms; Hemorrhage; Humans; Liver Neop | 2021 |
Pharmacological management of cerebral venous sinus thrombosis with full-dose IV heparin infusion and its clinical outcomes.
Topics: Anticoagulants; Comorbidity; Drug Administration Schedule; Enoxaparin; Female; Heparin; Humans; Infu | 2017 |
Comparison of the efficacy of fixed-dose enoxaparin and adjusted-dose unfractionated heparin in patients with cerebral venous thrombosis.
Topics: Adolescent; Adult; Aged; Anticoagulants; Cohort Studies; Dose-Response Relationship, Drug; Enoxapari | 2017 |
Venous Thromboembolism Prophylaxis After TKA: Aspirin, Warfarin, Enoxaparin, or Factor Xa Inhibitors?
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; D | 2017 |
An unusual case of neck pain in Hashimoto's thyroiditis.
Topics: Anticoagulants; Enoxaparin; Female; Hashimoto Disease; Humans; Middle Aged; Neck Pain; Thyroid Gland | 2017 |
Cost-Effectiveness Analysis of Rivaroxaban for Treatment of Deep Vein Thrombosis and Pulmonary Embolism in Greece.
Topics: Aged; Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Fibrinolytic Agents; Greece; Humans; Middle | 2017 |
Is a therapeutic anticoagulation window needed for delivery when using prophylactic low molecular weight heparin during pregnancy? A retrospective monocentric study.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Delivery, Obstetric; Enoxaparin; Female; Heparin, | 2017 |
Comparative Effectiveness and Safety of Drug Prophylaxis for Prevention of Venous Thromboembolism After Total Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Factor X | 2017 |
A Rare Complication of Campylobacter Sepsis in an Infant.
Topics: Anti-Bacterial Agents; Anticoagulants; Campylobacter Infections; Campylobacter jejuni; Ceftriaxone; | 2018 |
Thromboembolic Events Following Splenectomy: Risk Factors, Prevention, Management and Outcomes.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Male; Mesenteric Ischemia; Middle Aged; Ope | 2018 |
Can we reliably predict the level of anticoagulation after enoxaparin injection in elderly patients with renal failure?
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Hemorrhage; Heparin, Low-Molecular-Weig | 2018 |
Enoxaparin Dosing and the Prevention of Venous Thromboembolism in Plastic Surgery Patients.
Topics: Anticoagulants; Enoxaparin; Humans; Plastic Surgery Procedures; Surgery, Plastic; Thromboembolism; V | 2017 |
Bilateral Femoral Neuropathy Following Psoas Muscle Hematomas Caused by Enoxaparin Therapy.
Topics: Anticoagulants; Enoxaparin; Female; Femoral Neuropathy; Hematoma; Humans; Middle Aged; Psoas Muscles | 2017 |
Wound Discharge After Pharmacological Thromboprophylaxis in Lower Limb Arthroplasty.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2018 |
Varicella complicated by cellulitis and deep vein thrombosis.
Topics: Anti-Bacterial Agents; Anticoagulants; Cellulitis; Chickenpox; Diagnosis, Differential; Enoxaparin; | 2017 |
Once-Daily Versus Twice-Daily Enoxaparin for the Treatment of Acute Venous Thromboembolism in Cancer Patients.
Topics: Acute Disease; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Hemorrhage; H | 2018 |
A 71-year-old man with a hemorrhagic vesicular eruption.
Topics: Aged; Anticoagulants; Drug Eruptions; Enoxaparin; Hemorrhage; Humans; Male; Skin Diseases, Vesiculob | 2018 |
Are factor Xa inhibitors effective thromboprophylaxis following hip fracture surgery?: A large national database study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Databases, Factual; Enoxapa | 2017 |
Assessing risk factors, presentation, and management of portomesenteric vein thrombosis after sleeve gastrectomy: a multicenter case-control study.
Topics: Adult; Aged; Anticoagulants; Bariatric Surgery; Drug Therapy, Combination; Enoxaparin; Epidemiologic | 2018 |
Topics: Clinical Trials, Phase III as Topic; Enoxaparin; Germany; Guideline Adherence; Humans; Pulmonary Emb | 2018 |
Catheter-Related Venous Thrombosis in Hospitalized Pediatric Patients with Inflammatory Bowel Disease: Incidence, Characteristics, and Role of Anticoagulant Thromboprophylaxis with Enoxaparin.
Topics: Adolescent; Anticoagulants; Catheterization, Central Venous; Central Venous Catheters; Child; Enoxap | 2018 |
Evaluation of VTE prophylaxis and the impact of alternate regimens on post-operative bleeding and thrombotic complications following bariatric procedures.
Topics: Adolescent; Adult; Anticoagulants; Blood Transfusion; Drug Therapy, Combination; Enoxaparin; Female; | 2018 |
Incidence of symptomatic venous thromboembolism in 2372 knee and hip replacement patients after discharge: data from a thromboprophylaxis registry in Montreal, Canada.
Topics: Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee | 2018 |
Effects of Natural Hirudin and Low Molecular Weight Heparin in Preventing Deep Venous Thrombosis in Aged Patients with Intertrochanteric Fracture.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Fibrin Fibrinogen Degradation Products; Hip Fractures; Hir | 2018 |
Discussion: The Impact of Once- versus Twice-Daily Enoxaparin Prophylaxis on Risk for Venous Thromboembolism and Clinically Relevant Bleeding.
Topics: Anticoagulants; Enoxaparin; Fibrinolytic Agents; Humans; Risk; Venous Thromboembolism; Venous Thromb | 2018 |
Anticoagulation treatment of portal vein thrombosis in a patient with cirrhosis awaiting liver transplantation: A case report.
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Liver Transplant | 2018 |
Acute Onset of Unilateral Edema of Leg Followed by Hemiplegia in an Adolescent: A Case Report.
Topics: Adolescent; Angioplasty; Anticoagulants; Balloon Valvuloplasty; Diagnosis, Differential; Edema; Enox | 2018 |
Increased Enoxaparin Dosing Requirements for Treatment of Deep Vein Thrombosis in a Severely Burned Patient: Case Report and Literature Review.
Topics: Adult; Anticoagulants; Burns; Enoxaparin; Factor Xa; Humans; Male; Monitoring, Physiologic; Venous T | 2018 |
Utilization rates of enoxaparin and heparin in deep venous thrombosis prophylaxis after education and electronic order change at a single institution: a quality improvement study.
Topics: Adult; Aged; Aged, 80 and over; Drug Prescriptions; Education, Medical; Enoxaparin; Heparin; Humans; | 2018 |
Trends in Deep Vein Thrombosis Prophylaxis and Deep Vein Thrombosis Rates After Total Hip and Knee Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Clin | 2018 |
A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Blood Coagulation; Blood Coagulation Tes | 2019 |
Early thrombosis prophylaxis with enoxaparin is not associated with hematoma expansion in patients with spontaneous intracerebral hemorrhage.
Topics: Aged; Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Female; Glasgow Coma Scale; Hematoma; Humans; | 2019 |
Dengue shock syndrome complicated with acute liver failure and kidney injury, infective endocarditis, and deep vein thrombosis: a case report.
Topics: Acute Kidney Injury; Adult; Anticoagulants; Coinfection; Dengue; Endocarditis, Bacterial; Enoxaparin | 2018 |
Aspirin Alone Is Not Enough to Prevent Deep Venous Thrombosis After Total Joint Arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Chem | 2019 |
Utilization Patterns, Efficacy, and Complications of Venous Thromboembolism Prophylaxis Strategies in Primary Hip and Knee Arthroplasty as Reported by American Board of Orthopedic Surgery Part II Candidates.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Data | 2019 |
Anti-Xa guided enoxaparin dose adjustment improves pharmacologic deep venous thrombosis prophylaxis in burn patients.
Topics: Adult; Aged; Anticoagulants; Blood Coagulation Tests; Body Mass Index; Body Weight; Burns; Chemoprev | 2019 |
Determination of Optimal Weight-Based Enoxaparin Dosing and Associated Clinical Factors for Achieving Therapeutic Anti-Xa Assays for Deep Venous Thrombosis Prophylaxis.
Topics: Anticoagulants; Body Weight; Drug Administration Schedule; Enoxaparin; Female; Humans; Male; Middle | 2019 |
Venous thromboprophylaxis after total hip arthroplasty: aspirin, warfarin, enoxaparin, or factor Xa inhibitors?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Aspirin; Enoxaparin; | 2020 |
Extended Thromboprophylaxis for Medical Patients.
Topics: Aftercare; Anticoagulants; Benzamides; Duration of Therapy; Enoxaparin; Heparin, Low-Molecular-Weigh | 2020 |
Paget-Schroetter syndrome in a teenager after throwing firecrackers - A case report.
Topics: Acenocoumarol; Adolescent; Anticoagulants; Enoxaparin; Humans; Male; Subclavian Vein; Thrombolytic T | 2019 |
[Adequation of thromboprophylaxis during former admission in patients attended in emergencies with thromboembolic disease].
Topics: Enoxaparin; Female; Fibrinolytic Agents; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; | 2013 |
Contrast ultrasound for the quantification of deep vein thrombosis in living mice: effects of enoxaparin and P2Y12 receptor inhibition.
Topics: Adenosine; Animals; Anticoagulants; Chlorides; Contrast Media; Enoxaparin; Ferric Compounds; Male; M | 2013 |
Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin.
Topics: Animals; Anticoagulants; Antithrombin III; Blood Coagulation Tests; Enoxaparin; Factor Xa Inhibitors | 2013 |
[Thromboprophylaxis in medical ill patients from Emergency Department].
Topics: Enoxaparin; Female; Fibrinolytic Agents; Guideline Adherence; Heparin, Low-Molecular-Weight; Humans; | 2013 |
Is extended thromboprophylaxis necessary in elective colorectal cancer surgery?
Topics: Aged; Anticoagulants; Australia; Clinical Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; El | 2013 |
How I treat heterozygous hereditary antithrombin deficiency in pregnancy.
Topics: Adult; Antithrombin III; Antithrombin III Deficiency; Drug Administration Schedule; Enoxaparin; Fema | 2013 |
Superior mesenteric vein thrombosis after laparoscopic sleeve gastrectomy.
Topics: Anticoagulants; Enoxaparin; Female; Gastrectomy; Humans; Laparoscopy; Mesenteric Vascular Occlusion; | 2013 |
Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Topics: Administration, Oral; Alginates; Animals; Anticoagulants; Biological Availability; Chitosan; Drug Ca | 2013 |
Home therapy pathway - safe and streamlined method of initial management of ankle fractures.
Topics: Adult; Aged; Aged, 80 and over; Ankle Injuries; Anticoagulants; Case-Control Studies; Casts, Surgica | 2013 |
Retrospective comparison of three thromboprophylaxis agents, edoxaban, fondaparinux, and enoxaparin, for preventing venous thromboembolism in total knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Response Relationship, Drug; Enoxaparin; | 2014 |
Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
Topics: Anticoagulants; Cost-Benefit Analysis; Drug Therapy, Combination; Enoxaparin; Humans; Markov Chains; | 2014 |
Lower extremity deep vein thrombosis after heavy exertion.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Leg; Motor Activity; Physical Exertion; Popliteal | 2013 |
Excellent response to combined radioiodine and enoxaparin in the setting of tumor venous thrombosis from differentiated thyroid carcinoma involving internal jugular and subclavian veins.
Topics: Adult; Combined Modality Therapy; Enoxaparin; Female; Humans; Iodine Radioisotopes; Jugular Veins; L | 2013 |
Therapeutic effect of low-molecular weight heparin and incidence of lower limb deep venous thrombosis and pulmonary embolism after laparoscopic bariatric surgery.
Topics: Adolescent; Adult; Anastomosis, Roux-en-Y; Bariatric Surgery; Enoxaparin; Female; Heparin, Low-Molec | 2013 |
A retrospective analysis of the effectiveness of low molecular weight heparin for venous thromboembolism prophylaxis in trauma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Enoxaparin; Female; Huma | 2014 |
Two successful pregnancies in a carrier of heterozygous factor V LEIDEN mutation with aplasia of the inferior vena cava and a history of proximal deep venous thrombosis.
Topics: Anticoagulants; Enoxaparin; Factor V; Female; Heterozygote; Humans; Iliac Vein; Live Birth; Mutation | 2014 |
Order and execution of DVT prophylaxis: "the best-laid plans of mice and men".
Topics: Enoxaparin; Female; Humans; Male; Surgical Procedures, Operative; Trauma Centers; Venous Thrombosis; | 2014 |
Correlation of missed doses of enoxaparin with increased incidence of deep vein thrombosis in trauma and general surgery patients.
Topics: Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Follow-Up Studies; Humans; Inc | 2014 |
Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Length of Stay; Male; Middle Ag | 2014 |
Efficacy of postoperative anticoagulation therapy with enoxaparin for portal vein thrombosis after hepatic resection in patients with liver cancer.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Portal Vein; P | 2014 |
Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
Topics: Administration, Oral; Animals; Anticoagulants; Antithrombin III; Disease Models, Animal; Drug Admini | 2014 |
Perioperative thromboprophylaxis in Cushing's disease: What we did and what we are doing?
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adult; Aged; Anticoagulants; Antithrombin III; Case-Contr | 2015 |
[Thrombosis of inferior vena cava suprarenal portion and right atrium in case of stomach cancer].
Topics: Adenocarcinoma; Echocardiography, Three-Dimensional; Enoxaparin; Female; Fibrinolytic Agents; Gastre | 2014 |
Challenges in the management of iliofemoral deep vein thrombosis in a resource limited setting: a case series.
Topics: Adolescent; Adult; Anticoagulants; Developing Countries; Drug Therapy, Combination; Enoxaparin; Femo | 2014 |
The risks of thromboembolism vs. recurrent gastrointestinal bleeding after interruption of systemic anticoagulation in hospitalized inpatients with gastrointestinal bleeding: a prospective study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Benzimidazoles; beta-Alanine; Cohort Studies; Dabigatran; E | 2015 |
P-selectin inhibition therapeutically promotes thrombus resolution and prevents vein wall fibrosis better than enoxaparin and an inhibitor to von Willebrand factor.
Topics: Animals; Aptamers, Nucleotide; Blood Coagulation; Collagen; Disease Models, Animal; Enoxaparin; Fibr | 2015 |
A rare complication of pulmonary tuberculosis: a case report.
Topics: Adult; Antitubercular Agents; Clarithromycin; Drug Antagonism; Enoxaparin; Fatal Outcome; Female; Hu | 2015 |
Early prophylactic anticoagulation via transjugular intrahepatic route for portal vein thrombosis after splenectomy in cirrhotic portal hypertension.
Topics: Adult; Angiography, Digital Subtraction; Anticoagulants; Blood Flow Velocity; Drug Administration Sc | 2015 |
Safety and efficacy of thromboprophylaxis using enoxaparin sodium after cesarean section: A multi-center study in Japan.
Topics: Adult; Alanine Transaminase; Anticoagulants; Aspartate Aminotransferases; Asymptomatic Diseases; Bod | 2015 |
Polymeric Nanoparticles of Enoxaparin as a Delivery System: In Vivo Evaluation in Normal Rats and in a Venous Thrombosis Rat Model.
Topics: Animals; Anticoagulants; Disease Models, Animal; Drug Delivery Systems; Enoxaparin; Male; Nanopartic | 2015 |
Inherited antithrombin deficiency and anabolic steroids: a risky combination.
Topics: Antithrombins; Chest Pain; Dyspnea; Enoxaparin; Fibrinolytic Agents; Hemoptysis; Humans; Injections, | 2016 |
Death Associated with Inadequate Reassessment of Venous Thromboembolism Prophylaxis at and after Hospital Discharge.
Topics: Aged; Anticoagulants; Canada; Enoxaparin; Fatal Outcome; Female; Humans; Middle Aged; Nursing Care; | 2015 |
Emergent pediatric anticoagulation reversal using a 4-factor prothrombin complex concentrate.
Topics: Anticoagulants; Blood Coagulation Factors; Child; Enoxaparin; Female; Headache; Hemorrhage; Heparin | 2016 |
Ovarian vein thrombosis in a polytrauma patient.
Topics: Accidents, Traffic; Anticoagulants; Enoxaparin; Female; Humans; Multiple Trauma; Ovary; Patient Care | 2015 |
Clinical Performance of the 1st American Academy of Orthopaedic Surgeons Clinical Guideline on Prevention of Symptomatic Pulmonary Embolism after Total Knee Arthroplasty in Korean Patients.
Topics: Aged; Arthroplasty, Replacement, Knee; Aspirin; Cohort Studies; Enoxaparin; Female; Fibrinolytic Age | 2015 |
Spontaneous Upper Extremity Venous Thrombosis in a Collegiate Soccer Player: A Case Report.
Topics: Anticoagulants; Arm; Diagnosis, Differential; Enoxaparin; Factor Xa Inhibitors; Follow-Up Studies; H | 2016 |
Balancing Thromboprophylaxis and Bleeding in Total Joint Arthroplasty: Impact of Eliminating Enoxaparin and Predonation and Implementing Pneumatic Compression and Tranexamic Acid.
Topics: Aged; Anticoagulants; Antifibrinolytic Agents; Arthroplasty, Replacement, Hip; Arthroplasty, Replace | 2016 |
Comparison of Postoperative Bleeding in Total Hip and Knee Arthroplasty Patients Receiving Rivaroxaban or Enoxaparin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthropl | 2016 |
Safety of anticoagulation in thrombocytopenic patients with hematologic malignancies: A case series.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hematologic Neoplasms; Hemorrhage; Heparin, Low-Molecular- | 2017 |
Bacteremia and Deep Vein Thrombosis in an Infant.
Topics: Anti-Bacterial Agents; Anticoagulants; Bacteremia; Ceftriaxone; Clindamycin; Edema; Emergency Servic | 2016 |
[Ultrasound dynamics lysis apex thrombus as an objective criterion of effectiveness of anticoagulation therapy in venous thrombosis].
Topics: Aged; Anticoagulants; Drug Monitoring; Enoxaparin; Female; Humans; International Normalized Ratio; L | 2016 |
Straddling interatrial embolus: a rare clinical dilemma.
Topics: Anticoagulants; Dyspnea; Echocardiography; Enoxaparin; Humans; Male; Middle Aged; Thrombolytic Thera | 2016 |
[Quality of life of patients with venous thromboses in different variants of anticoagulant therapy].
Topics: Adult; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Humans; Lower Extremi | 2016 |
Acute pancreatitis complicated with deep vein thrombosis and pulmonary embolism: a case report.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Male; Pancreatitis; Pulmonary Embolism; Tomography, X-Ray | 2016 |
Unprovoked DVT, the clot thickens.
Topics: Adult; Anticoagulants; Contraceptives, Oral, Hormonal; Enoxaparin; Ethinyl Estradiol; Female; Fibrin | 2016 |
Resveratrol Reduces the Incidence of Portal Vein System Thrombosis after Splenectomy in a Rat Fibrosis Model.
Topics: Animals; Anticoagulants; Apoptosis; Blood Platelets; Enoxaparin; Fibrinolytic Agents; Liver Cirrhosi | 2016 |
Abdominal thrombotic complications following bariatric surgery.
Topics: Abdomen; Adult; Anticoagulants; Bariatric Surgery; Drug Administration Schedule; Enoxaparin; Female; | 2017 |
Anti-Xa-guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients.
Topics: Abbreviated Injury Scale; Adult; Aged; Anticoagulants; Enoxaparin; Factor Xa; Female; Humans; Male; | 2016 |
To anticoagulate? Controversy in the management of thrombotic complications of head & neck infections.
Topics: Adolescent; Anticoagulants; Aspirin; Cavernous Sinus Thrombosis; Cerebral Angiography; Child; Child, | 2016 |
Rate of Transfusions After Total Knee Arthroplasty in Patients Receiving Lovenox or High-Dose Aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Blood Transfusion | 2016 |
Ultrasound Characteristics of Calf Deep Vein Thrombosis and Residual Vein Obstruction After Low Molecular Weight Heparin Treatment.
Topics: Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Area Under Curve; Enoxaparin; Female; Huma | 2016 |
An analysis of deep vein thrombosis in burn patients (Part 1): Comparison of D-dimer and Doppler ultrasound as screening tools.
Topics: Adolescent; Adult; Body Surface Area; Burns; Disease Management; Enoxaparin; Female; Fibrin Fibrinog | 2016 |
Evidence of a clinically significant interaction between warfarin and intravesical gemcitabine.
Topics: Administration, Intravesical; Aged, 80 and over; Anticoagulants; Antimetabolites, Antineoplastic; BC | 2016 |
Treatment and follow-up of venous thrombosis in the neonatal intensive care unit: a retrospective study.
Topics: Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Hospitalization; Humans; Infant; Infant, Newb | 2017 |
End-Site-Specific Conjugation of Enoxaparin and Tetradeoxycholic Acid Using Nonenzymatic Glycosylation for Oral Delivery.
Topics: Administration, Oral; Animals; Cell Survival; Cholic Acids; Dogs; Dose-Response Relationship, Drug; | 2016 |
Use of patient-specific cutting blocks reduces blood loss after total knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Blood Loss, Surgical; Enoxaparin; Female; Hum | 2017 |
Goal directed enoxaparin dosing provides superior chemoprophylaxis against deep vein thrombosis.
Topics: Abbreviated Injury Scale; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Chemopreventio | 2017 |
Once versus twice daily enoxaparin for the initial treatment of acute venous thromboembolism.
Topics: Acute Disease; Aged; Anticoagulants; Drug Administration Schedule; Enoxaparin; Europe; Female; Hemor | 2017 |
Antiphospholipid Syndrome with Antiβ2glicoprotein-1 Antibodies as the Cause of Recurrent Tibial Vein Thrombosis in SAPHO syndrome.
Topics: Acquired Hyperostosis Syndrome; Adult; Antibodies, Anticardiolipin; Antiphospholipid Syndrome; Enoxa | 2016 |
Safety and efficacy of postoperative pharmacologic thromboprophylaxis with enoxaparin after pancreatic surgery.
Topics: Adult; Aged; Aged, 80 and over; Digestive System Surgical Procedures; Enoxaparin; Female; Fibrinolyt | 2017 |
Comparison of different dose regimens of enoxaparin in deep vein thrombosis therapy in pregnancy.
Topics: Adult; Anticoagulants; Dose-Response Relationship, Drug; Enoxaparin; Female; Humans; Injections, Sub | 2008 |
New anticoagulants--the path from discovery to clinical practice.
Topics: Anticoagulants; Enoxaparin; Factor Xa Inhibitors; Humans; Morpholines; Rivaroxaban; Thiophenes; Veno | 2008 |
Thromboembolic risk assessment and the efficacy of enoxaparin prophylaxis in excisional body contouring surgery.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Middle Aged; Obesity, Morbid; Plastic Surgery Pro | 2008 |
Prostasol and venous thromboembolism.
Topics: Aged; Aged, 80 and over; Complementary Therapies; Dietary Supplements; Drugs, Chinese Herbal; Enoxap | 2008 |
Stuttering priapism complicating warfarin therapy in a patient with protein C deficiency.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Male; Priapism; Protein C Deficiency; Pulmonary Embolism; | 2008 |
Submucosal hematoma presenting as small bowel obturator obstruction in a patient on low-molecular-weight heparin.
Topics: Anastomosis, Surgical; Child, Preschool; Enoxaparin; Female; Follow-Up Studies; Gastrointestinal Hem | 2008 |
Management of refractory venous thrombosis associated with malignancy using a supra-therapeutic enoxaparin regimen.
Topics: Adult; Carcinoma, Squamous Cell; Enoxaparin; Female; Fibrinolytic Agents; Humans; International Norm | 2009 |
Letter 1: use of enoxaparin results in more haemorrhagic complications after breast surgery than unfractionated heparin (Br J Surg 2008; 95: 834-836).
Topics: Anticoagulants; Body Mass Index; Breast Neoplasms; Enoxaparin; Female; Hematoma; Humans; Risk Factor | 2008 |
Spontaneous pectoral hematoma secondary to enoxaparin for the treatment of deep venous thrombosis in an elderly man.
Topics: Anticoagulants; Drainage; Enoxaparin; Hematoma; Heparin, Low-Molecular-Weight; Humans; Male; Treatme | 2008 |
The efficacy of prophylactic low-molecular-weight heparin to prevent pulmonary thromboembolism in immediate breast reconstruction using the TRAM flap.
Topics: Adult; Anticoagulants; Breast Neoplasms; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; | 2009 |
[Summary and perspectives. Rivaroxaban].
Topics: Administration, Oral; Aged; Anticoagulants; Clinical Trials, Phase III as Topic; Comorbidity; Enoxap | 2008 |
[Leg venous thrombosis after work accident: serious surprise in echocardiography].
Topics: Accidents, Occupational; Adult; Casts, Surgical; Critical Care; Echocardiography, Doppler, Color; En | 2008 |
Platelet-dense granule deficiency causes postoperative hemorrhage in patients receiving enoxaparin: a novel observation with dramatic clinical implications.
Topics: Adult; Anticoagulants; Blood Platelet Disorders; Cytoplasmic Granules; Enoxaparin; Gastric Bypass; H | 2009 |
High incidence of venous thrombosis after surgery for abdominal aortic aneurysm.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aortic Aneurysm, Abdominal; Drug Administration Schedule; E | 2009 |
Using thrombophilia testing to determine anticoagulation duration in pediatric thrombosis is not cost-effective.
Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Cost-Benefit Analysis; Decision Support Techniq | 2009 |
Ornithine transcarbamylase deficiency: a possible risk factor for thrombosis.
Topics: Anticoagulants; Compartment Syndromes; Enoxaparin; Humans; Infant; Infant, Newborn; Male; Ornithine | 2009 |
Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Fondaparinu | 2009 |
Incidence of deep venous thrombosis after temporary joint spanning external fixation for complex lower extremity injuries.
Topics: Adult; Anticoagulants; Clinical Protocols; Enoxaparin; External Fixators; Female; Fibula; Fracture F | 2009 |
Cerebral venous thrombosis treated with enoxaparin in an IUGR neonate with DIC.
Topics: Anticoagulants; Brain; Cerebral Hemorrhage; Cerebral Veins; Cerebrovascular Disorders; Disseminated | 2009 |
Retrospective evaluation of venous thromboembolism prophylaxis in the adult cancer population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Drug Therapy, Combination; Enoxaparin; F | 2010 |
[Anesthesia in a patient with homocystinuria and severe pulmonary embolism].
Topics: Acenocoumarol; Aggression; Anesthesia, General; Anesthetics; Anticoagulants; Contraindications; Enox | 2009 |
Traumatic brain injury is associated with the development of deep vein thrombosis independent of pharmacological prophylaxis.
Topics: Adult; Age Distribution; Analysis of Variance; Anticoagulants; Brain Injuries; Chi-Square Distributi | 2009 |
Thromboprophylaxis following surgery for colorectal cancer - is it worthwhile after hospital discharge?
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Colorectal Neoplasms; Enoxaparin; Humans; Length of | 2009 |
Thrombelastography versus AntiFactor Xa levels in the assessment of prophylactic-dose enoxaparin in critically ill patients.
Topics: Antibodies; Anticoagulants; Chemoprevention; Critical Illness; Enoxaparin; Factor Xa; Female; Humans | 2009 |
Use of deep vein thrombosis prophylaxis in hospitalized cancer patients.
Topics: Adult; Aged; Anticoagulants; Contraindications; Enoxaparin; Female; Humans; Inpatients; Male; Medica | 2009 |
New observations in postpartum ovarian vein thrombosis: experience of single center.
Topics: Adult; Anticoagulants; Aspirin; Cesarean Section; Early Diagnosis; Enoxaparin; Female; Humans; Incid | 2010 |
Air travel and pulmonary embolism: "economy class syndrome".
Topics: Adult; Aircraft; Anticoagulants; Enoxaparin; Humans; Male; Middle Aged; Pulmonary Embolism; Risk Fac | 2009 |
Dabigatran: new drug. Continue to use heparin, a better-known option.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Benzimidazoles; Dab | 2009 |
[Prophylaxis of deep vein thrombosis with enoxaparin 40 mg in outpatients compared to hospitalized medically ill patients].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Cross-Sectional Studies; Enoxaparin | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Drug Administration Schedule; Enoxaparin; Humans; M | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Knee; Clinical Trials, Phase III as | 2009 |
Rivaroxaban versus enoxaparin after total knee arthroplasty.
Topics: Anticoagulants; Arthroplasty, Replacement, Knee; Enoxaparin; Hemorrhage; Humans; Morpholines; Random | 2009 |
An unusual case of loin pain and nephritis.
Topics: Adolescent; Cyclosporine; DNA; Enoxaparin; Female; Glomerulonephritis, Membranous; Humans; Immunosup | 2010 |
Enoxaparin treatment of spontaneous deep vein thrombosis in a chronically catheterized rhesus macaque (Macaca mulatta).
Topics: Animals; Anticoagulants; Catheterization; Enoxaparin; Femoral Vein; Iliac Vein; Macaca mulatta; Male | 2009 |
[Enoxaparin-induced thrombocytopenia with associated arterial and venous thrombosis].
Topics: Aged, 80 and over; Anticoagulants; Enoxaparin; Femoral Vein; Humans; Male; Thrombocytopenia; Venous | 2011 |
Orthostatic stuttering priapism in a HIV positive man.
Topics: Anticoagulants; Enoxaparin; HIV Seropositivity; Humans; Male; Middle Aged; Priapism; Quality of Life | 2009 |
[Warfarin or enoxaparin: the choice for the patient with venous thrombosis in the first month of treatment].
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Venous Throm | 2009 |
Neuraxial hematoma and paralysis after enoxaparin administration 3 days after attempted spinal anesthesia for total knee arthroplasty.
Topics: Aged; Anesthesia, Spinal; Anticoagulants; Arthroplasty, Replacement, Knee; Dose-Response Relationshi | 2010 |
FXa inhibition and coagulation changes during DVT prophylaxis by enoxaparin over the course of a 15-day follow-up in septic patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Coagulation; Enoxaparin; Factor Xa Inhibitors; | 2010 |
[Septic pylephlebitis associated with Enterobacter cloacae septicemia].
Topics: Abdominal Pain; Adult; Anti-Bacterial Agents; Anticoagulants; Bacteremia; Ceftriaxone; Community-Acq | 2010 |
Anticoagulation for cerebral venous thrombosis with subarachnoid hemorrhage: a case report.
Topics: Adult; Enoxaparin; Female; Fibrinolytic Agents; Humans; Lateral Sinus Thrombosis; Magnetic Resonance | 2010 |
Successful surgical treatment of Nicolau's syndrome combined with intravenous iloprost.
Topics: Amputation, Surgical; Anti-Bacterial Agents; Anticoagulants; Cardiovascular Agents; Child, Preschool | 2009 |
Vein wall remodeling after deep vein thrombosis: differential effects of low molecular weight heparin and doxycycline.
Topics: Animals; Disease Models, Animal; Doxycycline; Elasticity; Enoxaparin; Fibrin Fibrinogen Degradation | 2010 |
Frequency of bleeding following invasive dental procedures in patients on low-molecular-weight heparin therapy.
Topics: Adolescent; Adult; Aged; Anticoagulants; Antifibrinolytic Agents; Aspirin; Enoxaparin; Female; Gelat | 2010 |
Standard prophylactic enoxaparin dosing leads to inadequate anti-Xa levels and increased deep venous thrombosis rates in critically ill trauma and surgical patients.
Topics: Adult; Anticoagulants; Enoxaparin; Factor Xa; Female; Humans; Injury Severity Score; Male; Prospecti | 2010 |
Enoxaparin for the prevention of venous thromboembolism.
Topics: Acute Disease; Aged; Anticoagulants; Double-Blind Method; Enoxaparin; Female; Hospitalization; Human | 2010 |
[Parturient at full term with inferior vena cava thrombosis: anesthesia during surgical delivery].
Topics: Adult; Anesthesia, General; Anesthesia, Obstetrical; Anticoagulants; Cesarean Section; Emergencies; | 2010 |
Gold Medal Forum Winner. Unfractionated heparin three times a day versus enoxaparin in the prevention of deep vein thrombosis in trauma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Cost Savings; Enoxaparin; Female; Head I | 2010 |
Thrombogenesis with continuous blood flow in the inferior vena cava. A novel mouse model.
Topics: Animals; Blood Coagulation; Disease Models, Animal; Electrolysis; Endothelial Cells; Enoxaparin; Fib | 2010 |
Supratherapeutic anticoagulation from low-molecular-weight heparin in lung transplant recipients.
Topics: Adult; Aged; Anticoagulants; Creatinine; Enoxaparin; Factor Xa; Female; Heparin, Low-Molecular-Weigh | 2010 |
[Pulmonary embolism as a cause of a reduced performance capacity of endurance trained men - report of 2 cases].
Topics: Acute Disease; Angiography; Anticoagulants; Athletic Performance; Diagnosis, Differential; Electroca | 2010 |
Successful surgical management of massive pulmonary embolism during the second trimester in a parturient with heparin-induced thrombocytopenia.
Topics: Adult; Anticoagulants; Cardiopulmonary Bypass; Echocardiography, Transesophageal; Embolectomy; Enoxa | 2010 |
FDA approves generic enoxaparin.
Topics: Anticoagulants; Drug Approval; Drugs, Generic; Enoxaparin; Humans; Injections, Subcutaneous; United | 2010 |
Improve the results of phase II trials of thromboprophylaxis with the new oral anticoagulant drugs.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Knee; Clinical Trials, Phase II as | 2010 |
Pulmonary embolectomy in heparin-induced thrombocytopenia and thrombosis? Safety of heparin use.
Topics: Anticoagulants; Cardiopulmonary Bypass; Embolectomy; Enoxaparin; Female; Fondaparinux; Heart Arrest, | 2010 |
Invited commentary.
Topics: Administration, Oral; Ambulatory Care; Anticoagulants; Blood Coagulation; Compression Bandages; Drug | 2010 |
Validation of the Caprini risk assessment model in plastic and reconstructive surgery patients.
Topics: Anticoagulants; Enoxaparin; Female; Humans; Male; Mammaplasty; Middle Aged; Plastic Surgery Procedur | 2011 |
A case of superior sagittal sinus thrombosis in pregnancy despite prophylactic antenatal heparin.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascula | 2010 |
A pilot retrospective comparison of fondaparinux and enoxaparin for the prevention of venous thromboembolism (VTE) in patients with stroke.
Topics: Aged; Aged, 80 and over; Enoxaparin; Female; Fibrinolytic Agents; Fondaparinux; Humans; Male; Middle | 2010 |
Mechanical thromboprophylaxis for patients undergoing hip fracture surgery.
Topics: Aged; Aged, 80 and over; Cohort Studies; Enoxaparin; Female; Fibrinolytic Agents; Fracture Fixation; | 2010 |
Deep vein thrombosis after total knee arthroplasty in asian patients without prophylactic anticoagulation.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthritis, Rheumatoid; Arthroplasty, Replacement, Kn | 2011 |
Recurrent miscarriages: caution regarding development of clinical trials using low molecular weight heparin and pregnancy.
Topics: Abortion, Habitual; Adult; Anticoagulants; Clinical Trials as Topic; Dose-Response Relationship, Dru | 2011 |
Bilateral orbital haematomas in an anticoagulated patient with severe H1N1 influenza.
Topics: Anticoagulants; Enoxaparin; Exophthalmos; Female; Functional Laterality; Humans; Influenza A Virus, | 2011 |
New insights on the role of direct thrombin inhibitors for the prevention of venous thromboembolism after major orthopaedic surgery.
Topics: Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Benzimidazoles; beta-Alanine; Dabigat | 2011 |
Microparticles as a strategy for low-molecular-weight heparin delivery.
Topics: Anticoagulants; Capsules; Delayed-Action Preparations; Drug Compounding; Enoxaparin; Humans; Lactic | 2011 |
Oral rivaroxaban for symptomatic venous thromboembolism.
Topics: Acute Disease; Administration, Oral; Anticoagulants; Enoxaparin; Hemorrhage; Humans; Morpholines; Pu | 2011 |
Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
Topics: Anticoagulants; Area Under Curve; Critical Illness; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Fem | 2011 |
Saddle pulmonary thromboembolism with zero Wells' score.
Topics: Anticoagulants; Blood Coagulation; Clinical Competence; Critical Pathways; Diagnosis, Differential; | 2011 |
Anticoagulant utilization evaluation in a teaching hospital: a prospective study.
Topics: Adult; Aged; Anticoagulants; Cross-Sectional Studies; Drug Monitoring; Drug Utilization Review; Enox | 2010 |
Heparin-induced thrombocytopenia: an increasingly common cause of bilateral adrenal hemorrhage.
Topics: Adrenal Gland Diseases; Adrenal Glands; Adrenal Insufficiency; Aged; Anticoagulants; Arthroplasty, R | 2011 |
[Improving recanalization of deep veins and the "outcomes" of venous thromboembolic complications in prolonged therapy with enoxaparin].
Topics: Adolescent; Adult; Aged; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Humans; Male; Middle | 2010 |
Practice in the perioperative prevention of deep vein thrombosis in german neurosurgical departments: is there a trend towards homogenization?
Topics: Brain; Contraindications; Drug Utilization; Enoxaparin; Fibrinolytic Agents; Germany; Health Care Su | 2011 |
Safety and efficacy of heparin or enoxaparin prophylaxis in blunt trauma patients with a head abbreviated injury severity score >2.
Topics: Abbreviated Injury Scale; Anticoagulants; Brain Injuries; Disease Progression; Enoxaparin; Heparin; | 2011 |
Coagulation: cascade!
Topics: Aged; Anticoagulants; Coumarins; Enoxaparin; Gangrene; Heparin; Humans; International Normalized Rat | 2011 |
[Gastrointestinal stromal tumor in pregnancy and control. Case report].
Topics: Adult; Anticoagulants; Cesarean Section; Embolism, Amniotic Fluid; Emergencies; Enoxaparin; Female; | 2010 |
Biochemical and pharmacological profile of darexaban, an oral direct factor Xa inhibitor.
Topics: Administration, Oral; Animals; Anticoagulants; Azepines; Benzamides; Bleeding Time; Disease Models, | 2011 |
Rapid-onset heparin-induced thrombocytopenia without previous heparin exposure.
Topics: Antibodies, Antiphospholipid; Anticoagulants; Antigen-Antibody Complex; Enoxaparin; Extremities; Fem | 2012 |
Preoperative enoxaparin is safe to use in major gynecologic surgery for prophylaxis of venous thromboembolism: a retrospective cohort study.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Follow-Up Studies; Genital Neoplasms, Female; Gynec | 2012 |
Inpatient enoxaparin and outpatient aspirin chemoprophylaxis regimen after primary hip and knee arthroplasty: a preliminary study.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Aspirin; Body Mass | 2012 |
Incidence of deep vein thrombosis is increased with 30 mg twice daily dosing of enoxaparin compared with 40 mg daily.
Topics: Anticoagulants; Drug Administration Schedule; Enoxaparin; Factor Xa; Female; Humans; Incidence; Male | 2012 |
Thrombotic biomarkers and left ventricle characteristics as short-term predictors of thrombotic events in patients hospitalized for acute decompensated heart failure.
Topics: Aged; Aged, 80 and over; Anticoagulants; Biomarkers; Echocardiography; Enoxaparin; Female; Fibrin Fi | 2012 |
Venous thromboprophylaxis in general surgery ward admissions: strategies for improvement.
Topics: Aged; Anticoagulants; Argentina; Chemoprevention; Clinical Protocols; Enoxaparin; Female; Guideline | 2012 |
Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients.
Topics: Adult; Aged; Cost-Benefit Analysis; Enoxaparin; Female; Humans; Markov Chains; Middle Aged; Ovarian | 2012 |
Benefits and risks of preventing thromboembolism with enoxaparin in patients with general surgery in real world--the CLEVER study.
Topics: Adult; Aged; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Venous Thromboembolism; | 2013 |
Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis.
Topics: Aged; Anticoagulants; Chi-Square Distribution; Endoscopy, Gastrointestinal; Enoxaparin; Esophageal a | 2012 |
Extensive venous thrombosis in a healthy young man with a short inferior vena cava syndrome treated successfully with rivaroxaban.
Topics: Adult; Anticoagulants; Edema; Enoxaparin; Humans; Iliac Vein; Incidental Findings; Male; Morpholines | 2012 |
Safety of peri-operative low-dose aspirin as a part of multimodal venous thromboembolic prophylaxis for total knee and hip arthroplasty.
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2012 |
Management of peripherally inserted central catheter associated deep vein thrombosis in children.
Topics: Anticoagulants; Catheterization, Central Venous; Child; Enoxaparin; Female; Heparin; Humans; Male; R | 2013 |
The effects of location and low-molecular-weight heparin administration on deep vein thrombosis outcomes in trauma patients.
Topics: Adult; Aged; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Injury | 2013 |
Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital.
Topics: Adolescent; Anticoagulants; Child; Child, Preschool; Drug Monitoring; Enoxaparin; Factor Xa; Female; | 2013 |
Klinefelter's syndrome and venous thrombosis.
Topics: Adult; Antibodies, Anticardiolipin; Anticoagulants; Enoxaparin; Factor VIII; Gene Expression Regulat | 2013 |
Management of acute proximal deep vein thrombosis: pharmacoeconomic evaluation of outpatient treatment with enoxaparin vs inpatient treatment with unfractionated heparin.
Topics: Ambulatory Care; Anticoagulants; Canada; Economics, Pharmaceutical; Enoxaparin; Female; Health Maint | 2002 |
A comparison of heparin/warfarin and enoxaparin thromboprophylaxis in spinal cord injury: the Sheffield experience.
Topics: Acute Disease; Adolescent; Adult; Anticoagulants; Child; Cohort Studies; Comorbidity; Drug Therapy, | 2002 |
Fondaparinux for post-operative venous thrombosis prophylaxis.
Topics: Canada; Clinical Trials, Phase III as Topic; Contraindications; Costs and Cost Analysis; Drug Approv | 2002 |
Septic superior ophthalmic vein thrombosis: to coagulate or not to coagulate?
Topics: Anticoagulants; Bacteremia; Enoxaparin; Humans; Orbit; Orbital Diseases; Staphylococcal Infections; | 2002 |
Septic superior ophthalmic vein thrombosis: enoxaparin needs to be monitored.
Topics: Anticoagulants; Bacteremia; Drug Monitoring; Enoxaparin; Humans; Orbit; Orbital Diseases; Staphyloco | 2002 |
Anaphylactoid reaction to enoxaparin in a patient with deep venous thrombosis.
Topics: Adult; Anaphylaxis; Enoxaparin; Humans; Male; Venous Thrombosis | 2002 |
Fondaparinux versus enoxaparin for prevention of venous thromboembolism.
Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fonda | 2002 |
Fondaparinux versus enoxaparin for prevention of venous.
Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fonda | 2002 |
Fondaparinux versus enoxaparin for prevention of venous.
Topics: Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fonda | 2002 |
Low-molecular weight heparin: treatment failure in a patient with primary antiphospholipid antibody syndrome.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Arginine; Arm; Enoxaparin; Female; Folic Acid | 2002 |
Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery.
Topics: Arthroplasty; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hemorrhage; Humans; Polysaccharides; Po | 2002 |
Enoxaparin or fondaparinux for thrombosis prevention after orthopaedic surgery.
Topics: Arthroplasty; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Polysacch | 2002 |
Results of an economic model to assess the cost-effectiveness of enoxaparin, a low-molecular-weight heparin, versus warfarin for the prophylaxis of deep vein thrombosis and associated long-term complications in total hip replacement surgery in the United
Topics: Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Cost-Benefit Analysis; Drug | 2002 |
Idraparinux and liver enzymes: observations from the PERSIST trial.
Topics: Adult; Aged; Alanine Transaminase; Anticoagulants; Aspartate Aminotransferases; Enoxaparin; Female; | 2003 |
[Venous thromboembolism prophylaxis with low molecular weight heparins in polytraumatized patients in intensive care unit (extended serie)].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; APACHE; Enoxaparin; Female; Hemorrhage; | 2003 |
A safety analysis of thromboprophylaxis in acute medical illness.
Topics: Acute Disease; Anticoagulants; Enoxaparin; Hemorrhage; Heparin; Humans; Risk Factors; Safety; Thromb | 2003 |
The effect of anticoagulation on the restoration of range of motion after total knee arthroplasty: enoxaparin versus aspirin.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Aspirin; Enoxaparin; Female; Fibrinolytic Age | 2003 |
Use of recombinant human antithrombin in patients with congenital antithrombin deficiency undergoing surgical procedures.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Arthroplasty, Replacemen | 2003 |
Images in clinical medicine. Hematoma of the rectus sheath.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Hematoma; Humans; Radiography; Rectus Abdominis; Venous Th | 2003 |
Cost analysis: fondaparinux versus preoperative and postoperative enoxaparin as venous thromboembolic event prophylaxis in elective hip arthroplasty.
Topics: Aged; Arthroplasty, Replacement, Hip; Costs and Cost Analysis; Drug Costs; Enoxaparin; Female; Fibri | 2003 |
Enoxaparin effect depends on body-weight and current doses may be inadequate in obese patients.
Topics: Adult; Aged; Anticoagulants; Body Weight; Enoxaparin; Female; Humans; Male; Middle Aged; Obesity; Pe | 2003 |
Postoperative deep vein thrombosis prophylaxis: a retrospective analysis in 1000 consecutive hip fracture patients treated in a community hospital setting.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Cohort Studies; Enoxaparin; Female; Frac | 2003 |
[Atraumatic retroperitoneal hemorrhage--interdisciplinary and differential diagnostic considerations based on a case report].
Topics: Aged; Anticoagulants; Biopsy, Needle; Diagnosis, Differential; Enoxaparin; Female; Glomerulonephriti | 2003 |
A randomised comparison of a foot pump and low-molecular-weight heparin in the prevention of deep-vein thrombosis after total knee replacement.
Topics: Arthroplasty, Replacement, Knee; Enoxaparin; Humans; Physical Therapy Modalities; Postoperative Care | 2003 |
[The problem of postoperative venous thromboembolic complications in general surgery].
Topics: Adult; Aged; Anticoagulants; Digestive System Surgical Procedures; Enoxaparin; Female; Humans; Leg; | 2003 |
Venous thromboembolic risk and prevention in acute medical illness.
Topics: Acute Disease; Aged; Anticoagulants; Cardiac Output, Low; Enoxaparin; Female; Hospitalization; Human | 2003 |
Enoxaparin-induced generalized exanthem.
Topics: Biopsy, Needle; Drug Eruptions; Enoxaparin; Exanthema; Female; Follow-Up Studies; Humans; Immunohist | 2003 |
[Evaluation of selected parameters of blood coagulation and fibrinolysis system in patients undergoing total hip replacement surgery with normovolemic hemodilution procedure and standard enoxaparine prophylaxis].
Topics: Aged; alpha-2-Antiplasmin; Anticoagulants; Antithrombins; Arthroplasty, Replacement, Hip; Blood Coag | 2003 |
Superior mesenteric vein thrombosis complicating appendicular masses.
Topics: Abdominal Pain; Adult; Anticoagulants; Appendectomy; Appendicitis; Enoxaparin; Humans; Male; Mesente | 2003 |
The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopedic surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cohort Studies; Cos | 2003 |
Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
Topics: Age Factors; Aged; Anticoagulants; Dalteparin; Enoxaparin; Hemorrhage; Humans; Meta-Analysis as Topi | 2003 |
Prophylactic and therapeutic enoxaparin during pregnancy: indications, outcomes and monitoring.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Pregnancy; Pregnancy Complications, Cardiovascula | 2003 |
Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound.
Topics: Adolescent; Arteries; Child; Child, Preschool; Enoxaparin; Female; Fibrinolytic Agents; Humans; Infa | 2004 |
Enoxaparin for postpartum ovarian vein thrombosis. A case report.
Topics: Adult; Anti-Bacterial Agents; Anticoagulants; Endometritis; Enoxaparin; Female; Humans; Ovary; Puerp | 2004 |
Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation.
Topics: Anticoagulants; Blood Cell Count; Coronary Angiography; Drug Therapy, Combination; Enoxaparin; Eptif | 2004 |
Upper-extremity deep venous thrombosis complicating whole-blood donation.
Topics: Adult; Blood Donors; Contraceptives, Oral, Sequential; Enoxaparin; Female; Humans; Risk Factors; Thr | 2004 |
Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX Study.
Topics: Acute Disease; Aged; Anticoagulants; Comorbidity; Enoxaparin; Female; Heart Failure; Hospitalization | 2004 |
Summaries for patients. Fondaparinux or enoxaparin for deep venous thrombosis?
Topics: Aged; Body Weight; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Fe | 2004 |
A cost-effectiveness analysis of fondaparinux sodium compared with enoxaparin sodium as prophylaxis against venous thromboembolism: use in patients undergoing major orthopaedic surgery.
Topics: Aged; Aged, 80 and over; Anticoagulants; Clinical Trials as Topic; Cohort Studies; Cost-Benefit Anal | 2004 |
Surveillance venous duplex is not clinically useful after total joint arthroplasty when effective deep venous thrombosis prophylaxis is used.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement; Bandages; Enoxaparin; Female; Femoral Vei | 2004 |
A case of warfarin skin necrosis despite enoxaparin anticoagulation in a patient with protein S deficiency.
Topics: Anticoagulants; Arterial Occlusive Diseases; Enoxaparin; Female; Fibrinolytic Agents; Heparin, Low-M | 2004 |
Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Belgium; Cost-Benef | 2004 |
Cost analysis of fondaparinux versus enoxaparin as venous thromboembolism prophylaxis in elective hip replacement surgery.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Costs and Cost Analysis; Elective Surgical Procedure | 2004 |
Hyperhomocysteinemia and deep vein thrombosis in orthotopic heart transplantation: a case report.
Topics: Adult; Anticoagulants; Enoxaparin; Heart Transplantation; Homocysteine; Humans; Hyperhomocysteinemia | 2004 |
Daily vs twice daily enoxaparin in the prevention of venous thromboembolic disorders during rehabilitation following acute spinal cord injury.
Topics: Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; | 2004 |
Advances in risk-benefit evaluation using probabilistic simulation methods: an application to the prophylaxis of deep vein thrombosis.
Topics: Anticoagulants; Decision Support Techniques; Enoxaparin; Hemorrhage; Heparin; Humans; Monte Carlo Me | 2004 |
[Etiology and therapy of the internal jugular vein thrombosis].
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Cefuroxime; Cellulitis; Diagnosis, Differe | 2004 |
Warfarin prophylaxis and venous thromboembolism in the first 5 days following hip and knee arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Case-Contr | 2004 |
Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study.
Topics: Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Dissent and Disputes; Enoxaparin | 2004 |
Risk factors for venous thromboembolism.
Topics: Anticoagulants; Enoxaparin; Hospitalization; Humans; Patient Selection; Risk Factors; Thromboembolis | 2004 |
The efficacy of a single daily dose of enoxaparin for deep vein thrombosis prophylaxis following total knee arthroplasty.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Arthroplasty, Replacement, Knee; Cohort Studies; D | 2004 |
In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
Topics: Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Enoxap | 2004 |
Antifactor Xa levels in four patients with burn injuries who received enoxaparin to prevent venous thromboembolism.
Topics: Adult; Antithrombin III; Burns; Enoxaparin; Female; Humans; Male; Venous Thrombosis | 2004 |
Deep vein thrombosis after total hip arthroplasty in Indian patients with and without enoxaparin.
Topics: Adult; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Female; Humans; Incidence; India; | 2004 |
Barriers to the use of outpatient enoxaparin therapy in patients with deep venous thrombosis.
Topics: Ambulatory Care; Anticoagulants; Clinical Protocols; Critical Pathways; Drug Utilization; Enoxaparin | 2005 |
Fondaparinux sodium compared with enoxaparin sodium: a cost-effectiveness analysis.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost-Benefit | 2005 |
Is heparin treatment the optimal management for cerebral venous thrombosis? Effect of abciximab, recombinant tissue plasminogen activator, and enoxaparin in experimentally induced superior sagittal sinus thrombosis.
Topics: Abciximab; Angiography; Animals; Antibodies, Monoclonal; Anticoagulants; Blood Platelets; Chlorides; | 2005 |
Outpatient delayed screening for patients with suspected deep vein thrombosis.
Topics: Ambulatory Care; Clinical Protocols; Emergency Medicine; Enoxaparin; Health Services Accessibility; | 2005 |
Celecoxib-induced deep-vein thrombosis.
Topics: Anticoagulants; Celecoxib; Cyclooxygenase Inhibitors; Enoxaparin; Gout; Humans; International Normal | 2005 |
[The cost-effectiveness of fondaparinux compared to enoxaparin as prophylaxis for deep-vein thrombosis in Denmark].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Cost Savings; Cost- | 2005 |
Deep-vein thrombosis in high-energy skeletal trauma despite thromboprophylaxis.
Topics: Acetabulum; Enoxaparin; Fibrinolytic Agents; Fractures, Bone; Humans; Magnetic Resonance Angiography | 2005 |
A retroperitoneal bleed induced by enoxaparin therapy.
Topics: Aged; Anticoagulants; Enoxaparin; Female; Humans; Laparotomy; Retroperitoneal Space; Shock, Hemorrha | 2005 |
Optimal dose of enoxaparin in critically ill trauma and surgical patients.
Topics: Anticoagulants; Critical Illness; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Agents; Humans; Pro | 2005 |
[Thrombosis prophylaxis and rational pharmacotherapy].
Topics: Anticoagulants; Drug Costs; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Humans; Polysaccharides; | 2005 |
Renal failure and low molecular weight heparins. A dangerous liaison? The case of retroperitoneal hematoma.
Topics: Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Hematoma; Heparin, Low-Molecular-Weight; Humans | 2005 |
[Is there a difference between low-molecular-weight heparins?].
Topics: Anticoagulants; Coronary Disease; Dalteparin; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin | 2005 |
Current practice of thromboprophylaxis in the burn population: a survey study of 84 US burn centers.
Topics: Anticoagulants; Burn Units; Burns; Dalteparin; Enoxaparin; Health Surveys; Heparin; Humans; Risk Fac | 2005 |
Treatment options and considerations for the newly diagnosed myeloma patient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Dexamethasone; Enoxapar | 2005 |
Selecting an anticoagulant for recurrent venous thromboembolism in cancer.
Topics: Anticoagulants; Clinical Trials as Topic; Dalteparin; Enoxaparin; Heparin, Low-Molecular-Weight; Hum | 2005 |
Identifying orthopedic patients at high risk for venous thromboembolism despite thromboprophylaxis.
Topics: Adult; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, | 2005 |
Thromboprophylaxis after vaginal delivery: a district general hospital experience.
Topics: Adolescent; Adult; Anticoagulants; Bandages; Chemoprevention; Delivery, Obstetric; Enoxaparin; Femal | 2006 |
Thromboprophylaxis post vaginal delivery: are we forgetting it? Audit on thromboprophylaxis prescription post vaginal births.
Topics: Anticoagulants; Bandages; Dehydration; Delivery, Obstetric; Early Ambulation; Enoxaparin; Female; Gu | 2006 |
Eczema-like plaques secondary to enoxaparin.
Topics: Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anticoagulants; Diagnosi | 2006 |
[Thromboembolisms endanger the internist patients, too: who needs heparin].
Topics: Age Factors; Aged; Anticoagulants; Dalteparin; Enoxaparin; Family Practice; Female; Fibrinolytic Age | 2006 |
[Prophylaxis of venous thromboembolism in acutely ill medical patients].
Topics: Acute Disease; Aged; Dalteparin; Enoxaparin; Fibrinolytic Agents; Health Status; Humans; Middle Aged | 2006 |
Development of a dosage strategy in patients receiving enoxaparin by continuous intravenous infusion using modelling and simulation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Creatinine; Critical Care; | 2006 |
Comparative study of isovolemic hemodilution with 3% albumin, dextran-40, and prophylactic enoxaparin (LMWH) on thrombus formation at venous microanastomosis in rats.
Topics: Anastomosis, Surgical; Animals; Dextrans; Disease Models, Animal; Drug Therapy, Combination; Enoxapa | 2006 |
Epidural blood patch in a patient receiving large dose enoxaparin (Lovenox).
Topics: Adult; Anticoagulants; Blood Patch, Epidural; Enoxaparin; Female; Headache; Humans; Pseudotumor Cere | 2006 |
Treatment with an oral small molecule inhibitor of P selectin (PSI-697) decreases vein wall injury in a rat stenosis model of venous thrombosis.
Topics: Animals; Anticoagulants; Constriction, Pathologic; Disease Models, Animal; Enoxaparin; Fibrosis; Hyd | 2006 |
Continuous peripheral nerve block in combat casualties receiving low-molecular weight heparin.
Topics: Adult; Anticoagulants; Drug Administration Schedule; Enoxaparin; Female; Humans; Iraq; Male; Middle | 2006 |
Reactive thrombocytosis associated with enoxaparin.
Topics: Accidents; Adult; Enoxaparin; Humans; Male; Thrombocytosis; Venous Thrombosis | 2006 |
Minimizing costs for treating deep vein thrombosis: the role for fondaparinux.
Topics: Body Weight; Costs and Cost Analysis; Enoxaparin; Fondaparinux; Hemorrhage; Heparin, Low-Molecular-W | 2007 |
A simple venous thromboembolism prophylaxis protocol for patients undergoing bariatric surgery.
Topics: Anticoagulants; Bariatric Surgery; Body Mass Index; Enoxaparin; Hemorrhage; Heparin; Humans; Obesity | 2006 |
Long-term safety and efficacy data on childhood venous thrombosis treated with a low molecular weight heparin: an open-label pilot study of once-daily versus twice-daily enoxaparin administration.
Topics: Adolescent; Child; Child, Preschool; Drug Administration Schedule; Enoxaparin; Female; Follow-Up Stu | 2006 |
Selecting an agent for prophylaxis of venous thromboembolism.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Enoxaparin; Fibrinolytic Agents; Formularies, Hos | 2006 |
Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient.
Topics: Costs and Cost Analysis; Enoxaparin; Heparin; Hospital Costs; Hospitalization; Humans; Medicare; Ven | 2006 |
Unfractionated- versus low-molecular-weight-heparin-associated HIT in hospitalized medical patients.
Topics: Enoxaparin; Heparin, Low-Molecular-Weight; Hospitalization; Humans; Randomized Controlled Trials as | 2006 |
Dendrimers as a carrier for pulmonary delivery of enoxaparin, a low-molecular weight heparin.
Topics: Animals; Azure Stains; Coloring Agents; Dendrimers; Drug Carriers; Drug Delivery Systems; Drug Inter | 2007 |
Venous thromboembolism in a general hospital. An update with low molecular weight heparin prophylaxis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Dose-Response Relationship, Drug; Drug A | 2007 |
Education together with a preprinted sticker improves the prescribing of prophylactic enoxaparin.
Topics: Aged; Anticoagulants; Drug Labeling; Drug Prescriptions; Drug Utilization Review; Education, Medical | 2007 |
Upper-extremity deep-vein thrombosis in an elderly man.
Topics: Aged; Anticoagulants; Arm; Chest Pain; Dyspnea; Edema; Enoxaparin; Exercise; Factor V; Humans; Male; | 2007 |
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery.
Topics: Anticoagulants; Clinical Trials as Topic; Enoxaparin; Hip Prosthesis; Humans; Knee Prosthesis; Phleb | 2007 |
Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy.
Topics: Adolescent; Blood Coagulation Disorders; Child; Child, Preschool; Enoxaparin; Female; Humans; Male; | 2007 |
Thromboprophylaxis after hip fracture: evaluation of 3 pharmacologic agents.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Dextrans; Enoxaparin; Female; Fibrinolytic Agents; | 2007 |
[Hereditary thrombophilia and systemic sclerosis. An unusual case report].
Topics: Adult; Anticoagulants; Blood Coagulation Disorders, Inherited; Drug Therapy, Combination; Enoxaparin | 2007 |
Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
Topics: Adult; Cohort Studies; Dalteparin; Drug Administration Schedule; Enoxaparin; Female; Fibrinolytic Ag | 2007 |
Development of oral anticoagulants.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Clinical Trials, Pha | 2007 |
Ulnar deep venous thrombosis in a professional baseball pitcher: a case report.
Topics: Adult; Baseball; Enoxaparin; Fibrinolytic Agents; Forearm Injuries; Humans; Male; Ultrasonography; V | 2007 |
Successful percutaneous retrieval of a swan-ganz catheter entrapped in an inferior vena cava filter.
Topics: Aged, 80 and over; Anticoagulants; Catheterization, Swan-Ganz; Catheters, Indwelling; Colonoscopy; D | 2007 |
Clinical problem-solving. A sinister development--a 35-year-old woman presented to the emergency department with a 2-day history of progressive swelling and pain in her left leg, without antecedent trauma.
Topics: Adult; Anticoagulants; Constriction, Pathologic; Contraceptives, Oral; Edema; Enoxaparin; Female; Fi | 2007 |
A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Topics: Adult; Anticoagulants; Bayes Theorem; Canada; Cost-Benefit Analysis; Decision Support Techniques; De | 2007 |
Management of thrombosis in a neuro-oncology patient.
Topics: Adult; Anticoagulants; Astrocytoma; Brain Neoplasms; Enoxaparin; Humans; Injections, Subcutaneous; L | 2007 |
Prevention of venous thromboembolism after acute ischaemic stroke.
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxaparin; Heparin, Low-Molecular-W | 2007 |
Prevention of venous thromboembolism after acute ischaemic stroke.
Topics: Anticoagulants; Cost-Benefit Analysis; Enoxaparin; Heparin; Humans; Ischemic Attack, Transient; Pres | 2007 |
Extended travel after hip arthroplasty surgery. Is it safe?
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Enoxaparin; Fondaparinux; Hip Joint; Hum | 2007 |
Trials of venous thromboembolism prevention.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Benzimidazoles; Dabigatran; Enoxaparin; Humans; Post | 2007 |
A newly developed oral heparin derivative for deep vein thrombosis: non-human primate study.
Topics: Administration, Oral; Animals; Anticoagulants; Capsules; Chemistry, Pharmaceutical; Deoxycholic Acid | 2007 |
Case report: Patient adherence to drug regimens vital to treatment.
Topics: Anticoagulants; Drug Prescriptions; Enoxaparin; Female; Femoral Vein; Follow-Up Studies; Humans; Mid | 2007 |
Superficial venous thrombosis associated with congenital absence of the inferior vena cava and previous episode of deep venous thrombosis.
Topics: Adult; Anticoagulants; Enoxaparin; Humans; Male; Thrombophlebitis; Tomography, X-Ray Computed; Treat | 2008 |
A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.
Topics: Adult; Clinical Trials as Topic; Cost-Benefit Analysis; Decision Trees; Enoxaparin; Female; Heparin; | 2007 |
Best Poster Award. A comparison of thromboembolic and bleeding events following laparoscopic gastric bypass in patients treated with prophylactic regimens of unfractionated heparin or enoxaparin.
Topics: Adult; Enoxaparin; Fibrinolytic Agents; Gastric Bypass; Heparin; Humans; Laparoscopy; Middle Aged; P | 2007 |
Multimodal thromboprophylaxis for total hip and knee arthroplasty based on risk assessment.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replac | 2007 |
Bilateral axillary vein thrombosis in a young patient with lupus anticoagulant and clavicular bone spurs.
Topics: Adolescent; Anticoagulants; Antiphospholipid Syndrome; Axillary Vein; Clavicle; Enoxaparin; Humans; | 2007 |
Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Confounding Factors, Epidemiologic; Cont | 2008 |
Prophylactic P-selectin inhibition with PSI-421 promotes resolution of venous thrombosis without anticoagulation.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Blood Platelets; Disease Models, A | 2008 |
[Thoracic venous thrombosis in the course of sarcoidosis].
Topics: Anticoagulants; Enoxaparin; Glucocorticoids; Humans; Male; Middle Aged; Prednisone; Sarcoidosis, Pul | 2008 |
Risk factors for upper limb deep vein thrombosis associated with the use of central vein catheter in cancer patients.
Topics: Anticoagulants; Antineoplastic Agents; Catheterization, Central Venous; Catheters, Indwelling; Confi | 2008 |
Cutaneous microangiopathic thrombosis complicated by pyoderma gangrenosum in post-cardiac surgery heparin-induced thrombocytopaenia.
Topics: Aged; Aortic Valve Stenosis; Autoantibodies; Cardiopulmonary Bypass; Enoxaparin; Female; Fibrinolyti | 2009 |
Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Enoxaparin; Fibrosis; Indoleaceti | 2008 |
Hepatitis C-associated leukocytoclastic vasculitis with anticardiolipin antibodies causing penile necrosis and deep venous thrombosis in the absence of cryoglobulinemia.
Topics: Antibodies, Anticardiolipin; Anticoagulants; Cryoglobulinemia; Debridement; Enoxaparin; Hepatitis C; | 2008 |
The role of heparin in alleviating complement-mediated acute intravascular haemolysis.
Topics: 3' Untranslated Regions; Acute Disease; Adult; Anemia, Hemolytic, Autoimmune; Azathioprine; Combined | 2008 |
A novel model of venous thrombosis in the vena cava of rabbits.
Topics: Animals; Bleeding Time; Blood Coagulation; Disease Models, Animal; Enoxaparin; Fibrinolytic Agents; | 1998 |
Enoxaparin in neurosurgical patients.
Topics: Anticoagulants; Bandages; Combined Modality Therapy; Enoxaparin; Hemorrhage; Heparin; Humans; Thromb | 1998 |
Delayed onset of anterior tibial compartment syndrome in a patient receiving low-molecular-weight heparin. A case report.
Topics: Adult; Anterior Compartment Syndrome; Anticoagulants; Enoxaparin; Femoral Fractures; Humans; Male; P | 1998 |
Inappropriate use of enoxaparin in the treatment of deep-vein thrombosis.
Topics: Contraindications; Drug Approval; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; Medication | 1999 |
Intrahepatic hemorrhage after use of low-molecular-weight heparin for total hip arthroplasty.
Topics: Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Chemical and Drug Induced Liver Injury; Eno | 1999 |
Why didn't this patient respond to enoxaparin?
Topics: Anticoagulants; Enoxaparin; Female; Humans; Hysterectomy; Pulmonary Embolism; Venous Thrombosis | 1999 |
Economic analysis of low-dose heparin vs the low-molecular-weight heparin enoxaparin for prevention of venous thromboembolism after colorectal surgery.
Topics: Anticoagulants; Canada; Colorectal Surgery; Cost-Benefit Analysis; Digestive System Surgical Procedu | 1999 |
Bleeding complications with enoxaparin for deep venous thrombosis prophylaxis.
Topics: Aged; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Case-Control Studies; Drug Ad | 1999 |
LMW heparins: from transition to fruition.
Topics: Anticoagulants; Coronary Disease; Cost-Benefit Analysis; Enoxaparin; Heparin, Low-Molecular-Weight; | 1999 |
Retroperitoneal hematoma and enoxaparin.
Topics: Aged; Anticoagulants; Enoxaparin; Fatal Outcome; Hematoma; Humans; Male; Retroperitoneal Space; Veno | 1999 |
[Deep venous thrombosis during pregnancy: long-term treatment with low molecular weight heparin].
Topics: Adult; Dose-Response Relationship, Drug; Enoxaparin; Female; Heparin, Low-Molecular-Weight; Humans; | 1999 |
[Resistance to activated protein C and pregnancy: thromboprophylaxis with low molecular weight heparin].
Topics: Activated Protein C Resistance; Adult; Anticoagulants; Enoxaparin; Factor V; Female; Humans; Point M | 1999 |
Enoxaparin for the prevention of VT in acutely ill patients.
Topics: Acute Disease; Adult; Anticoagulants; Double-Blind Method; Enoxaparin; Hospitalization; Humans; Pulm | 1999 |
Risk factors and management of patients with upper limb deep vein thrombosis.
Topics: Activated Protein C Resistance; Adult; Aged; Antithrombin III Deficiency; Drug Therapy, Combination; | 2000 |
Enoxaparin for the prevention of venous thromboembolism.
Topics: Anticoagulants; Confidence Intervals; Enoxaparin; Hemorrhage; Humans; Pulmonary Embolism; Thromboemb | 2000 |
Evaluation of the safety and efficacy of enoxaparin and warfarin for prevention of deep vein thrombosis after total knee arthroplasty.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Knee; Case-Control Studies; Enoxaparin; Female; Hum | 2000 |
Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Antithrombins; Arteriovenous Shunt, Surgic | 2000 |
Thrombosis prophylaxis in hospitalised medical patients: does prophylaxis in all patients make sense?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Humans; Incidence; Male; Neoplasms; | 2000 |
Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin.
Topics: 3' Untranslated Regions; Abortion, Habitual; Activated Protein C Resistance; Adult; Anticoagulants; | 2000 |
Orally administered unfractionated heparin with carrier agent is therapeutic for deep venous thrombosis.
Topics: Administration, Oral; Animals; Anticoagulants; Caprylates; Disease Models, Animal; Drug Carriers; En | 2000 |
Noncompliance in the inpatient administration of enoxaparin in conjunction with epidural or spinal anesthesia.
Topics: Anesthesia, Epidural; Anesthesia, Spinal; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplas | 2000 |
Therapeutic interchange of low-molecular-weight heparins.
Topics: Anticoagulants; Cost Savings; Dalteparin; Enoxaparin; Humans; Therapeutic Equivalency; Venous Thromb | 2000 |
Therapeutic interchange of low-molecular-weight heparins.
Topics: Anticoagulants; Cost Savings; Dalteparin; Enoxaparin; Humans; Therapeutic Equivalency; Venous Thromb | 2000 |
Therapeutic interchange of low-molecular-weight heparins.
Topics: Anticoagulants; Dalteparin; Enoxaparin; Humans; Pulmonary Embolism; Therapeutic Equivalency; Venous | 2000 |
Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery.
Topics: Biomarkers; Double-Blind Method; Drug Monitoring; Enoxaparin; Factor Xa Inhibitors; Fibrinolytic Age | 2000 |
Effectiveness and economic impact associated with a program for outpatient management of acute deep vein thrombosis in a group model health maintenance organization.
Topics: Aged; Ambulatory Care; Anticoagulants; Colorado; Cost Savings; Endpoint Determination; Enoxaparin; F | 2000 |
Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism.
Topics: Animals; Antibodies; Anticoagulants; Balloon Occlusion; Dalteparin; Diagnostic Imaging; Disease Mode | 2000 |
A potentially expanded role for enoxaparin in preventing venous thromboembolism in high risk blunt trauma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle | 2001 |
Redesigning heparin.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin; Heparin; Humans; Oligosaccharides; Posto | 2001 |
Management of heparin allergy during pregnancy with danaparoid.
Topics: Adult; Cesarean Section; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Drug Hypersensit | 2001 |
Thigh hematoma after femoral venipuncture in a patient treated with low-molecular-weight heparin.
Topics: Aged; Anticoagulants; Enoxaparin; Hematoma; Humans; Injections, Subcutaneous; Male; Soft Tissue Inju | 2001 |
Implementation and evaluation of guidelines for use of enoxaparin as deep vein thrombosis prophylaxis after major trauma.
Topics: Adult; Enoxaparin; Female; Guidelines as Topic; Humans; Male; Middle Aged; Venous Thrombosis; Wounds | 2001 |
Prophylaxis of thromboembolism in spinal injuries--results of enoxaparin used in 276 patients.
Topics: Acute Disease; Adult; Anticoagulants; Enoxaparin; Female; Humans; Male; Middle Aged; Pulmonary Embol | 2001 |
A synthetic pentasaccharide for the prevention of deep-vein thrombosis.
Topics: Anesthesia, Epidural; Anesthesia, Spinal; Anticoagulants; Arthroplasty, Replacement, Hip; Enoxaparin | 2001 |
A synthetic pentasaccharide for the prevention of deep-vein thrombosis.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Drug Administration Schedule; Enoxaparin; Humans; Ol | 2001 |
Enoxaparin treatment in high-risk trauma patients limits the utility of surveillance venous duplex scanning.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Enoxaparin; Female; Fibrinolytic Agents; Humans; Male; M | 2001 |
Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Comorbidity; Drug Administration Schedule; Enoxapari | 2001 |
Enoxaparin for thromboprophylaxis after major trauma: potential cost implications.
Topics: Anticoagulants; Cost-Benefit Analysis; Decision Making; Enoxaparin; Heparin, Low-Molecular-Weight; H | 2001 |
Venous thromboembolism prophylaxis after trauma: dollars and sense.
Topics: Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; Venous Thrombosis; Wounds and Inj | 2001 |
Treatment of vascular thrombosis with enoxaparin in orthotopic heart transplant patients during the early postoperative period.
Topics: Adult; Anticoagulants; Biopsy; Echocardiography, Transesophageal; Enoxaparin; Female; Graft Rejectio | 2001 |
Deep venous thrombosis: outpatient therapy with low-molecular-weight heparin.
Topics: Ambulatory Care; Anticoagulants; Enoxaparin; Heparin, Low-Molecular-Weight; Humans; United States; V | 1999 |
Outpatient treatment of DVT in a 170,000-member HMO.
Topics: Ambulatory Care; Anticoagulants; Cost Control; Disease Management; Enoxaparin; Health Maintenance Or | 1999 |
Reimbursement of enoxaparin for outpatient therapy. Proceedings of regional meetings.
Topics: Ambulatory Care; Anticoagulants; Education, Continuing; Enoxaparin; Formularies as Topic; Humans; In | 1999 |
Economic issues in the treatment and prevention of deep vein thrombosis from a managed care perspective.
Topics: Anticoagulants; Clinical Trials as Topic; Cost of Illness; Cost-Benefit Analysis; Enoxaparin; Humans | 2001 |
Cost comparison of tinzaparin versus enoxaparin as deep venous thrombosis prophylaxis in spinal cord injury: preliminary data.
Topics: Cost-Benefit Analysis; Data Collection; Drug Administration Schedule; Enoxaparin; Fibrinolytic Agent | 2001 |
The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis.
Topics: Amidines; Animals; Anticoagulants; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; E | 2001 |
Venous thromboembolism during pregnancy: a retrospective study of enoxaparin safety in 624 pregnancies.
Topics: Adult; Anticoagulants; Cerebral Hemorrhage; Enoxaparin; Female; Humans; Infant, Newborn; Intracrania | 2001 |
Choosing a parenteral anticoagulant agent.
Topics: Angina, Unstable; Anticoagulants; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecu | 2001 |
Could deep vein thrombosis be safely treated at home?
Topics: Ambulatory Care; Anticoagulants; Bandages; Bed Rest; Early Ambulation; Enoxaparin; Fibrinolytic Agen | 2001 |
Dalteparin vs. enoxaparin as prophylaxis for deep-vein thrombosis after total hip or knee arthroplasty: a retrospective analysis.
Topics: Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Costs and Cos | 2001 |
A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery.
Topics: Adult; Anticoagulants; Enoxaparin; Female; Humans; Male; Obesity, Morbid; Risk Factors; Venous Throm | 2002 |
Prevention of venous thromboembolism with fondaparinux.
Topics: Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Hip Fractures; Humans; | 2002 |
Prevention of venous thromboembolism with fondaparinux.
Topics: Drug Administration Schedule; Enoxaparin; Fibrinolytic Agents; Fondaparinux; Humans; Polysaccharides | 2002 |
Prevention of venous thromboembolism with fondaparinux.
Topics: Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Polysaccharide | 2002 |
Prevention of venous thromboembolism with fondaparinux.
Topics: Enoxaparin; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molecular-Weight; Humans; Polysaccharide | 2002 |
Enoxaparin: a pharmacoeconomic review of its use in the prevention and treatment of venous thromboembolism and in acute coronary syndromes.
Topics: Coronary Disease; Enoxaparin; Fibrinolytic Agents; Humans; Thromboembolism; Venous Thrombosis | 2002 |
Prospective evaluation of the safety of enoxaparin prophylaxis for venous thromboembolism in patients with intracranial hemorrhagic injuries.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Enoxaparin; Humans; Intracranial Hemorrh | 2002 |
Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention.
Topics: Arthroplasty, Replacement, Hip; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Fondapari | 2002 |
Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
Topics: Administration, Oral; Animals; Anticoagulants; Blood Coagulation; Blood Coagulation Tests; Disease M | 2017 |
[Intravenous or subcutaneous heparin. What is better in deep venous thrombosis?].
Topics: Biological Availability; Clinical Trials as Topic; Heparin; Heparin, Low-Molecular-Weight; Humans; I | 2002 |
Reviparin after leg injury requiring immobilization.
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Immobilization; Leg Injuries; Research Design | 2003 |
Reviparin after leg injury requiring immobilization.
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Immobilization; Leg Injuries; Postoperative C | 2003 |
Reviparin after leg injury requiring immobilization.
Topics: Anticoagulants; Heparin, Low-Molecular-Weight; Humans; Immobilization; Incidence; Leg Injuries; Risk | 2003 |
[Low molecular weight heparin certoparin. Clear simplification of thrombosis treatment].
Topics: Anticoagulants; Dose-Response Relationship, Drug; Heparin, Low-Molecular-Weight; Humans; Injections, | 2003 |
[Body weight adapted anticoagulation is passé. Thrombosis therapy without scales].
Topics: Body Weight; Clinical Trials as Topic; Follow-Up Studies; Heparin, Low-Molecular-Weight; Humans; Inj | 2003 |
[Initial results of the PROTECT Study publicized. Stroke patients need effective thrombosis prevention].
Topics: Anticoagulants; Cerebral Infarction; Double-Blind Method; Hemorrhage; Heparin; Heparin, Low-Molecula | 2005 |
Long-term follow-up of portal vein thrombosis in an American Cocker Spaniel with lobular dissecting hepatitis: a case report.
Topics: Animals; Anticoagulants; Computed Tomography Angiography; Dalteparin; Dog Diseases; Dogs; Follow-Up | 2021 |
Prophylactic Dose of Dalteparin in Pregnant Women With History of Venous Thromboembolisms and/or Thrombophilia: Real-World Data.
Topics: Anticoagulants; Dalteparin; Female; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Pregnancy; Pr | 2023 |
Evaluation of Low-Molecular-Weight Heparin for Treatment of Portal Vein Thrombosis in Liver Cirrhosis Patients.
Topics: Anticoagulants; Dalteparin; Heparin, Low-Molecular-Weight; Humans; Liver Cirrhosis; Portal Vein; Rec | 2023 |
Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH.
Topics: Administration, Oral; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Factor Xa Inhibitors; H | 2018 |
DVT following foot and ankle surgery: risk to the patient and surgeon.
Topics: Ankle; Anticoagulants; Dalteparin; Foot; Humans; Incidence; Orthopedic Procedures; Risk Factors; Ven | 2013 |
A 51-year-old woman with dyspnea.
Topics: Anticoagulants; Contraindications; Dalteparin; Dyspnea; Female; Fibrinolytic Agents; Humans; Middle | 2013 |
Lessons from recurrent deep vein thrombosis in Glanzmann thrombasthenia.
Topics: Aged; Dalteparin; Female; Fibrinolytic Agents; Humans; Platelet Membrane Glycoprotein IIb; Recurrenc | 2013 |
Venous thrombosis in pancreaticobiliary tract cancer: outcome and prognostic factors.
Topics: Aged; Anticoagulants; Biliary Tract Neoplasms; Dalteparin; Female; Humans; Male; Middle Aged; Pancre | 2015 |
Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment.
Topics: Aged, 80 and over; Antibodies; Anticoagulants; Blood Platelets; Dalteparin; Female; Fondaparinux; Hi | 2015 |
Comparison of the effect of dabigatran and dalteparin on thrombus stability in a murine model of venous thromboembolism.
Topics: Animals; Anticoagulants; Antithrombins; Dabigatran; Dalteparin; Disease Models, Animal; Disease Prog | 2016 |
Argatroban for Treatment of Heparin-Induced Thrombocytopenia and Thrombosis in a Patient with Multiple Myeloma Undergoing Hemodialysis.
Topics: Aged, 80 and over; Anticoagulants; Antithrombins; Arginine; Dalteparin; Female; Humans; Multiple Mye | 2016 |
Analysis of contributing factors influencing thromboembolic events after total knee arthroplasty.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Knee; Dalteparin; Electiv | 2017 |
Transvaginal color Doppler for the visualization of pelvic vein thrombosis during pregnancy.
Topics: Adult; Anticoagulants; Dalteparin; Female; Humans; Iliac Vein; Pregnancy; Pregnancy Complications; T | 2009 |
Kinetics of D-dimer after general surgery.
Topics: Abdomen; Abdominal Neoplasms; Adult; Aged; Anticoagulants; Cohort Studies; Dalteparin; Female; Fibri | 2009 |
The Janus face of thromboprophylaxis in patients with high risk for both thrombosis and bleeding during intracranial surgery: report of five exemplary cases.
Topics: Aged; Atrial Fibrillation; Cerebral Hemorrhage; Coronary Artery Disease; Dalteparin; Fatal Outcome; | 2009 |
High incidence of in-hospital pulmonary embolism following joint arthroplasty with dalteparin prophylaxis.
Topics: Aged; Anticoagulants; Arthroplasty; Dalteparin; Drug Administration Schedule; Elective Surgical Proc | 2010 |
Evaluation of AR-H067637, the active metabolite of the new direct thrombin inhibitor AZD0837, in models of venous and arterial thrombosis and bleeding in anaesthetised rats.
Topics: Amidines; Animals; Antithrombin III; Antithrombins; Azetidines; Blood Coagulation; Chlorides; Daltep | 2010 |
PROphylaxis for ThromboEmbolism in Critical Care Trial protocol and analysis plan.
Topics: Critical Care; Dalteparin; Fibrinolytic Agents; Heparin; Humans; Injections, Subcutaneous; Intensive | 2011 |
Dalteparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Heparin; Humans; Thrombocytopenia; Venous Thrombosis | 2011 |
Dalteparin in critically ill patients.
Topics: Anticoagulants; Critical Illness; Dalteparin; Heparin; Humans; Incidence; Outcome Assessment, Health | 2011 |
Safety of a regimen for thromboprophylaxis in head and neck cancer microvascular reconstructive surgery: non-concurrent cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Loss, Surgical; Cohort Studies; Dalteparin; Fe | 2012 |
Dalteparin and heparin-induced thrombocytopenia.
Topics: Anticoagulants; Critical Illness; Dalteparin; Female; Heparin; Humans; Male; Venous Thrombosis | 2011 |
In vivo monitoring of venous thrombosis in mice.
Topics: Animals; Anticoagulants; Blood Coagulation; Chlorides; Dalteparin; Disease Models, Animal; Ferric Co | 2012 |
42-year-old man with hemoptysis, dyspnea, and orthopnea.
Topics: Adult; Anticoagulants; Dalteparin; Diagnosis, Differential; Dyspnea; Hemoptysis; Humans; Male; Mitra | 2012 |
Superior ophthalmic vein thrombosis as an initial manifestation of antiphospholipid syndrome.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Dalteparin; Drug Therapy, Combination; Exophthalmo | 2013 |
Treatment of deep venous thrombosis with low-molecular-weight heparin during pregnancy.
Topics: Adult; Dalteparin; Drug Evaluation; Female; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Huma | 2002 |
Outpatient treatment of community acquired venous thromboembolism--the Christchurch experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Anticoagulants; Dalteparin; Drug Therap | 2002 |
Should patients with deep vein thrombosis alone be treated as those with concomitant asymptomatic pulmonary embolism? A prospective study.
Topics: Anticoagulants; Cohort Studies; Dalteparin; Hemorrhage; Humans; Prospective Studies; Pulmonary Embol | 2002 |
Cancer-associated thrombosis.
Topics: Anticoagulants; Dalteparin; Humans; Neoplasms; Pulmonary Embolism; Risk Factors; Secondary Preventio | 2003 |
Effect of 3.2 vs. 3.8% sodium citrate concentration on anti-Xa levels for patients on therapeutic low molecular weight heparin.
Topics: Anticoagulants; Blood Coagulation Tests; Citrates; Dalteparin; Dose-Response Relationship, Drug; Fac | 2003 |
Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
Topics: Acenocoumarol; Administration, Oral; Anticoagulants; Bias; Dalteparin; Humans; International Normali | 2003 |
Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
Topics: Anticoagulants; Dalteparin; Humans; Injections, Subcutaneous; Patient Satisfaction; Venous Thrombosi | 2003 |
Dalteparin compared with an oral anticoagulant for thromboprophylaxis in patients with cancer.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Humans; Injections, Subcutaneous; Venous Thrombos | 2003 |
Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.
Topics: Adult; Aged; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Female; Fibrinolytic Agents; Heparin | 2004 |
Low molecular weight heparin induced priapism.
Topics: Anticoagulants; Automobile Driving; Dalteparin; Humans; Male; Middle Aged; Priapism; Venous Thrombos | 2004 |
Fixed-dose low-molecular-weight heparin for secondary prevention of venous thromboembolism in patients with disseminated cancer: a prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Blood Platelets; Body Weight; Brain Neoplasms; Cohor | 2004 |
[Prevention and treatment of venous thromboses and thromboembolism: pentasaccharides as novel anticoagulants selectively blocking Xe factor, their position and potential (data of the XIX International Congress on Thromboses and Hemostasis)].
Topics: Adult; Anticoagulants; Complement Factor H; Dalteparin; Fondaparinux; Humans; Middle Aged; Polysacch | 2004 |
The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Body Weight; Dalteparin; Female; Humans; Internation | 2005 |
Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the PREVENT trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Humans; Logistic Models; Male; Multivar | 2005 |
Low-molecular-weight heparin (dalteparin) in women with gynecologic malignancy.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Cohort Studies; Dalteparin; Dose-Response Relation | 2005 |
Life-threatening hemorrhage after dalteparin therapy in a patient with impaired renal function.
Topics: Aged; Aged, 80 and over; Anticoagulants; Dalteparin; Female; Hematoma; Heparin Antagonists; Humans; | 2005 |
The safety of dosing dalteparin based on actual body weight for the treatment of acute venous thromboembolism in obese patients: a rebuttal.
Topics: Bioethics; Body Weight; Dalteparin; Factor Xa; Factor Xa Inhibitors; Heparin, Low-Molecular-Weight; | 2005 |
[Anesthetic management of a patient with paroxysmal nocturnal hemoglobinuria and suspected abdominal venous thrombosis].
Topics: Anesthesia, General; Dalteparin; Fibrinolytic Agents; Hemoglobinuria, Paroxysmal; Humans; Interverte | 2005 |
Cost effectiveness of dalteparin for preventing venous thromboembolism in abdominal surgery.
Topics: Abdomen; Aged; Aged, 80 and over; Anticoagulants; Cost-Benefit Analysis; Dalteparin; Female; Humans; | 2005 |
Utility of once-daily dose of low-molecular-weight heparin to prevent venous thromboembolism in multisystem trauma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Clinical Protocols; Dalteparin; Feasibil | 2007 |
A pilot study of central venous catheter survival in cancer patients using low-molecular-weight heparin (dalteparin) and warfarin without catheter removal for the treatment of upper extremity deep vein thrombosis (The Catheter Study).
Topics: Aged; Anticoagulants; Catheterization, Central Venous; Cohort Studies; Dalteparin; Female; Humans; I | 2007 |
Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Anticoagulants; Dalteparin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Middle | 2007 |
Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors.
Topics: Aged; Anticoagulants; APACHE; Critical Illness; Dalteparin; Female; Hemorrhage; Humans; Incidence; I | 2008 |
Thromboembolic events following arthroscopic knee surgery.
Topics: Adult; Aged; Anticoagulants; Arthroscopy; Dalteparin; Female; Humans; Knee Joint; Male; Middle Aged; | 1999 |
Outpatient use of low molecular weight heparin (Dalteparin) for the treatment of deep vein thrombosis of the upper extremity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Arm; Catheterization, Central Venous; C | 1999 |
Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin.
Topics: Adult; Anticoagulants; Antithrombins; Dalteparin; Female; Heparin; Hirudin Therapy; Humans; Lupus Er | 2000 |
Superior mesenteric and portal vein thrombosis following laparoscopic nissen fundoplication.
Topics: Abdominal Pain; Anticoagulants; Dalteparin; Fundoplication; Gastroesophageal Reflux; Humans; Male; M | 2000 |
Cost effectiveness of deep venous thrombosis prophylaxis after hip fracture.
Topics: Anticoagulants; Cost-Benefit Analysis; Dalteparin; Hip Fractures; Humans; Leg; Postoperative Complic | 2000 |
Drug eruption due to low molecular weight heparin.
Topics: Adult; Dalteparin; Drug Eruptions; Female; Fibrinolytic Agents; Humans; Injections, Subcutaneous; Pr | 2000 |
Alopecia and dalteparin: a previously unreported association.
Topics: Alopecia; Anticoagulants; Child; Dalteparin; Female; Humans; Venous Thrombosis | 2000 |
Arterial and venous disease and deep vein thrombosis. Injecting drug use is major risk factor for deep vein thrombosis.
Topics: Anticoagulants; Dalteparin; Humans; Leg; Risk Factors; Substance Abuse, Intravenous; Venous Thrombos | 2000 |
Stasis ulcers refractory to therapy--accelerated healing by treatment with clopidogrel +/- dalteparin: a preliminary report.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antiphospholipid Syndrome; Clopidogrel; Dalteparin; | 2001 |
Dalteparin vs warfarin in hip arthroplasty patients.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Dalteparin; Humans; Treatment Outcome; Venous Thromb | 2001 |
Accumulation of low molecular mass heparin during prophylactic treatment in pregnancy.
Topics: Adult; Anticoagulants; Dalteparin; Factor Xa Inhibitors; Female; Gestational Age; Heparin; Humans; P | 2001 |
A low-molecular-weight heparin preparation contraindicated during pregnancy.
Topics: Adult; Anticoagulants; Benzyl Alcohol; Contraindications; Dalteparin; Female; Humans; Infant; Pregna | 2001 |
P-selectin antagonism causes dose-dependent venous thrombosis inhibition.
Topics: Animals; Anticoagulants; Balloon Occlusion; Dalteparin; Disease Models, Animal; Dose-Response Relati | 2001 |
[The role of low molecular weight heparin (fragmin) in the prophylaxis and treatment of venous thromboembolism in major abdominal operations].
Topics: Dalteparin; Digestive System Surgical Procedures; Heparin, Low-Molecular-Weight; Humans; Pulmonary E | 2000 |
Dalteparin new treatment duration: new dosage. Is prolonged prophylaxis needed?
Topics: Anticoagulants; Clinical Trials as Topic; Cost-Benefit Analysis; Dalteparin; Double-Blind Method; Fr | 2000 |
[Low-molecular weight heparins in the prophylaxis and treatment of pulmonary thromboembolism].
Topics: Dalteparin; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Practice Guidelines as Topic | 2001 |
Successful use of heparinoids in a pregnancy complicated by allergy to heparin.
Topics: Adult; Anticoagulants; Chondroitin Sulfates; Dalteparin; Dermatan Sulfate; Drug Combinations; Drug H | 2001 |
The antithrombotic efficacy of AT-1459, a novel, direct thrombin inhibitor, in rat models of venous and arterial thrombosis.
Topics: Administration, Oral; Amidines; Animals; Arginine; Azepines; Bleeding Time; Carotid Artery Thrombosi | 2001 |
The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism.
Topics: Adult; Anticoagulants; Biomarkers; Blood Coagulation Tests; Dalteparin; Factor Xa Inhibitors; Female | 2002 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Risk of recurrent thromboembolic events according to treatment duration in patients with superficial vein thrombosis treated with intermediate dose of tinzaparin.
Topics: Aged; Anticoagulants; Duration of Therapy; Female; Humans; Male; Middle Aged; Prospective Studies; P | 2023 |
Treatment of superficial vein thrombosis with intermediate dose of tinzaparin: A real word cohort study - The SeVEN EXTension study.
Topics: Anticoagulants; Cohort Studies; Heparin, Low-Molecular-Weight; Humans; Thrombosis; Tinzaparin; Treat | 2021 |
Tinzaparin in intermediate dose for the treatment of superficial vein thrombosis: Results from an observational multicenter study-SeVEN study.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Male; Middle Aged; Retrospective Studies; Tinzaparin | 2018 |
Ovarian vein thrombosis after delivery.
Topics: Adult; Cesarean Section; Delivery, Obstetric; Diagnosis, Differential; Female; Follow-Up Studies; He | 2018 |
A 52-year-old-male patient with metastatic non-small-cell lung cancer and recurrent venous thromboembolism in unusual sites despite anticoagulation.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Fibrinolytic Agents; Heparin, Low-Mol | 2013 |
Tolerance of Fondaparinux in Immediate-type Hypersensitivity to Heparins.
Topics: Anticoagulants; Drug Hypersensitivity; Female; Fibrinolytic Agents; Fondaparinux; Heparin, Low-Molec | 2015 |
Treatment of deep venous thrombosis in pregnant women.
Topics: Adult; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Gestatio | 2008 |
[An image of vena cava thrombosis].
Topics: Adenocarcinoma, Clear Cell; Aged, 80 and over; Angiogenesis Inhibitors; Fibrinolytic Agents; Heart A | 2009 |
Tinzaparin: excess mortality in elderly patients with renal failure. Unfractionated heparin is best in this setting.
Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Fibrinolytic Agents; Heparin; Heparin, Low-Molecu | 2009 |
Effects of long-term anticoagulant therapy on levels of circulating microparticles in patients with deep venous thrombosis.
Topics: Acenocoumarol; Anticoagulants; Cell-Derived Microparticles; Female; Heparin, Low-Molecular-Weight; H | 2011 |
Thromboprophylaxis for women undergoing caesarean section.
Topics: Cesarean Section; Female; Fibrinolytic Agents; Guideline Adherence; Heparin, Low-Molecular-Weight; H | 2012 |
[Necrotizing tonsillitis and renal vein thrombosis due to acute myeloid leukaemia].
Topics: Adult; Antineoplastic Agents; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Le | 2012 |
Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis.
Topics: Ambulatory Care; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Fibrinolytic Agents; H | 2002 |
High-dose tinzaparin in pregnancy and the need for urgent delivery.
Topics: Adult; Anesthesia, Obstetrical; Anticoagulants; Female; Fibrinolytic Agents; Heparin, Low-Molecular- | 2002 |
Severe bleeding associated with use of low molecular weight heparin and selective serotonin reuptake inhibitors.
Topics: Aged; Anticoagulants; Drug Interactions; Female; Fibrinolytic Agents; Fluoxetine; Hemorrhage; Hepari | 2002 |
Management dilemma of cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia.
Topics: Aged; Axillary Vein; Cardiopulmonary Bypass; Female; Fibrinolytic Agents; Heart Atria; Heart Neoplas | 2002 |
Atrial fibrillation, stroke, and acute antithrombotic therapy.
Topics: Aspirin; Atrial Fibrillation; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Randomized | 2003 |
Splenic spontaneous rupture (SSR) and hemoperitoneum associated with low molecular weight heparin: a case report.
Topics: Aged; Anticoagulants; Carcinoma, Small Cell; Female; Fibrinolytic Agents; Hemoperitoneum; Heparin, L | 2003 |
[Treatment of deep vein thrombosis with low molecular weight heparins at home].
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Female; Fibrinolytic Agents; Heparin, Low-Molecular | 2003 |
Tinzaparin in the treatment of venous thromboembolism.
Topics: Administration, Oral; Anticoagulants; Clinical Trials as Topic; Cost-Benefit Analysis; Female; Fibri | 2003 |
Outpatient treatment of venous thromboembolic disease based in an emergency department.
Topics: Ambulatory Care; British Columbia; Emergency Service, Hospital; Endpoint Determination; Female; Fibr | 2005 |
A six-year old with fatal pulmonary embolism.
Topics: Child; Fatal Outcome; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Humans; Iliac Vein; Lupus | 2005 |
Ruptured 'fem-pop' vein graft presenting as deep venous thrombosis.
Topics: Aged, 80 and over; Aneurysm, False; Aortic Dissection; Blood Vessel Prosthesis; Diagnostic Errors; E | 2004 |
Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Female; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; | 2007 |
Inferior vena cava filter thrombo-prophylaxis in high-risk twin pregnancy.
Topics: Adult; Anticoagulants; Combined Modality Therapy; Female; Fibrinolytic Agents; Heparin; Heparin, Low | 2007 |
Early discharge of patients with pulmonary embolism: a two-phase observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cohort Studies; Female; Follow-Up Studies; Heparin, Low- | 2007 |
Tinzaparin in long-term treatment of deep venous thrombosis.
Topics: Drug Administration Schedule; Fibrinolytic Agents; Hemorrhage; Heparin, Low-Molecular-Weight; Humans | 2007 |
Thrombosis in a duplicated superficial femoral vein in a patient with haemophilia A.
Topics: Adult; Factor VIII; Femoral Vein; Fibrinolytic Agents; Hemophilia A; Heparin, Low-Molecular-Weight; | 2000 |
Achieving home-based care for deep vein thrombosis.
Topics: Adult; Community Health Nursing; Continuity of Patient Care; Drug Monitoring; Female; Fibrinolytic A | 1999 |
Tinzaparin is newest entry into low-molecular-weight heparin market.
Topics: Heparin, Low-Molecular-Weight; Humans; Injections, Subcutaneous; Tinzaparin; Venous Thrombosis | 2000 |
Tinzaparin, a low molecular weight heparin for treatment of deep vein thrombosis.
Topics: Costs and Cost Analysis; Dose-Response Relationship, Drug; Double-Blind Method; Heparin, Low-Molecul | 2001 |
[Fever and calf tenderness after travel in Thailand: murine typhus and deep vein thrombosis].
Topics: Adult; Anti-Infective Agents; Ciprofloxacin; Dehydration; Fever; Fibrinolytic Agents; Germany; Hepar | 2001 |
The outcome of ambulatory DVT management using a multidisciplinary approach.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care; Disease Management; Drug Evaluation; Fe | 2001 |
Serious adverse vascular events associated with perioperative interruption of antiplatelet and anticoagulant therapy.
Topics: Aged; Anticoagulants; Aspirin; Carcinoma, Basal Cell; Clopidogrel; Drug Administration Schedule; Fem | 2002 |
Prolonged prophylaxis after joint replacement: another step sideways?
Topics: Ambulatory Care; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Drug Administratio | 2000 |